Drug Interaction ID	Drug 1 Name	Drug 1 RxCUI	Drug 1 Class Name	Drug 1 Code	Drug 2 Name	Drug 2 RxCUI	Drug 2 Class Name	Drug 2 Code	Clinical Source	Source File	Description	Severity	Comment
0	ABATACEPT	614391			ANTI-TNF ALPHA				ANSM	1-ABATACEPT.html	Increase of immunosupression	Not recommended	
1	ABATACEPT	614391					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	1-ABATACEPT.html	Risk of possibly fatal generalized vaccine disease	Not recommended	as well as for the three months following the end of the treatment.
2	FUSIDIC ACID	4608					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	10-FUSIDIC-ACID.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type.	CONTRAINDICATION	If possible, stop the treatment with the HMG-COA Reductase Inhibitor before starting the treatment with fusidic acid or use another antibiotic.
3	FUSIDIC ACID	4608					OMBITASVIR + PARITAPEVIR	OMPA	ANSM	10-FUSIDIC-ACID.html	Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir	CONTRAINDICATION	
4	BOTULINUM TOXIN	1716					AMINOGLYCOSIDES	J01GB-001	ANSM	100-BOTULINUM-TOXIN.html	Risk of increase of the effects of the botulinum toxin with the aminoglycosides (by extrapolation from the effects observed during the course of the botulism)	Not recommended	Use another antibiotic.
5			BRADYCARIA INDUCING DRUGS	C0N0S0			OTHER BRADYCARIA INDUCING DRUGS	C0N0S0	ANSM	101-BRADYCARIA-INDUCING-DRUGS.html	Risk of excessive bradycardia (addition of the effects)	Take into account	
6			BRADYCARIA INDUCING DRUGS	C0N0S0	FINGOLIMOD	1012892			ANSM	101-BRADYCARIA-INDUCING-DRUGS.html	Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms	Not recommended	Clinical monitoring and sustained EKG during the 24 hours following the first dose.
7			BRADYCARIA INDUCING DRUGS	C0N0S0			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	101-BRADYCARIA-INDUCING-DRUGS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these together.
8	BRENTUXIMAB				BLEOMYCIN	1622			ANSM	102-BRENTUXIMAB.html	Risk of increase of pulmonary toxicity	CONTRAINDICATION	
9	BRENTUXIMAB						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	102-BRENTUXIMAB.html	Increase of the concentrations of the active metabolite of the brentuximab, with risk of neutropenia	Take into account	
10	BUPRENORPHINE	1819			ATAZANAVIR	343047			ANSM	103-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
11	BUPRENORPHINE	1819					BENZODIAZEPINES AND RELATED	N05-001	ANSM	103-BUPRENORPHINE.html	With the buprenorphine used in opioid replacement therapy: increased risk of respiratory depression which could be fatal.	Take into account	Evaluate carefully the risk/benefits relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed dosages.
12	BUPRENORPHINE	1819			FOSAMPRENAVIR	358262			ANSM	103-BUPRENORPHINE.html	Risk of increase or of decrease of the effects of the A to take into account buprenorphine [sic], simultaneously by inhibition and acceleration of its metabolism by the protease inhibitor.	Take into account	
13	BUPRENORPHINE	1819					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	103-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
14	BUPRENORPHINE	1819			ITRACONAZOLE	28031			ANSM	103-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
15	BUPRENORPHINE	1819			KETOCONAZOLE	6135			ANSM	103-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
16	BUPROPION	42347			CLOMIPRAMINE	2597			ANSM	104-BUPROPION.html	Risk of increase of the undesirable effects of the cloripramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the clomipramine during the treatment with the bupropion.
17	BUPROPION	42347			DESIPRAMINE	3247			ANSM	104-BUPROPION.html	Risk of increase of the undesirable effects of the desipramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the desipramine during the treatment with the bupropion.
18	BUPROPION	42347			FLECAINIDE	4441			ANSM	104-BUPROPION.html	Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the bupropion.
19	BUPROPION	42347					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	104-BUPROPION.html	Risk of hypertensive crises. From the fact of the length of action of the MAOI, this interaction is still theoretically possible two weeks after it is stopped	CONTRAINDICATION	
20	BUPROPION	42347					REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	104-BUPROPION.html	Risk of hypertensive crises	CONTRAINDICATION	
21	BUPROPION	42347					MAOI-B	N04BD0-001	ANSM	104-BUPROPION.html	Risk of hypertensive crises	CONTRAINDICATION	
22	BUPROPION	42347			MEQUITAZINE	29528			ANSM	104-BUPROPION.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
23	BUPROPION	42347			METOPROLOL	6918			ANSM	104-BUPROPION.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
24	BUPROPION	42347			NORTRIPTYLINE	7531			ANSM	104-BUPROPION.html	Risk of increase of the undesirable effects of the nortriptyline due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the nortriptyline during the treatment with the bupropion.
25	BUPROPION	42347			PROPAFENONE	8754			ANSM	104-BUPROPION.html	Risk of increase of the undesirable effects of the propafenone due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the bupropion.
26	BUPROPION	42347			TAMOXIFEN	10324			ANSM	104-BUPROPION.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine [sic]	Not recommended	
27	BUPROPION	42347			TRAMADOL	10689			ANSM	104-BUPROPION.html	Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications	Take into account	
28	BUPROPION	42347			VEMURAFENIB	1147220			ANSM	104-BUPROPION.html	Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity	Take into account	
29	BUSPIRONE	1827			DIAZEPAM	3322			ANSM	105-BUSPIRONE.html	Risk of increase of the undesirable effects of the buspirone	Take into account	
30	BUSPIRONE	1827			DILTIAZEM	3443			ANSM	105-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the diltiazem, with increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
31	BUSPIRONE	1827			ERYTHROMYCIN	4053			ANSM	105-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
32	BUSPIRONE	1827			ITRACONAZOLE	28031			ANSM	105-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
33	BUSPIRONE	1827			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	105-BUSPIRONE.html	Rick of increase of the undesirable effects of the buspirone due to decrease of its metabolism by the grapefruit	Take into account	
34	BUSPIRONE	1827			RIFAMPICIN	9384			ANSM	105-BUSPIRONE.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.
35	BUSPIRONE	1827			VERAPAMIL	11170			ANSM	105-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects.	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
36	BUSULFAN	1828			DEFERASIROX	614373			ANSM	106-BUSULFAN.html	Risk of increase of the toxicity of the busulfan due to decrease of its clearance by the deferasirox	Take into account	
37	BUSULFAN	1828			ITRACONAZOLE	28031			ANSM	106-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the itraconazole	Not recommended	
38	BUSULFAN	1828			METRONIDAZOLE	6922			ANSM	106-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
39	CABAZITAXEL	996051					ENZYMATIC INDUCERS	N03-J05-001	ANSM	107-CABAZITAXEL.html	Decrease of the concentrations of the cytotoxic by increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
40	CABAZITAXEL	996051					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	107-CABAZITAXEL.html	Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzymatic inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the cabazitaxel during the treatment with the enzymatic inhibitor.
41	CAFFEINE	1886			CIPROFLOXACIN	2551			ANSM	108-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
42	CAFFEINE	1886			DIPYRIDAMOLE	3521			ANSM	108-CAFFEINE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine	Precaution for use	Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consuming coffee, tea, chocolate, or cola during the 24 hours that precede the test.
43	CAFFEINE	1886			ENOXACIN	3925			ANSM	108-CAFFEINE.html	Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism	Not recommended	
44	CAFFEINE	1886			LITHIUM	6448			ANSM	108-CAFFEINE.html	In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the lithemia	Take into account	
45	CAFFEINE	1886			MEXILETINE	6926			ANSM	108-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine	Take into account	
46	CAFFEINE	1886			NORFLOXACINE	7517			ANSM	108-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
47	CAFFEINE	1886			STIRIPENTOL	37119			ANSM	108-CAFFEINE.html	Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of caffeine.
48	CALCITONIN	36118			LITHIUM	6448			ANSM	109-CALCITONIN.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together.
49	NICOTINIC ACID	446722			ALCOHOL (DRINK OR INGREDIENT)				ANSM	11-NICOTINIC-ACID.html	Risk of rash, redness, and heat linked to an increase of the vasodilator effect	Take into account	
50	CALCIUM	1428011					BISPHOSPHONATES	M05B-001	ANSM	110-CALCIUM.html	For the calcium salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	Take calcium salts and antacids at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).
51	CALCIUM	1428011					TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	110-CALCIUM.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the calcium salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
52	CALCIUM	1428011			DIGOXIN	3407			ANSM	110-CALCIUM.html	Risk of serious arrhythmias, even lethal ones, with the calcium salts administered by IV route.	Contraindication	-with the calcium salts via IV, except for parenteral supplementation
53	CALCIUM	1428011					THIAZIDE DIURETICS AND RELATED	C03-003	ANSM	110-CALCIUM.html	Risk of hypercalcemia due to decrease of the urinary elimination of the calcium.	Take into account	
54	CALCIUM	1428011			ESTRAMUSTINE	4089			ANSM	110-CALCIUM.html	Decrease of the digestive absorption of the estramustine	Precaution for use	Take the calcium salts at a different time from the estramustine (more than 2 hours apart, if possible).
55	CALCIUM	1428011			IRON	1431589			ANSM	110-CALCIUM.html	With the iron salts by oral route: decrease of the digestive absorption of the iron salts	Precaution for use	Take the iron salts at a different time from meals and in the absence of calcium.
56	CALCIUM	1428011					THYROID HORMONES	H03AA	ANSM	110-CALCIUM.html	Decrease of the absorption of the thyroid hormones	Precaution for use	Take the calcium salts at a different time from the thyroid hormones (more than 2 hours apart, if possible).
57	CALCIUM	1428011			STRONTIUM	81638			ANSM	110-CALCIUM.html	With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the calcium salts (more than two hours apart, if possible).
58	CALCIUM	1428011			ZINC				ANSM	110-CALCIUM.html	Decrease of the digestive absorption of the zinc by the calcium	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart, if possible).
59	CANAKINUMAB	853491					ANTI-TNF ALPHA	4ABO	ANSM	111-CANAKINUMAB.html	Risk of increase of serious infections	Not recommended	
60	CARBAMAZEPINE	2002			ACETAZOLAMIDE	167			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose.	Precaution for use	Clinical monitoring, and, if needed, testing of the plasma concentrations of carbamazepine and possible reduction of its dosage
61	CARBAMAZEPINE	2002			CIMETIDINE	2541			ANSM	112-CARBAMAZEPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine, especially during the first days of treatment with the cimetidine
62	CARBAMAZEPINE	2002			CLARITHROMYCIN	21212			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
63	CARBAMAZEPINE	2002			CLONAZEPAM	2598			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of the clonazepam due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinincal monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants
64	CARBAMAZEPINE	2002			CLOZAPINE	2626			ANSM	112-CARBAMAZEPINE.html	Risk of increase of the serious hematological effects	Not recommended	
65	CARBAMAZEPINE	2002			DANAZOL	3102			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine, with signs of overdose	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
66	CARBAMAZEPINE	2002			DIGOXIN	3407			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine and decrease of the digoxinemia	Precaution for use	Exercise caution in the interpretation of the plasma concentrations.
67	CARBAMAZEPINE	2002					POTASSIUM LOWERING DIURETICS	C03	ANSM	112-CARBAMAZEPINE.html	Risk of symptomatic hyponatremia	Precaution for use	Clinical and biological monitoring. If possible, use another class of diuretics.
68	CARBAMAZEPINE	2002			ERYTHROMYCIN	4053			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	
69	CARBAMAZEPINE	2002			ETHOSUXIMIDE	4135			ANSM	112-CARBAMAZEPINE.html	Decrease of the plasma concentrations of ethosuximide	Precaution for use	Clinical monitoring, plasma dosage of the ethosuximide and possible increase of its dosage.
70	CARBAMAZEPINE	2002			FELBAMATE	24812			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of felbamate due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants.
71	CARBAMAZEPINE	2002			FLUCONAZOLE	4450			ANSM	112-CARBAMAZEPINE.html	For doses of fluconazole >=200 mg per day: possible increase of the undesirable effects of the carbamazepine	Precaution for use	Adjust the dosage of carbamazepine, during the antifungal treatmentand after it is stopped.
72	CARBAMAZEPINE	2002			FLUOXETINE	4493			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.
73	CARBAMAZEPINE	2002			FLUVOXAMINE	42355			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.
74	CARBAMAZEPINE	2002			ISONIAZID	6038			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
75	CARBAMAZEPINE	2002			JOSAMYCIN	6084			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and. if needed, plasma dosage and possible reduction of the dosage of the carbamazepine.
76	CARBAMAZEPINE	2002			LAMOTRIGINE	28439			ANSM	112-CARBAMAZEPINE.html	Risk of increase of the neurological effects (vertigo, ataxia, diplopia) of the carbamazepine when the lamotrigine is introduced	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
77	CARBAMAZEPINE	2002			LITHIUM	6448			ANSM	112-CARBAMAZEPINE.html	Risk of neurotoxicity manifesting as disorders of the cerebellum, confusion, drowsiness, ataxia. These disorders are reversible when the treatment with lithium is stopped.	Not recommended	
78	CARBAMAZEPINE	2002			ST JOHN'S WORT	258326			ANSM	112-CARBAMAZEPINE.html	Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine	Not recommended	
79	CARBAMAZEPINE	2002			NINTEDANIB	1592737			ANSM	112-CARBAMAZEPINE.html	Decrease of the plasma concentrations of nintedanib due to decrease of its absorption by the carbamazepine	Precaution for use	Clinical monitoring during the administration of these substances together.
80	CARBAMAZEPINE	2002			OLANZAPINE	61381			ANSM	112-CARBAMAZEPINE.html	Risk of decrease of the plasma concentrations of the olanzapine and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and if needed, adjustment of the dosage of the olanzapine.
81	CARBAMAZEPINE	2002			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine, with risk of overdose, due to inhibition of its metabolism by the grapefruit	Not recommended	
82	CARBAMAZEPINE	2002			PAROXETINE	32937			ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.
83	CARBAMAZEPINE	2002					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	112-CARBAMAZEPINE.html	Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness	Take into account	Use prudence with respect to the interpretation of the plasma concentrations.
84	CARBAMAZEPINE	2002					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	112-CARBAMAZEPINE.html	Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)	Take into account	Use prudence in the interpretation of the plasma concentrations.
85	CARBAMAZEPINE	2002			RIFAMPICIN	9384			ANSM	112-CARBAMAZEPINE.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, testing of the plasma concentrations, and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.
86	CARBAMAZEPINE	2002			RISPERIDONE	35636			ANSM	112-CARBAMAZEPINE.html	Risk of decrease of the active fraction of the risperidone and of its therapeutic effectiveness due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone.
87	CARBAMAZEPINE	2002			SIMVASTATIN	36567			ANSM	112-CARBAMAZEPINE.html	Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism	Not recommended	
88	CARBAMAZEPINE	2002			TOPIRAMATE	38404			ANSM	112-CARBAMAZEPINE.html	Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and if needed, adjustment of the dosage of the topiramate during the treatment with the carbamazepine and after it is stopped.
89	CARBAMAZEPINE	2002					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	112-CARBAMAZEPINE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, plasma dosages, and adjustment of the dosage of the two anticonvulsants.
90	CARMUSTINE	2105			CIMETIDINE	2541			ANSM	113-CARMUSTINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine)	Not recommended	
91	CARVEDILOL	20352			CIMETIDINE	2541			ANSM	114-CARVEDILOL.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine	CONTRAINDICATION	Use another gastric H2 receptor antagonist.
92	CARVEDILOL	20352			RIFAMPICIN	9384			ANSM	114-CARVEDILOL.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
93	SODIUM POLYSTYRENE CALCIUM				SORBITOL	9945			ANSM	115-SODIUM POLYSTYRENE CALCIUM.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal	CONTRAINDICATION	
94	SODIUM POLYSTYRENE SULFONATE	56512			SORBITOL	9945			ANSM	116-SODIUM POLYSTYRENE SULFONATE.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal	Not recommended	
95	CEFALOTIN	2236					AMINOGLYCOSIDES	J01GB-001	ANSM	117-CEFALOTIN.html	Increase of the nephrotoxicity of the aminoglycosides by the cefalotin is under discussion	Precaution for use	Monitoring of renal function.
96	CEFAMANDOLE	2178					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	118-CEFAMANDOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
97	CEFOPERAZONE	2184					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	119-CEFOPERAZONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
98			BILE ACIDS	A05AA-001	CICLOSPORIN	3008			ANSM	12-BILE-ACIDS.html	Risk of variation of the blood concentrations of ciclosporin	Take into account	
99	CEFOTETAN	2187					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	120-CEFOTETAN.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
100	CEFTRIAXONE	2193					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	121-CEFTRIAXONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
101	CHLORDIAZEPOXIDE	2356			CIMETIDINE	2541			ANSM	122-CHLORDIAZEPOXIDE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn patients of the increase of risk when driving an automobile or using machinery.
102	CHLOROQUINE	2393			CICLOSPORIN	3008			ANSM	123-CHLOROQUINE.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped.
103	CHLOROQUINE	2393			CIMETIDINE	2541			ANSM	123-CHLOROQUINE.html	Slowing of the elimination of the chloroquine and risk of overdose	Take into account	
104	CHLOROQUINE	2393					THYROID HORMONES	H03AA	ANSM	123-CHLOROQUINE.html	Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped.
105	CHLORPROMAZINE	2403			INSULIN				ANSM	124-CHLORPROMAZINE.html	With strong doses (100 mg per day of chlorpromazine): elevation of glycemia (decrease of the freeing of insulin)	Precaution for use	Inform the patient and reinforce self monitoring of blood glucose. Possible adjustment of the dosage of the insulin durin the treatment with the neuroleptic and after it is stopped.
106	CHLORPROMAZINE						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	124-CHLORPROMAZINE.html	With strong doses (100 mg per day of chlorpromazine): elevation of glycemia (decrease of the freeing of insulin)	Precaution for use	Inform the patient and reinforce self monitoring of blood glucose. Possible adjustment of the dosage of the insulin durin the treatment with the neuroleptic and after it is stopped.
107	CICLOSPORIN	3008					BILE ACIDS	A05AA-001	ANSM	125-CICLOSPORIN.html	Risk of variation of the blood concentrations of ciclosporin	Take into account	
108	CICLOSPORIN	3008			AFATINIB	1430438			ANSM	125-CICLOSPORIN.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the ciclosporin	Precaution for use	It is recommended that the ciclosporin be administered as far from the afatinib as possible, preferably an interval of 6 to 12 hours away from the administration of the dose of afatinib.
109	CICLOSPORIN	3008			ALISKIREN	325646			ANSM	125-CICLOSPORIN.html	Increase by nearly 5 times the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	CONTRAINDICATION	
110	CICLOSPORIN	3008			AMBRISENTAN	358274			ANSM	125-CICLOSPORIN.html	Doubling of the concentrations of ambrisentan, with increase of the vasodilator effect (severe headaches )	Take into account	
111	CICLOSPORIN	3008					AMINOGLYCOSIDES	J01GB-001	ANSM	125-CICLOSPORIN.html	Larger increase of the creatinemia than with ciclosporin alone, with increase of the nephrotoxic risk	Take into account	
112	CICLOSPORIN	3008			AMIODARONE	703			ANSM	125-CICLOSPORIN.html	Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects	Not recommended	Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage of the ciclosporin during the treatment with the amiodarone
113	CICLOSPORIN	3008			AMPHOTERICIN B	732			ANSM	125-CICLOSPORIN.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
114	CICLOSPORIN	3008					SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	125-CICLOSPORIN.html	With the ciclosporin administered orally:reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).	Precaution for use	Increase of the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analog is stopped
115	CICLOSPORIN	3008					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	125-CICLOSPORIN.html	Risk of addition of the nephrotoxic effects, especially with older patients.	Precaution for use	Monitor renal function at the beginning of the treatment with the NSAI.
116	CICLOSPORIN	3008			ATORVASTATIN	83367			ANSM	125-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the intestinal absorption of the cholesterol lowering medication)	Precaution for use	Do not exceed the dosage of 10mg/day of atorvastatin. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.
117	CICLOSPORIN	3008			AZITHROMYCIN	18631			ANSM	125-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the two substances together and after the macrolide is stopped
118	CICLOSPORIN	3008			BOSENTAN	75207			ANSM	125-CICLOSPORIN.html	Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan	CONTRAINDICATION	
119	CICLOSPORIN	3008			CHLOROQUINE	2393			ANSM	125-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped.
120	CICLOSPORIN	3008			CIMETIDINE	2541			ANSM	125-CICLOSPORIN.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
121	CICLOSPORIN	3008			CLINDAMYCIN	2582			ANSM	125-CICLOSPORIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.
122	CICLOSPORIN	3008			COLCHICINE	2683			ANSM	125-CICLOSPORIN.html	Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, especially in cases of pre-existing renal insufficiency	Not recommended	
123	CICLOSPORIN	3008			DABIGATRAN				ANSM	125-CICLOSPORIN.html	Increase by more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
124	CICLOSPORIN	3008			DANAZOL	3102			ANSM	125-CICLOSPORIN.html	Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
125	CICLOSPORIN	3008					POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	125-CICLOSPORIN.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
126	CICLOSPORIN	3008					POTASSIUM LOWERING DIURETICS	C03	ANSM	125-CICLOSPORIN.html	Risk of increase of the creatinemia without modification of the blood concentrations of the ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout	Tale into account	
127	CICLOSPORIN	3008			ERIBULINE	1045453			ANSM	125-CICLOSPORIN.html	Increase of the plasma concentrations of eribuline by the ciclosporin	Not recommended	
128	CICLOSPORIN	3008			EVEROLIMUS	141704			ANSM	125-CICLOSPORIN.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together	Precaution for use	Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function during the administration of the two together and after it is stopped.
129	CICLOSPORIN	3008			EZETIMIBE	341248			ANSM	125-CICLOSPORIN.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
130	CICLOSPORIN	3008			FENOFIBRATE	8703			ANSM	125-CICLOSPORIN.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical and biological monitoring of renal function during and after the administration of the two medications together.
131	CICLOSPORIN	3008			FIDAXOMICIN	1111103			ANSM	125-CICLOSPORIN.html	Increase of the plasma concentrations of the fidaxomicin.	Not recommended	
132	CICLOSPORIN	3008			JOSAMYCIN	6084			ANSM	125-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of these medications together and after the macrolide is stopped.
133	CICLOSPORIN	3008			LERCANIDIPINE	135056			ANSM	125-CICLOSPORIN.html	Moderate increase of the blood concentrations of the immunosuppressant and larger increase of the concentrations of the lercanidipine	Precaution for use	Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications together and after it is stopped.
134	CICLOSPORIN	3008			METHOTREXATE	6851			ANSM	125-CICLOSPORIN.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	Blood concentration dosage of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.
135	CICLOSPORIN	3008			METHYLPREDNISOLONE	6902			ANSM	125-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
136	CICLOSPORIN	3008			MIDECAMYCIN	30005			ANSM	125-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the macrolide is stopped.
137	CICLOSPORIN	3008			MODAFINIL	30125			ANSM	125-CICLOSPORIN.html	Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant	Not recommended	
138	CICLOSPORIN	3008			NIFEDIPINE	7417			ANSM	125-CICLOSPORIN.html	Risk of addition of undesirable effects of the gum disorders type.	Not recommended	Use another dihydropyridine.
139	CICLOSPORIN	3008			NINTEDANIB	1592737			ANSM	125-CICLOSPORIN.html	Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the ciclosporin	Precaution for use	Clinical monitoring during the administration of there substances together.
140	CICLOSPORIN	3008			ORLISTAT	37925			ANSM	125-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity	Not recommended	Take the orlistat at a different time form the ciclosporin (at least 3 hours apart). Reinforce testing of blood dosages of the ciclosporin, especially at the beginning of the administration of the medications together, and at the time of a possible increase in the dosage of the orlistat.
141	CICLOSPORIN	3008			PITAVASTATIN	861634			ANSM	125-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin	CONTRAINDICATION	
142	CICLOSPORIN	3008			POTASSIUM	8588			ANSM	125-CICLOSPORIN.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Avoid the administration of these two substances together unless there is pre-existing hypokalemia.
143	CICLOSPORIN	3008			PREDNISOLONE	8638			ANSM	125-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
144	CICLOSPORIN	3008			REPAGLINIDE	73044			ANSM	125-CICLOSPORIN.html	Increase of more than double of the concentrations of the repaglinide due to increase of its absorption	Not recommended	
145	CICLOSPORIN	3008			ROSUVASTATIN	301542			ANSM	125-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin	CONTRAINDICATION	
146	CICLOSPORIN	3008			ROXITHROMYCIN	9478			ANSM	125-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped.
147	CICLOSPORIN	3008			SIMVASTATIN	36567			ANSM	125-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolosis type due to decrease of the metabolism of the simvastatin	Precaution for use	Do not exceed the dosage of 10mg/day of simavastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction.
148	CICLOSPORIN	3008			SIROLIMUS	35302			ANSM	125-CICLOSPORIN.html	Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together	Precaution for use	It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped.
149	CICLOSPORIN	3008			SULFINPYRAZONE	10205			ANSM	125-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with sulfinpyrazone and after it is stopped.
150	CICLOSPORIN	3008			TENEFOVIR ALAFENAMIDE	1721603			ANSM	125-CICLOSPORIN.html	Increase of the plasma concentrations of tenofovir alafenamide due to increase of its absorption	Precaution for use	In case of administration with the ciclosporin, the dose of tenofovir alafenamide must be limited to 10 mg per day.
151	CICLOSPORIN	3008			TERBINAFINE	37801			ANSM	125-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped.
152	CICLOSPORIN	3008			TICLOPIDINE	10594			ANSM	125-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage when the ticlodipine is stopped.
153	CICLOSPORIN	3008			TRIMETHOPRIM	10829			ANSM	125-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
154	CICLOSPORIN	3008			VERAPAMIL	11170			ANSM	125-CICLOSPORIN.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
155	CIMETIDINE	2541			ALFENTANIL	480			ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the cimetidine.
156	CIMETIDINE	2541					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped.
157	CIMETIDINE	2541			CARBAMAZEPINE	2002			ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine, especially during the first days of treatment with the cimetidine
158	CIMETIDINE	2541			CARMUSTINE	2105			ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine)	Not recommended	
159	CIMETIDINE	2541			CARVEDILOL	20352			ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine	CONTRAINDICATION	Use another H2 receptor antagonist.
160	CIMETIDINE	2541			CHLORDIAZEPOXIDE	2356			ANSM	126-CIMETIDINE.html	With the cemitidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn patients of the increase of risk when driving an automobile or using machinery.
161	CIMETIDINE	2541			CHLOROQUINE	2393			ANSM	126-CIMETIDINE.html	Slowing of the elimination of the chloroquine and risk of overdose	Take into account	
162	CIMETIDINE	2541			CICLOSPORIN	3008			ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
163	CIMETIDINE	2541			DIAZEPAM	3322			ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn the patient of the increase of risk when driving an automobile or using machinery.
164	CIMETIDINE	2541			LIDOCAINE	6387			ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped.
165	CIMETIDINE	2541			LOMUSTINE	6466			ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)	Not recommended	
166	CIMETIDINE	2541			METHADONE	6813			ANSM	126-CIMETIDINE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, notably of torsades de pointes.	Precaution for use	Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during the treatment with the cimetidine and after it is stopped.
167	CIMETIDINE	2541			METOPROLOL	6918			ANSM	126-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the cimetidine
168	CIMETIDINE	2541			MOCLOBEMIDE	30121			ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring with possible adjustment of the dosage of the moclobemide
169	CIMETIDINE	2541			NIFEDIPINE	7417			ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped.
170	CIMETIDINE	2541					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with the possibility of appearance of the usual signs of overdose	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring, plasma concentration dosages of the phenytoin, and possible adjustment of its dosage during the treatment with cimetidine and after it is stopped.
171	CIMETIDINE	2541					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	126-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia. If there is reason for it, adjustment of the theophylline during the treatment with the cimetidine and after it is stopped.
172	CINACALCET	407990			DEXTROMETHORPHAN	3289			ANSM	127-CINACALCET.html	Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	CONTRAINDICATION	
173	CINACALCET	407990			FLECAINIDE	4441			ANSM	127-CINACALCET.html	Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with cinacalcet.
174	CINACALCET	407990			MEQUITAZINE	29528			ANSM	127-CINACALCET.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
175	CINACALCET	407990			METOPROLOL	6918			ANSM	127-CINACALCET.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with cinacalcet.
176	CINACALCET	407990			PROPAFENONE	8754			ANSM	127-CINACALCET.html	Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with cinacalcet.
177	CINACALCET	407990			VORTIOXETINE	1455099			ANSM	127-CINACALCET.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the cinacalcet and after it is stopped.
178	CIPROFLOXACIN	2551			AGOMELATINE	306718			ANSM	128-CIPROFLOXACIN.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects.	Not recommended	
179	CIPROFLOXACIN	2551			CAFFEINE	1886			ANSM	128-CIPROFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
180	CIPROFLOXACIN	2551			CLOZAPINE	2626			ANSM	128-CIPROFLOXACIN.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with the ciprofloxacin and after it is stopped.
181	CIPROFLOXACIN	2551			METHOTREXATE	6851			ANSM	128-CIPROFLOXACIN.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
182	CIPROFLOXACIN	2551					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	128-CIPROFLOXACIN.html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with ciprofloxacin	Precaution for use	Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloxacin and after it is stopped.
183	CIPROFLOXACIN	2551			ROPINIROLE	72302			ANSM	128-CIPROFLOXACIN.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped.
184	CIPROFLOXACIN	2551					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	128-CIPROFLOXACIN.html	Increased risk of ventricular arrythmias, especially of torsades de pointes.	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
185	CIPROFLOXACIN	2551					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	128-CIPROFLOXACIN.html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia
186			CITRATES	V09HX			ALUMINUM (SALTS)	A02AD0-001	ANSM	129-CITRATES.html	Risk of facilitation of systemic uptake of the aluminum, especially in case of altered renal function.	Precaution for use	Take the aluminum based gastrointestinal medications at a different time (more than 2 hours apart if possible) from the citrates, including natural citrates (citrus fruit juices).
187	ACITRETIN	16818			ALCOHOL (DRINK OR INGREDIENT)				ANSM	13-ACITRETIN.html	With women of child bearing age, risk of transformation of the acitretin into etretinate, a powerful agent of birth defects and malformations with a very prolonged half life (120 days), exposing the woman to a major risk of these birth defects and malformations of the child in case of pregnancy, during the treatment and two months after it ends.	CONTRAINDICATION	
188	ACITRETIN	16818			METHOTREXATE	6851			ANSM	13-ACITRETIN.html	Risk of increase of the hepatotoxicity of the methotrexate	Not recommended	If administering these substances together is judged necessary, strengthen liver function testing.
189	CLADRIBINE	44157			LAMIVUDINE	68244			ANSM	130-CLADRIBINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
190	CLARITHROMYCIN	21212			ATAZANAVIR	343047			ANSM	131-CLARITHROMYCIN.html	Increase of the plasma concentrations of clarithyromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these together.
191	CLARITHROMYCIN	21212			ATORVASTATIN	83367			ANSM	131-CLARITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Administer weaker doses of the cholesterol lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
192	CLARITHROMYCIN	21212			CARBAMAZEPINE	2002			ANSM	131-CLARITHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
193	CLARITHROMYCIN	21212			DEXAMETHASONE	3264			ANSM	131-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushings syndrome	Take into account	
194	CLARITHROMYCIN	21212			DIGOXIN	3407			ANSM	131-CLARITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with clarithromycin and after it is stopped.
195	CLARITHROMYCIN	21212			EBASTINE	23796			ANSM	131-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed subjects (congenital long QT syndrome)	Not recommended	
196	CLARITHROMYCIN	21212			ERIBULINE	1045453			ANSM	131-CLARITHROMYCIN.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
197	CLARITHROMYCIN	21212			ETRAVIRINE	475969			ANSM	131-CLARITHROMYCIN.html	In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine	Take into account	
198	CLARITHROMYCIN	21212			FIDAXOMICIN	1111103			ANSM	131-CLARITHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
199	CLARITHROMYCIN	21212			GLIBENCLAMIDE	4815			ANSM	131-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
200	CLARITHROMYCIN	21212			GLIMEPIRIDE	25789			ANSM	131-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic.	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin
201	CLARITHROMYCIN	21212			HALOFANTRINE	50749			ANSM	131-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If it is possible, interrupt the macrolide. If administering these two together cannot be avoided, test of the QT before hand and monitor EKG.
202	CLARITHROMYCIN	21212					IMMUNOSUPPRESSANTS	L04A	ANSM	131-CLARITHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
203	CLARITHROMYCIN	21212					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	131-CLARITHROMYCIN.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of treatment.
204	CLARITHROMYCIN	21212			LINEZOLIDE	190376			ANSM	131-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the linezolide by the clarithromycin due to increase of its absorption	Take into account	
205	CLARITHROMYCIN	21212			LUMEFANTRINE	847728			ANSM	131-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to induce torsades de pointes. If administering these medications together cannot be avoided, testing of the QT before hand and EKG monitoring.
206	CLARITHROMYCIN	21212			MIDAZOLAM	6960			ANSM	131-CLARITHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism with increase of sedation.	Not recommended	-with the midazolam by mouth
207	CLARITHROMYCIN	21212			MIZOLASTINE	61455			ANSM	131-CLARITHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
208	CLARITHROMYCIN	21212			PRAVASTATIN	42463			ANSM	131-CLARITHROMYCIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical and biological monitoring during the treatment with the antibiotic
209	CLARITHROMYCIN	21212			REPAGLINIDE	73044			ANSM	131-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the hypoglycemic agent during the treatment with the clarithromycin.
210	CLARITHROMYCIN	21212			RIFABUTIN	55672			ANSM	131-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together.
211	CLARITHROMYCIN	21212			RIFAMPICIN	9384			ANSM	131-CLARITHROMYCIN.html	Decrease of the plasma concentrations and risk of lower effectiveness of the clarithromycin, especially with the HIV patient, due to increase of its hepatic metabolism by the rifampacin	Precaution for use	Regular clinical and biological monitoring.
212	CLARITHROMYCIN	21212			SIMVASTATIN	36567			ANSM	131-CLARITHROMYCIN.html	Increased risk of undesirable effects (contentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	CONTRAINDICATION	
213	CLARITHROMYCIN	21212					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	131-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de points	Precaution for use	Clinical monitoring and EKG during the administration of these medications together.
214	CLARITHROMYCIN	21212					BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	131-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
215	CLARITHROMYCIN	21212					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	131-CLARITHROMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
216	CLARITHROMYCIN	21212			VENLAFAXINE	39786			ANSM	131-CLARITHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
217	CLARITHROMYCIN	21212					VINCA ALKALOIDS	L01CA	ANSM	131-CLARITHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin.	Precaution for use	Strict clinical and biological monitoring. Possibly, use another antibiotic.
218	CLINDAMYCIN	2582					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	132-CLINDAMYCIN.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage.	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the clindamycin and after it is stopped.
219	CLINDAMYCIN	2582			CICLOSPORIN	3008			ANSM	132-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.
220	CLINDAMYCIN	2582			TACROLIMUS	42316			ANSM	132-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage.
221	CLOBAZAM	21241			STIRIPENTOL	37119			ANSM	133-CLOBAZAM.html	Increase of the plasma concentrations of these anticonvulsants, with risk of overdose, due to inhibition of their hepatic metabolism	Precaution for use	Clinical monitoring, plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of the dosage of the anticonvulsant taken with it as well.
222	CLOMIPRAMINE	2597			BUPROPION	42347			ANSM	134-CLOMIPRAMINE.html	Risk of increase of the undesirable effects of the clomipramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the clomipramine during the treatment with the bupropion.
223	CLONAZEPAM	2598			CARBAMAZEPINE	2002			ANSM	135-CLONAZEPAM.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of the clonazepam due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants
224	CLONIDINE	2599					TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	136-CLONIDINE.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
225	CLONIDINE	2599			DILTIAZEM	3443			ANSM	136-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
226	CLONIDINE	2599			VERAPAMIL				ANSM	136-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
227	CLONIDINE	2599			YOHIMBINE	220982			ANSM	136-CLONIDINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
228	CLOPIDOGREL	32968			ACETYLSALICYLIC ACID	1191			ANSM	137-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-aside from validated indications for this combination of drugs in acute coronary syndromes.
229	CLOPIDOGREL	32968			PACLITAXEL	56946			ANSM	137-CLOPIDOGREL.html	Increase of the concentrations of the paclitaxel by the clopidogrel, with risk of increase of the undesirable effects.	Take into account	
230	CLOPIDOGREL	32968					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	137-CLOPIDOGREL.html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin.
231	CLOPIDOGREL	32968			REPAGLINIDE	73044			ANSM	137-CLOPIDOGREL.html	Increase of the concentrations of the repaglinide by the clopidogrel, with risk of increase of the undesirable effects.	Take into account	
232	CLOZAPINE	2626					BENZODIAZEPINES AND RELATED	N05-001	ANSM	138-CLOZAPINE.html	Accrued risk of drop in blood pressure with respiratory and/or cardiac arrest.	Take into account	
233	CLOZAPINE	2626			CARBAMAZEPINE	2002			ANSM	138-CLOZAPINE.html	Risk of increase of the serious hematological effects	Not recommended	
234	CLOZAPINE	2626			CIPROFLOXACIN	2551			ANSM	138-CLOZAPINE.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with the ciprofloxacin and after it is stopped.
235	CLOZAPINE	2626			FLUVOXAMINE	42355			ANSM	138-CLOZAPINE.html	Increase of the plasma concentrations of clozapine with signs of overdose	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the clozapine during the treatment with the fluvoxamine and after it is stopped.
236	CLOZAPINE	2626					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	138-CLOZAPINE.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the phenytoin.
237	CLOZAPINE	2626			RIFAMPICIN	9384			ANSM	138-CLOZAPINE.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
238	COBICISTAT	1306284			AMIODARONE	703			ANSM	139-COBICISTAT.html	Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat	CONTRAINDICATION	
239	COBICISTAT	1306284					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	139-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to the increase of its metabolism by the inducer	CONTRAINDICATION	
240	COBICISTAT	1306284					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	139-COBICISTAT.html	Risk of increase of the plasma concentratons of the cobicistat or of the inhibitor of CYP3A4	Take into account	To know the risks and levels of severity of each interaction, consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) of each medication.
241	COBICISTAT	1306284			ITRACONAZOLE	28031			ANSM	139-COBICISTAT.html	Risk of increase of the concentrations of itraconazole by the cobicistat	Precaution for use	Clinical monitoring during the administration of these medications together. Large doses of itraconazole (>200 mg per day) are not recommended.
242	COBICISTAT	1306284			ST JOHNS WORT	258326			ANSM	139-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	CONTRAINDICATION	
243	COBICISTAT	1306284			QUINIDINE	9068			ANSM	139-COBICISTAT.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	CONTRAINDICATION	
244	COBICISTAT	1306284			RIFABUTIN	55672			ANSM	139-COBICISTAT.html	Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat	Precaution for use	Adjustment of the dosage of the rifabutin (in principle, reduction of the doses by half).
245	COBICISTAT	1306284			RIFAMPICIN	9384			ANSM	139-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	CONTRAINDICATION	
246	COBICISTAT	1306284			TENEFOVIR ALAFENAMIDE	1721603			ANSM	139-COBICISTAT.html	With the atazanavir, the darunavir or the lopinavir boosted by cobicistat, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption.	Precaution for use	In case of administration of these together, the dose of tenofovir alafenamide must be limited to 10 mg per day. The combination with the other protease inhibitors of the HIV has not been studied.
247	COBICISTAT	1306284					VINCA ALKALOIDS	L01CA	ANSM	139-COBICISTAT.html	Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat	Precaution for use	Strict clinical monitoring and possible adjustment of the dosage of the antimitotic
248	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992					HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	14-ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precautions for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult.
249	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992					TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	14-ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
250	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	14-ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
251	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992					MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	14-ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
252	COCAINE	2653			DISULFIRAM	3554			ANSM	140-COCAINE.html	Increase of the concentrations of cocaine due to decrease of its metabolism by the disulfiram, with increased risk of torsades de pointes	Take into account	
253	COLCHICINE	2683					AZOLE ANTIFUNGALS	J02AC-001	ANSM	141-COLCHICINE.html	Increase of the undesirable effects of the colchicine with potentially fatal consequences	Not recommended	
254	COLCHICINE	2683					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	141-COLCHICINE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the colchicine and a week after it is stopped.
255	COLCHICINE	2683			CICLOSPORIN	3008			ANSM	141-COLCHICINE.html	Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, espceially in cases of pre-existing renal insufficiency	Not recommended	
256	COLCHICINE	2683					FIBRATES	C01AB-001	ANSM	141-COLCHICINE.html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis	Precaution for use	Clinical and biological monitoring, particularly at the beginning of the administration of these substances together.
257	COLCHICINE	2683					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	141-COLCHICINE.html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis	Precaution for use	Clinical and biological monitoring, especially at the beginning of the administration of these substances together.
258	COLCHICINE	2683					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	141-COLCHICINE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Not recommended	
259	COLCHICINE	2683					MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	141-COLCHICINE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	CONTRAINDICATION	
260	COLCHICINE	2683					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	141-COLCHICINE.html	Increase od the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the therapy with ombitasvir + paritaprevir	CONTRAINDICATION	-with patients having renal and/or hepatic insufficiency
261	COLCHICINE	2683			PRISTINAMYCIN	66958			ANSM	141-COLCHICINE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	CONTRAINDICATION	
262	COLCHICINE	2683			TELAPREVIR	1102261			ANSM	141-COLCHICINE.html	Risk of increase of the undesirable effects of the colchicine, due to decrease of its metabolism	Not recommended	In particular with patients having renal and hepatic insufficiency.
263	COLCHICINE	2683			VERAPAMIL	11170			ANSM	141-COLCHICINE.html	Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil	Not recommended	
264	COLISTIN	2709					CURARES	M03A-001	ANSM	142-COLISTIN.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarization at the end of anesthesia.
265	CRIZOTINIB	1148495					SUBSTRATES AT RISK OF CYP3A4	L01N01	ANSM	143-CRIZOTINIB.html	Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib	Not recommended	
266			CURARES	M03A-001			AMINOGLYCOSIDES	J01GB-001	ANSM	144-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	Monitor the degree of curarization at the end of anesthesia
267			CURARES	M03A-001	COLISTIN	2709			ANSM	144-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of the curarization at the end of anesthesia.
268			CURARES	M03A-001			LINCOSANIDES	J01FF0	ANSM	144-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarisation at the end of anesthesia.
269			CURARES	M03A-001	POLYMYXIN B	8536			ANSM	144-CURARES.html	Increase of the effects of the curares when the antibiotic is admininstered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarisation at the end of anesthesia.
270			NON-DEPOLARIZING CURARES	M03A-002			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	145-NON-DEPOLARIZING-CURARES.html	With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).	Take into account	
271	CYANOCOBALAMIN	11248					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	146-CYANOCOBALAMIN.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12	Take into account	
272	CYANOCOBALAMIN	11248					PROTON PUMP INHIBITORS	A02BC-001	ANSM	146-CYANOCOBALAMIN.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.	Take into account	
273			TETRACYCLINE ANTIBIOTICS	J01AA			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	147-TETRACYCLINE-ANTIBIOTICS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tetracycline antibiotic and after it is stopped.
274			TETRACYCLINE ANTIBIOTICS	J01AA	CALCIUM	1428011			ANSM	147-TETRACYCLINE-ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the calcium salts at a different time from the tetracycline antibiotic (more than two hours apart, if possible).
275			TETRACYCLINE ANTIBIOTICS	J01AA	IRON	1431589			ANSM	147-TETRACYCLINE-ANTIBIOTICS.html	With the tetracycline antibiotics administered by oral route: decrease of the digestive absorption of the tetracycline antibiotics (formation of complexes)	Precaution for use	Take the iron salts at a different time from the tetracycline antibiotics (more than 2 hours apart, if possible).
276			TETRACYCLINE ANTIBIOTICS	J01AA			RETINOIDS	D05-D10	ANSM	147-TETRACYCLINE-ANTIBIOTICS.html	Risk of intracranial hypertension	CONTRAINDICATION	
277			TETRACYCLINE ANTIBIOTICS	J01AA	STRONTIUM	81638			ANSM	147-TETRACYCLINE-ANTIBIOTICS.html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the tetracycline antibiotics (more than two hours apart, if possible).
278			TETRACYCLINE ANTIBIOTICS	J01AA	VITAMIN A	11246			ANSM	147-TETRACYCLINE-ANTIBIOTICS.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension	CONTRAINDICATION	
279			TETRACYCLINE ANTIBIOTICS	J01AA	ZINC				ANSM	147-TETRACYCLINE-ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
280	CYCLOPHOSPHAMIDE	3002			PENTOSTATIN	8011			ANSM	148-CYCLOPHOSPHAMIDE.html	Increase of the risk of pulmonary toxicity which could be fatal	Not recommended	
281	CYPROHEPTADINE	3013					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	149-CYPROHEPTADINE.html	Risk of decrease of the effectiveness of the antidepressant	Take into account	
282	AFATINIB	1430438			AMIODARONE	703			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the amiodarone.	Precaution for use	It is recommended that the amiodarone be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
283	AFATINIB	1430438					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	15-AFATINIB.html	Decrease of the plasma concentrations of afatinib due to increase of its metabolisn by these substances	Precaution for use	Clinical monitoring during the administration of these substances together and 1 to 2 weeks after they are stopped.
284	AFATINIB	1430438			CICLOSPORIN	3008			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the ciclosporin	Precaution for use	It is recommended that the ciclosporin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
285	AFATINIB	1430438			ERYTHROMYCIN	4053			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin.	Precaution for use	It is recommended that the erythromycin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
286	AFATINIB	1430438					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the protease inhibiter.	Precaution for use	It is recommended that the protease inhibitor be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
287	AFATINIB	1430438			ITRACONAZOLE	28031			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the itraconazole.	Precaution for use	It is recommended that the itraconazole be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
288	AFATINIB	1430438			KETOCONAZOLE	6135			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the ketoconazole.	Precaution for use	It is recommended that the ketoconazole be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
289	AFATINIB	1430438			PRIMIDONE	8691			ANSM	15-AFATINIB.html	Decrease of the plasma concentrations of the afatinib due to the increase of its metabolism by the primidone	Precaution for use	Clinical monitoring during the administration of these together and 1 to 2 weeks after they are stopped.
290	AFATINIB	1430438			RIFAMPICIN	9384			ANSM	15-AFATINIB.html	Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring during the administration of these together and 1 to 2 weeks after they are stopped.
291	AFATINIB	1430438			VERAPAMIL	11170			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the verapamil.	Precaution for use	It is recommended that the verapamil be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
292	CYPROTERONE	3014			APREPITANT	358255			ANSM	150-CYPROTERONE.html	Risk of decrease of the concentrations of cyproterone with risk of lower contraceptive effectiveness	Precaution for use	--in its use as a hormonal contraceptive. Use a reliable contraceptive method, additional or alternative, during the length of the administration of these substances together
293	CYPROTERONE	3014			BOSENTAN	75207			ANSM	150-CYPROTERONE.html	Risk of decrease of the effectiveness of the cyproterone	Precaution for use	In its indications as an anti-androgen, clinical monitoring and if possible adjustment of the dosage of the cyproterone during the administration with the bosentan and after it is stopped.
294	CYPROTERONE	3014					ENZYMATIC INDUCERS	N03-J05-001	ANSM	150-CYPROTERONE.html	Risk of decrease of the effectiveness of the cyproterone	Not recommended	-for its use as a hormonal contraceptive: use another method of contraception in particular a barrier type, during the length of the administration of these substances together and a cycle following
295	CYPROTERONE	3014					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	150-CYPROTERONE.html	Risk of decrease of the effectiveness of the cyproterone	Not recommended	-in its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the administration of these substances together
296	CYPROTERONE	3014			ST JOHNS WORT	258326			ANSM	150-CYPROTERONE.html	Risk of decrease of the effectiveness of the cyproterone, due to increase of its hepatic metabolism by the St Johns Wort	CONTRAINDICATION	
297	CYPROTERONE	3014			PERAMPANEL	1356552			ANSM	150-CYPROTERONE.html	For doses of perampenel >or = to 12 mg/day, risk of decrease of the effectiveness of the cyproterone.	Not recommended	In its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the administration of these substances together.
298	CYPROTERONE	3014			ULIPRISTAL	1005921			ANSM	150-CYPROTERONE.html	Risk of antagonism of the progestin effects	Not recommended	Do not take a progestin treatment fewer than 12 hours after the ulipristal is stopped.
299			CYTOTOXICS	L01			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	151-CYTOTOXICS.html	Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy	Precaution for use	More frequent testing of the INR
300			CYTOTOXICS	L01			IMMUNOSUPPRESSANTS	L04A	ANSM	151-CYTOTOXICS.html	Excessive immunodepression with risk of lymphoproliferative syndrome	Take into account	
301			CYTOTOXICS	L01			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	151-CYTOTOXICS.html	Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only by the cytotoxic, or risk of increase of the toxicity or loss of effectiveness of the cytotoxic due to the increase of its hepatic metabolism by the phenytoin or the fosphenytoin	Not recommended	
302			CYTOTOXICS	L01			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	151-CYTOTOXICS.html	Risk of general vaccine disease, possibly fatal	Contraindication	--and during the 6 months following the end of the chemotherapy
303	DABIGATRAN				AMIODARONE	703			ANSM	152-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	For post surgical indications:
304	DABIGATRAN						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	152-DABIGATRAN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
305	DABIGATRAN				CICLOSPORIN	3008			ANSM	152-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
306	DABIGATRAN				DRONEDARONE	233698			ANSM	152-DABIGATRAN.html	Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
307	DABIGATRAN				ITRACONAZOLE	28031			ANSM	152-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
308	DABIGATRAN				KETOCONAZOLE	6135			ANSM	152-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding	CONTRAINDICATION	
309	DABIGATRAN				QUINIDINE	9068			ANSM	152-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.
310	DABIGATRAN				RIFAMPICIN	9384			ANSM	152-DABIGATRAN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
311	DABIGATRAN				TACROLIMUS	42316			ANSM	152-DABIGATRAN.html	Risk of increase of the plasma concentrations of dabigatran	CONTRAINDICATION	
312	DABIGATRAN				TICAGRELOR	1116632			ANSM	152-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Take into account	
313	DABIGATRAN				VERAPAMIL	11170			ANSM	152-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150mg/day in one dose, or even 75mg/day in case of moderate renal insufficiency.
314	DACARBAZINE	3098			FOTEMUSTINE	25287			ANSM	153-DACARBAZINE.html	With the dacarbazine in large doses: risk of pulmonary toxicity (adult respiratory distress syndrome).	Precaution for use	Do not use these medications simultaneously, but wait a week between the last administration of fotemustine and the first day of the treatment with dacarbazine.
315	DACLATASVIR	1606218			AMIODARONE	703			ANSM	154-DACLATASVIR.html	Only in the combination daclatasvir/sofosbuvir:Possibly abrupt onset of bradycardia, that can have fatal consequences	Not recommended	If the administration of these medications together cannot be avoided, strict clinical monitoring and EKG, in particular during the first weeks of treatment with the daclatasvir/sofosbuvir combination
316	DACLATASVIR	1606218			DEXAMETHASONE	3264			ANSM	154-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	CONTRAINDICATION	With the exception of the dexamethasone administered in a single dose.
317	DACLATASVIR	1606218					ENZYMATIC INDUCERS	N03-J05-001	ANSM	154-DACLATASVIR.html	Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication:	-with rifampicin
318	DACLATASVIR	1606218					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	154-DACLATASVIR.html	Increase of the concentrations of daclatasvir by the inhibitor.	Precaution for use	The dose of daclatasvir must be decreased to 30 mg 1 time per day in case of administration with the inhibitor.
319	DACLATASVIR	1606218			ST JOHNS WORT	258326			ANSM	154-DACLATASVIR.html	Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns Wort	CONTRAINDICATION	
320	DALFOPRISTIN	229369			DIHYDROERGOTAMINE	3418			ANSM	155-DALFOPRISTIN.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
321	DALFOPRISTIN	229369			ERGOTAMINE	4025			ANSM	155-DALFOPRISTIN.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
322	DALFOPRISTIN	229369					IMMUNOSUPPRESSANTS	L04A	ANSM	155-DALFOPRISTIN.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.
323	DALFOPRISTIN	229369			PIMOZIDE	8331			ANSM	155-DALFOPRISTIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes.	Not recommended	
324	DANAZOL	3102					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	156-DANAZOL.html	Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the danazol and after it is stopped.
325	DANAZOL	3102			CARBAMAZEPINE	2002			ANSM	156-DANAZOL.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
326	DANAZOL	3102			CICLOSPORIN	3008			ANSM	156-DANAZOL.html	Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
327	DANAZOL	3102			INSULIN	5856			ANSM	156-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped.
328	DANAZOL	3102			SIMVASTATIN	36567			ANSM	156-DANAZOL.html	Increased risk of onset of rhabdomyolysis.	Not recommended	If administering these medications together is deemed necessary, do not exceed the dose of 10mg of simvastatin.
329	DANAZOL	3102					BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	156-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If the administration of these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic during the treatment with the danazol and after it is stopped.
330	DANAZOL	3102			TACROLIMUS	42316			ANSM	156-DANAZOL.html	Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration of it with the danazol and after it is stopped, with testing of the renal function.
331	DANTROLENE	3105					DIHYDROPYRIDINES	C08CA-002	ANSM	157-DANTROLENE.html	With the dantrolene administered via IV: cases of fatal ventricular fibrillations are constantly observed in animals when verapamil and dantrolene are administered via IV. The administration of a calcium channel blocker and dantrolene is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Not recommended	
332	DANTROLENE	3105			DILTIAZEM	3443			ANSM	157-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	CONTRAINDICATION	
333	DANTROLENE	3105			VERAPAMIL	11170			ANSM	157-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	CONTRAINDICATION	
334	DAPOXETINE	69394					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	158-DAPOXETINE.html	Risk of increase of the undesirable effects, especially of the vertigo or syncope type	CONTRAINDICATION	
335	DAPOXETINE	69394					MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION	N05AA-001	ANSM	158-DAPOXETINE.html	Risk of increase of the undesirable effects, especially of the vertigo and fainting type	Nor recommended	-with the type 5 phosphodiesterase inhibitors
336	DAPSONE	3108			ZIDOVUDINE	11413			ANSM	159-DAPSONE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
337	AGOMELATINE	306718			CIPROFLOXACIN	2551			ANSM	16-AGOMELATINE.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects.	Not Recommended	
338	AGOMELATINE	306718			FLUVOXAMINE	42355			ANSM	16-AGOMELATINE.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects.	CONTRAINDICATION	
339	DAPTOMYCIN	22299					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	160-DAPTOMYCIN.html	Risk of addition of undesirable effects (dose dependent) of the rhabdomyolysis type.	Not recommended	If administering these substances together cannot be avoided, reinforce biological monitoring (CPK levels more than once a week) and strict clinical monitoring.
340	DARIFENACIN	136198			FLECAINIDE	4441			ANSM	161-DARIFENACIN.html	Increase of the plasma concentrations of felcainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with darifenacin.
341	DARIFENACIN	136198			METOPROLOL	6918			ANSM	161-DARIFENACIN.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
342	DARIFENACIN	136198			PROPAFENONE	8754			ANSM	161-DARIFENACIN.html	Increase of the plasma concentrations of propafenone, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with darifenacin.
343	DASABUVIR	1597381			ETHINYLESTRADIOL	4124			ANSM	162-DASABUVIR.html	Increase of the hepatoxicity	CONTRAINDICATION	
344	DASABUVIR	1597381			GEMFIBROZIL	4719			ANSM	162-DASABUVIR.html	Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil	CONTRAINDICATION	
345	DASABUVIR	1597381					ENZYMATIC INDUCERS	N03-J05-001	ANSM	162-DASABUVIR.html	Risk of reduction of the plasma concentrations of the dasabuvir by the inducer.	CONTRAINDICATION	
346	DASABUVIR	1597381			ST JOHNS WORT	258326			ANSM	162-DASABUVIR.html	Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort	CONTRAINDICATION	
347	DASABUVIR	1597381			MITOTANE	7004			ANSM	162-DASABUVIR.html	Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane	CONTRAINDICATION	
348	DEFERASIROX	614373			ACETYLSALICYLIC ACID	1191			ANSM	163-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
349	DEFERASIROX	614373					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	163-DEFERASIROX.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.
350	DEFERASIROX	614373					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	163-DEFERASIROX.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
351	DEFERASIROX	614373					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	163-DEFERASIROX.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
352	DEFERASIROX	614373			BUSULFAN	1828			ANSM	163-DEFERASIROX.html	Risk of increase of the toxocity of the bufulfan by decrease of its clearance by the deferasirox.	Take into account	
353	DEFERASIROX	614373			DEFERIPRONE	11645			ANSM	163-DEFERASIROX.html	Risk of hyperchelation	CONTRAINDICATION	
354	DEFERASIROX	614373			DEFEROXAMINE	3131			ANSM	163-DEFERASIROX.html	Risk of hyperchelation	CONTRAINDICATION	
355	DEFERASIROX	614373			REPAGLINIDE	73044			ANSM	163-DEFERASIROX.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the deferasirox	Not recommended	If administering these medications together cannot be avoided, strict clinical and biological monitoring.
356	DEFERASIROX	614373			RIFAMPICIN	9384			ANSM	163-DEFERASIROX.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjust the dosage of deferasirox.
357	DEFERIPRONE	11645			DEFERASIROX	614373			ANSM	164-DEFERIPRONE.html	Risk of hyperchelation	CONTRAINDICATION	
358	DEFEROXAMINE	3131			ASCORBIC ACID	1151			ANSM	165-DEFEROXAMINE.html	With large doses of the ascorbic acid and by intravenous route: cardiac function anomalies, even acute heart failure (generally reversible by ending administration of the Vitamin C).	Precaution for use:	In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
359	DEFEROXAMINE	3131			DEFERASIROX	614373			ANSM	165-DEFEROXAMINE.html	Risk of hyperchelation	CONTRAINDICATION	
360	DEFIBROTIDE	1311089					PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	166-DEFIBROTIDE.html	Increased risk of hemorrhage	Not recommended	
361	DEFIBROTIDE	1311089					ORAL ANTICOAGULANTS	B01A-001	ANSM	166-DEFIBROTIDE.html	Increased risk of hemorrhage.	Not recommended	
362	DEFIBROTIDE	1311089					HEPARINS	B01AB	ANSM	166-DEFIBROTIDE.html	Increased risk of hemorrhage.	Not recommended	
363	DEFIBROTIDE	1311089					THROMBOLYTICS	B01AD	ANSM	166-DEFIBROTIDE.html	Increased risk of hemorrhage.	CONTRAINDICATION	
364	DELAMANID	1344662					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	167-DELAMANID.html	Decrease of the plasma concentrations de delamanid due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
365	DELAMANID	1344662			RIFAMPICIN	9384			ANSM	167-DELAMANID.html	Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
366			DERIVATIVES OF AMINOSALICYLIC ACID (ASA)	A07EC-001			ANTIPURINES	ANTIPUR	ANSM	168-DERIVATIVES-OF-AMINOSALICYLIC-ACID-(ASA).html	Risk of increase of the myelosuppression of the immunomodulator by inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TMPT)	Take into account	
367			NITRATE DERIVATIVES AND RELATED	C01D-001			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	169-NITRATE-DERIVATIVES-AND-RELATED.html	Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and especially provoking an acute coronary accident	CONTRAINDICATION	
368			NITRATE DERIVATIVES AND RELATED	C01D-001			MEDICATIONS THAT LOWER BLOOD PRESSURE	MLBP	ANSM	169-NITRATE-DERIVATIVES-AND-RELATED.html	Increase of the risk of hypotension, especially orthostatic.	Take into account	
369			NITRATE DERIVATIVES AND RELATED	C01D-001	RIOCIGUAT	1439816			ANSM	169-NITRATE-DERIVATIVES-AND-RELATED.html	Risk of significant hypotension (synergic effect).	CONTRAINDICATION	
370	ALBENDAZOLE	430					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	17-ALBENDAZOLE.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of lower effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.
371	ALBENDAZOLE	430					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	17-ALBENDAZOLE.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of lower effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer [sic] and after it is stopped.
372	ALBENDAZOLE	430			RIFAMPICIN				ANSM	17-ALBENDAZOLE.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of lower effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.
373	DESIPRAMINE	3247			BUPROPION	42347			ANSM	170-DESIPRAMINE.html	Risk of increase of the undesirable effects of the desipramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the desipramine during the treatment with the bupropion.
374	DEXAMETHASONE	3264			AMINOGLUTETHIMIDE	677			ANSM	171-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone.
375	DEXAMETHASONE	3264			CLARITHROMYCIN	21212			ANSM	171-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
376	DEXAMETHASONE	3264			DACLATASVIR	1606218			ANSM	171-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	CONTRAINDICATION	With the exception of dexamethasone administered in a single dose.
377	DEXAMETHASONE	3264			ERYTHROMYCIN	4053			ANSM	171-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
378	DEXAMETHASONE	3264					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	171-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
379	DEXAMETHASONE	3264			ITRACONAZOLE	28031			ANSM	171-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
380	DEXAMETHASONE	3264			KETOCONAZOLE	6135			ANSM	171-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
381	DEXAMETHASONE	3264			POSACONAZOLE	282446			ANSM	171-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
382	DEXAMETHASONE	3264			PRAZIQUANTEL	8628			ANSM	171-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
383	DEXAMETHASONE	3264			RILPIVIRINE	1102270			ANSM	171-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	CONTRAINDICATION	With the exception of dexamethasone administered in a single dose.
384	DEXAMETHASONE	3264			SIMEPREVIR	1482790			ANSM	171-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir by increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
385	DEXAMETHASONE	3264			TELITHROMYCIN	274786			ANSM	171-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
386	DEXAMETHASONE	3264			VORICONAZOLE	121243			ANSM	171-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
387	DEXTRAN 40	42635					LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	172-DEXTRAN-40.html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
388	DEXTRAN 40	42635					UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-003	ANSM	172-DEXTRAN-40.html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
389	DEXTROMETHORPHAN	3289			CINACALCET	407990			ANSM	173-DEXTROMETHORPHAN.html	Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	CONTRAINDICATION	
390	DEXTROMETHORPHAN	3289					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	173-DEXTROMETHORPHAN.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
391	DEXTROMETHORPHAN	3289					REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	173-DEXTROMETHORPHAN.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not recommended	
392	DIAZEPAM	3322			BUSPIRONE	1827			ANSM	174-DIAZEPAM.html	Risk of increase of the undesirable effects of the buspirone	Take into account	
393	DIAZEPAM	3322			CIMETIDINE	2541			ANSM	174-DIAZEPAM.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn the patients of the increase of risk when driving an automobile or using machinery.
394	DIAZEPAM	3322					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	174-DIAZEPAM.html	Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin.
395	DIAZEPAM	3322			STIRIPENTOL	37119			ANSM	174-DIAZEPAM.html	Increase of the plasma concentrations of the diazepam, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of the dosage of the anticonvulsant taken with it as well.
396	DIDANOSINE	3364			ALLOPURINOL	519			ANSM	175-DIDANOSINE.html	Increase of the plasma concentrations of didanosine and of its undesirable effects	Not recommended	
397	DIDANOSINE	3364			GANCICLOVIR	4678			ANSM	175-DIDANOSINE.html	Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours	Not recommended	
398	DIDANOSINE	3364			PENTAMIDINE	7994			ANSM	175-DIDANOSINE.html	Increased risk of onset of pancreatitis due to addition of undesirable effects	Precaution for use	Monitoring of the blood amylase level. Do not use these two medications together if the blood amylase level is at the high range of normal.
399	DIDANOSINE	3364			RIBAVIRIN	9344			ANSM	175-DIDANOSINE.html	Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite	Not recommended	
400	DIDANOSINE	3364			TENOFOVIR DISOPROXIL	300195			ANSM	175-DIDANOSINE.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitchondrial toxicity of the didanosine	Not recommended	
401	DIDANOSINE	3364			THALIDOMIDE	10432			ANSM	175-DIDANOSINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together.
402	DIDANOSINE	3364			ZALCITABINE	3363			ANSM	175-DIDANOSINE.html	Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and monitoring of the amylasemia. Do not administer these substances together if the amylasemia is at the high range of normal.
403	DIGOXIN	3407			AMIODARONE	703			ANSM	176-DIGOXIN.html	Depression of self-regulation (excessive bradycardia) and difficulties with atrioventricular conduction. In addition, increase of the digoninemia due to decrease of the clearance of digoxin	Precaution for use	Clinical monitoring, EKG, and, if there is reason for it, testing of the digoxinemia and adjustment of the dosage.
404	DIGOXIN	3407			AZITHROMYCIN	18631			ANSM	176-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during treatment with the azithromycin and after it is stopped.
405	DIGOXIN	3407					BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	176-DIGOXIN.html	Difficulties with autoregulation (bradycardia, sinus arrest) and difficulties with sinoauricular and atrioventricular conduction	Take into account	
406	DIGOXIN	3407			CALCIUM				ANSM	176-DIGOXIN.html	Risk of serious arrhythmias, even lethal ones with the calcium salts administered via IV	Contraindication	-with the calcium salts by IV route, except for parenteral supplementation.
407	DIGOXIN	3407			CARBAMAZEPINE	2002			ANSM	176-DIGOXIN.html	Increase of the plasma concentrations of carbamazepine and decrease of the digoxinemia	Precaution for use	Exercise caution in the interpretation of the plasma concentrations.
408	DIGOXIN	3407			CLARITHROMYCIN	21212			ANSM	176-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped.
409	DIGOXIN	3407			DRONEDARONE	233698			ANSM	176-DIGOXIN.html	Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. In addition, increase of the digoxinemia due to decrease of the metabolism of the digoxin. Clinical monitoring and EKG.	Not recommended	Reduce the doses of digoxin by half.
410	DIGOXIN	3407			ERYTHROMYCIN	4053			ANSM	176-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erythromycin and after it is stopped.
411	DIGOXIN	3407			HYDROQUINIDINE	27220			ANSM	176-DIGOXIN.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction).	Precaution for use	Clinical monitoring and EKG. In the case of unexpected results, test the digoxinemia and adjust the dosage.
412	DIGOXIN	3407					POTASSIUM LOWERING AGENTS	C03-001	ANSM	176-DIGOXIN.html	Hypokaliemia producing toxic effects of the digitalics	Precaution for use	Correct beforehand all hypokaliemia and do clinical, electrolytic, and EKG monitoring.
413	DIGOXIN	3407					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	176-DIGOXIN.html	Increase of the digoxinemia, more marked for IV route, due to increase of the absorption of the digoxin or decrease of its renal clearance.	Precaution for use	Clinical monitoring and, if there is reason for them, EKG and monitoring of the digoxinemia, with possible adjustment of the dosage of digoxin.
414	DIGOXIN	3407			ITRACONAZOLE	28031			ANSM	176-DIGOXIN.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias.	Precaution for use	Clinical monitoring, and, if there is reason for them, EKG, and monitoring of the digoxinemia with adjustment of the dosage of the digoxin during the treatment with the itraconazole and after it is stopped.
415	DIGOXIN	3407			MIDODRINE	6963			ANSM	176-DIGOXIN.html	Difficulties with autoregulation (increase of the bradycardia inducing effect of the midodrine) and difficulties with atrioventricular conduction.	Not recommended	If this combination cannot be avoided, reinforce clinical monitoring and EKG.
416	DIGOXIN	3407			ST JOHNS WORT	258326			ANSM	176-DIGOXIN.html	Decrease of the digoxinemia, by reason of the enzyme inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure).	CONTRAINDICATION	In the case of the two substances being taken together by accident, do not stop the St Johns wort abruptly, but test the plasma concentrations (or the effectiveness) of the digoxin before and then after the St Johns wort is stopped.
417	DIGOXIN	3407			OMEPRAZOLE	7646			ANSM	176-DIGOXIN.html	Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole	Precaution for use	Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient.
418	DIGOXIN	3407			POSACONAZOLE	282446			ANSM	176-DIGOXIN.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias.	Precaution for use	Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia, with adjustment of the dosage of the digxoin during the treatment with the posaconazole and after it is stopped.
419	DIGOXIN	3407			PROPAFENONE	8754			ANSM	176-DIGOXIN.html	Risk of increase of the digoxinemia, especially with older patients	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with propafenone and after it is stopped.
420	DIGOXIN	3407			QUINIDINE	9068			ANSM	176-DIGOXIN.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)	Precaution for use	Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage.
421	DIGOXIN	3407			QUININE	9071			ANSM	176-DIGOXIN.html	Moderate increase of the digoxinemia	Precaution for use	Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.
422	DIGOXIN	3407			RANOLAZINE	35829			ANSM	176-DIGOXIN.html	Increase of the digoxinemia	Precaution for use	Clinical, biological, and possibly EKG monitoring. Adjustment of the dosage of the digoxin if needed.
423	DIGOXIN	3407			SUCRALFATE	10156			ANSM	176-DIGOXIN.html	Decrease of the digestive absorption of the digoxin	Precaution for use	Take the sucralfate at a different time from the digoxin (more than 2 hours apart, if possible).
424	DIGOXIN	3407			SULFASALAZINE	9524			ANSM	176-DIGOXIN.html	Decrease of the digoxinemia that can reach 50%	Precaution for use	Clinical monitoring, EKG, and, possibly, monitoring of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the sulfasalazine and after it is stopped.
425	DIGOXIN	3407			TELAPREVIR	1102261			ANSM	176-DIGOXIN.html	Increase of the digoxinemia	Precaution for use	Clinical and biological monitoring, and adjustment, if needed, of the dosage of the digoxin during the treatment with the telaprevir and after it is stopped.
426	DIGOXIN	3407			TELITHROMYCIN	274786			ANSM	176-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the telithromycin and after it is stopped
427	DIGOXIN	3407			VERAPAMIL	11170			ANSM	176-DIGOXIN.html	Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extra-renal elimination of the digoxin	Precaution for use	Clinical monitoring, EKG, and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped.
428	DIHYDROERGOTAMINE	3418			DALFOPRISTIN	229369			ANSM	177-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
429	DIHYDROERGOTAMINE	3418			DILTIAZEM	3443			ANSM	177-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
430	DIHYDROERGOTAMINE	3418			EFAVIRENZ	195085			ANSM	177-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
431	DIHYDROERGOTAMINE	3418					MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	177-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).	CONTRAINDICATION	
432	DIHYDROERGOTAMINE	3418			QUINUPRISTINE	135098			ANSM	177-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
433	DIHYDROERGOTAMINE	3418			STIRIPENTOL	37119			ANSM	177-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).	CONTRAINDICATION	
434	DIHYDROERGOTAMINE	3418			TRICLABENDAZOLE	38608			ANSM	177-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	Wait 24 hours between stopping the triclabendazole and the dose of the medication derived from ergot of rye, and the reverse.
435	DIHYDROERGOTAMINE	3418			VORICONAZOLE	121243			ANSM	177-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
436			DIHYDROPYRIDINES	C08CA-002			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	178-DIHYDROPYRIDINES.html	Hypotension, heart failure with patients having latent or uncontrolled cardiac insufficiency (addition of the negative inotropic effects). The beta blocking agent can furthermore minimize the sympathetic reflex reaction brought into play in the case of excessive hemodynamic repercussion	Take into account	
437			DIHYDROPYRIDINES	C08CA-002			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	178-DIHYDROPYRIDINES.html	Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative inotropic effect of the dihydropyridines in vitro, more or less marked, and susceptible of adding to the negative inotropic effects of the beta blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion.	Take into account	
438			DIHYDROPYRIDINES	C08CA-002	DANTROLENE	3105			ANSM	178-DIHYDROPYRIDINES.html	With the dantrolene administered via IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered via IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.	Not recommended	
439	DILTIAZEM	3443			ALFENTANIL	480			ANSM	179-DILTIAZEM.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when there is treatment with the diltiazem.
440	DILTIAZEM	3443			AMIODARONE	703			ANSM	179-DILTIAZEM.html	For diltiazem by injection: risk of bradycardia and of atrioventricular blockFor diltiazem by mouth: risk of bradycardia or of atrioventricular block, especially in older persons.	Not recommended	-with diltiazem administered intravenously
441	DILTIAZEM	3443			ATORVASTATIN	83367			ANSM	179-DILTIAZEM.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction.
442	DILTIAZEM	3443					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	179-DILTIAZEM.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	The administration of these medications together should only be done under strict clinical monitoring and EKG, in particular with older patients or at the beginning of treatment.
443	DILTIAZEM	3443					BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	179-DILTIAZEM.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction	CONTRAINDICATION	
444	DILTIAZEM	3443			BUSPIRONE	1827			ANSM	179-DILTIAZEM.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the diltiazem, with increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
445	DILTIAZEM	3443			CLONIDINE	2599			ANSM	179-DILTIAZEM.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
446	DILTIAZEM	3443			DANTROLENE	3105			ANSM	179-DILTIAZEM.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantolene together is thus potentially dangerous. However, some patients have received nifedipine and dantolene together without incident	CONTRAINDICATION	
447	DILTIAZEM	3443			DIHYDROERGOTAMINE	3418			ANSM	179-DILTIAZEM.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
448	DILTIAZEM	3443			DRONEDARONE	233698			ANSM	179-DILTIAZEM.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Begin the treatment with the calcium channel blocker at the minimum recommended dosages and adjust the doses according to the EKG.
449	DILTIAZEM	3443			ERGOTAMINE	4025			ANSM	179-DILTIAZEM.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	CONTRAINDICATION	
450	DILTIAZEM	3443			ESMOLOL	49737			ANSM	179-DILTIAZEM.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac arrest.	Not recommended	-in case of alteration of left ventricular function
451	DILTIAZEM	3443			IBRUTINIB	1442981			ANSM	179-DILTIAZEM.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the diltiazem	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg/day during the length of time that these medications are administered together.
452	DILTIAZEM	3443					IMMUNOSUPPRESSANTS	L04A	ANSM	179-DILTIAZEM.html	Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.
453	DILTIAZEM	3443			IVABRADINE	77417			ANSM	179-DILTIAZEM.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules.	CONTRAINDICATION	
454	DILTIAZEM	3443			MIDAZOLAM	6960			ANSM	179-DILTIAZEM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the diltiazem
455	DILTIAZEM	3443			NIFEDIPINE	7417			ANSM	179-DILTIAZEM.html	Large increase of the concentrations of nefidipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	CONTRAINDICATION	
456	DILTIAZEM	3443			OLAPARIB				ANSM	179-DILTIAZEM.html	Increase of the plasma concentrations of olaparib by the diltiazem	Not recommended	If administering these together cannot be avoided, limit the dose of olaparib to 200 mg twice a day.
457	DILTIAZEM	3443			PIMOZIDE	8331			ANSM	179-DILTIAZEM.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
458	DILTIAZEM	3443			SIMVASTATIN	36567			ANSM	179-DILTIAZEM.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Do not exceed the dosage of 20 mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction
459	DILTIAZEM	3443			TAMSULOSINE	77492			ANSM	179-DILTIAZEM.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzymatic inhibitor and after it is stopped, if the situation requires.
460	DILTIAZEM	3443			TICAGRELOR	1116632			ANSM	179-DILTIAZEM.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolsim	Take into account	
461			URINARY ALKALIZERS	B05-001	HYDROQUINIDINE	27220			ANSM	18-URINARY-ALKALIZERS.html	Increase of the plasma concentrations of the hydroquinidine and risk of overdose (decrease of the renal excretion of the hydroquinidine by alkalinizing of the urine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the concentrations of the hydroquinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
462			URINARY ALKALIZERS	B05-001	QUINIDINE	9068			ANSM	18-URINARY-ALKALIZERS.html	Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).	Precaution for use	Clinical monitoring, EKG, and possibly testing of the concentrations of quinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
463	DIMETHYL FUMARATE	1373478					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	180-DIMETHYL-FUMARATE.html	Possible increase of the risk of infection	Take into account	
464	DIPROPHYLLINE	3714			PROBENECID	8698			ANSM	181-DIPROPHYLLINE.html	Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)	Precaution for use	Reduce the dosage of diprophylline during the treatment with the probenicid
465	DIPYRIDAMOLE	3521			THEINE				ANSM	182-DIPYRIDAMOLE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theine	Precaution for use	Avoid the consumption of theine based products during the 24 hours before myocardial perfusion imaging with dipyridamole
466	DIPYRIDAMOLE	3521					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	182-DIPYRIDAMOLE.html	With the dipyridamole by injection: increase of the antihypertensive effect	Take into account	
467	DIPYRIDAMOLE	3521			CAFFEINE	1886			ANSM	182-DIPYRIDAMOLE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine	Precaution for use	Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consuming coffee, tea, chocolate, or cola during the 24 hours that precede the test.
468	DIPYRIDAMOLE	3521					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	182-DIPYRIDAMOLE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theophylline	Precaution for use	Interrupt a treatment with theophylline at lease 5 days before myocardial perfusion imaging with the dipyridamole.
469	DISOPYRAMIDE	3541					ENZYMATIC INDUCERS	N03-J05-001	ANSM	183-DISOPYRAMIDE.html	Risk of decrease of the concentrations of the disopyramide by the inducer.	Precaution for use	Clinical monitoring and possibly adjustment of the dosage of the disopyramide during the administration of these medications together and 1 to 2 weeks after the inducer is stopped.
470	DISOPYRAMIDE	3541					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	183-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide due to decrease of its metabolism.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the disopyramide
471	DISOPYRAMIDE	3541			JOSAMYCIN	6084			ANSM	183-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsade de pointes type.	Precaution for use	Regular clinical, biological and EKG monitoring,
472	DISULFIRAM	3554					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	184-DISULFIRAM.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the disulfiram and a week after it is stopped
473	DISULFIRAM	3554			COCAINE	2653			ANSM	184-DISULFIRAM.html	Increase of the concentrations of cocaine due to decrease of its metabolism by the disulfirame, with risk of increase of inducing torsades de pointes	Take into account	
474	DISULFIRAM	3554			ISONIAZID	6038			ANSM	184-DISULFIRAM.html	Disorders of behavior and of coordination	Not recommended	
475	DISULFIRAM	3554			METRONIDAZOLE	6922			ANSM	184-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
476	DISULFIRAM	3554					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	184-DISULFIRAM.html	Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)	Not recommended	If the administration of these substances together cannot be avoided, clinical monitoring and monitoring of the plasma concentrations of phenytoin during the treatment with the disulfiram and after it is stopped.
477			DIURETICS	C0E-001	ACETYLSALICYLIC ACID	1191			ANSM	185-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
478			DIURETICS	C0E-001			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	185-DIURETICS.html	Acute renal insufficiency with the patient at risk (older patient and/or dehydrated one) due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the NSAIs). Furthermore, reduction of the antihypertensive effect	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment
479			DIURETICS	C0E-001			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	185-DIURETICS.html	In case of dehydration caused by the diuretics, increased risk of acute functional renal insufficiency, in particular when large doses of the contrast media are used.	Precaution for use	Rehydrate before administration of the iodinated product
480			LOOP DIURETICS	C03CA-001			AMINOGLYCOSIDES	J01GB-001	ANSM	186-LOOP-DIURETICS.html	Increase of the nephrotoxic and ototoxic risks of the aminoglycoside (functional renal insufficiency linked to the dehydration caused by the diuretic)	Precaution for use	
481			LOOP DIURETICS	C03CA-001	LITHIUM	6448			ANSM	186-LOOP-DIURETICS.html	Increase of the lithemia with signs of overdose of lithium as with a low sodium regimen (decrease of the urinary excretion of the lithium)		
482			LOOP DIURETICS	C03CA-001	METFORMIN	6809			ANSM	186-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
483			LOOP DIURETICS	C03CA-001			PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS	L01XA	ANSM	186-LOOP-DIURETICS.html	Risk of addition of the ototoxic and/or nephrotoxic effects		
484			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004			OTHER POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	187-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	CONTRAINDICATION	Contraindication unless there is hypokalemia.
485			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	187-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Risk of hyperkalemia (possibly lethal) especially when there is renal insufficiency (addition of the effects of the hyperkalemia inducing substances)	Not recommended	--if administering these medications together is justified, strict testing of the kalemia and of the renal function.
486			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	CICLOSPORIN	3008			ANSM	187-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
487			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004			POTASSIUM LOWERING DIURETICS	C03	ANSM	187-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	The rational choice of these two medications, useful for some patients, does not exclude the onset of hypokalemia or, in particular with patients having renal insufficiency and diabetes, of hyperkalemia	Precaution for use	Monitor the kalemia, possibly EKG and, if there is reason to, reconsider the treatment.
488			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	187-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Risk of hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia producing effects)	Not recommended	-if the administration of the two medications together is justified, strict testing of the kalemia and of the renal function.
489			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	LITHIUM	6448			ANSM	187-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Increase of the lithemia with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
490			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	POTASSIUM	8588			ANSM	187-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially with renal insufficiency (addition of the hyperkalemia producing effects)	Contraindication	-aside from hypokalemia or in case of parenteral use of the potassium salts
491			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	TACROLIMUS	42316			ANSM	187-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
492			POTASSIUM LOWERING DIURETICS	C03			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	188-POTASSIUM-LOWERING-DIURETICS.html	Risk of abrupt arterial hypotension and/or acute renal insufficiency at the beginning of or at an increase in the dosage of a treatment with an angiotensin II antagonist where there is pre-existing fluid depletion.	Precaution for use	With arterial hypertension, where there has been pre-existing diuretic treatment that has caused fluid depletion, it is necessary:
493			POTASSIUM LOWERING DIURETICS	C03	CARBAMAZEPINE	2002			ANSM	188-POTASSIUM-LOWERING-DIURETICS.html	Risk of symptomatic hyponatremia	Precaution for use	Clinical and biological monitoring. If possible, use another class of diuretics.
494			POTASSIUM LOWERING DIURETICS	C03	CICLOSPORIN	3008			ANSM	188-POTASSIUM-LOWERING-DIURETICS.html	Risk of increase of the creatinemia without modification of the blood concentrations of the ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout	Take into account	
495			POTASSIUM LOWERING DIURETICS	C03			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	188-POTASSIUM-LOWERING-DIURETICS.html	The rational choice of these medications, useful for some patients, does not exclude the onset of hypokalemia or, in particular with patients having renal insufficiency and diabetes, of hyperkalemia	Precaution for use	Monitor the kalemia, possibly EKG and, if there is reason to, reconsider the treatment.
496			POTASSIUM LOWERING DIURETICS	C03			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	188-POTASSIUM-LOWERING-DIURETICS.html	Risk of abrupt arterial hypotension and/or renal insufficiency at the start of or when there is an increase of the dosage of the treatment with the ACE inihitor in cases of pre-existing fluid depletion	Precaution for use	In arterial hypertension, when there is fluid depletion from previous treatment with a diuretic, it is necessary:
497			THIAZIDE DIURETICS AND RELATED	C03-003	CALCIUM	1428011			ANSM	189-THIAZIDE-DIURETICS-AND-RELATED.html	Risk of hypercalcemia due to decrease of the urinary elimination of the calcium.	Take into account	
498			THIAZIDE DIURETICS AND RELATED	C03-003	LITHIUM	6448			ANSM	189-THIAZIDE-DIURETICS-AND-RELATED.html	Increase of the lithemia with signs of overdose of lithium, as with a reduced sodium regimen (decrease of the urinary excretion of the lithium)	Not recommended	If administering the substances together cannot be avoided, strict monitoring of the lithemia and adjustment of the dosage of the lithium.
499			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not Recommended	
500			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001			ANTIPARKINSONIAN ANTICHOLINERGICS	N04AA-001	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of increase of neuropsychological disorders	Precaution for use:	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
501			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose.	Not recommended	
502			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001			ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)	R01AA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
503			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
504	DOCETAXEL	72962			DRONEDARONE	233698			ANSM	190-DOCETAXEL.html	Risk of increase of the toxicity of the docetaxel due to decrease of its metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzymatic inhibitor.
505	DOCETAXEL	72962					ENZYMATIC INDUCERS	N03-J05-001	ANSM	190-DOCETAXEL.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
506	DOCETAXEL	72962					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	190-DOCETAXEL.html	Risk of increase of the undesirable dose-dependent effects of the docetaxel due to inhibition of its metabolism by the enzymatic inhibitor	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzymatic inhibitor.
507	DOLUTEGRAVIR	1433868					ENZYMATIC INDUCERS	N03-J05-001	ANSM	191-DOLUTEGRAVIR.html	Decrease of the plasma concentrations of dolutegravir by increase of its metabolism by the inducer	Not recommended	-in case of resistance to the class of integrase inhibitors
508	DOLUTEGRAVIR	1433868			METFORMIN	6809			ANSM	191-DOLUTEGRAVIR.html	Increase of the plasma concentrations of metformin by the dolutegravir and of its undesirable effects of the lactic acidosis type	Precaution for use	With the patient having moderate renal insufficiency (stage 3a, clearance of the creatinin between 45 and 59 ml/min), clinical and biological monitoring, and possible adjustment of the dosage of metformin.
509	DOLUTEGRAVIR	1433868			ST JOHNS WORT	258326			ANSM	191-DOLUTEGRAVIR.html	Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort.	Not recommended	
510	DOMPERIDONE	3626			FLUCONAZOLE	4450			ANSM	192-DOMPERIDONE.html	Risk of problems with ventricular rhythm, especially of torsades de pointes	CONTRAINDICATION	
511	DOMPERIDONE	3626					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	192-DOMPERIDONE.html	Increase of the plasma concentrations of domperidone due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
512			DOPAMINERGICS	N04B-002			ANTIEMITIC NEUROLEPTICS	A03FA-001	ANSM	193-DOPAMINERGICS.html	Reciprocal antagonism between the dopaminergic and the neuropleptic	CONTRAINDICATION	Use an antiemetic that does not have extrapyramidal effects.
513			DOPAMINERGICS	N04B-002	TETRABENAZINE	10390			ANSM	193-DOPAMINERGICS.html	Reciprocal antagonism between the dopaminergic and the tetrabenazine	Not recommended	
514			DOPAMINERGICS, EXCEPT PARKINSON	G02CB-002			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	194-DOPAMINERGICS,-EXCEPT-PARKINSON.html	Reciprocal antagonism of the dopamine agonist and the neuroleptics	CONTRAINDICATION	
515	DOXORUBICIN	3639			VERAPAMIL	11170			ANSM	195-DOXORUBICIN.html	Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations	Take into account	
516	DOXYCYCLINE	3640					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	196-DOXYCYCLINE.html	Decrease of the plasma concentations of the doxycycline due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the doxycycline.
517	DRONEDARONE	233698					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	197-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite	Not recommended	
518	DRONEDARONE	233698					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	197-DRONEDARONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the dronedarone and a week after it is stopped.
519	DRONEDARONE	233698			DABIGATRAN				ANSM	197-DRONEDARONE.html	Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
520	DRONEDARONE	233698			DIGOXIN	3407			ANSM	197-DRONEDARONE.html	Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. In addition, increase of the digoxinemia due to decrease of the metabolism of the digoxin. Clinical monitoring and EKG.	Not recommended	Reduce the doses of digoxin by half.
521	DRONEDARONE	233698			DILTIAZEM	3443			ANSM	197-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Start the treatment with the calcium channel blocker with minimum recommended dosages, and adjust the doses according to the EKG.
522	DRONEDARONE	233698			DOCETAXEL	72962			ANSM	197-DRONEDARONE.html	Risk of increase of the toxicity of the docetaxel due to decrease of its metabolism.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzyme inhibitor.
523	DRONEDARONE	233698			FIDAXOMICIN	1111103			ANSM	197-DRONEDARONE.html	Increase of the plasma concentrations of fidaxomicin.	Not recommended	
524	DRONEDARONE	233698					IMMUNOSUPPRESSANTS	L04A	ANSM	197-DRONEDARONE.html	Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Not recommended	
525	DRONEDARONE	233698					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	197-DRONEDARONE.html	Large increase of the concentrations of drodedarone due to decrease of its metabolism	CONTRAINDICATION	
526	DRONEDARONE	233698			ST JOHNS WORT	258326			ANSM	197-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite	Not recommended	
527	DRONEDARONE	233698			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	197-DRONEDARONE.html	Increase of the concentrations of dronedarone due to inhibition of its metabolism by the grapefruit	Not recommended	
528	DRONEDARONE	233698			QUINIDINE	9068			ANSM	197-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine	Precaution for use	Start the treatment with the quinidine at the minimum recommended dosages, and adjust the doses according to the EKG.
529	DRONEDARONE	233698			RIFAMPICIN	9384			ANSM	197-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
530	DRONEDARONE	233698			SIMVASTATIN	36567			ANSM	197-DRONEDARONE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Not recommended	
531	DRONEDARONE	233698			VERAPAMIL	11170			ANSM	197-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG.
532	DROSPIRENONE	840781			BOCEPREVIR	1102129			ANSM	198-DROSPIRENONE.html	Increase of more than double of the concentrations of drosperinone when taken with the boceprevir	Not recommended	Choose a contraceptive with another progestin, especially in cases of hyperkalemia
533	DULOXETINE	72625			ENOXACIN	3925			ANSM	199-DULOXETINE.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the enoxacin	CONTRAINDICATION	
534	DULOXETINE	72625			FLECAINIDE	4441			ANSM	199-DULOXETINE.html	Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with the duloxetine and after it is stopped.
535	DULOXETINE	72625			FLUVOXAMINE	42355			ANSM	199-DULOXETINE.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine	CONTRAINDICATION	
536	DULOXETINE	72625			MEQUITAZINE	29528			ANSM	199-DULOXETINE.html	Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
537	DULOXETINE	72625			METOPROLOL	6918			ANSM	199-DULOXETINE.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped.
538	DULOXETINE	72625			PROPAFENONE	8754			ANSM	199-DULOXETINE.html	Increase of the plasma concentrations of propafenone with risk of overdose due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with the duloxetine and after it is stopped.
539	DULOXETINE	72625			TAMOXIFEN	10324			ANSM	199-DULOXETINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine	Not recommended	
540	ABIRATERONE	1100072					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	2-ABIRATERONE.html	Notable decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
541	ABIRATERONE	1100072			FLECAINIDE	4441			ANSM	2-ABIRATERONE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the abiraterone
542	ABIRATERONE	1100072			METOPROLOL	6918			ANSM	2-ABIRATERONE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metopolol during the treatment with the abiraterone
543	ABIRATERONE	1100072			PROPAFENONE	8754			ANSM	2-ABIRATERONE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the abiraterone
544	ABIRATERONE	1100072			RIFAMPICIN	9384			ANSM	2-ABIRATERONE.html	Substantial decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
545			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
546			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or of those of the extremities (ergotism), or of rapid elevation of blood pressure.	CONTRAINDICATION	
547			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of the coronary arteries or of those of the extremities (ergotism), or of rapid elevation of blood pressure.	CONTRAINDICATION	
548			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			OMBITASVIR + PARITAPEVIR	OMPA	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye by decrease of its hepatic metabolism by the therapy with the two medications.	CONTRAINDICATION	
549			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)	R01AA	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure.	Not recommended	
550			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
551			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			TRIPTANS	N02CC-001	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of arterial hypertension, of constriction of coronary arteries	CONTRAINDICATION	Wait 6 to 24 hours, depending on the triptan, between its dose and that of the ergot alkaloid.
552	EBASTINE	23796			CLARITHROMYCIN	21212			ANSM	200-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
553	EBASTINE	23796			ERYTHROMYCIN	4053			ANSM	200-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
554	EBASTINE	23796			ITRACONAZOLE	28031			ANSM	200-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
555	EBASTINE	23796			JOSAMYCIN	6084			ANSM	200-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
556	EBASTINE	23796			KETOCONAZOLE	6135			ANSM	200-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
557	ECONAZOLE	3743					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	201-ECONAZOLE.html	Regardless of the route of administration of the econazole:Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped
558	EFAVIRENZ	195085					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	202-EFAVIRENZ.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist
559	EFAVIRENZ	195085			ATAZANAVIR	343047			ANSM	202-EFAVIRENZ.html	Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism	Not recommended	If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together.
560	EFAVIRENZ	195085			ATOVAQUONE	60212			ANSM	202-EFAVIRENZ.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
561	EFAVIRENZ	195085			DIHYDROERGOTAMINE	3418			ANSM	202-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
562	EFAVIRENZ	195085			ERGOTAMINE	4025			ANSM	202-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)	CONTRAINDICATION	
563	EFAVIRENZ	195085			FOSAMPRENAVIR	358262			ANSM	202-EFAVIRENZ.html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
564	EFAVIRENZ	195085			INDINAVIR	114289			ANSM	202-EFAVIRENZ.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.
565	EFAVIRENZ	195085			PIMOZIDE	8331			ANSM	202-EFAVIRENZ.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
566	EFAVIRENZ	195085			RIFABUTIN	55672			ANSM	202-EFAVIRENZ.html	Decrease by about half of the concentrations of rifabutin, due to increase of its hepatic metabolism by the efavirenz	Precaution for use	Adjustment of the dosage of the rifabutin during the treatment with efavirenz.
567	EFAVIRENZ	195085			RIFAMPICIN	9384			ANSM	202-EFAVIRENZ.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
568	EFAVIRENZ	195085			VORICONAZOLE	121243			ANSM	202-EFAVIRENZ.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz	Not recommended	If administering these substances together cannot be avoided, strict clinical monitoring and adjustment of the dosage of the voriconazole and of the efavirenz during the administration of the two together.
569	ELTROMBOPAG	711942					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	203-ELTROMBOPAG.html	Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the statin.
570	ELVITEGRAVIR	1306286					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	204-ELVITEGRAVIR.html	Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. Furthermore, increase of the concentrations of the progestin	Precaution for use	Use an estroprogestin contraceptive with at leaset 30ug of ethinylestradiol.
571	ELVITEGRAVIR	1306286			ITRACONAZOLE	28031			ANSM	204-ELVITEGRAVIR.html	Increase pf the plasma concentrations of elvitegravir by decrease of its metabolism by the itraconazole	Precaution for use	With the elvitegravir co-administered with the cobicistat [sic], clinical monitoring. Limit the maximum dose of itraconazole to 200 mg/day.
572	ELVITEGRAVIR	1306286			KETOCONAZOLE	6135			ANSM	204-ELVITEGRAVIR.html	Increase of the plasma concentrations of elvitegravir by decrease of its metabolism by the ketoconazole	Precaution for use	Avec the elvitegravir co-administered with the cobicistat [sic], clinical monitoring. Limit the maximum dose of ketoconazole to 200 mg/day.
573	ELVITEGRAVIR	1306286			RIFABUTIN	55672			ANSM	204-ELVITEGRAVIR.html	Decrease of the minimal concentrations of elvitegravir	Take into account	
574	ENOXACIN	3925			CAFFEINE	1886			ANSM	205-ENOXACIN.html	Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism	Not recommended	
575	ENOXACIN	3925			DULOXETINE	72625			ANSM	205-ENOXACIN.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the exnoxacin	CONTRAINDICATION	
576	ENOXACIN	3925			ROPINIROLE	72302			ANSM	205-ENOXACIN.html	Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with the enoxacin and after it is stopped.
577	ENOXACIN	3925					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	205-ENOXACIN.html	Overdose of theophylline due to substantial decrease of its metabolism	CONTRAINDICATION	
578	ENTACAPONE	60307			IRON	1431589			ANSM	206-ENTACAPONE.html	Decrease of the digestive absorption of the entacapone and of the iron due to chelation of the latter by the entacapone	Precaution for use	Take the iron salts at a different time from the entacapone (more than 2 hours apart if possible).
579	ENZALUTAMIDE	1307298			GEMFIBROZIL	4719			ANSM	207-ENZALUTAMIDE.html	Increase of the active fraction of the enzalutamide	Precaution for use	Reduce the dose of enzalutamide by half when it is administered with the gemfibrozil
580	EPLERENONE	298869					ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	208-EPLERENONE.html	Increase of the risk of hyperkalemia, especially with older patients	Precaution for use	Strict testing of the kalemia and of the renal function during the administration of these substances together.
581	EPLERENONE	298869					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	208-EPLERENONE.html	Increase of the risk of hyperkalemia, especially with older patients.	Precaution for use	Strict testing of the kalemia and of the renal function during the administration of these substances together.
582	EPLERENONE	298869					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	208-EPLERENONE.html	Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia	CONTRAINDICATION	
583	ERGOTAMINE	4025			DALFOPRISTIN	229369			ANSM	209-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
584	ERGOTAMINE	4025			DILTIAZEM	3443			ANSM	209-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	CONTRAINDICATION	
585	ERGOTAMINE	4025			EFAVIRENZ	195085			ANSM	209-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).	CONTRAINDICATION	
586	ERGOTAMINE	4025					MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	209-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	CONTRAINDICATION	
587	ERGOTAMINE	4025			OXPRENOLOL	7801			ANSM	209-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together.
588	ERGOTAMINE	4025			PROPRANOLOL	8787			ANSM	209-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together.
589	ERGOTAMINE	4025			QUINUPRISTINE	135098			ANSM	209-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	CONTRAINDICATION	
590	ERGOTAMINE	4025			STIRIPENTOL	37119			ANSM	209-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of the ergot of rye).	CONTRAINDICATION	
591	ERGOTAMINE	4025			TRICLABENDAZOLE	38608			ANSM	209-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	CONTRAINDICATION	Wait 24 hours between stopping the triclabendazole and the ergotaine, and the reverse
592	ALDESLEUKIN	70223					IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	21-ALDESLEUKIN.html	Increase of the risk of reaction to the contrast media in cases of previous treatment with interleukin2: skin rash or more rarely low blood pressure, oliguria, or even renal failure	Take into account	
593	ERIBULINE	1045453			CICLOSPORIN	3008			ANSM	210-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the ciclosporin.	Not recommended	
594	ERIBULINE	1045453			CLARITHROMYCIN	21212			ANSM	210-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
595	ERIBULINE	1045453					ENZYMATIC INDUCERS	N03-J05-001	ANSM	210-ERIBULINE.html	Risk of decrease of the plasma concentrations of eribuline by the inducer	Not recommended	
596	ERIBULINE	1045453					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	210-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the ritonavir.	Not recommended	
597	ERIBULINE	1045453			ST JOHNS WORT	258326			ANSM	210-ERIBULINE.html	Risk of decrease of the plasma concentrations of eribuline by the St John's wort.	Not recommended	
598	ERIBULINE	1045453			VERAPAMIL	11170			ANSM	210-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the verapamil.	Not recommended	
599	ERYTHROMYCIN	4053			AFATINIB	1430438			ANSM	211-ERYTHROMYCIN.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin	Precaution for use	It is recommendedthat the erythromycin be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.
600	ERYTHROMYCIN	4053			ALFENTANIL	480			ANSM	211-ERYTHROMYCIN.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the erythromycin
601	ERYTHROMYCIN	4053			ATORVASTATIN	83367			ANSM	211-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
602	ERYTHROMYCIN	4053			BUSPIRONE	1827			ANSM	211-ERYTHROMYCIN.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
603	ERYTHROMYCIN	4053			CARBAMAZEPINE	2002			ANSM	211-ERYTHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	
604	ERYTHROMYCIN	4053			DEXAMETHASONE	3264			ANSM	211-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
605	ERYTHROMYCIN	4053			DIGOXIN	3407			ANSM	211-ERYTHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erithromycin and after it is stopped.
606	ERYTHROMYCIN	4053			EBASTINE	23796			ANSM	211-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
607	ERYTHROMYCIN	4053			FIDAXOMICIN	1111103			ANSM	211-ERYTHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
608	ERYTHROMYCIN	4053			GLIBENCLAMIDE	4815			ANSM	211-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
609	ERYTHROMYCIN	4053			GLIMEPIRIDE	25789			ANSM	211-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
610	ERYTHROMYCIN	4053			HALOFANTRINE	50749			ANSM	211-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
611	ERYTHROMYCIN	4053					IMMUNOSUPPRESSANTS	L04A	ANSM	211-ERYTHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these medications are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
612	ERYTHROMYCIN	4053			LUMEFANTRINE	847728			ANSM	211-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
613	ERYTHROMYCIN	4053			MIDAZOLAM	6960			ANSM	211-ERYTHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Not recommended	-with the midazolam by mouth
614	ERYTHROMYCIN	4053			MIZOLASTINE	61455			ANSM	211-ERYTHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
615	ERYTHROMYCIN	4053			NINTEDANIB	1592737			ANSM	211-ERYTHROMYCIN.html	Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the erythromycin	Precaution for use	Clinical monitoring during the administration of these substances together.
616	ERYTHROMYCIN	4053			PRAVASTATIN	42463			ANSM	211-ERYTHROMYCIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	Clinical and biological monitoring during the treatment with the antibiotic.
617	ERYTHROMYCIN	4053			SIMVASTATIN	36567			ANSM	211-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent).	CONTRAINDICATION	
618	ERYTHROMYCIN	4053					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	211-ERYTHROMYCIN.html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children	Not recommended	
619	ERYTHROMYCIN	4053			VENLAFAXINE	39786			ANSM	211-ERYTHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
620	ERYTHROMYCIN	4053			VERAPAMIL	11170			ANSM	211-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
621	ERYTHROMYCIN	4053					VINCA ALKALOIDS	L01CA	ANSM	211-ERYTHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin.	Precaution for use	Strict clinical and biological monitoring. Possibly use another antibiotic.
622	ESMOLOL	49737			AMIODARONE	703			ANSM	212-ESMOLOL.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
623	ESMOLOL	49737					CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	212-ESMOLOL.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
624	ESMOLOL	49737			DILTIAZEM	3443			ANSM	212-ESMOLOL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac arrest	Not recommended	-in case of alteration of left ventricular function
625	ESMOLOL	49737			PROPAFENONE	8754			ANSM	212-ESMOLOL.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG.
626	ESMOLOL	49737			VERAPAMIL	11170			ANSM	212-ESMOLOL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	-in case of alteration of left ventricular function
627	ESTRAMUSTINE	4089			CLODRONIC ACID	3350			ANSM	213-ESTRAMUSTINE.html	Risk of increase of the plasma concentrations of estramustine by the clodronate	Precaution for use:	Clinical monitoring during the administration of these substances together.
628	ESTRAMUSTINE	4089			CALCIUM	1428011			ANSM	213-ESTRAMUSTINE.html	Decrease of the digestive absorption of the estramustine	Precaution for use	Take the calcium salts at a different time from the estramustine (more than 2 hours apart if possible).
629	ESTRAMUSTINE	4089					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	213-ESTRAMUSTINE.html	Risk of increase of the undesirable effects of the angioneurotic edema type (angioedema)	Not recommended	
630			NON-CONTRACEPTIVE ESTROGENS	G03C-001			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	214-NON-CONTRACEPTIVE-ESTROGENS.html	Decrease of the effectiveness of the estrogen .	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped.
631			NON-CONTRACEPTIVE ESTROGENS	G03C-001	BOCEPREVIR	1102129			ANSM	214-NON-CONTRACEPTIVE-ESTROGENS.html	Decrease of the effectiveness of the estrogen	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the boceprevir.
632			NON-CONTRACEPTIVE ESTROGENS	G03C-001			THYROID HORMONES	H03AA	ANSM	214-NON-CONTRACEPTIVE-ESTROGENS.html	Risk of clinical hypothyroidism in cases of estrogen replacement therapy.	Precaution for use	Clinical and biological monitoring; possible adjustment of the doses of the thyroid hormone for menopausal women taking estrogens.
633			NON-CONTRACEPTIVE ESTROGENS	G03C-001	OXCARBAZEPINE	32624			ANSM	214-NON-CONTRACEPTIVE-ESTROGENS.html	Risk of decrease of the effectiveness of the hormonal treatment, due to increase of its hepatic metabolism by the oxcarbazepine.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the treatment with oxcarbazepin and after it is stopped.
634			NON-CONTRACEPTIVE ESTROGENS	G03C-001	TELAPREVIR	1102261			ANSM	214-NON-CONTRACEPTIVE-ESTROGENS.html	Decrease of the effectiveness of the estrogen.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the telaprevir and after it is stopped.
635			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	APREPITANT	358255			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Decrease of the concentrations of the estrogen-progestin or of the progestatif, with risk of lower contraceptive effectiveness.	Precaution for use	Use another method of contraception, in particular a barrier type, during the treatment with the aprepitant and a cycle after.
636			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	BOCEPREVIR	1102129			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Except for the combination with ethinylestradiol (0.035 mg)/norethisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir.	Precaution for use	Use an additional or alternative reliable contraceptive method during the length of the administration of these together.
637			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	BOSENTAN	75207			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the length of time that the two substances are administered together and for a cycle after.
638			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ELVITEGRAVIR	1306286			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. In addition, increase of the concentrations of the progestin	Precaution for use	Use a combined estrogen-progestin contraceptive with at least 30ug of ethinylestradiol
639			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	GRISEOFULVIN	5021			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism	Precaution for use	Another method of contraception, in particular a barrier type, should be used during the time the two substances are administered together and a cycle after.
640			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001			ENZYMATIC INDUCERS	N03-J05-001	ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Decrease of the contraceptive effectiveness, due to increase of the hepatic metabolism of the hormonal contraceptive by the inducer	Not recommended	Another method of contraception, in particular a barrier type, should be used during the time the substances are administered together and a cycle after.
641			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive because of the increase of its hepatic metabolism by the ritonavir.	Not recommended	Another method of contraception, in particular a barrier type (condom or IUD), should be used during the length of the treatment with these medications together and a cycle following.
642			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	LAMOTRIGINE	28439			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism	Not recommended	-avoid starting an oral contraceptive during the period of adjustment of the dosage of the lamotrigine.
643			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ST JOHN'S WORT	258326			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, of the contraceptive, which can possibly have serious consequences (pregnancy).	CONTRAINDICATON	
644			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	MODAFINIL	30125			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential	Not recommended	Use oral contraceptives with ethinylestradiol or another method of contraception
645			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	RUFINAMIDE	69036			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Moderate decrease of the concentrations of ethinylestradiol	Precaution for use	Another contraceptive method, in particular a barrier type, should be used.
646			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	TELAPREVIR	1102261			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness by increase of the hepatic metabolism of the hormonal contraceptive by the telaprevir	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the time these are administered together and two cycles following.
647			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	TOPIRAMATE	38404			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	For doses of topiramate >=200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of estrogen	Not recommended	Another method of contraception, in particular a barrier type, should be used.
648			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ULIPRISTAL	1005921			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Risk of antagonism of the effects of the progestin.	Not recommended	Do not restart a treatment with estrogen-progestin contraceptives fewer than 12 days after stopping the ulipristal.
649			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	VEMURAFENIB	1147220			ANSM	215-COMBINED-ESTROGEN-PROGESTIN -CONTRACEPTIVES.html	Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness	Not recommended	
650	ETANERCEPT	214555			ANAKINRA	72435			ANSM	216-ETANERCEPT.html	Increased risk of serious infections and neutropenia	Not recommended	
651	ETHINYLESTRADIOL	4124			DASABUVIR	1597381			ANSM	217-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	CONTRAINDICATION	
652	ETHINYLESTRADIOL	4124			ETORICOXIB	307296			ANSM	217-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
653	ETHINYLESTRADIOL	4124					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	217-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	CONTRAINDICATION	
654	ETHOSUXIMIDE	4135			CARBAMAZEPINE	2002			ANSM	218-ETHOSUXIMIDE.html	Decrease of the plasma concentrations of ethosuximide	Precaution for use	Clinical monitoring, plasma dosage of the ethosuximide and possible increase of its dosage.
655	ETORICOXIB	307296			ETHINYLESTRADIOL	4124			ANSM	219-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
656	ALFENTANIL	480			CIMETIDINE	2541			ANSM	22-ALFENTANIL.html	With cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the cimetidine.
657	ALFENTANIL	480			DILTIAZEM	3443			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the diltiazem.
658	ALFENTANIL	480			ERYTHROMYCIN	4053			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the erythromycin
659	ALFENTANIL	480			FLUCONAZOLE	4450			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the fluconazole
660	ALFENTANIL	480					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism.	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when administered with a strong inhibitor of CYP3A4.
661	ETRAVIRINE	475969			CLARITHROMYCIN	21212			ANSM	220-ETRAVIRINE.html	In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine	Take into account	
662	EVEROLIMUS	141704			CICLOSPORIN	3008			ANSM	221-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together	Precaution for use	Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function, during the administration of the two together and after it is stopped
663	EVEROLIMUS	141704					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	221-EVEROLIMUS.html	Increase of the risk of angioedema	Take into account	
664	EVEROLIMUS	141704			VERAPAMIL	11170			ANSM	221-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two medications together and after it is stopped.
665	EXEMESTANE	258494			RIFAMPICIN	9384			ANSM	222-EXEMESTANE.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
666	EZETIMIBE	341248			CICLOSPORIN	3008			ANSM	223-EZETIMIBE.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
667	EZETIMIBE	341248			FENOFIBRATE	8703			ANSM	223-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
668	FELBAMATE	24812			CARBAMAZEPINE	2002			ANSM	224-FELBAMATE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of felbamate due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants.
669	FELBAMATE	24812					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	224-FELBAMATE.html	Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenobarbital with adjustment of the dosage if needed.
670	FELBAMATE	24812					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	224-FELBAMATE.html	Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate	Precaution for use	Clinical monitoring, testing of the plasma concentrations of phenytoin, and if needed, adjustment of its dosage during the treatment with the felbamate.
671	FELBAMATE	24812					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	224-FELBAMATE.html	Increase of the plasma concentrations of the valproic acid, with risk of overdose	Precaution for use	Clinical and biological monitoring, and possible adjustment of the dosage of the valproate or of the valpromide during the treatment with the felbamate and after it is stopped.
672	FENOFIBRATE	8703			CICLOSPORIN	3008			ANSM	225-FENOFIBRATE.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical and biological monitoring of the renal function, during and after the administration of the two medications together.
673	FENOFIBRATE	8703			EZETIMIBE	341248			ANSM	225-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
674	FENTANYL	4337					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	226-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant	Not recommended	Choose another opioid.
675	FENTANYL	4337					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	226-FENTANYL.html	Risk of increase of the opioid analgesic's effect of respiratory depression due to slight decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is treatment with a strong inhibitor of CYP3A4.
676	FENTANYL	4337			RIFAMPICIN	9384			ANSM	226-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
677	IRON				INJECTABLE IRON SALTS	1431591			ANSM	227-IRON.html	Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin	Not recommended	
678	IRON				ACETOHYDROXAMIC ACID	16728			ANSM	227-IRON.html	Decrease of the digestive absorption of these two medications due to chelation of the iron	Take into account	
679	IRON						BISPHOSPHONATES	M05B-001	ANSM	227-IRON.html	For the iron salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	Take the iron salts at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).
680	IRON				CALCIUM	1428011			ANSM	227-IRON.html	With the iron salts by oral route: decrease of the digestive absorption of the iron salts	Precaution for use	Take the iron salts at a different time from meals and in the absence of calcium.
681	IRON						TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	227-IRON.html	With the tetracycline antibiotics administered by oral route: decrease of the digestive absorption of the tetracycline antibiotics (formation of complexes)	Precaution for use	Take the iron salts at a different time from the tetracycline antibiotics (more than 2 hours apart if possible).
682	IRON				ENTACAPONE	60307			ANSM	227-IRON.html	Decrease of the digestive absorption of the entacapone and of the iron due to chelation of the latter by the entacapone	Precaution for use	Take the iron salts at a different time from the entacapone (more than 2 hours apart if possible).
683	IRON						FLUOROQUINOLONES	J01MA-001	ANSM	227-IRON.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the iron salts at a different time from the fluoroquinolones (more that 2 hours apart if possible).
684	IRON						THYROID HORMONES	H03AA	ANSM	227-IRON.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	Take the thyroid hormones at a different time from the iron (more than 2 hours apart, if possible).
685	IRON				LEVODOPA	6375			ANSM	227-IRON.html	Decrease of the digestive absorption of the levodopa	Precaution for use	Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).
686	IRON				METHYLDOPA	6876			ANSM	227-IRON.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart if possible).
687	IRON				PENICILLAMINE	7975			ANSM	227-IRON.html	Decrease of the digestive absorption of the penicillamine	Precaution for use	Take the iron salts at a different time from the penicillamine (more than 2 hours apart if possible).
688	IRON				STRONTIUM	81638			ANSM	227-IRON.html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the iron salts (more than two hours apart if possible).
689	IRON				ZINC	1431163			ANSM	227-IRON.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
690			FIBRATES	C01AB-001			OTHER FIBRATES	C01AB-001	ANSM	228-FIBRATES.html	Increased risk of undesirable effects of the rhabdomyolosis type and of pharmacodynamic antagonism between the two molecules	CONTRAINDICATION	
691			FIBRATES	C01AB-001			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	228-FIBRATES.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fibrate and a week after it is stopped.
692			FIBRATES	C01AB-001	COLCHICINE	2683			ANSM	228-FIBRATES.html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolosis	Precaution for use	Clinical and biological monitoring, particularly at the beginning of the administration of these substances together.
693			FIBRATES	C01AB-001			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	228-FIBRATES.html	Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. Furthermore, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin	Contraindication	--for doses of 40mg of rosuvastatin
694	FIDAXOMICIN	1111103			AMIODARONE	703			ANSM	229-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
695	FIDAXOMICIN	1111103			CICLOSPORIN	3008			ANSM	229-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
696	FIDAXOMICIN	1111103			CLARITHROMYCIN	21212			ANSM	229-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
697	FIDAXOMICIN	1111103			DRONEDARONE	233698			ANSM	229-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
698	FIDAXOMICIN	1111103			ERYTHROMYCIN	4053			ANSM	229-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
699	FIDAXOMICIN	1111103			KETOCONAZOLE	6135			ANSM	229-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
700	FIDAXOMICIN	1111103			VERAPAMIL	11170			ANSM	229-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
701	ALFUZOSIN	17300					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	23-ALFUZOSIN.html	Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects. .	CONTRA-INDICATION	
702	ALFUZOSIN	17300					OMBITASVIR + PARITAPEVIR	OMPA	ANSM	23-ALFUZOSIN.html	Increase of the plasma concentrations of the alfuzosin by decrease of its hepatic metabolism by the therapy with the two medications.	CONTRA-INDICATION	
703	FINGOLIMOD	1012892					BRADYCARDIA INDUCING DRUGS	C0N0S0	ANSM	230-FINGOLIMOD.html	Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms	Not recommended	Clinical monitoring and continuous EKG during the 24 hours following the first dose.
704	FLECAINIDE	4441			ABIRATERONE				ANSM	231-FLECAINIDE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the abiraterone
705	FLECAINIDE	4441			BUPROPION	42347			ANSM	231-FLECAINIDE.html	Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the bupropion.
706	FLECAINIDE	4441			CINACALCET	407990			ANSM	231-FLECAINIDE.html	Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with cinacalcet.
707	FLECAINIDE	4441			DARIFENACIN	136198			ANSM	231-FLECAINIDE.html	Increase of the plasma concentrations of flecainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with darifenacin.
708	FLECAINIDE	4441			DULOXETINE	72625			ANSM	231-FLECAINIDE.html	Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with the duloxetine and after it is stopped.
709	FLECAINIDE	4441			MIRABEGRON	1300786			ANSM	231-FLECAINIDE.html	Increase of the plasma concentrations of the flecainide by decrease of its metabolism by the mirabegron	Precaution for use	Clinical monitoring and possible reduction of the dosage of the flecainide during the administration of it and the mirabegron together.
710	FLECAINIDE	4441			TERBINAFINE	37801			ANSM	231-FLECAINIDE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the terbinafine.
711	FLUCONAZOLE	4450			ALFENTANIL	480			ANSM	232-FLUCONAZOLE.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when there is treatment with the fluconazole
712	FLUCONAZOLE	4450			AMIODARONE	703			ANSM	232-FLUCONAZOLE.html	Risk of lengthening of the QT interval	Precaution for use	Clinical monitoring, especially with strong doses of fluconazole (800 mg/day)
713	FLUCONAZOLE	4450					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	232-FLUCONAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped.
714	FLUCONAZOLE	4450			APIXABAN	1364430			ANSM	232-FLUCONAZOLE.html	Increase of the plasma concentrations of the apixaban by the flucoonazole, with increase of the risk of bleeding	Not recommended	
715	FLUCONAZOLE	4450			CARBAMAZEPINE	2002			ANSM	232-FLUCONAZOLE.html	For doses of fluconazole >=200 mg per day: possible increase of the undesirable effects of the carbamazepine	Precaution for use	Adjust the dosage of carbamazepine, during and after the end of the antifungal treatment
716	FLUCONAZOLE	4450			DOMPERIDONE	3626			ANSM	232-FLUCONAZOLE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
717	FLUCONAZOLE	4450					IMMUNOSUPPRESSANTS	L04A	ANSM	232-FLUCONAZOLE.html	Risk of increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism and of the creatinemia	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the immunosuppressant's dosage during the administration of the substances together and after it is stopped.
718	FLUCONAZOLE	4450			IVACAFTOR	1243041			ANSM	232-FLUCONAZOLE.html	Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	Reduce the dose by half, that is 150 mg/day.
719	FLUCONAZOLE	4450			LOSARTAN	52175			ANSM	232-FLUCONAZOLE.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
720	FLUCONAZOLE	4450			NEVIRAPINE	53654			ANSM	232-FLUCONAZOLE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
721	FLUCONAZOLE	4450			OLAPARIB	1597582			ANSM	232-FLUCONAZOLE.html	Increase of the plasma concentrations of olaparib by the fluconazole	Not recommended	If administering these medications together cannot be avoided, limit the dose of olaparib to 200mg twice a day.
722	FLUCONAZOLE	4450					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	232-FLUCONAZOLE.html	Increase of the plasma oncentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin	Precaution for use	Strict clinical and biological monitoring.
723	FLUCONAZOLE	4450			PIMOZIDE	8331			ANSM	232-FLUCONAZOLE.html	Increased risk of disorders of ventricular rhythm, especially of torsades de pointes.	CONTRAINDICATION	
724	FLUCONAZOLE	4450			RIFABUTIN	55672			ANSM	232-FLUCONAZOLE.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the treatment with the two medications together.
725	FLUCONAZOLE	4450			RIFAMPICIN	9384			ANSM	232-FLUCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the fluconazole by increase of its metabolism by the rifampacin	Not recommended	
726	FLUCONAZOLE	4450			RIVAROXABAN	1114195			ANSM	232-FLUCONAZOLE.html	Increase of the plasma concentrations of the rivaroxaban by the fluconazole, with increase of the risk of bleeding	Not recommeded	
727	FLUCONAZOLE	4450					BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	232-FLUCONAZOLE.html	Increase of the half life of the sulfonamide with possible onset of hypoglycemia	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the sulfonamide during the treatment with the fluconazole.
728	FLUCONAZOLE	4450					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	232-FLUCONAZOLE.html	Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the fluconazole and after it is stopped.
729	FLUCYTOSINE	4451			ZIDOVUDINE (AZT)	11413			ANSM	233-FLUCYTOSINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
730	FLUDARABINE	24698			PENTOSTATIN	8011			ANSM	234-FLUDARABINE.html	Increase of the risk of pulmonary toxicity that could be fatal.	Not recommended	
731			FLUOROQUINOLONES	J01MA-001			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	235-FLUOROQUINOLONES.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped.
732			FLUOROQUINOLONES	J01MA-001	IRON	1431589			ANSM	235-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the iron salts at a different time from the fluoroquinolones (more that 2 hours apart if possible).
733			FLUOROQUINOLONES	J01MA-001			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	235-FLUOROQUINOLONES.html	Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving prolonged corticotherapy	Take into account	
734			FLUOROQUINOLONES	J01MA-001	MYCOPHENOLATE MOFETIL				ANSM	235-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness.	Take into account	
735			FLUOROQUINOLONES	J01MA-001	STRONTIUM	81638			ANSM	235-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the fluoroquinolones (more than two hours apart if possible).
736			FLUOROQUINOLONES	J01MA-001	SUCRALFATE	10156			ANSM	235-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the sucralfate at a different time from the fluoroquinolone (more than 2 hours apart if possible).
737			FLUOROQUINOLONES	J01MA-001	ZINC	1431163			ANSM	235-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
738			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	FOLINIC ACID	6313			ANSM	236-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html	Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil.	Take into account	
739			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	236-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	If taking these medications together cannot be avoided, more frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the cytotoxic and a week after it is stopped.
740			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	INTERFERON ALFA				ANSM	236-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
741			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	METRONIDAZOLE	6922			ANSM	236-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
742			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ORNIDAZOLE	7701			ANSM	236-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
743	FLUOXETINE	4493			CARBAMAZEPINE	2002			ANSM	237-FLUOXETINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.
744	FLUOXETINE	4493			MEQUITAZINE	29528			ANSM	237-FLUOXETINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzymatic inhibitor	Not recommended	
745	FLUOXETINE	4493			METOPROLOL	6918			ANSM	237-FLUOXETINE.html	Risk of increase of the undesirable effects of the metoprolol, especially with excessive bradycardia, due to inhibition of its metabolism by the fluoxetine.	Precaution for use	Increased clinical monitoring, if needed, adjustment of the dosage of themetoprolol during the length of the treatment with the fluoxetine and after it is stopped.
746	FLUOXETINE	4493			NEBIVOLOL	31555			ANSM	237-FLUOXETINE.html	Risk of increase of the undesirable effects of the nebivolol, especially with excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
747	FLUOXETINE	4493					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	237-FLUOXETINE.html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin	Precaution for use	Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with the fluoxetine and after it is stopped.
748	FLUOXETINE	4493			RISPERIDONE	35636			ANSM	237-FLUOXETINE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone.
749	FLUOXETINE	4493			TAMOXIFEN	10324			ANSM	237-FLUOXETINE.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine.	Not recommended	
750	FLUOXETINE	4493			VORTIOXETINE	1455099			ANSM	237-FLUOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with fluoxetine and after it is stopped.
751	FLUVOXAMINE	42355			AGOMELATINE	306718			ANSM	238-FLUVOXAMINE.html	Increase of the concentrations of agomelatine, with risk of increase of the undesirable effects.	CONTRAINDICATION	
752	FLUVOXAMINE	42355			CARBAMAZEPINE	2002			ANSM	238-FLUVOXAMINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.
753	FLUVOXAMINE	42355			CLOZAPINE	2626			ANSM	238-FLUVOXAMINE.html	Increase of the plasma concentrations of clozapine with signs of overdose	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the clozapine during the treatment with the fluvoxamine and after it is stopped.
754	FLUVOXAMINE	42355			DULOXETINE	72625			ANSM	238-FLUVOXAMINE.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine	CONTRAINDICATION	
755	FLUVOXAMINE	42355			LIDOCAINE	6387			ANSM	238-FLUVOXAMINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
756	FLUVOXAMINE	42355			METHADONE	6813			ANSM	238-FLUVOXAMINE.html	Increase of the plasma concentrations of methodone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Strengthen clinical monitoring and EKG; if needed, adjustment of the dosage of the methadone during the treatment with the fluvoxamine and after it is stopped.
757	FLUVOXAMINE	42355			MEXILETINE	6926			ANSM	238-FLUVOXAMINE.html	Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and EKG. Adjustment of the dosage of the mexiletine during the treatment with the fluvoxamine and after it is stopped.
758	FLUVOXAMINE	42355			OLANZAPINE	61381			ANSM	238-FLUVOXAMINE.html	Increase of the concentrations of the olanzapine, with risk of increase of the undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and possible reduction of the dosage of the olanzapine during the treatment with fluvoxamine.
759	FLUVOXAMINE	42355					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	238-FLUVOXAMINE.html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage of the phenytoin during the treatment with the fluvoxamine and after it is stopped.
760	FLUVOXAMINE	42355			PIRFENIDONE	88221			ANSM	238-FLUVOXAMINE.html	Increase of the plasma concentrations of pirfenidone with signs of overdose	CONTRAINDICATION	
761	FLUVOXAMINE	42355			PROPRANOLOL	8787			ANSM	238-FLUVOXAMINE.html	Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia	Precaution for use	Increased clinical monitoring, and, if needed, adjustment of the dosage of the propranolol during the treatment with the fluvoxamine and after it is stopped.
762	FLUVOXAMINE	42355			ROPINIROLE	72302			ANSM	238-FLUVOXAMINE.html	Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with fluvoxamine and after it is stopped.
763	FLUVOXAMINE	42355					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	238-FLUVOXAMINE.html	Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if needed, adjustment of the dosage of the theophylline during the treatment with fluvoxamine and after it is stopped.
764			FOLATES	V03-			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	239-FOLATES.html	Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	Clinical monitoring, testing of the plasma concentrations, and adjustment, if there is reason for it, of the dosage of the phenobarbital during the folic supplementation and after it is stopped.
765			FOLATES	V03-			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	239-FOLATES.html	Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin. Possible adjustment of the dosage of the phenytoin during the folic supplementation and after it is stopped.
766	ALISKIREN	325646					ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	24-ALISKIREN.html	Risk of hyperkalemia, renal insufficiency, increase of mortality due to cardio vascular disease	Contraindication	-for patients with diabetes or renal insufficiency
767	ALISKIREN	325646			CICLOSPORIN	3008			ANSM	24-ALISKIREN.html	The plasma concentrations of aliskiren increase by nearly 5 times and increase of the risk of its undesirable effects.	CONTRAINDICATION	
768	ALISKIREN	325646					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	24-ALISKIREN.html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardio vascular disease	Contraindication	-for patients with diabetes or renal insufficiency
769	ALISKIREN	325646			ITRACONAZOLE	28031			ANSM	24-ALISKIREN.html	The plasma concentrations of aliskiren increase by nearly 6 times and increase of the risk of its undesirable effects.	CONTRAINDICATION	
770	ALISKIREN	325646			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	24-ALISKIREN.html	Risk of decrease of the effectiveness of the aliskiren when grapefruit is consumed	Not recommended	
771	ALISKIREN	325646			QUINIDINE	9068			ANSM	24-ALISKIREN.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	CONTRAINDICATION	
772	ALISKIREN	325646			SACUBITRIL	1656328			ANSM	24-ALISKIREN.html	With patients who have diabetes or renal insufficiency, increase of the undesirable effects such as hypotension, hyperkalemia	CONTRAINDICATION	
773	ALISKIREN	325646			VERAPAMIL	11170			ANSM	24-ALISKIREN.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Precaution for use	Clinical monitoring
774	FOSAMPRENAVIR	358262			BUPRENORPHINE	1819			ANSM	240-FOSAMPRENAVIR.html	Risk of increase or of decrease of the effects of the A to take into account buprenorphine [sic], simultaneously by inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
775	FOSAMPRENAVIR	358262			EFAVIRENZ	195085			ANSM	240-FOSAMPRENAVIR.html	Risk of lower effectiveness of the amprenavir.	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
776	FOSAMPRENAVIR	358262			MARAVIROC	620216			ANSM	240-FOSAMPRENAVIR.html	Significant decrease of the concentrations of amprenavir that can lead to a loss of viralogical response	Not recommended	
777	FOSAMPRENAVIR	358262			METHADONE	6813			ANSM	240-FOSAMPRENAVIR.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ampernavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
778	FOSAMPRENAVIR	358262			NEVIRAPINE	53654			ANSM	240-FOSAMPRENAVIR.html	Risk of lower effectiveness of the amprenavir	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
779	FOSCARNET	33562			PENTAMIDINE	7994			ANSM	241-FOSCARNET.html	Risk of severe hypocalcemia	Precaution for use	Monitoring of the calcemia and supplementation if necessary.
780	FOTEMUSTINE	25287			DACARBAZINE	3098			ANSM	242-FOTEMUSTINE.html	With the dacarbazine in large doses: risk of pulmonary toxicity (adult acute respiratory distress syndrome ).	Precaution for use	Do not use these medications simultaneously, but wait a week between the last administration of fotemustine and the first day of the treatment with dacarbazine.
781	FUROSEMIDE	460					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	243-FUROSEMIDE.html	Decrease of the diuretic effect which can reach 50%	Precaution for use	Possibly use higher doses of furosemide.
782	GANCICLOVIR	4678			DIDANOSINE	3364			ANSM	244-GANCICLOVIR.html	Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours	Not recommended	
783	GANCICLOVIR	4678			ZALCITABINE	3363			ANSM	244-GANCICLOVIR.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together.
784	GANCICLOVIR	4678			ZIDOVUDINE	11413			ANSM	244-GANCICLOVIR.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses.
785	GEMFIBROZIL	4719			DASABUVIR	1597381			ANSM	245-GEMFIBROZIL.html	Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil	CONTRAINDICATION	
786	GEMFIBROZIL	4719			ENZALUTAMIDE	130729			ANSM	245-GEMFIBROZIL.html	Increase of the active fraction of the enzalutamide	Precaution for use	Reduce the dose of enzalutamide by half when administered with the gemfibrozil.
787	GEMFIBROZIL	4719			PIOGLITAZONE	33738			ANSM	245-GEMFIBROZIL.html	Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring.
788	GEMFIBROZIL	4719			REPAGLINIDE	73044			ANSM	245-GEMFIBROZIL.html	Risk of severe hypoglycemia, even coma, due to substantial increase of the plasma concentrations of repaglinide by the gemfiborzil	CONTRAINDICATION	
789	GLIBENCLAMIDE	4815			BOSENTAN	75207			ANSM	246-GLIBENCLAMIDE.html	Risk of reduced effectiveness of the glibenclamide due to decrease of its plasma concentrations, because of the inducer effect of the bosentan. Furthermore, cases of hepatoxicity have been reported with these substances administered together.	Precaution for use	Monitoring of the glycemia, adjustment of the treatment if needed, and monitoring of the hepatic biological constants
790	GLIBENCLAMIDE	4815			CLARITHROMYCIN	21212			ANSM	246-GLIBENCLAMIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin
791	GLIBENCLAMIDE	4815			ERYTHROMYCIN	4053			ANSM	246-GLIBENCLAMIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
792	GLIMEPIRIDE	25789			CLARITHROMYCIN	21212			ANSM	247-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic.	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin
793	GLIMEPIRIDE	25789			ERYTHROMYCIN	4053			ANSM	247-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
794			GLINIDES	A10BX-001			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	248-GLINIDES.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient, and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose
795			GLINIDES	A10BX-001			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	248-GLINIDES.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient, and reinforce, especially at the beginning of treatment, self-monitoring of blood glucose.
796	GLIPIZIDE	4821			VORICONAZOLE	121243			ANSM	249-GLIPIZIDE.html	Risk of increase of the plasma concentrations of the glipizide at the origin of potentially severe hypoglycemia.	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during and after the treatment with voriconazole.
797	ALLOPURINOL	519					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	25-ALLOPURINOL.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the allopurinol and a week after it is stopped.
798	ALLOPURINOL	519			DIDANOSINE	3364			ANSM	25-ALLOPURINOL.html	Increase of the plasma concentrations of didanosine and of its undesirable effects	Not recommended	
799	ALLOPURINOL	519					AMINOPENICILLINS	J01CA	ANSM	25-ALLOPURINOL.html	Increased risk of cutaneous reactions	Take into account	
800	ALLOPURINOL	519			VIDARABINE	11194			ANSM	25-ALLOPURINOL.html	Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral	Not recommended	
801			GLIPTINS	A10B-001			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	250-GLIPTINS.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose
802			GLIPTINS	A10B-001			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	250-GLIPTINS.html	Increase of the risk of the onset of angioedema, due to the reduction of the activity of the enzyme dipetidyl peptidase-4 (DDP-4) by the gliptin, in patients treated with the angiotensin converting enzyme inhibitor	Take into account	
803			ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001			IMMUNOSUPPRESSANTS	L04A	ANSM	251-ANTI-LYMPHOCYTE-GLOBULINS.html	Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)	Take into account	
804			ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	251-ANTI-LYMPHOCYTE-GLOBULINS.html	Risk of possibly fatal general illness. This risk is increased in older patients already immunodepressed by the underlying disease.	Take into account	In particular, use an inactivated vaccine when one exists (poliomyelitis)
805			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ACETYLSALICYLIC ACID	1191			ANSM	252-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
806			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			ORAL ANTICOAGULANTS	B01A-001	ANSM	252-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the Vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) in large doses or in treatment prolonged beyond 10 days.	Precaution for use	When administering substances from these groups together is justified, strengthen monitoring: if the situation requires, with the vitamin K antagonists, biological testing on the 8th day, then every two weeks after that during the corticotherapy and after it is stopped.
807			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	252-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have Addisons disease treated with hydrocortisone and in cases of organ transplants	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped.
808			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	252-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Increase of the risk of ulceration and of gastrointestinal hemorrhage	Take into account	
809			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			NON-DEPOLARIZING CURARES	M03A-002	ANSM	252-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).	Take into account	
810			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			FLUOROQUINOLONES	J01MA-001	ANSM	252-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving corticotherapy for a prolonged period	Take into account	
811			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ISONIAZID	6038			ANSM	252-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Described for prednisolone. Decrease of the plasma concentrations of the isoniazid. Mechanism proposed: increase of the hepatic metabolism of the isoniazid and decrease of that of the glucocorticoides	Precaution for use	Clinical and biological monitoring.
812			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	RIFAMPICIN	9384			ANSM	252-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with rifampicin and after it is stopped.
813			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	252-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	With the exception of inhaled and local routes, and for doses greater than 10mg/day of prednisone-equivalent (or > 2mg/kg/day for a child or > 20mg/day for a child weighing more than 10 kg) during more than two weeks and for the "bolus" of corticoids: risk of possibly fatal general vaccine disease.	CONTRAINDICATION	And during the 3 months following the end of the therapy with the corticoid.
814	GLUCOSAMINE	4845					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	253-GLUCOSAMINE.html	Increase of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K Antagonist
815	GLYCEROL	4910			LITHIUM	6448			ANSM	254-GLYCEROL.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
816	GRISEOFULVIN	5021					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	255-GRISEOFULVIN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvin	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with griseofulvin and a week after it is stopped
817	GRISEOFULVIN	5021					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	255-GRISEOFULVIN.html	Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism	Precaution for use	Another method of contraception, in particular a barrier type, should be used during the time the two substances are administered together and a cycle after.
818	GRISEOFULVIN	5021					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	255-GRISEOFULVIN.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the length of time these substances are administered together and a cycle following.
819	GUANETHIDINE	5036					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	256-GUANETHIDINE.html	With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension	CONTRAINDICATION	Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.
820	HALOFANTRINE	50749					AZOLE ANTIFUNGALS	J02AC-001	ANSM	257-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering the substances together cannot be avoided, testing of the QT interval before the beginning of the treatment and EKG monitoring
821	HALOFANTRINE	50749			CLARITHROMYCIN	21212			ANSM	257-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT interval before the beginning of the treatment and EKG monitoring
822	HALOFANTRINE	50749			ERYTHROMYCIN	4053			ANSM	257-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT interval before the beginning of the treatment and EKG monitoring
823	HALOFANTRINE	50749					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	257-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
824	HALOFANTRINE	50749			JOSAMYCIN	6084			ANSM	257-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT interval before the beginning of the treatment and EKG monitoring
825	HALOFANTRINE	50749			MICONAZOLE	6932			ANSM	257-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering the substances together cannot be avoided, testing of the QT interval before the beginning of the treatment and EKG monitoring
826	HALOFANTRINE	50749			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	257-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
827	HALOFANTRINE	50749			STIRIPENTOL	37119			ANSM	257-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
828	HALOPERIDOL	5093					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	258-HALOPERIDOL.html	Clinical monitoring and, if needed, adjustment of the dosage during the treatment with the carbamazepine and after it is stopped	Precaution for use	Clinical monitoring and, if needed, adjustment of the dosage during the treatment with the carbamazepine and after it is stopped.
829	HALOPERIDOL	5093			RIFAMPICIN	9384			ANSM	258-HALOPERIDOL.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped.
830	HALOTHANE	5095					BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	259-HALOTHANE.html	In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity	Not recommended	Interrupt treatment with the beta-2 agonist if the anesthesia must be done with halothane
831	HALOTHANE	5095					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	259-HALOTHANE.html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
832			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001	ANSM	26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html	Increase of the hypotensive effect. Risk of severe orthostatic hypotension.	Not recommended	
833			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001			ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001	ANSM	26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html	Increase of the hypotensive effect. Increased risk of orthostatic hypotension	Take into account	
834			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html	Risk of orthostatic hypotension, especially in older patients	Not recommended	-with doxazosin
835			HEPARINS	B01AB			PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	260-HEPARINS.html	Increased risk of hemorrhage	Take into account	
836			HEPARINS	B01AB	DEFIBROTIDE	1311089			ANSM	260-HEPARINS.html	Accrued risk of hemorrhage	Not recommended	
837			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ACETYLSALICYLIC ACID	1191			ANSM	261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
838			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001			ORAL ANTICOAGULANTS	B01A-001	ANSM	261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage	Precaution for use	If the administration of these together cannot be avoided, strengthen clinical monitoring and, if the situation requires, biological monitoring.
839			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
840			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	DEXTRAN 40	42635			ANSM	261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
841			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001			THROMBOLYTICS	B01AD	ANSM	261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage	Take into account	
842			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ACETYLSALICYLIC ACID	1191			ANSM	262-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical and possibly biological monitoring.	Take into account	
843			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	262-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	Increase of the risk of hemorrhage	Take into account	
844			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ACETYLSALICYLIC ACID	1191			ANSM	263-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
845			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	263-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
846			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	263-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage	Precaution for use	When the heparin alternates with the vitamin K antagonist, strengthen clinical monitoring.
847			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	DEXTRAN 40	42635			ANSM	263-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
848			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003			THROMBOLYTICS	B01AD	ANSM	263-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage	Take into account	
849			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ACETYLSALICYLIC ACID	1191			ANSM	264-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
850			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	264-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	Increase of the risk of hemorrhage	Take into account	
851			THYROID HORMONES	H03AA			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	265-THYROID-HORMONES.html	Risk of clinically low thyroid in patients with hypothyroidism, due to increase of the metabolism of the T3 and of the T4	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the inducer and after it is stopped.
852			THYROID HORMONES	H03AA	CALCIUM	1428011			ANSM	265-THYROID-HORMONES.html	Decrease of absorption of the thyroid hormones	Precaution for use	Take the calcium salts at a different time from the thyroid hormones (more than 2 hours apart, if possible).
853			THYROID HORMONES	H03AA	CHLOROQUINE	2393			ANSM	265-THYROID-HORMONES.html	Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment of the dosage of the thyroid hormone if needed during the treatment with the antimalarial and after it is stopped.
854			THYROID HORMONES	H03AA			NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	265-THYROID-HORMONES.html	Risk of clinical hypothyroidism in cases of estrogen substitution therapy	Precaution for use	Clinical and biological monitoring; possible adjustment of the doses of the thyroid hormone for menopausal women taking estrogens.
855			THYROID HORMONES	H03AA	IRON	1431589			ANSM	265-THYROID-HORMONES.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	Take the thyroid hormones at a different time from the iron (more than 2 hours apart, if possible).
856			THYROID HORMONES	H03AA	IMATINIB	282388			ANSM	265-THYROID-HORMONES.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
857			THYROID HORMONES	H03AA			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	265-THYROID-HORMONES.html	Risk of reduction of the effectiveness of the thyroid hormones due to the increase of their hepatic metabolism by the ritonavir	Precaution for use	Clinical and biological monitoring and possible adjustment of the dosage of the thyroid hormones.
858			THYROID HORMONES	H03AA	ORLISTAT	37925			ANSM	265-THYROID-HORMONES.html	Risk of disequilibrium of the thyroid replacement therapy in cases where there is treatment with orlistat	Take into account	
859			THYROID HORMONES	H03AA	PROGUANIL	2382			ANSM	265-THYROID-HORMONES.html	Risk of clinically low thyroid with patients having thyroid replacement therapy	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped.
860			THYROID HORMONES	H03AA			CHELATING RESINS	C10-V0	ANSM	265-THYROID-HORMONES.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	Take the thyroid hormones at a different time from the resin (more than 2 hours apart, if possible).
861			THYROID HORMONES	H03AA	RIFABUTIN	55672			ANSM	265-THYROID-HORMONES.html	Described for phenytoin, rifampicin, and carbamazepine. [sic]Risk of clinical hypothyroidism in patients with low thyroid, due to increase of the metabolism of the T3 and T4	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with rifabutin and after it is stopped.
862			THYROID HORMONES	H03AA	RIFAMPICIN	9384			ANSM	265-THYROID-HORMONES.html	Risk of clinically low thyroid in patients with already low thyroid due to increase of the metabolism of the T3 and the T4.	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormones during treatment with rifampicin and after it is stopped.
863			THYROID HORMONES	H03AA	SUCRALFATE	10156			ANSM	265-THYROID-HORMONES.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	Take the thyroid hormones at a different time from the sulcralfate (more than 2 hours apart if possible).
864			THYROID HORMONES	H03AA	SUNITINIB	357977			ANSM	265-THYROID-HORMONES.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
865			MINERAL OILS	A06AA-	LATEX CONDOMS				ANSM	266-MINERAL-OILS.html	Risk of rupture of the condom when used with lubricants containing mineral oils (paraffin oil, silicone oil, etc...)	CONTRAINDICATION	Use hydrosoluble lubricants (glycerin, polyacrylamide...).
866	HYDROCORTISONE	5492					ENZYMATIC INDUCERS	N03-J05-001	ANSM	267-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped.
867	HYDROQUINIDINE	27220					URINARY ALKALIZERS	B05-001	ANSM	268-HYDROQUINIDINE.html	Increase of the plasma concentrations of the hydroquinidine and risk of overdose (decrease of the renal excretion of the hydroquinidine due to alkalinizing of the urine )	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the concentrations of the hydroquinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
868	HYDROQUINIDINE	27220			DIGOXIN	3407			ANSM	268-HYDROQUINIDINE.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction).	Precaution for use	Clinical monitoring and EKG. In the case of unexpected results, test the digoxinemia and adjust the dosage.
869	HYDROQUINIDINE	27220			ITRACONAZOLE	28031			ANSM	268-HYDROQUINIDINE.html	Risk of tinnitis and/or loss of hearing acuity: cinchonism linked to a decrease of the hepatic metabolism of the antiarrythmic by the itraconazole	Precaution for use	Monitoring of the plasma concentrations of the antiarrythmic and possible decrease of its dosage if necessary.
870	HYDROXYCARBAMIDE	5552					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	269-HYDROXYCARBAMIDE.html	When indicated for a patient with drepanocytosis (sickle cell anemia), theoretical risk of general fatal vaccine disease.	Not recommended	Administering these together should be considered only if the benefits are estimated to be higher than the this risk.
871	ALPHA-TOCOPHEROL	11256					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	27-ALPHA-TOCOPHEROL.html	With the vitamin E used in doses greater than or equal to 500 mg per day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with vitamin E and after it is stopped.
872	HYDROXYCHLOROQUINE	5521			METOPROLOL	6918			ANSM	270-HYDROXYCHLOROQUINE.html	With the metoprolol used in heart failure: risk of increase of the undesirable effects of metoprolol due to decrease of its hepatic metabolism by the hydroxycloroquine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the hydroxychloroquine
873	HYDROXYCHLOROQUINE	5521			RIFAMPICIN	9384			ANSM	270-HYDROXYCHLOROQUINE.html	Risk of decrease of the therapeutic effect of the hydroxychloroquine, due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hydroxychloroquine during the treatment with rifampicin and after it is stopped.
874	HYDROXYCHLOROQUINE	5521					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	270-HYDROXYCHLOROQUINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	--with the citalopram, the domperidone, the escitalopram, the hydroxyzine and the piperaquine
875			HYPERKALEMIA INDUCING MEDICATIONS	M01A-001			OTHER HYPERKALEMIA INDUCING MEDICATIONS	M01A-001	ANSM	271-HYPERKALEMIA-INDUCING-MEDICATIONS.html	Risk of increase of hyperkalemia, potentially lethal.	Take into account	
876			HYPNOTICS	N05-R06			OTHER HYPNOTICS	N05-R06	ANSM	272-HYPNOTICS.html	Increase of central nervous system depression	Take into account	
877			POTASSIUM LOWERING AGENTS	C03-001			OTHER POTASSIUM LOWERING AGENTS	C03-001	ANSM	273-POTASSIUM-LOWERING-MEDICATIONS.html	Increased risk of hypokalemia	Precaution for use	Monitoring of kalemia with correction if needed.
878			POTASSIUM LOWERING AGENTS	C03-001	DIGOXIN	3407			ANSM	273-POTASSIUM-LOWERING-MEDICATIONS.html	Hypokaliemia that promotes the toxic effects of the digitalics.	Precaution for use	Correct beforehand any hypokaliemia; maintain clinical monitoring, electrolite monitoring, and EKG.
879			POTASSIUM LOWERING AGENTS	C03-001			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	273-POTASSIUM-LOWERING-MEDICATIONS.html	Increased risk of ventricular arrhythmias, especially torsades de pointes	Precaution for use	Correct any hypokalemia before administering the product and maintain clinical monitoring, electrolyte monitoring and electrocardiographic monitoring.
880			HYPONATREMIA INDUCING MEDICATIONS	C03EA			OTHER HYPONATREMIA INDUCING MEDICATIONS	C03EA	ANSM	274-HYPONATREMIA-INDUCING-MEDICATIONS.html	Increase of the risk of hyponatremia	Take into account	
881	IBRUTINIB	1442981			AMIODARONE	703			ANSM	275-IBRUTINIB.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the amiodarone	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of time these medications are administered together.
882	IBRUTINIB	1442981			DILTIAZEM	3443			ANSM	275-IBRUTINIB.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the diltiazem	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg/day during the length of time these medications are administered together.
883	IBRUTINIB	1442981			VERAPAMIL	11170			ANSM	275-IBRUTINIB.html	Increase of the plasma concentrations of irutinib due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140mg per day during the length of time these medications are administered together.
884	IDELALISIB	1544460					CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	276-IDELALISIB.html	Increase of the undesirable effects of the calcium channel blocker, of the orthostatic hypotension sort, especially with older patients	Precaution for use	Clinical monitoring and adjustment of the dosage of the calcium channel blocker during the treatment with idelalisib and after it is stopped.
885	IDELALISIB	1544460					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	276-IDELALISIB.html	Decrease of the plasma concentratioins of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer	Not recommended	
886	IDELALISIB	1544460					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	276-IDELALISIB.html	Increase of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor	Take into account	
887	IDELALISIB	1544460			ST JOHNS WORT	258326			ANSM	276-IDELALISIB.html	Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
888	IDELALISIB	1544460			RIFAMPICIN	9384			ANSM	276-IDELALISIB.html	Decease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer.	Not recommended	
889	IDELALISIB	1544460					SUBSTRATES AT RISK OF CYP3A4	L01N01	ANSM	276-IDELALISIB.html	Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idelalisib.	Not recommended	
890	IFOSFAMIDE	5657			APREPITANT	358255			ANSM	277-IFOSFAMIDE.html	Risk of increase of the neurotoxicity of the ifosfamide	Take into account	
891	IFOSFAMIDE	5657					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	277-IFOSFAMIDE.html	Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital	Not recommended	
892	IFOSFAMIDE	5657			VEMURAFENIB	1147220			ANSM	277-IFOSFAMIDE.html	Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity	Take into account	
893			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ALCOHOL (DRINK OR INGREDIENT)				ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Increase of the hypertensive and/or hyperthermic effects of the tyramine present in certain alcoholic drinks (chianti, certain beers, etc.)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
894			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	A01AD	ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	Limit the amount, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
895			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	BUPROPION	42347			ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of hypertensive crises. From the fact of the length of action of the MAOI, this interaction is still theoretically possible two weeks after it is stopped	CONTRAINDICATION	
896			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	DEXTROMETHORPHAN	3289			ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
897			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	GUANETHIDINE	5036			ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension	CONTRAINDICATION	Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.
898			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT)	COMT	ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Increase of the pharmacological effects, and especially increase in blood pressure and contraction of the blood vessels by the catecholamines due to the combined inhibition of their metabolism	CONTRAINDICATION	
899			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	Wait two weeks between the discontinuation of the MAOI and the start of the treatment with the SSRI, and at least a week between the end of treatment with the SSRI (except fluoxetine: five weeks) and the start [sic].
900			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	CONTRAINDICATION	Wait two weeks between stopping the MAOI and the start of the other treatment, and at least a week between the end of that treatment and the start of the MAOI.
901			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	MIDODRINE	6963			ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped.	CONTRAINDICATION	
902			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ST JOHNS WORT	258326			ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
903			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	PETHIDINE	6754			ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
904			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	RESERPINE	9260			ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Psychomotor agitation, convulsions, hypertension	CONTRAINDICATION	
905			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL ROUTES)	R01AA	ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped	Not recommended	
906			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Increase of the pressor action of the sympathomimetic, most often moderate.	Precaution for use	Only use under strict medical monitoring.
907			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Paroxysmal hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped	CONTRAINDICATION	
908			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	TETRABENAZINE	10390			ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of hypertensive crises. Because of the duration of the action of the MAOI, this interaction is still theoretically possible two weeks after the MAOI is stopped	CONTRAINDICATION	
909			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	TIANEPTINE	38252			ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of drop in blood pressure, paroxysmal hypertension, hyperthermia, convulsions, death	Not recommended	
910			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	TRAMADOL	10689			ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	CONTRAINDICATION	
911			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			TRIPTANS METABOLIZED BY THE MAO	N02CC-002	ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of arterial hypertension, of constriction of the coronary arteries	CONTRAINDICATION	
912			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003	ANSM	278-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
913			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	BUPROPION	42347			ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of hypertensive crises	CONTRAINDICATION	
914			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	DEXTROMETHORPHAN	3289			ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not Recommended	
915			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			MAOI-B	N04BD0-001	ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of rapid elevation of blood pressure, due to loss of selectivity on the monoamine oxydase, especially in case of eating food rich in tyramine (cheese, beer, ...)	CONTRAINDICATION	
916			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not recommended	If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration at minimum recommended dosages.
917			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, confusion, even coma	Not recommended	If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration of the substances together with minimum recommended dosages.
918			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ST JOHN'S WORT	258326			ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
919			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	PETHIDINE	6754			ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	CONTRAINDICATION	
920			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	By extrapolation from the non selective MAOIs: risk of increase of the pressor action.	Precaution for use	To be used only under strict medical monitoring.
921			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
922			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	TRAMADOL	10689			ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	Not Recommended	
923			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			TRIPTANS METABOLIZED BY THE MAO	N02CC-002	ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of arterial hypertension, of constriction of coronary arteries	CONTRAINDICATION	
924			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003	ANSM	279-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of arterial hypertension, of constriction of coronary arteries	Not Recommended	
925	ALPRAZOLAM	596					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	28-ALPRAZOLAM.html	Possible increase of the sedative effect of the alprazolam	Take into account	
926			MAOI-B	N04BD0-001	BUPROPION	42347			ANSM	280-MAOI-B.html	Risk of hypertensive crises	CONTRAINDICATION	
927			MAOI-B	N04BD0-001			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	280-MAOI-B.html	Risk of rapid elevation of blood pressure, due to loss of selectivity on the monamine oydase, especially in case of consuming food rich in tyramine (cheese, beer,)	CONTRAINDICATION	
928			MAOI-B	N04BD0-001			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	280-MAOI-B.html	Risk of appearance of a serotonin syndrome	Take into account	
929			MAOI-B	N04BD0-001	LEVODOPA	6375			ANSM	280-MAOI-B.html	Increased risk of orthostatic hypotension	Take into account	
930			MAOI-B	N04BD0-001	PETHIDINE	6754			ANSM	280-MAOI-B.html	Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
931			MAOI-B	N04BD0-001	TRAMADOL	10689			ANSM	280-MAOI-B.html	Risk of appearance of a serotonin syndrome	Take into account	
932			MAOI-B	N04BD0-001			TRIPTANS METABOLIZED BY THE MAO	N02CC-002	ANSM	280-MAOI-B.html	Risk of arterial hypertension, of constriction of the coronary arteries	CONTRAINDICATION	
933			MAOI-B	N04BD0-001			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003	ANSM	280-MAOI-B.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
934	IMATINIB	282388					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	281-IMATINIB.html	Increase of the risk of hemorrhage	Not reommended	If administering these together cannot be avoided, strict clinical monitorinig and frequent testing of the INR
935	IMATINIB	282388					THYROID HORMONES	H03AA	ANSM	281-IMATINIB.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
936			IMMUNOSUPPRESSANTS	L04A	BOCEPREVIR	1102129			ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant (especially for the ciclosporin, extremely large for the tacrolimus)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the administration of the medications together and after it is stopped.
937			IMMUNOSUPPRESSANTS	L04A	CLARITHROMYCIN	21212			ANSM	282-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these must be administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
938			IMMUNOSUPPRESSANTS	L04A			CYTOTOXICS	L01	ANSM	282-IMMUNOSUPPRESSANTS.html	Excessive immunodepression with risk of lymphoproliferative syndrome	Take into account	
939			IMMUNOSUPPRESSANTS	L04A	DALFOPRISTIN	229369			ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.
940			IMMUNOSUPPRESSANTS	L04A	DILTIAZEM	3443			ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.
941			IMMUNOSUPPRESSANTS	L04A	DRONEDARONE	233698			ANSM	282-IMMUNOSUPPRESSANTS.html	Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Not recommended	
942			IMMUNOSUPPRESSANTS	L04A	ERYTHROMYCIN	4053			ANSM	282-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
943			IMMUNOSUPPRESSANTS	L04A	FLUCONAZOLE	4450			ANSM	282-IMMUNOSUPPRESSANTS.html	Risk of increase of the blood concentrations of the immunosuppressant due to the inhibition of its metabolism and of the creatinemia	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
944			IMMUNOSUPPRESSANTS	L04A			ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001	ANSM	282-IMMUNOSUPPRESSANTS.html	Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)	Take into account	
945			IMMUNOSUPPRESSANTS	L04A			ENZYMATIC INDUCERS	N03-J05-001	ANSM	282-IMMUNOSUPPRESSANTS.html	Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer	Precaution for use	Increase the dosage of the immunosuppressant according to tests of the blood concentrations. Reduce the dosage after the inducer is stopped.
946			IMMUNOSUPPRESSANTS	L04A			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	282-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and adjustment of its dosage.
947			IMMUNOSUPPRESSANTS	L04A	ITRACONAZOLE	28031			ANSM	282-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.
948			IMMUNOSUPPRESSANTS	L04A	KETOCONAZOLE	6135			ANSM	282-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.
949			IMMUNOSUPPRESSANTS	L04A	ST JOHNS WORT	258326			ANSM	282-IMMUNOSUPPRESSANTS.html	Decrease of the blood concentrations of the immunosuppressant, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect which can have possibly serious consequences (rejection of a graft).	CONTRAINDICATION	
950			IMMUNOSUPPRESSANTS	L04A	NICARDIPINE	7396			ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the treatment and after it is stopped.
951			IMMUNOSUPPRESSANTS	L04A	GRAPEFRUIT (JUICE AND FRUIT)				ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the bioavailability of the immunosuppressant and as a result of its undesirable effects.	Not recommended	
952			IMMUNOSUPPRESSANTS	L04A	POSACONAZOLE	282446			ANSM	282-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
953			IMMUNOSUPPRESSANTS	L04A	PRISTINAMYCIN	66958			ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the medications together and after it is stopped.
954			IMMUNOSUPPRESSANTS	L04A	QUINUPRISTINE	135098			ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped.
955			IMMUNOSUPPRESSANTS	L04A	RANOLAZINE	35829			ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine	Precaution for use	Clinical and biological monitoring and possible adjustment of the dosage of the immunosuppressant.
956			IMMUNOSUPPRESSANTS	L04A	STIRIPENTOL	37119			ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)	CONTRAINDICATION	
957			IMMUNOSUPPRESSANTS	L04A	TELAPREVIR	1102261			ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the substances together and after it is stopped.
958			IMMUNOSUPPRESSANTS	L04A	TELITHROMYCIN	274786			ANSM	282-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
959			IMMUNOSUPPRESSANTS	L04A			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	282-IMMUNOSUPPRESSANTS.html	Risk of general vaccinal disease, possibly fatal.	CONTRAINDICATION	And during the 3 months following the treatment.
960			IMMUNOSUPPRESSANTS	L04A	VEMURAFENIB	1147220			ANSM	282-IMMUNOSUPPRESSANTS.html	Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness	Not recommended	
961			IMMUNOSUPPRESSANTS	L04A	VORICONAZOLE	121243			ANSM	282-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole	Not recommended	-with the everolimus, the sirolimus, and the temsirolimus
962	INDINAVIR	114289			EFAVIRENZ	195085			ANSM	283-INDINAVIR.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.
963	INDINAVIR	114289			NEVIRAPINE	53654			ANSM	283-INDINAVIR.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.
964			ENZYMATIC INDUCERS	N03-J05-001			ANDROGENS	A14AA0	ANSM	284-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of the androgen and as a result of its effectiveness, due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical and biological monitoring during the administrations of these substances together and 1 to 2 weeks after the inducer is discontinued.
965			ENZYMATIC INDUCERS	N03-J05-001	ARIPIPRAZOLE	89013			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the aripiprazole	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the aripiprazole during the administration of these substances together and 1 to 2 weeks after the inducer is stopped
966			ENZYMATIC INDUCERS	N03-J05-001	BEDAQUILINE	1364504			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
967			ENZYMATIC INDUCERS	N03-J05-001	BORTEZOMIB	358258			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
968			ENZYMATIC INDUCERS	N03-J05-001	CABAZITAXEL	996051			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
969			ENZYMATIC INDUCERS	N03-J05-001	CYPROTERONE	3014			ANSM	284-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the cyproterone	Not recommended	--in its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the time these substances are administered together
970			ENZYMATIC INDUCERS	N03-J05-001	DACLATASVIR	1606218			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer	Contraindication	-with the rifampicin
971			ENZYMATIC INDUCERS	N03-J05-001	DASABUVIR	1597381			ANSM	284-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of the dasabuvir by the inducer.	CONTRAINDICATION	
972			ENZYMATIC INDUCERS	N03-J05-001	DISOPYRAMIDE	3541			ANSM	284-ENZYMATIC-INDUCERS.html	Risk of decrease of the concentrations of the disopyramide by the inducer	Precaution for use	Clinical monitoring and possibly adjustment of the disopyramide during the administration of these substances together and 1 to 2 weeks after the inducer is stopped
973			ENZYMATIC INDUCERS	N03-J05-001	DOCETAXEL	72962			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
974			ENZYMATIC INDUCERS	N03-J05-001	DOLUTEGRAVIR	1433868			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer	Not recommended	-in case of resistance to the class of integrase inhibitors
975			ENZYMATIC INDUCERS	N03-J05-001	ERIBULINE	1045453			ANSM	284-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of eribuline by the inducer.	Not recommended	
976			ENZYMATIC INDUCERS	N03-J05-001			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the contraceptive effectiveness, due to increase of the hepatic metabolism of the hormonal contraceptive by the inducer	Not recommended	Another method of contraception, in particular a barrier type, should be used during the treatment with these substances together and a cycle following.
977			ENZYMATIC INDUCERS	N03-J05-001	HYDROCORTISONE	5492			ANSM	284-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped.
978			ENZYMATIC INDUCERS	N03-J05-001			IMMUNOSUPPRESSANTS	L04A	ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer	Precaution for use	Increase the dosage of the immunosuppressant according to tests of the blood concentrations. Reduce the dosage after the inducer is stopped.
979			ENZYMATIC INDUCERS	N03-J05-001	IRINOTECAN	51499			ANSM	284-ENZYMATIC-INDUCERS.html	Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	Not recommended	
980			ENZYMATIC INDUCERS	N03-J05-001	ISAVUCONAZOLE	1720882			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
981			ENZYMATIC INDUCERS	N03-J05-001	ITRACONAZOLE	28031			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the inducer	Not recommended	
982			ENZYMATIC INDUCERS	N03-J05-001	IVACAFTOR	1243041			ANSM	284-ENZYMATIC-INDUCERS.html	Large decrease of the concentrations of the ivacaftor, with risk of loss of effectiveness	Not recommended	
983			ENZYMATIC INDUCERS	N03-J05-001	LURASIDONE	1040028			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the inducer.	CONTRAINDICATION	
984			ENZYMATIC INDUCERS	N03-J05-001	MACITENTAN	1442132			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of macitentan due to increase of its metabolism by the inducer	Not recommended	
985			ENZYMATIC INDUCERS	N03-J05-001	MARAVIROC	620216			ANSM	284-ENZYMATIC-INDUCERS.html	In the absence of co-administration with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer.	Precaution for use	The dose of maraviroc must be increased to 600mg twice a day in this situation.
986			ENZYMATIC INDUCERS	N03-J05-001	METHADONE	6813			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism	Precaution for use	Increase the frequency of the doses of methadone (2 to 3 times a day instead of a single dose per day).
987			ENZYMATIC INDUCERS	N03-J05-001	MIANSERIN	6929			ANSM	284-ENZYMATIC-INDUCERS.html	Risk of ineffectiveness of the mianserin	Not recommended	
988			ENZYMATIC INDUCERS	N03-J05-001	OLAPARIB				ANSM	284-ENZYMATIC-INDUCERS.html	Decrease, possibly very large depending on the inducer, of the plasma concentrations of the olaparib due to increase of its hepatic metabolism by the inducer	Not recommended	
989			ENZYMATIC INDUCERS	N03-J05-001			OMBITASVIR + PARITAPREVIR	OMPA	ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the bitherapy due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
990			ENZYMATIC INDUCERS	N03-J05-001	OXYCODONE	7804			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the inducer	Not recommended	Possible adjustment of the dosage of oxycodone
991			ENZYMATIC INDUCERS	N03-J05-001			PROGESTIN CONTRACEPTIVES	G03-001	ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer.	Not recommended	Another method of contraception, in particular a barrier type, should be used during the length of time that the two substances are administered together and one cycle following.
992			ENZYMATIC INDUCERS	N03-J05-001			NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the effectiveness of the progestogen	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped.
993			ENZYMATIC INDUCERS	N03-J05-001	REGORAFENIB	1312397			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the regorafenib due to increase of its metabolism by the inducer	Not recommended	
994			ENZYMATIC INDUCERS	N03-J05-001	RILPIVIRINE	1102270			ANSM	284-ENZYMATIC-INDUCERS.html	Significant decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
995			ENZYMATIC INDUCERS	N03-J05-001	SERTRALINE	36437			ANSM	284-ENZYMATIC-INDUCERS.html	Risk of ineffectiveness of the treatment by the antidepressant	Not recommended	
996			ENZYMATIC INDUCERS	N03-J05-001	SIMEPREVIR	1482790			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the inducer	Not recommended	
997			ENZYMATIC INDUCERS	N03-J05-001	SOFOSBUVIR				ANSM	284-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the enzymatic inducer.	Contraindication	--wth the rifampicin
998			ENZYMATIC INDUCERS	N03-J05-001	TENEFOVIR ALAFENAMIDE	1721603			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the inducer	Not recommended	If administration of these together cannot be avoided, clinical monitoring during the administration and 1 to 2 weeks after the inducer is stopped
999			ENZYMATIC INDUCERS	N03-J05-001	VEMURAFENIB	1147220			ANSM	284-ENZYMATIC-INDUCERS.html	Risk of decrease of the concentrations of the vermurafenib, with lower effectiveness	Not recommended	
1000			ENZYMATIC INDUCERS	N03-J05-001	VISMODEGIB	1242987			ANSM	284-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of vismodegib due to increase of its hepatic metabolism by the inducer	Not recommended	
1001			ENZYMATIC INDUCERS	N03-J05-001	VORTIOXETINE	1455099			ANSM	284-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the vortioxetine	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the administration with the inducer and 1 to 2 weeks after the inducer is stopped.
1002			CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT)	COMT			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	285-CATECHOL-O-METHYLTRANSFERASE-INHIBITORS-(COMT).html	Increase of the pharmacological effects, and especially increase in blood pressure and contraction of the blood vessels, by the catecholamines due to the combined inhibition of their metabolism	CONTRAINDICATION	
1003			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001	ANSM	286-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of orthostatic hypotension, especially with older patients	Not recommended	-with the doxazosin
1004			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001	ANSM	286-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of orthostatic hypotension, especially with older patients	Not recommended	-with the doxazosine
1005			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE			NITRATE DERIVATIVES AND RELATED	C01D-001	ANSM	286-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and provoking an acute coronary accident	CONTRAINDICATION	
1006			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	286-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase (very large for the avanafil and the vardenafil) of the plasma concentrations of the type 5 phosphodiesterase inhibitor, with risk of hypotension (severe with the vardenafil)	To know the risks and the levels of constraint for each Type 5 phosphodiesterase inhibitor with the strong inhibitors of CYP3A4, consult the AMM ["Authorisation de la mise au marche", a French document for all medications authorized to be marketed in France with information about them] specific for each one of them.	
1007			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	RIOCIGUAT	1439816			ANSM	286-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of large drop in blood pressure (synergic effect)	CONTRAINDICATION	
1008			XANTHINE OXYDASE INHIBITORS	M04AA0			ANTIPURINES	ANTIPUR	ANSM	287-XANTHINE-OXYDASE-INHIBITORS.html	Possibly serious medullary insufficiency	CONTRAINDICATION	
1009			XANTHINE OXYDASE INHIBITORS	M04AA0			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	287-XANTHINE-OXYDASE-INHIBITORS.html	With large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism.	Precaution for use	Clinical monitoring and testing of the theohyllinemia up to two or three weeks after the beginning of the treatment with the inhibitor; if there is reason for it, adjustment of the dosage during the treatment with these substances together.
1010			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ACETYLSALICYLIC ACID	1191			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
1011			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ALISKIREN	325646			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease	Contraindication:	-for patients with diabetes or renal insufficiency
1012			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	In situations where the administration of these medications together is possible, increased risk of degradation of renal function, even acute renal insufficiency, and increase of the hyperkalemia as well as hypotension and fainting or loss of consciousness.	Take into account	
1013			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Acute renal insufficiency with patients at risk (older patients, dehydrated ones, those taking diuretics, those having altered renal function) due to decrease of the glomerular filtration (inhibition of the vasodilating prostaglandins due to the NSAIs). These effects are generally reversible. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment and regularly during the administration of these substances together.
1014			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia producing effects)	Not recommended	--if the administration of these medications together is justified, strict testing of the kalemia and of the renal function.
1015			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			POTASSIUM LOWERING DIURETICS	C03	ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of abrupt arterial hypotension and/or acute renal insufficiency at the start of or when there is an increase of the dosage of the treatment with the ACE inhibitor in cases of pre-existing fluid depletion	Precaution for use	In arterial hypertension, when there is fluid depletion from a previous treatment with a diuretic, it is necessary:
1016			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	EPLERENONE	298869			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the risk of hyperkalemia, especially with older patients.	Precaution for use	Strict testing of the kalemia and of renal function during the administration of these substances together.
1017			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ESTRAMUSTINE	4089			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of increase of the undesirable effects of the angioneurotic edema type (angioedema)	Not recommended	
1018			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	EVEROLIMUS	141704			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the risk of angioedema	Take into account	
1019			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			GLIPTINS	A10B-001	ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the risk of the onset of angioedema, due to reduction of the activity of the enzyme dipetidyl peptidase-4 (DDP-4) by the gliptin, in patients treated with the ACE inhibitor	Take into account	
1020			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	INSULIN	5856			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
1021			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	LITHIUM	6448			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the lithemia which can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	If the use of an ACE inhibitor is indispensable, strict monitoring of the lithemia and adjustment of the dosage of the lithium.
1022			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	GOLD	691572			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the gold salts administered by IV route: risk of nitritoid reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)	Take into account	
1023			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	POTASSIUM	8588			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Unless there is hypokalemia.
1024			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	RACECADOTRIL	16738			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of increase of the undesirable effects of the angioedema type.	Contraindication	--in case of preceding angioedema with ACE inhibitors
1025			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	SACUBITRIL	1656328			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the risk of angiodema	Contraindication	
1026			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	SPIRONOLACTONE	9997			ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the spironolactone at dosages from 12.5 to 50 mg per day, and with low doses of ACE inhibitorsIn the treatment of class III or IV heart failure (NYHA) with an ejection fraction <35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescribed doses for this combination of medications.	Precaution for use	Verify the absence of pre-existing hyperkalemia and renal insufficiency. Strict biological monitoring of the kalemia and of the creatinemia (1 time per week during the first month, then one time per month thereafter).
1027			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	288-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in diabetic patients treated with glucose lowering sulfonamides. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for the glucose lowering sulfonamides)	Precaution for use	Reinforce self-monitoring of blood glucose.
1028			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	FUSIDIC ACID				ANSM	289-HMG-COA REDUCTASE INHIBITORS (STATINS).html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type.	Not recommended	Stop the treatment with the HMG Co-A reductase inhibitor before starting a treatment with fusidic acid or use another antibiotic
1029			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	289-HMG-COA REDUCTASE INHIBITORS (STATINS).html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
1030			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	COLCHICINE	2683			ANSM	289-HMG-COA REDUCTASE INHIBITORS (STATINS).html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis	Precaution for use	Clinical and biological monitoring, especially at the beginning of the administration of these substances together.
1031			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	DAPTOMYCIN	22299			ANSM	289-HMG-COA REDUCTASE INHIBITORS (STATINS).html	Risk of addition of the undesirable effects (dose dependent) of the rhabdomyolysis type.	Not recommended	If the administration of these medications together cannot be avoided, reinforce biological monitoring (dosage of the CPK more than once a week) and strict clinical monitoring.
1032			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ELTROMBOPAG	711942			ANSM	289-HMG-COA REDUCTASE INHIBITORS (STATINS).html	Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the statin.
1033			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA			FIBRATES	C01AB-001	ANSM	289-HMG-COA REDUCTASE INHIBITORS (STATINS).html	Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. Furthermore, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin	Contraindication	--for doses of 40mg of rosuvastatin
1034			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	LEDIPASVIR	1591922			ANSM	289-HMG-COA REDUCTASE INHIBITORS (STATINS).html	Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolosis type.	Contraindication	--with the rosuvastatin.
1035			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	LENALIDOMIDE	342369			ANSM	289-HMG-COA REDUCTASE INHIBITORS (STATINS).html	Increased risk of the appearance of rhabdomyolysis	Precaution for use	Reinforce clinical and biological monitoring, especially during the first weeks of treatment.
1036			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	AFATINIB	1430438			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the protease inhibitor	Precaution for use	It is recommended that that the protease inhibitor be administered as far from the afatinib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
1037			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ALBENDAZOLE	430			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of reduction of its effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.
1038			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	CONTRAINDICATION	
1039			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
1040			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Variation of the effect of the vitamin K antagonist, most often by decreasing it	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the length of the treatment
1041			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ATORVASTATIN	83367			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Not recommended	Use weaker doses of atorvastatin. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
1042			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ATOVAQUONE	60212			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism	Not recommended	
1043			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome, even of adrenal insufficiency	Take into account	
1044			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	BOCEPREVIR	1102129			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure	Not recommended	
1045			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	BUPRENORPHINE	1819			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
1046			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	CLARITHROMYCIN	21212			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of treatment with these medications together.
1047			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	COLCHICINE	2683			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Not recommended	
1048			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	CYPROTERONE	3014			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of edimumution [sic] of the effectiveness of the cyyproterone.	Not recommended	--in its use as a hormonal contraceptive: use instead another method ofcontraception in particular a barrier type, during the administration of these substances together and a cycle following
1049			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	DEXAMETHASONE	3264			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
1050			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	DIGOXIN	3407			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the digoxinemia, more marked for IV route, due to increase of the absorption of the digoxin or decrease of its renal clearance.	Precaution for use	Clinical monitoring and, if there is reason for them, EKG and monitoring of the digoxinemia, with possible adjustment of the dosage of digoxin.
1051			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ERIBULINE	1045453			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the plasma concentrations of eribuline by the ritonavir	Not recommended	
1052			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive, because of the increase of its hepatic metabolism by the ritonavir.	Not recommended	Another method of contraception, in particular a barrier type (condom or IUD), should be used during the length of the treatment with these medications together and a cycle following.
1053			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	HALOFANTRINE	50749			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1054			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			THYROID HORMONES	H03AA	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of reduction of the effectiveness of the thyroid hormones due to increase of their hepatic metabolism by the ritonavir	Precaution for use	Clinical and biological monitoring and possible adjustment of the dosage of the thyroid hormones.
1055			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			IMMUNOSUPPRESSANTS	L04A	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and adjustment of its dosage.
1056			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of increase of the plasma concentration of the ritonavir boosted protease inhibitor or of the CYP3A4 inhibitor.	Take into account	To know the risks and levels of severity of each ritonavir boosted protease inhibitor taken with the strong inhibitors of CYP3A4, consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them.
1057			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ITRACONAZOLE	28031			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of increase of the concentrations of itraconazole by the protease inhibitor	Precaution for use	Clinical monitoring during the administration of these together. Administering large doses of itraconazole (>200 mg per day) is not recommended.
1058			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	LAMOTRIGINE	28439			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir	Not recommended	-Avoid beginning the treatment with ritonavir during the period of adjustment of the dosage of lamotrigine
1059			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	LUMEFANTRINE	847728			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1060			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	METHADONE	6813			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
1061			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	MIDAZOLAM	6960			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use with:	- the midazolam IV and sublingual
1062			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ST JOHNS WORT	258326			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)	CONTRAINDICATION	In the case of the substances being taken together by accident, do not stop the St Johns wort abruptly, but test the plasma concentrations (or the effectiveness) of the protease inhibitor before and then after the St Johns wort is stopped.
1063			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	MIZOLASTINE	61455			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1064			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	NINTEDANIB	1592737			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the plasma concentrations of nintedanib due to increase of its absorption by the ritonavir boosted protease inhibitor	Precaution for use	Clinical monitoring during the administration of these substances together.
1065			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			PROGESTIN CONTRACEPTIVES	G03-001	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir	Not recommended	Another method of contraception, in particular a barrier type (condom or IUD), should be used during the time the substances are administered together and one cycle following.
1066			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	QUINIDINE	9068			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1067			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	RIFABUTIN	55672			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin, for another thing.	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1068			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	RIFAMPICIN	9384			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	CONTRAINDICATION	Until additional information about the ritonavir boosted protease inhibitors is available.
1069			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ROSUVASTATIN	301542			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption	Precaution for use	Clinical and biological monitoring.
1070			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	SIMVASTATIN	36567			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metoblism of the simvastatin).	CONTRAINDICATION	
1071			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	TELAPREVIR	1102261			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure.	Not recommended	
1072			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	TENEFOVIR ALAFENAMIDE	1721603			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	With the atazanavir, the darunavir or the lopinavir, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its aborption	Precaution for use	In case of administration of these together, the dose of tenofovir alafenamide must be limited to 10 mg per day. The administration with the other protease inhibitors of HIV has not been studied.
1073			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the protease inhibitor and after it is stopped.
1074			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ULIPRISTAL	1005921			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
1075			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	VENLAFAXINE	39786			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
1076			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			VINCA ALKALOIDS	L01CA	ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor.	Precaution for use	Strict clinical monitoring and possible adjustment of the dosage of the antimitotic.
1077			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	VORICONAZOLE	121243			ANSM	289-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment	Not recommended	
1078			ALUMINUM (SALTS)	A02AD0-001			CITRATES	V09HX	ANSM	29-ALUMINUM-(SALTS).html	Risk of facilitating systemic uptake of the aluminum salts especially when there is altered renal function	Precaution for use	Take aluminum based gastrointestinal medications at a different time (more than 2 hours apart if possible) from the citrates, including the natural ones such as citrus fruits and juices.
1079			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	AFATINIB	1430438			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the protease inhibitor	Precaution for use	It is recommended that that the protease inhibitor be administered as far from the afatinib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
1080			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ALBENDAZOLE	430			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of reduction of its effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.
1081			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	CONTRAINDICATION	
1082			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
1083			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Variation of the effect of the vitamin K antagonist, most often by decreasing it	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the length of the treatment
1084			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ATORVASTATIN	83367			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Not recommended	Use weaker doses of atorvastatin. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
1085			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ATOVAQUONE	60212			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism	Not recommended	
1086			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome, even of adrenal insufficiency	Take into account	
1087			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	BOCEPREVIR	1102129			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure	Not recommended	
1088			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	BUPRENORPHINE	1819			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
1089			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	CLARITHROMYCIN	21212			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of treatment with these medications together.
1090			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	COLCHICINE	2683			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Not recommended	
1091			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	CYPROTERONE	3014			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of edimumution [sic] of the effectiveness of the cyyproterone.	Not recommended	--in its use as a hormonal contraceptive: use instead another method ofcontraception in particular a barrier type, during the administration of these substances together and a cycle following
1092			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	DEXAMETHASONE	3264			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
1093			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	DIGOXIN	3407			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the digoxinemia, more marked for IV route, due to increase of the absorption of the digoxin or decrease of its renal clearance.	Precaution for use	Clinical monitoring and, if there is reason for them, EKG and monitoring of the digoxinemia, with possible adjustment of the dosage of digoxin.
1094			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ERIBULINE	1045453			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of eribuline by the ritonavir	Not recommended	
1095			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive, because of the increase of its hepatic metabolism by the ritonavir.	Not recommended	Another method of contraception, in particular a barrier type (condom or IUD), should be used during the length of the treatment with these medications together and a cycle following.
1096			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	HALOFANTRINE	50749			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1097			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			THYROID HORMONES	H03AA	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of reduction of the effectiveness of the thyroid hormones due to increase of their hepatic metabolism by the ritonavir	Precaution for use	Clinical and biological monitoring and possible adjustment of the dosage of the thyroid hormones.
1098			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			IMMUNOSUPPRESSANTS	L04A	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and adjustment of its dosage.
1099			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of increase of the plasma concentration of the ritonavir boosted protease inhibitor or of the CYP3A4 inhibitor.	Take into account	To know the risks and levels of severity of each ritonavir boosted protease inhibitor taken with the strong inhibitors of CYP3A4, consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them.
1100			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ITRACONAZOLE	28031			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of increase of the concentrations of itraconazole by the protease inhibitor	Precaution for use	Clinical monitoring during the administration of these together. Administering large doses of itraconazole (>200 mg per day) is not recommended.
1101			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	LAMOTRIGINE	28439			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir	Not recommended	-Avoid beginning the treatment with ritonavir during the period of adjustment of the dosage of lamotrigine
1102			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	LUMEFANTRINE	847728			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1103			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	METHADONE	6813			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
1104			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	MIDAZOLAM	6960			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use with:	- the midazolam IV and sublingual
1105			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ST JOHNS WORT	258326			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)	CONTRAINDICATION	In the case of the substances being taken together by accident, do not stop the St Johns wort abruptly, but test the plasma concentrations (or the effectiveness) of the protease inhibitor before and then after the St Johns wort is stopped.
1106			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	MIZOLASTINE	61455			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1107			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	NINTEDANIB	1592737			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of nintedanib due to increase of its absorption by the ritonavir boosted protease inhibitor	Precaution for use	Clinical monitoring during the administration of these substances together.
1108			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			PROGESTIN CONTRACEPTIVES	G03-001	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir	Not recommended	Another method of contraception, in particular a barrier type (condom or IUD), should be used during the time the substances are administered together and one cycle following.
1109			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	QUINIDINE	9068			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1110			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	RIFABUTIN	55672			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin, for another thing.	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1111			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	RIFAMPICIN	9384			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	CONTRAINDICATION	Until additional information about the ritonavir boosted protease inhibitors is available.
1112			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ROSUVASTATIN	301542			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption	Precaution for use	Clinical and biological monitoring.
1113			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	SIMVASTATIN	36567			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metoblism of the simvastatin).	CONTRAINDICATION	
1114			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	TELAPREVIR	1102261			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure.	Not recommended	
1115			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	TENEFOVIR ALAFENAMIDE	1721603			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	With the atazanavir, the darunavir or the lopinavir, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its aborption	Precaution for use	In case of administration of these together, the dose of tenofovir alafenamide must be limited to 10 mg per day. The administration with the other protease inhibitors of HIV has not been studied.
1116			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the protease inhibitor and after it is stopped.
1117			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ULIPRISTAL	1005921			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
1118			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	VENLAFAXINE	39786			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
1119			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			VINCA ALKALOIDS	L01CA	ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor.	Precaution for use	Strict clinical monitoring and possible adjustment of the dosage of the antimitotic.
1120			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	VORICONAZOLE	121243			ANSM	290-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment	Not recommended	
1121			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	291-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the enzymatic inducer	Not recommended	
1122			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE			H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	291-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Risk of decrease of the bioavailability of the tyrosine-kinase inhibitor, by reason of its pH dependent absorption	Take into account	-except with the vandetanib.
1123			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE			PROTON PUMP INHIBITORS	A02BC-001	ANSM	291-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Risk of decrease of the bioavailability of the tyrosine-kinase inhibitor, by reason of its pH dependent absorption	Take into account	-except with the imatinib and the vandetanib
1124			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	291-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Risk of increase of the undesirable effects of the tyrosine kinase inhibitor due to decrease of its metabolism	Not recommeded:	--with the axitinib, the bosutinib, the ceritinib, the cobimetinib, the dabrafenib, the dasatinib, the nilotinib, the sunitinib
1125			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ST JOHNS WORT	258326			ANSM	291-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns wort	CONTRAINDICATION	
1126			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	RIFAMPICIN	9384			ANSM	291-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
1127			DIRECT THROMBIN INHIBITORS	BO1AE	OTHER MEDICATIONS ACTING ON HEMOSTASIS				ANSM	292-DIRECT-THROMBIN -NHIBITORS.html	Increase of the risk of hemorrhage	Take into account	
1128			STRONG INHIBITORS OF CYP3A4	J02-J05			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of constriction of the coronary arteries or of those of the extremities (ergotism), or of rapid elevation of blood pressure.	CONTRAINDICATION	
1129			STRONG INHIBITORS OF CYP3A4	J02-J05	ALFENTANIL	480			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism.	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is treatment with a strong inhibitor of CYP3A4
1130			STRONG INHIBITORS OF CYP3A4	J02-J05	ALFUZOSIN	17300			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects	CONTRAINDICATION	
1131			STRONG INHIBITORS OF CYP3A4	J02-J05	ALRRAZOLAM	596			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Possible increase of the sedative effect of the alprazolam	Take into account	
1132			STRONG INHIBITORS OF CYP3A4	J02-J05			CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.	Precaution for use	Clinical monitoring and dosage adjustment during the treatment with the enzyme inhibitor and after it is stopped
1133			STRONG INHIBITORS OF CYP3A4	J02-J05			URINARY ANTISPASMODICS	DFST	ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects	Contraindication	--with darifenacine
1134			STRONG INHIBITORS OF CYP3A4	J02-J05	APIXABAN	1364430			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the apixaban by the inhibitor, with increased risk of bleeding	Not recommended	
1135			STRONG INHIBITORS OF CYP3A4	J02-J05	BEDAQUILINE	1364504			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor.	Not recommended	If taking these medications together is necessary, more frequent EKG and monitoring of the transaminases are recommended.
1136			STRONG INHIBITORS OF CYP3A4	J02-J05	BORTEZOMIB	358258			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the bortezomib during the length of the treatment with the enzyme inhibitor.
1137			STRONG INHIBITORS OF CYP3A4	J02-J05	BOSENTAN	75207			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increased risk of the undesirable effects of the bosentan, especially of hepatic attacks, due to decrease of its metabolism by the inhibitor	Precaution for use	Clinical and biological monitoring during the administration of these together
1138			STRONG INHIBITORS OF CYP3A4	J02-J05	BRENTUXIMAB	1147320			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of the active metabolite of the brentuximab, with risk of neutropenia	Take into account	
1139			STRONG INHIBITORS OF CYP3A4	J02-J05	CABAZITAXEL	996051			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzyme inhibitor	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the cabazitaxel during the treatment with the enzyme inhibitor
1140			STRONG INHIBITORS OF CYP3A4	J02-J05	COBICISTAT	1306284			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the cobicistat or of the inhibitor of CYP3A4	Take into account	To know the risks and levels of severity of each interaction,consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them.
1141			STRONG INHIBITORS OF CYP3A4	J02-J05	DACLATASVIR	1606218			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of daclatasvir by the inhibitor	Precaution for use	The dose of daclatasvir should be decreased to 30mg once a day when it is administered with the inhibitor.
1142			STRONG INHIBITORS OF CYP3A4	J02-J05	DAPOXETINE	69394			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects, especially of the vertigo or syncope type.	CONTRAINDICATION	
1143			STRONG INHIBITORS OF CYP3A4	J02-J05	DISOPYRAMIDE	3541			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of the undesirable effects of the disopyramide due to decrease of its metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of disopyramide.
1144			STRONG INHIBITORS OF CYP3A4	J02-J05	DOCETAXEL	72962			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable dose-dependent effects of the docetaxel due to inhibition of its metabolism by the enzyme inhibitor	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzyme inhibitor.
1145			STRONG INHIBITORS OF CYP3A4	J02-J05	DOMPERIDONE	3626			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of domperidone due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1146			STRONG INHIBITORS OF CYP3A4	J02-J05	DRONEDARONE	233698			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Large increase of the concentrations of dronedarone due to decrease of its metabolism	CONTRAINDICATION	
1147			STRONG INHIBITORS OF CYP3A4	J02-J05	EPLERENONE	298869			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia	CONTRAINDICATION	
1148			STRONG INHIBITORS OF CYP3A4	J02-J05	FENTANYL	4337			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the opioid analgesic's effect of respiratory depression due to slight decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.
1149			STRONG INHIBITORS OF CYP3A4	J02-J05	IDELALISIB	1544460			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increaese of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor	Take into account	
1150			STRONG INHIBITORS OF CYP3A4	J02-J05			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase (very large for avanafil and vardenafil) of the plasma concentrations of the type 5 phospodiesterase inhibitor, with risk of hypotension (severe with vardenafil)	Contraindication - Not recommended - Precaution for use	To know the risks and levels of severity for each type 5 phospodiesterase inhibitor, consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them.
1151			STRONG INHIBITORS OF CYP3A4	J02-J05			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the protease inhibitor boosted by ritonavir or of the inhibitor of CYP3A4	Take into account	To know the risks and levels of severity for each protease inhibitor boosted by ritonavir with the strong inhibitors of CYP3A4, consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them.
1152			STRONG INHIBITORS OF CYP3A4	J02-J05			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the tyrosine kinase inhibitor due to decrease of its metabolism	Not recommended	-with axitinib, bosutinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib
1153			STRONG INHIBITORS OF CYP3A4	J02-J05	IRINOTECAN	51499			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite	Not recommended	
1154			STRONG INHIBITORS OF CYP3A4	J02-J05	ISAVUCONAZOLE	1720882			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of isavuconazole due to decrease of its hepatic metabolism by the inhibitor	Contraindication	--with the ketoconazole
1155			STRONG INHIBITORS OF CYP3A4	J02-J05	IVABRADINE	77417			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).	CONTRAINDICATION	
1156			STRONG INHIBITORS OF CYP3A4	J02-J05	IVACAFTOR	1243041			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Large increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	Reduce the dose by a fourth, that is 150 mg every other day.
1157			STRONG INHIBITORS OF CYP3A4	J02-J05	LOMITAPIDE	1364479			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the lomitapide due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1158			STRONG INHIBITORS OF CYP3A4	J02-J05	LURASIDONE	1040028			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of lurasidone due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1159			STRONG INHIBITORS OF CYP3A4	J02-J05	MARAVIROC	620216			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of maraviroc by the inhibitor.	Precaution for use	The dose of maraviroc must be decreased to 150 mg twice a day when administered with this inhibitor.
1160			STRONG INHIBITORS OF CYP3A4	J02-J05	METHYLPREDNISOLONE				ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	In case of prolonged use by oral or inhaled route, increase of the plasma concentration of the corticoid due to decrease of its hepatic metabolism by the in inhibitor, with risk of appearance of a cushings syndrome	Take into account	
1161			STRONG INHIBITORS OF CYP3A4	J02-J05	OLAPARIB				ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the olaparib due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If admininstering these together cannot be avoided, limit the dose of olaparib to 150 mg twice a day.
1162			STRONG INHIBITORS OF CYP3A4	J02-J05			OMBITASVIR + PARITAPREVIR	OMPA	ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the ombitsavir + paritaprevir combination due to decrease of its hepatic metabolism by the inhibitor.	CONTRAINDICATION	--except with ritonavir
1163			STRONG INHIBITORS OF CYP3A4	J02-J05	OXYCODONE	7804			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the oxycodone	Not recommended	Clinical monitoring and possible adjustment of the dosage of oxycodone during the length of the treatment with the enzyme inhibitor.
1164			STRONG INHIBITORS OF CYP3A4	J02-J05	PANOBINOSTAT	1603350			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects, especially cardiac ones, of the panobinostat due to decrease of its metabolism by the inhibitor	Precaution for use	Clinical monitoring and EKG. Possible adjustment of the dosage of the panobinostat
1165			STRONG INHIBITORS OF CYP3A4	J02-J05	PIMOZIDE	8331			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk increase of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1166			STRONG INHIBITORS OF CYP3A4	J02-J05	QUETIAPINE	51272			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Large increase of the concentrations of quetiapine, with risk of overdose	CONTRAINDICATION	
1167			STRONG INHIBITORS OF CYP3A4	J02-J05	QUININE	9071			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory disorders (cinchonism).	Not recommended	-with the protease inhibitors
1168			STRONG INHIBITORS OF CYP3A4	J02-J05	RANOLAZINE	35829			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of ranolazine due to decrease of its metabolism by the inhibitor	CONTRAINDICATION	
1169			STRONG INHIBITORS OF CYP3A4	J02-J05	REGORAFENIB	1312397			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
1170			STRONG INHIBITORS OF CYP3A4	J02-J05	RIOCIGUAT	1439816			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of riociquat due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
1171			STRONG INHIBITORS OF CYP3A4	J02-J05	RIVAROXABAN	1114195			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of rivaroxaban, with increase of the risk of bleeding	Not recommended	
1172			STRONG INHIBITORS OF CYP3A4	J02-J05	SIMEPREVIR	1482790			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of simeprevir due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
1173			STRONG INHIBITORS OF CYP3A4	J02-J05			SUBSTRATES AT RISK OF CYP3A4	L01N01	ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the undesirable effects specific to each substrate, with frequently severe consequences	Take into account	
1174			STRONG INHIBITORS OF CYP3A4	J02-J05	SUFENTANIL	56795			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.
1175			STRONG INHIBITORS OF CYP3A4	J02-J05	TAMSULOSINE	77492			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Not recommended	
1176			STRONG INHIBITORS OF CYP3A4	J02-J05	TELITHROMYCIN	274786			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects, especially of the cardiac arrhythmia type.	CONTRAINDICATION	with the patient who has severe renal or hepatic insufficiency
1177			STRONG INHIBITORS OF CYP3A4	J02-J05	TICAGRELOR	1116632			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1178			STRONG INHIBITORS OF CYP3A4	J02-J05	TRASTUZUMAB EMTANSINE				ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the DM1, a componant element of the trastuzumab emtansine, due to inhibition of its metabolism by the inhibitor	Not recommended	
1179			STRONG INHIBITORS OF CYP3A4	J02-J05	VERAPAMIL	11170			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, if the situation requires.
1180			STRONG INHIBITORS OF CYP3A4	J02-J05	ZOLPIDEM	39993			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Slight increase of the sedative effect of the zolpidem	Take into account	
1181			STRONG INHIBITORS OF CYP3A4	J02-J05	ZOPICLONE	40001			ANSM	293-STRONG-INHIBITORS-OF-CYP3A4.html	Slight increase of the sedative effect of the zopiclone	Take into account	
1182			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ACETYLSALICYLIC ACID	1191			ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
1183			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			ORAL ANTICOAGULANTS	B01A-001	ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Precaution for use	Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration with the SSRI and after it is stopped.
1184			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects	Precaution for use	Increased clinical monitoring and, if necessary, adjustment of the dosage
1185			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
1186			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	CYPROHEPTADINE	3013			ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of decrease of the effectiveness of the antidepressant	Take into account	
1187			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	Wait at least two weeks between the discontinuation of the irreversible MAOI and the start of treatment with the SSRI, and at least a week between the end of treatment with the SSRI (except fluoxetine: five weeks) and the beginning [sic].
1188			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not recommended	If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration with minimum recommended dosages.
1189			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			MAOI-B	N04BD0-001	ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome	Take into account	
1190			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	LITHIUM	6448			ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1191			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ST JOHNS WORT	258326			ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1192			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ORLISTAT	37925			ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1193			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	TRAMADOL	10689			ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
1194			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			TRIPTANS	N02CC-001	ANSM	294-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of serotonin syndrome	Take into account	
1195	INSULIN	5856			ALCOHOL				ANSM	295-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
1196	INSULIN	5856					SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	295-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
1197	INSULIN	5856					BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	295-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
1198	INSULIN	5856					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	295-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose.
1199	INSULIN	5856					BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	295-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
1200	INSULIN	5856			CHLORPROMAZINE	2403			ANSM	295-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped.
1201	INSULIN	5856			DANAZOL	3102			ANSM	295-INSULIN.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped.
1202	INSULIN	5856					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	295-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
1203	INTERFERON ALFA						FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ANSM	296-INTERFERON-ALFA.html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
1204	IPILIMUMAB	1094833					ORAL ANTICOAGULANTS	B01A-001	ANSM	297-IPILIMUMAB.html	Increase of the risk of digestive system hemorrhage	Precaution for use	Strict clinical monitoring
1205	IRINOTECAN	51499					ENZYMATIC INDUCERS	N03-J05-001	ANSM	298-IRINOTECAN.html	Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	Not recommended	
1206	IRINOTECAN	51499					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	298-IRINOTECAN.html	Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite	Not recommended	
1207	IRINOTECAN	51499			ST JOHNS WORT	258326			ANSM	298-IRINOTECAN.html	Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	CONTRAINDICATION	
1208	ISAVUCONAZOLE	1720882					ENZYMATIC INDUCERS	N03-J05-001	ANSM	299-ISAVUCONAZOLE.html	Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
1209	ISAVUCONAZOLE	1720882					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	299-ISAVUCONAZOLE.html	Increase of the plasma concentrations of isavuconazole due to decrease of its hepatic metabolism by the inhibitor	Contraindication	--with the ketoconazole
1210	ISAVUCONAZOLE	1720882			ST JOHN'S WORT	258326			ANSM	299-ISAVUCONAZOLE.html	Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1211	ACETAZOLAMIDE	167			ACETYLSALICYLIC ACID				ANSM	3-ACETAZOLAMIDE.html	Increase of the undesirable effects, and especially of metabolic acidosis, of the acetylsalicylic acid in large doses and of the acetazolamide, due to decrease of the elimination of the acetylsalicylic acid by the acetazolamide	Not recommended	
1212	ACETAZOLAMIDE	167			CARBAMAZEPINE	2002			ANSM	3-ACETAZOLAMIDE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, and, if needed, testing of the plasma concentrations of carbamazepine and possible reduction of its dosage.
1213	ACETAZOLAMIDE	167			LITHIUM	6448			ANSM	3-ACETAZOLAMIDE.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
1214	ACETAZOLAMIDE	167					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	3-ACETAZOLAMIDE.html	Increase of the hyperammonemia, with incresed risk of encephalopathy	Precaution for use	Regular clinical and biological monitoring.
1215	AMBRISENTAN	358274			CICLOSPORIN	3008			ANSM	30-AMBRISENTAN.html	Doubling of the concentrations of ambrisentan, with increase of the vasodilator effect (severe headaches )	Take into account	
1216	ISONIAZID	6038					HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	300-ISONIAZID.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after.
1217	ISONIAZID	6038			CARBAMAZEPINE	2002			ANSM	300-ISONIAZID.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
1218	ISONIAZID	6038			DISULFIRAM	3554			ANSM	300-ISONIAZID.html	Disorders of behavior and of coordination	Not recommended	
1219	ISONIAZID	6038					GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	300-ISONIAZID.html	Described for the prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical and biological monitoring.
1220	ISONIAZID	6038			KETOCONAZOLE	6135			ANSM	300-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage.
1221	ISONIAZID	6038					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	300-ISONIAZID.html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped.
1222	ISONIAZID	6038			PYRAZINAMIDE	8987			ANSM	300-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical and biological monitoring.
1223	ISONIAZID	6038			RIFAMPICIN	9384			ANSM	300-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical and biological monitoring of this classic combination. In case of hepatitis, stop the isoniazid.
1224	ISONIAZID	6038			STAVUDINE	59763			ANSM	300-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1225	ISOPRENALINE	6054					HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	301-ISOPRENALINE.html	Serious ventricular arrhythmias due to increase of cardiac sensitization.	Not recommended	
1226	ITRACONAZOLE	28031			AFATINIB	1430438			ANSM	302-ITRACONAZOLE.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the itraconazole.	Precaution for use	It is recommended that the itraconazole be administered as far distant from the afatinib as possible, preferably at an interval of 6 to 12 hours away from the dose of afatinib.
1227	ITRACONAZOLE	28031			ALISKIREN	325646			ANSM	302-ITRACONAZOLE.html	Increase by nearly six times of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	CONTRAINDICATION	
1228	ITRACONAZOLE	28031					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	302-ITRACONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
1229	ITRACONAZOLE	28031					PROTON PUMP INHIBITORS	A02BC-001	ANSM	302-ITRACONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the proton pump inhibitor	Take into account	
1230	ITRACONAZOLE	28031					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	302-ITRACONAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the itraconazole and a week after it is stopped
1231	ITRACONAZOLE	28031			APREPITANT	358255			ANSM	302-ITRACONAZOLE.html	Increase of the concentrations of aprepitant due to decrease of its hepatic metabolism by the intraconazole.	Take into account	
1232	ITRACONAZOLE	28031			ATORVASTATIN	83367			ANSM	302-ITRACONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
1233	ITRACONAZOLE	28031					OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ANSM	302-ITRACONAZOLE.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the itraconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency	Take into account	
1234	ITRACONAZOLE	28031			BUPRENORPHINE	1819			ANSM	302-ITRACONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped .
1235	ITRACONAZOLE	28031			BUSPIRONE	1827			ANSM	302-ITRACONAZOLE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
1236	ITRACONAZOLE	28031			BUSULFAN	1828			ANSM	302-ITRACONAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the itraconazole	Not recommended	
1237	ITRACONAZOLE	28031			COBICISTAT	1306284			ANSM	302-ITRACONAZOLE.html	Risk of increase of the concentrations of itraconazole by the cobicistat	Precaution for use	Clinical monitoring during the administration of these together. The administration of large doses of itraconazole (>200mg per day) is not recommended
1238	ITRACONAZOLE	28031			DABIGATRAN				ANSM	302-ITRACONAZOLE.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
1239	ITRACONAZOLE	28031			DEXAMETHASONE	3264			ANSM	302-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
1240	ITRACONAZOLE	28031			DIGOXIN	3407			ANSM	302-ITRACONAZOLE.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias	Precaution for use	Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia with adjustment of the dosage of the digoxin during the treatment with the itraconazole and after it is stopped.
1241	ITRACONAZOLE	28031			EBASTINE	23796			ANSM	302-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
1242	ITRACONAZOLE	28031			ELVITEGRAVIR	1306286			ANSM	302-ITRACONAZOLE.html	Increase of the plasma concentrations of elvitegravir due to decrease of its metabolism by the itraconazole	Precaution for use	With the elvitegravir in combination with cobicistat, clinical monitoring. Limit the maximum dose of itraconazole to 200 mg/day.
1243	ITRACONAZOLE	28031			HYDROQUINIDINE	27220			ANSM	302-ITRACONAZOLE.html	Risk of tinnitis and/or loss of hearing acuity: cinchonism linked to a decrease of the hepatic metabolism of the antiarrythmic by the itraconazole	Precaution for use	Monitoring of the plasma concentrations of the antiarrythmic and possible decrease of its dosage if necessary.
1244	ITRACONAZOLE	28031					IMMUNOSUPPRESSANTS	L04A	ANSM	302-ITRACONAZOLE.html	Very large increase of the blood concentrations of the immusuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant and possible adjustment of the dosage.
1245	ITRACONAZOLE	28031					ENZYMATIC INDUCERS	N03-J05-001	ANSM	302-ITRACONAZOLE.html	Decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the inducer.	Not recommended	
1246	ITRACONAZOLE	28031					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	302-ITRACONAZOLE.html	Risk of increase of the concentrations of itraconazole by the protease inhibitor	Precaution for use	Clinical monitoring during the administration of these medications together. Using large doses of itraconazole (>200 mg per day) is not recommended.
1247	ITRACONAZOLE	28031			LERCANIDIPINE	135056			ANSM	302-ITRACONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydorpyridine	Not recommended	
1248	ITRACONAZOLE	28031			LUMEFANTRINE	847728			ANSM	302-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the torsadegenic medication. If administering these two together cannot be avoided, testing of the QT beforehand and EKG monitoring.
1249	ITRACONAZOLE	28031			ST JOHNS WORT	258326			ANSM	302-ITRACONAZOLE.html	Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1250	ITRACONAZOLE	28031			MIZOLASTINE	61455			ANSM	302-ITRACONAZOLE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1251	ITRACONAZOLE	28031			NINTEDANIB	1592737			ANSM	302-ITRACONAZOLE.html	Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the itraconazole	Precaution for use	Clinical monitoring during the administration of these medications together.
1252	ITRACONAZOLE	28031			QUINIDINE	9068			ANSM	302-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine	CONTRAINDICATION	
1253	ITRACONAZOLE	28031			SALMETEROL	36117			ANSM	302-ITRACONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole	Take into account	
1254	ITRACONAZOLE	28031			SIMVASTATIN	36567			ANSM	302-ITRACONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolosis type (decrease of the hepatic metabolism of the simvastatin)	CONTRAINDICATION	
1255	ITRACONAZOLE	28031			TELAPREVIR	1102261			ANSM	302-ITRACONAZOLE.html	Risk of increase of the plasma concentrations of telaprevir and of the itraconazole.	Precaution for use	Clinical monitoring. Avoid large doses of itraconazole (>200 mg per day).
1256	ITRACONAZOLE	28031			TENEFOVIR ALAFENAMIDE	1721603			ANSM	302-ITRACONAZOLE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption.	Precaution for use	In case of co-administration with the itraconazole, the dose of tenofovir alafenamide should be limited to 10 mg per day.
1257	ITRACONAZOLE	28031			TRABECTEDIN	1716278			ANSM	302-ITRACONAZOLE.html	Risk of increase of the plasma concentrations of the trabectedin by the itraconazole	Not recommended	If administering these medications together is necessary, clinical monitoring and possible adjustment of the dosage of the trabectedin during the length of the treatment with the itraconazole.
1258	ITRACONAZOLE	28031			VENLAFAXINE	39786			ANSM	302-ITRACONAZOLE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
1259	ITRACONAZOLE	28031					VINCA ALKALOIDS	L01CA	ANSM	302-ITRACONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the itraconazole	Not recommended	
1260	IVABRADINE	77417					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	303-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer.	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of these substances together and after the inducer is stopped.
1261	IVABRADINE	77417			AZITHROMYCIN	18631			ANSM	303-IVABRADINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes. In addition, increase of the plasma concentrations of the ivabradine due to decrease of its metabolism by the azithromycin	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
1262	IVABRADINE	77417			DILTIAZEM	3443			ANSM	303-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules	CONTRAINDICATION	
1263	IVABRADINE	77417					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	303-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).	CONTRAINDICATION	
1264	IVABRADINE	77417			JOSAMYCIN	6084			ANSM	303-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).	CONTRAINDICATION	
1265	IVABRADINE	77417			ST JOHNS WORT	258326			ANSM	303-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the St Johns wort	Not recommended	
1266	IVABRADINE	77417			GRAPEFRUIT (JUICE OR FRUIT)				ANSM	303-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit).	Not recommended	
1267	IVABRADINE	77417			RIFAMPICIN	9384			ANSM	303-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped..
1268	IVABRADINE	77417			VERAPAMIL	11170			ANSM	303-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules	CONTRAINDICATION	
1269	JOSAMYCIN	6084			CARBAMAZEPINE	2002			ANSM	305-JOSAMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and. if needed, plasma dosage and possible reduction of the dosage of the carbamazepine.
1270	JOSAMYCIN	6084			CICLOSPORIN	3008			ANSM	305-JOSAMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped.
1271	JOSAMYCIN	6084			DISOPYRAMIDE	3541			ANSM	305-JOSAMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical, biological and electrocardiographic testing.
1272	JOSAMYCIN	6084			EBASTINE	23796			ANSM	305-JOSAMYCIN.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
1273	JOSAMYCIN	6084			HALOFANTRINE	50749			ANSM	305-JOSAMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
1274	JOSAMYCIN	6084			IVABRADINE	77417			ANSM	305-JOSAMYCIN.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).	CONTRAINDICATION	
1275	JOSAMYCIN	6084			PIMOZIDE	8331			ANSM	305-JOSAMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1276	JOSAMYCIN	6084			SILDENAFIL	136411			ANSM	305-JOSAMYCIN.html	Increase of the plasma concentrations of sildenafil, with risk of hypotension	Precaution for use	Start the treatment with sildenafil at the minimun dose when it is administered with josamycin.
1277	JOSAMYCIN	6084			TACROLIMUS	42316			ANSM	305-JOSAMYCIN.html	Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin	Not recommended	
1278	JOSAMYCIN	6084					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	305-JOSAMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
1279	KETOCONAZOLE	6135			AFATINIB	1430438			ANSM	306-KETOCONAZOLE.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the ketoconazole.	Precaution for use	It is recommended that the ketoconazole be administered as far from the afatinib as possible, preferably at an interval of 6 or 12 hours away from doses of the afatinib
1280	KETOCONAZOLE	6135					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	306-KETOCONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
1281	KETOCONAZOLE	6135					PROTON PUMP INHIBITORS	A02BC-001	ANSM	306-KETOCONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the anitsecretory	Take into account	
1282	KETOCONAZOLE	6135			ATORVASTATIN	83367			ANSM	306-KETOCONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
1283	KETOCONAZOLE	6135					OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ANSM	306-KETOCONAZOLE.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency	Take into account	
1284	KETOCONAZOLE	6135			BUPRENORPHINE	1819			ANSM	306-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
1285	KETOCONAZOLE	6135			DABIGATRAN				ANSM	306-KETOCONAZOLE.html	Increase of more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
1286	KETOCONAZOLE	6135			DEXAMETHASONE	3264			ANSM	306-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
1287	KETOCONAZOLE	6135			EBASTINE	23796			ANSM	306-KETOCONAZOLE.html	Increased risk of ventricular arrhythmias with predisposed patients (congenital long QT syndrome)	Not recommended	
1288	KETOCONAZOLE	6135			ELVITEGRAVIR	1306286			ANSM	306-KETOCONAZOLE.html	Increase of the plasma concentrations of elvitegravir due to decrease of its metabolism by the ketoconazole	Precaution for use	With the elvitegravir combined with cobicistat, clinical monitoring. Limit the maximum dose of ketoconazole to 200 mg/day.
1289	KETOCONAZOLE	6135			FIDAXOMICIN	1111103			ANSM	306-KETOCONAZOLE.html	Increase of the plasma concentrations of the fidaxomicine	Not recommended	
1290	KETOCONAZOLE	6135					IMMUNOSUPPRESSANTS	L04A	ANSM	306-KETOCONAZOLE.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Not recommended	If these substances are administered together, strict monitoring of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
1291	KETOCONAZOLE	6135			ISONIAZID	6038			ANSM	306-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage.
1292	KETOCONAZOLE	6135			LERCANIDIPINE	135056			ANSM	306-KETOCONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
1293	KETOCONAZOLE	6135			LUMEFANTRINE	847728			ANSM	306-KETOCONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand, and EKG monitoring.
1294	KETOCONAZOLE	6135			MIZOLASTINE	61455			ANSM	306-KETOCONAZOLE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1295	KETOCONAZOLE	6135			NEVIRAPINE	53654			ANSM	306-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	CONTRAINDICATION	
1296	KETOCONAZOLE	6135			NINTEDANIB	1592737			ANSM	306-KETOCONAZOLE.html	Increase of the plasma concentrations of nintedanib due to increase of its absorption by the ketoconazole	Precaution for use	Clinical monitoring during the administration of these substances together.
1297	KETOCONAZOLE	6135			RIFAMPICIN	9384			ANSM	306-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
1298	KETOCONAZOLE	6135			SALMETEROL	36117			ANSM	306-KETOCONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
1299	KETOCONAZOLE	6135			SIMVASTATIN	36567			ANSM	306-KETOCONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metabolism of the cholesterol lowering substance)	CONTRAINDICATION	Use a statin not affected by this type of interaction.
1300	KETOCONAZOLE	6135			TENEFOVIR ALAFENAMIDE	1721603			ANSM	306-KETOCONAZOLE.html	Increase of the plasma concentrations of tenofovir alafenamide due to increase of its absorption	Precaution for use	In case of co-administration with the ketoconazole, the dose of tenofovir alafenamide must be limited to 10 mg per day.
1301	KETOCONAZOLE	6135			VENLAFAXINE	39786			ANSM	306-KETOCONAZOLE.html	Increase of the concentrations of vanlafaxine with risk of overdose	Take into account	
1302	KETOCONAZOLE	6135					VINCA ALKALOIDS	L01CA	ANSM	306-KETOCONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole	Not recommended	
1303	LAMIVUDINE	68244			CLADRIBINE	44157			ANSM	307-LAMIVUDINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
1304	LAMIVUDINE	68244			ZALCITABINE	3363			ANSM	307-LAMIVUDINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
1305	LAMOTRIGINE	28439			CARBAMAZEPINE	2002			ANSM	308-LAMOTRIGINE.html	Risk of increase of the neurological effects (vertigo, ataxia, diplopia) of the carbamazepine when the lamotrigine is introduced	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
1306	LAMOTRIGINE	28439					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	308-LAMOTRIGINE.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism	Not recommended	-avoid starting an oral contraceptive during the period of adjustment of the dosage of the lamotrigine.
1307	LAMOTRIGINE	28439					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	308-LAMOTRIGINE.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir	Not recommended	-Avoid beginning the treatment with ritonavir during the period of adjustment of the dosage of the lamotrigine
1308	LAMOTRIGINE	28439			OXCARBAZEPINE	32624			ANSM	308-LAMOTRIGINE.html	Decrease of the concentrations of the lamotrigine with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	Clinical monitoring and testing of the plasma concentrations, with adjustment of the dosage of the lamotrigine if needed.
1309	LAMOTRIGINE	28439					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	308-LAMOTRIGINE.html	Increased risk of serious cutaneous reactions (Lyell's syndrome). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)	Not recommended	If this combination of medications is judged necessary, strict clinical monitoring.
1310	LANSOPRAZOLE	17128			TACROLIMUS	42316			ANSM	309-LANSOPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped.
1311	AMINOGLUTETHIMIDE	677					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	31-AMINOGLUTETHIMIDE.html	Described for warfarin and acenocoumarol. Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide.	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist during the treatment with aminoglutethimide and two weeks after it is stopped.
1312	AMINOGLUTETHIMIDE	677			DEXAMETHASONE	3264			ANSM	31-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone.
1313	LEDIPASVIR	1591922			AMIODARONE	703			ANSM	310-LEDIPASVIR.html	Only when ledipasvir is combined with sofosbuvir, appearance of bradycardia, possibly abruptly, which can have fatal consequences.	Not recommended	If administering these together cannot be avoided, strict monitoring of patients is recommended, in particular during the first weeks of treatment with the ledipasvir/sofosbuvir combination (clinical monitoring and EKG).
1314	LEDIPASVIR	1591922					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	310-LEDIPASVIR.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer.	CONTRAINDICATION	
1315	LEDIPASVIR	1591922					PROTON PUMP INHIBITORS	A02BC-001	ANSM	310-LEDIPASVIR.html	Decrease of the concentrations of the ledipasvir when the proton pump inhibitor is administered before the ledipasvir	Precaution for use	It is recommended that the proton pump inhibitor and the ledipasvir be administered simultaneously
1316	LEDIPASVIR	1591922					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	310-LEDIPASVIR.html	Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolysis type	Contraindication	--with the rosuvastatin
1317	LEDIPASVIR	1591922			ST JOHNS WORT	258326			ANSM	310-LEDIPASVIR.html	Risk of large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1318	LEDIPASVIR	1591922			RIFAMPICIN	9384			ANSM	310-LEDIPASVIR.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the ripampicin	CONTRAINDICATION	
1319	LEDIPASVIR	1591922			TENOFOVIR DISOPROXIL	300195			ANSM	310-LEDIPASVIR.html	When administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir	Precaution for use	Clinical and biological monitoring, especially of the renal function
1320	LENALIDOMIDE	342369					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	311-LENALIDOMIDE.html	Increased risk of onset of rhabdomyolysis	Precaution for use	Strengthen clinical and biological monitoring, especially during the first weeks of treatment.
1321	LERCANIDIPINE	135056			CICLOSPORIN	3008			ANSM	312-LERCANIDIPINE.html	Moderate increase of the blood concentrations of the immunosuppressant and more notable increase of the concentrations of the lercanidipine	Precaution for use	Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications together and after it is stopped
1322	LERCANIDIPINE	135056			ITRACONAZOLE	28031			ANSM	312-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydorpyridine	Not recommended	
1323	LERCANIDIPINE	135056			KETOCONAZOLE	6135			ANSM	312-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
1324	LERCANIDIPINE	135056			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	312-LERCANIDIPINE.html	Increased risk of undesirable effects, especially of edema, due to decrease of the intestinal metabolism of the dihydropyridine	Take into account	
1325	LEVOCARNITINE	42955					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	313-LEVOCARNITINE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the levocarnitine and a week after it is stopped.
1326	LEVODOPA	6375			BACLOFEN	1292			ANSM	314-LEVODOPA.html	Risk of aggravation of the Parkinsonian syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)	Take into account	
1327	LEVODOPA	6375			IRON	1431589			ANSM	314-LEVODOPA.html	Decrease of the digestive absorption of the levodopa	Precaution for use	Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).
1328	LEVODOPA	6375					MAOI-B	N04BD0-001	ANSM	314-LEVODOPA.html	Increase of the risk of orthostatic hypotension	Take into account	
1329	LEVODOPA	6375			METHYLDOPA	6876			ANSM	314-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
1330	LEVODOPA	6375					ANTIEMITIC NEUROLEPTICS	A03FA-001	ANSM	314-LEVODOPA.html	Reciprocal antagonism between the levodopa and the neuroleptic	CONTRAINDICATION	Use an antiemitic without extrapyramidal effects.
1331	LEVODOPA	6375					ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	314-LEVODOPA.html	Reciprocal antagonism between the levodopa and the neuroleptics	Not recommended	With a parkinsons patient, use the minimum effective dosees of each of the two medications.
1332	LEVODOPA	6375			RESERPINE	9260			ANSM	314-LEVODOPA.html	Inhibition of the effects of the levodopa	CONTRAINDICATION	
1333	LEVODOPA	6375			SPIRAMYCIN	9991			ANSM	314-LEVODOPA.html	When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa.
1334	LEVODOPA	6375			TETRABENAZINE	10390			ANSM	314-LEVODOPA.html	Reciprocal antagonism between the levodopa and the tetrabenazine	Not recommended	
1335	LEVOFLOXACINE	82122					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	315-LEVOFLOXACIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administrations of these substances together.
1336	LIDOCAINE	6387			AMIODARONE	703			ANSM	316-LIDOCAINE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
1337	LIDOCAINE	6387					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	316-LIDOCAINE.html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment if needed of the dosage of the lidocaine
1338	LIDOCAINE	6387					BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	316-LIDOCAINE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
1339	LIDOCAINE	6387			CIMETIDINE	2541			ANSM	316-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped.
1340	LIDOCAINE	6387			FLUVOXAMINE	42355			ANSM	316-LIDOCAINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
1341			LINCOSANIDES	J01FF0			CURARES	M03A-001	ANSM	317-LINCOSANIDES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarisation at the end of anesthesia.
1342	LINEZOLIDE	190376			CLARITHROMYCIN	21212			ANSM	318-LINEZOLIDE.html	Risk of increase of the undesirable effects of the linezolide by the clarithromycin, due to increase of its absorption	Take into account	
1343	LINEZOLIDE	190376			RIFAMPICIN	9384			ANSM	318-LINEZOLIDE.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
1344	LITHIUM	6448			ACETAZOLAMIDE	167			ANSM	319-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precautions for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium.
1345	LITHIUM	6448					ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	319-LITHIUM.html	Increase of the lithemia that can attain toxic values (decrease of the renal excretion of the lithium).	Not recommended	If the use of the angiotensin II antagonist is indispensable, strict monitoring of the lithemia and adjustment of the dosage
1346	LITHIUM	6448					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	319-LITHIUM.html	Increase of the lithemia that can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	If administering the substances together cannot be avoided, monitor the lithemia closely and adjust the dosage of the lithium during the administration of the substances together and after the NSAI is stopped.
1347	LITHIUM	6448			CAFFEINE	1886			ANSM	319-LITHIUM.html	In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the lithemia	Take into account	
1348	LITHIUM	6448			CALCITONIN	36118			ANSM	319-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1349	LITHIUM	6448			CARBAMAZEPINE	2002			ANSM	319-LITHIUM.html	Risk of neurotoxicity manifesting as disorders of the cerebellum, confusion, drowsiness, ataxia. These disorders are reversible when the treatment with lithium is stopped	Not recommended	
1350	LITHIUM	6448					LOOP DIURETICS	C03CA-001	ANSM	319-LITHIUM.html	Increase of the lithemia with signs of overdose of lithium as with a low sodium regimen (decrease of the urinary excretion of the lithium)	Not recommended	If administering these substances together cannot be avoided, strict monitoring of the lithemia and adjustment of the dosage of lithium.
1351	LITHIUM	6448					POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	319-LITHIUM.html	Increase of the lithemia with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
1352	LITHIUM	6448					THIAZIDE DIURETICS AND RELATED	C03-003	ANSM	319-LITHIUM.html	Increase of the lithemia with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)	Not recommended	If administering the substances together cannot be avoided, strict monitoring of the lithemia and adjustment of the dosage of the lithium.
1353	LITHIUM	6448			GLYCEROL	4910			ANSM	319-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium.
1354	LITHIUM	6448					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	319-LITHIUM.html	Increase of the lithemia which can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	If the use of an ACE inhibitor is indispensable, strict monitoring of the lithemia and adjustment of the dosage of the lithium.
1355	LITHIUM	6448					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	319-LITHIUM.html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
1356	LITHIUM	6448			MANNITOL	6628			ANSM	319-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium.
1357	LITHIUM	6448			METHYLDOPA	6876			ANSM	319-LITHIUM.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium.
1358	LITHIUM	6448			METRONIDAZOLE	6922			ANSM	319-LITHIUM.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
1359	LITHIUM	6448					NEUROLEPTICS	N05AA-003	ANSM	319-LITHIUM.html	Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning	Precaution for use	Regular clinical amd biological monitoring, especially at the beginning of the administration of the substances together.
1360	LITHIUM	6448			ORLISTAT	37925			ANSM	319-LITHIUM.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1361	LITHIUM	6448			SODIUM BICARBONATE				ANSM	319-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.
1362	LITHIUM	6448			SODIUM CHLORIDE	9863			ANSM	319-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts.	Precaution for use	Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.
1363	LITHIUM	6448			THEOPHYLLINE	10438			ANSM	319-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
1364	LITHIUM	6448			TOPIRAMATE	38404			ANSM	319-LITHIUM.html	For doses of topiramate >= 200 mg/day: increase of the lithemia that can reach toxic values, with signs of overdose of lithium.	Precaution for use	Clinical and biological monitoring. Adjustment of the dosage of the lithium.
1365			AMINOGLYCOSIDES	J01GB-001			OTHER AMINOGLYCOSIDES	J01GB-001	ANSM	32-AMINOGLYCOSIDES.html	Increased risk of nephrotoxicity and ototoxicity (the ototoxicity is cumulative in cases of successive administrations of the aminoglycosides)	Contraindication	-in case of simultaneous administration
1366			AMINOGLYCOSIDES	J01GB-001	AMPHOTERICIN B	732			ANSM	32-AMINOGLYCOSIDES.html	With the amphotericin B administered intravenously:increased risk of nephrotoxicity	Take into account	
1367			AMINOGLYCOSIDES	J01GB-001	ATALUREN				ANSM	32-AMINOGLYCOSIDES.html	Risk of increase of the renal toxicity of the aminoside.	CONTRAINDICATION	
1368			AMINOGLYCOSIDES	J01GB-001	BOTULINUM TOXIN	1716			ANSM	32-AMINOGLYCOSIDES.html	Risk of increase of the effects of the botulinum toxin with the aminoglycosides (due to extrapolation from the effects observed during the course of the botulism)	Not recommended	Use another antibiotic
1369			AMINOGLYCOSIDES	J01GB-001	CEFALOTIN	2236			ANSM	32-AMINOGLYCOSIDES.html	Increase of the nephrotoxicity of the aminoglycosides by the cefalotin is under discussion	Precaution for use	Monitoring of renal function
1370			AMINOGLYCOSIDES	J01GB-001	CICLOSPORIN	3008			ANSM	32-AMINOGLYCOSIDES.html	Larger increase of the creatinemia than with ciclosporin alone, with increase of the nephrotoxic risk	Take into account	
1371			AMINOGLYCOSIDES	J01GB-001			CURARES	M03A-001	ANSM	32-AMINOGLYCOSIDES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	Monitor the degree of curarization at the end of anesthesia
1372			AMINOGLYCOSIDES	J01GB-001			LOOP DIURETICS	C03CA-001	ANSM	32-AMINOGLYCOSIDES.html	Increase of the nephrotoxic and ototoxic risks of the aminoglycoside (functional renal insufficiency linked to the dehydration caused by the diuretic)	Precaution for use	The two medications may be taken together when there is monitoring of the state of hydration, of the renal and cochleovestibulary functions, and, possibly, of the plasma concentrations of the aminoglycoside.
1373			AMINOGLYCOSIDES	J01GB-001			PLATINUM-BASED ANTINEOPLASTIC DRUGS	ORGAPLA	ANSM	32-AMINOGLYCOSIDES.html	Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency	Take into account	
1374			AMINOGLYCOSIDES	J01GB-001	POLYMYXIN B	8536			ANSM	32-AMINOGLYCOSIDES.html	Addition of the nephrotoxic effects	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
1375			AMINOGLYCOSIDES	J01GB-001	TACROLIMUS	42316			ANSM	32-AMINOGLYCOSIDES.html	Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
1376	LOMITAPIDE	1364479					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	320-LOMITAPIDE.html	Increase of the plasma concentrations of the lomitapide due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1377	LOMITAPIDE	1364479			ST JOHNS WORT	258326			ANSM	320-LOMITAPIDE.html	Risk of decrease of the plasma concentrations of the lomitapide	Not recommended	
1378	LOMUSTINE	6466			CIMETIDINE	2541			ANSM	321-LOMUSTINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)	Not recommended	
1379	LOSARTAN	52175			FLUCONAZOLE	4450			ANSM	322-LOSARTAN.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
1380	LUMEFANTRINE	847728			CLARITHROMYCIN	21212			ANSM	323-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the two together cannot be avoided, testing of the QT before hand and EKG monitoring.
1381	LUMEFANTRINE	847728			ERYTHROMYCIN	4053			ANSM	323-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
1382	LUMEFANTRINE	847728					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	323-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1383	LUMEFANTRINE	847728			ITRACONAZOLE	28031			ANSM	323-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
1384	LUMEFANTRINE	847728			KETOCONAZOLE	6135			ANSM	323-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
1385	LURASIDONE	1040028					ENZYMATIC INDUCERS	N03-J05-001	ANSM	324-LURASIDONE.html	Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
1386	LURASIDONE	1040028					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	324-LURASIDONE.html	Increase of the plasma concentrations of lurasidone due to decrease of its hepatic metabolism by the inhibitor	CONTRANDICATION	
1387	LURASIDONE	1040028			ST JOHN'S WORT	258326			ANSM	324-LURASIDONE.html	Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1388	LURASIDONE	1040028			GRAGEFRUIT (JUICE AND FRUIT)				ANSM	324-LURASIDONE.html	Increase of the plasma concentrations of the lurasidone due to decrease of its metabolism by the grapefruit	Not recommended	
1389	MACITENTAN	1442132					ENZYMATIC INDUCERS	N03-J05-001	ANSM	325-MACITENTAN.html	Decrease of the plasma concentrations of macitentan due to increase of its metabolism by the inducer	Not recommended	
1390	MACITENTAN	1442132			ST JOHNS WORT	258326			ANSM	325-MACITENTAN.html	Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort	Not recommended	
1391			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	326-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose.	Not recommended	
1392			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	326-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the macrolide and after it is stopped
1393			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	COLCHICINE	2683			ANSM	326-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	CONTRAINDICATION	
1394			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	DIHYDROERGOTAMINE	3418			ANSM	326-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).	CONTRAINDICATION	
1395			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ERGOTAMINE	4025			ANSM	326-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	CONTRAINDICATION	
1396	MANNITOL	6628			LITHIUM	6448			ANSM	327-MANNITOL.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
1397	MARAVIROC	620216			FOSAMPRENAVIR	358262			ANSM	328-MARAVIROC.html	Significant decrease of the concentrations of amprenavir that could lead to a loss of the virological response	Not recommended	
1398	MARAVIROC	620216					ENZYMATIC INDUCERS	N03-J05-001	ANSM	328-MARAVIROC.html	In the absence of the administration at the same time with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer	Precaution for use	The dose of maraviroc must be increased to 600 mg twice a day in this situation.
1399	MARAVIROC	620216					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	328-MARAVIROC.html	Increase of the concentrations of maraviroc by the inhibitor	Precaution for use	The dose of maraviroc must be reduced to 150 mg twice a day if it is taken with this inhibitor.
1400	MARAVIROC	620216			ST JOHNS WORT	258326			ANSM	328-MARAVIROC.html	Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of the virological response	Not recommended	
1401			MEDICATIONS AT THE ORIGIN OF A SEROTONIN SYNDROME	N06A-002			OTHER MEDICATIONS AT THE ORIGIN OF A SEROTONIN SYNDROME	N06A-002	ANSM	329-MEDICATIONS-AT-THE-ORIGIN-OF-A-SEROTONIN-SYNDROME.html	Risk of appearance or of increased severity of a serotonin syndrome in case of administering any of these medications with any of the others.	Take into account	
1402	AMIODARONE				AFATINIB	1430438			ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the amiodarone.	Precaution for use	It is recommended that the amiodarone be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.
1403	AMIODARONE						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	33-AMIODARONE.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the amiodarone and a week after it is stopped.
1404	AMIODARONE						BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001	ANSM	33-AMIODARONE.html	Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
1405	AMIODARONE						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	33-AMIODARONE.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia	Precaution for use	Regular clinical monitoring and EKG
1406	AMIODARONE				CICLOSPORIN	3008			ANSM	33-AMIODARONE.html	Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects	Not recommended	Blood concentration dosages of ciclosporin, testing of the renal function, and adjustment of the dosage of the ciclosporin during the treatment with the amiodarone.
1407	AMIODARONE				COBICISTAT	1306284			ANSM	33-AMIODARONE.html	Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat	CONTRAINDICATION	
1408	AMIODARONE				DABIGATRAN				ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of dabigatran, with greater risk of bleeding	Precaution for use	For post surgical indications:
1409	AMIODARONE				DACLATASVIR	1606218			ANSM	33-AMIODARONE.html	Only with the bitherapy daclatasvir/sofosbuvi:Appearance of bradycardia, possibly abrupt, that can have fatal consequences.	Not recommended	If administering these medications together cannot be avoided, clinical monitoring and strict EKG, in particular during the first weeks of treatment with the bitherapy
1410	AMIODARONE				DIGOXIN	3407			ANSM	33-AMIODARONE.html	Depression of autoregulation (excessive bradycardia) and difficulties with atrioventricular conduction. Furthermore, increase of the blood concentrations of digoxin due to decrease of the clearance of the digoxin.	Precaution for use	Clinical monitoring and EKG and, if there is need for it, testing of the digoxinemia and adjustment of the dosage of the digoxin.
1411	AMIODARONE				DILTIAZEM	3443			ANSM	33-AMIODARONE.html	For diltiazem by injection: risk of bradycardia and of atrioventricular blockFor diltiazem by mouth: risk of bradycardia or of atrioventricular block, especially in older persons.	Not recommended	-with diltiazem administered by IV
1412	AMIODARONE				ESMOLOL	49737			ANSM	33-AMIODARONE.html	Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
1413	AMIODARONE				FIDAXOMICIN	1111103			ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
1414	AMIODARONE				FLUCONAZOLE	4450			ANSM	33-AMIODARONE.html	Risk of lengthening of the QT interval	Precaution for use	Clinical monitoring, particularly with large doses of fluconazole (800mg/d)
1415	AMIODARONE				IBRUTINIB	1442981			ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of ibrutinib by decease of its hepatic metabolism by the amiodarone	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the time these two medications are administered together.
1416	AMIODARONE				LEDIPASVIR	1591922			ANSM	33-AMIODARONE.html	Only with the ledipasvir/sofosbuvir bitherapy, appearance of bradycardia, possibly abrupt, that can have fatal consequences	Not recommended	If the use of these medications together cannot be avoided, close monitoring of patients is recommended, in particular during the first weeks of treatment with the bitherapy (clinical monitoring and EKG).
1417	AMIODARONE				LIDOCAINE	6387			ANSM	33-AMIODARONE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precaution for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
1418	AMIODARONE				NINTEDANIB	1592737			ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of nintedanib due to increase of its absorption by the amiodarone.	Precaution for use	Clinical monitoring during the administration of these medications together.
1419	AMIODARONE				OLAPARIB				ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of olaparib by the amiodarone	Not recommended	If administering these together cannot be avoided, limit the dose of olaparib to 200 mg twice a day with the amiodarone.
1420	AMIODARONE						OMBITASVIR + PARITAPEVIR	OMPA	ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of the amiodarone due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir	CONTRAINDICATION	
1421	AMIODARONE				ORLISTAT	37925			ANSM	33-AMIODARONE.html	Risk of decrease of the plasma concentrations of the amiodarone and of its active metabolite	Precaution for use	Clinical monitoring and, if needed, EKG
1422	AMIODARONE						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)	Precaution for use	Clinical monitoring, testing of the plasma concentrations of phenytoin and possible adjustment of its dosage
1423	AMIODARONE				SIMVASTATIN	36567			ANSM	33-AMIODARONE.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin).	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction
1424	AMIODARONE				SOFOSBUVIR	1484911			ANSM	33-AMIODARONE.html	Only when administered with the combinations daclatasvir/sofosbuvir or ledispasvir/sofosbuvir:Possibly abrupt appearance of bradycardia, which can have fatal consequences.	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and EKG, in particular during the first weeks of treatment with the combinations with sofosbuvir.
1425	AMIODARONE				TACROLIMUS	42316			ANSM	33-AMIODARONE.html	Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone.	Precaution for use	Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during the administration of it and the amiodarone together and when the amiodarone is stopped.
1426	AMIODARONE				TAMSULOSIN	77492			ANSM	33-AMIODARONE.html	Risk of increase of the undesirable effects of the tamsulosin due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzymatic inhibitor and after it is stopped, if the situation requires.
1427	AMIODARONE				TELAPREVIR	1102261			ANSM	33-AMIODARONE.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia	CONTRAINDICATION	
1428	AMIODARONE				VERAPAMIL	11170			ANSM	33-AMIODARONE.html	For verapamil by injection: -risk of bradycardia or of atrioventricular block. For verapamil by mouth:-risk of bradycardia or of atrioventricular block, especially with older patients	Not recommended with:	-verapamil administered via IV
1429	AMIODARONE	703			VORICONAZOLE	121243			ANSM	33-AMIODARONE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, due to possible decrease of the metabolism of the amiodarone	Precaution for use	Clinical monitoring and EKG, and possible adjustment of the dosage of the amiodarone.
1430			MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION	N05AA-001	DAPOXETINE	69394			ANSM	330-MEDICATIONS-AT-THE-ORIGIN-OF-ORTHOSTATIC-HYPOTENSION.html	Risk of increase of the undesirable effects, especially of the vertigo and fainting type	Not recommended	-with the type 5 phospohdisterase inhibitors
1431			MEDICATIONS AT HE ORIGIN OF ORTHOSTATIC HYPOTENSION	N05AA-001			MEDICATIONS THAT LOWER BLOOD PRESSURE	MLBP	ANSM	330-MEDICATIONS-AT-THE-ORIGIN-OF-ORTHOSTATIC-HYPOTENSION.html	Risk of increase of hypotension, especially orthostatic	Take into account	
1432			MEDICATIONS AT RISK WHEN WITHDRAWING FROM TOBACCO	N0-R0-002			NICOTINE SUBSTITUTION TREATMENT	N07BA	ANSM	331-MEDICATIONS-AT-RISK-WHEN-WITHDRAWING-FROM-TOBACCO.html	Risk of overdose when replacing tobacco by the replacement therapy	Take into account	
1433			MEDICATIONS THAT LOWER BLOOD PRESSURE	MLBP			NITRATE DERIVATIVES AND RELATED	C01D-001	ANSM	332-MEDICATIONS-THAT-LOWER-BLOOD-PRESSURE.html	Increase of the risk of hypotension, especially orthostatic	Take into account	
1434			MEDICATIONS THAT LOWER BLOOD PRESSURE	MLBP			MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION	N05AA-001	ANSM	332-MEDICATIONS-THAT-LOWER-BLOOD-PRESSURE.html	Risk of increase of hypotension, especially orthostatic	Take into account	
1435			MEDICATIONS THAT LOWER THE EPILEPTIC THRESHOLD	N05AA-002			OTHER MEDICATIONS THAT LOWER THE EPILEPTIC THRESHOLD	N05AA-002	ANSM	333-MEDICATIONS-THAT-LOWER-THE-EPILEPTIC-THRESHOLD.html	Accrued risk of convulsions	Take into account	
1436			ATROPINIC MEDICATIONS	R06AA			OTHER ATROPINIC MEDICATIONS	R06AA	ANSM	334-ATROPINIC-MEDICATIONS.html	Addition of the undesirable atropinic effects such as urinary retention, constipation, dry mouth	Take into account	
1437			METHEMOGLOBINIZING MEDICATIONS	METGL			OTHER METHEMOGLOBINIZING MEDICATIONS	METGL	ANSM	335-METHEMOGLOBINIZING-MEDICATIONS.html	Risk of addition of the effects of the methomoglobinizing agents.	Take into account	
1438			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)				ANSM	336-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precautions for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
1439			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A			ORAL ANTICOAGULANTS	B01A-001	ANSM	336-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Increase of the risk of hemorrhage	Precaution for use	Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration of these medications together and after it is stopped.
1440			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	336-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	CONTRAINDICATION	Wait two weeks between stopping the MAOI and the start of the other treatment, and at least a week between the end of that treatment and the start of the MAOI.
1441			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	336-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, confusion, even coma	Not recommended	If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration of the substances together with minimum recommended dosages.
1442			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ORLISTAT	37925			ANSM	336-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1443			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	336-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Paroxysmal hypertension with possibility of ventricular arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
1444			NEPHROTOXIC MEDICATIONS	J01-J05			OTHER NEPHROTOXIC MEDICATIONS	J01-J05	ANSM	337-NEPHROTOXIC-MEDICATIONS.html	Risk of increase of the nephrotoxicity	Take into account	
1445			OTOTOXIC MEDICATIONS	J01GB-J01XA			OTHER OTOTOXIC MEDICATIONS	J01GB-J01XA	ANSM	338-OTOTOXIC-MEDICATIONS.html	Increase of the ototoxicity	Take into account	
1446			SEDATIVE MEDICATIONS	N04-N05-N06	ALCOHOL (DRINK OR INGREDIENT)				ANSM	339-SEDATIVE-MEDICATIONS.html	Increase by the alcohol of the sedative effect of these substances. The alteration of alertness can make driving vehicles or using machines dangerous	Not recommended	Avoid taking alcoholic beverages or medications containing alcohol.
1447			SEDATIVE MEDICATIONS	N04-N05-N06			OTHER SEDATIVE MEDICATIONS	N04-N05-N06	ANSM	339-SEDATIVE-MEDICATIONS.html	Increase of central nervous center depression. The alteration of alertness can make driving vehicles or using machines dangerous	Not recommended	--with sodium oxybate
1448	AMLODIPINE	17767			SIMVASTATIN	36567			ANSM	34-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
1449	MEFLOQUINE	6694			QUININE	9071			ANSM	340-MEFLOQUINE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine.
1450	MEQUITAZINE	29528			BUPROPION	42347			ANSM	341-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1451	MEQUITAZINE	29528			CINACALCET	407990			ANSM	341-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1452	MEQUITAZINE	29528			DULOXETINE	72625			ANSM	341-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1453	MEQUITAZINE	29528			FLUOXETINE	4493			ANSM	341-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1454	MEQUITAZINE	29528			PAROXETINE	32937			ANSM	341-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1455	MEQUITAZINE	29528			TERBINAFINE	37801			ANSM	341-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1456	METFORMIN	6809			ALCOHOL (DRINK OR INGREDIENT)				ANSM	342-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
1457	METFORMIN	6809					LOOP DIURETICS	C03CA-001	ANSM	342-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	Do not use metformin when the creatinemia is greater than 15mg/l (135 umol/l) for men, and 12 mg/l (110umol/l) for women.
1458	METFORMIN	6809			DOLUTEGRAVIR	1433868			ANSM	342-METFORMIN.html	Increase of the plasma concentrations of metformin by the dolutegravir and of its undesirable effects of the lactic acidosis type	Precaution for use	--with the patient having moderate renal insufficiency (stage 3a, clearance of the creatinine between 45 and 59 ml/min), clinical and biological monitoring , and possible adjustment of the dosage of metformin
1459	METFORMIN	6809					IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	342-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	CONTRAINDICATION	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later.
1460	METHADONE	6813					MORPHINE LIKE ANTITUSSIVES	R05DA0-001	ANSM	343-METHADONE.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
1461	METHADONE	6813					TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	ANSM	343-METHADONE.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
1462	METHADONE	6813			BOCEPREVIR	1102129			ANSM	343-METHADONE.html	Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
1463	METHADONE	6813			CIMETIDINE	2541			ANSM	343-METHADONE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during treatment with the cimetidine and after it is stopped.
1464	METHADONE	6813			FLUVOXAMINE	42355			ANSM	343-METHADONE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Strengthen clinical and electrocardiographic monotoring; if needed, adjustment of the dosage of the methadone during the treatment wth the fluvoxamine and after it is stopped.
1465	METHADONE	6813			FOSAMPRENAVIR	358262			ANSM	343-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the amprenavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
1466	METHADONE	6813					ENZYMATIC INDUCERS	N03-J05-001	ANSM	343-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism	Precaution for use	Increase the frequency of the doses of methadone (2 to 3 times a day instead of once a day).
1467	METHADONE	6813					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	343-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
1468	METHADONE	6813					AGONIST-ANTAGONIST OPIOIDS	NO2A-001	ANSM	343-METHADONE.html	Decrease of the effect of the methadone due to competitive blockage of the receptors.	CONTRAINDICATION	
1469	METHADONE	6813					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	343-METHADONE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	--with the citalopram, the domperidone, the escitalopram, the hydroxyzine and the piperaquine
1470	METHENAMINE	6832			SULFAMETHIZOLE	10179			ANSM	344-METHENAMINE.html	Precipitation of crystals in the urinary tract (due to the acidification of the urine)	Not recommended	
1471	METHOTREXATE	6851			ACETYLSALICYLIC ACID	1191			ANSM	345-METHOTREXATE.html	Increase of the toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in anatalgic, antipyretic, or anti-inflammatory doses
1472	METHOTREXATE	6851			ACITRETIN	16818			ANSM	345-METHOTREXATE.html	Risk of increase of the hepatoxicity of the methotrexate	Not recommended	If administering these substances together is judged necessary, strengthen liver function testing
1473	METHOTREXATE	6851					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	345-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).	Contraindication	--with the phenylbutazone, regardless of the dose of methotrexate and for all the forms of phenylbutazone, including topical.
1474	METHOTREXATE	6851					PROTON PUMP INHIBITORS	A02BC-001	ANSM	345-METHOTREXATE.html	Risk of increase of the toxicity of the methotrexate due to decrease of its elimination	Not recommended	--with the methotrexate in doses > 20mg /week
1475	METHOTREXATE	6851			CICLOSPORIN	3008			ANSM	345-METHOTREXATE.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.
1476	METHOTREXATE	6851			CIPROFLOXACIN	2551			ANSM	345-METHOTREXATE.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
1477	METHOTREXATE	6851					PENICILLINS	J01C	ANSM	345-METHOTREXATE.html	Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins	Not recommended	
1478	METHOTREXATE	6851			PROBENECID	8698			ANSM	345-METHOTREXATE.html	Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid	CONTRAINDICATION	
1479	METHOTREXATE	6851					ANTIBACTERIAL SULFONAMIDES	JO1E	ANSM	345-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate	Precaution for use	Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the time of the administration of the substances together and after it is stopped.
1480	METHOTREXATE	6851			TRIMETHOPRIM	10829			ANSM	345-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	CONTRAINDICATION	
1481	METHYLDOPA	6876			IRON	1431589			ANSM	346-METHYLDOPA .html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart, if possible).
1482	METHYLDOPA	6876			LEVODOPA	6375			ANSM	346-METHYLDOPA .html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
1483	METHYLDOPA	6876			LITHIUM	6448			ANSM	346-METHYLDOPA .html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium.
1484	METHYLPREDNISOLONE	6902					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	347-METHYLPREDNISOLONE.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythylprednisolone or in the presence of signs of hemorrhage
1485	METHYLPREDNISOLONE	6902			CICLOSPORIN	3008			ANSM	347-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
1486	METHYLPREDNISOLONE	6902					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	347-METHYLPREDNISOLONE.html	In case of prolonged use by oral or inhaled route, increase of the plasma concentrations of the corticoid, because of decrease of its hepatic metabolism by the inhibitor, with risk of appearance of cushing syndrome	Take into account	
1487	METOPROLOL	6918			ABIRATERONE	1100072			ANSM	348-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use:	Clinical monitoring. If needed, adjustment of the dosage of the metropolol during the treatment with the abiraterone
1488	METOPROLOL	6918			BUPROPION	42347			ANSM	348-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
1489	METOPROLOL	6918			CIMETIDINE	2541			ANSM	348-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with cimetidine
1490	METOPROLOL	6918			CINACALCET	407990			ANSM	348-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the metopolol during the treatment with cinacalcet.
1491	METOPROLOL	6918			DARIFENACIN	136198			ANSM	348-METOPROLOL.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
1492	METOPROLOL	6918			DULOXETINE	72625			ANSM	348-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped.
1493	METOPROLOL	6918			FLUOXETINE	4493			ANSM	348-METOPROLOL.html	Risk of increase of the undesirable effects of the metoprolol, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the metoprolol during the length of the treatment with the fluoxetine and after it is stopped.
1494	METOPROLOL	6918			HYDROXYCHLOROQUINE	5521			ANSM	348-METOPROLOL.html	With the metoprolol used in heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the hydroxychloroquine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the hydroxychloroquine
1495	METOPROLOL	6918			MIRABEGRON	1300786			ANSM	348-METOPROLOL.html	With the metoprolol used in heart failure, increase of the plasma concentrations of the metoprolol due to decrease of its metabolism by the mirabegron	Precaution for use	Clinical monitoring and possible reduction of the dosage of the metoprolol during the administration of it with the mirabegron
1496	METOPROLOL	6918			PAROXETINE	32937			ANSM	348-METOPROLOL.html	Risk of increase of the undesirable effects of the metoprolol, especially with excessive bradycardia, due to inhibition of its metabolism by the paroxetine	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the metoprolol during the treatment with the paroxetine and after it is stopped.
1497	METOPROLOL	6918					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	348-METOPROLOL.html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
1498	METOPROLOL	6918			RIFAMPICIN	9384			ANSM	348-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
1499	METOPROLOL	6918			TERBINAFINE	37801			ANSM	348-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine.
1500	METRONIDAZOLE	6922					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	349-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped.
1501	METRONIDAZOLE	6922			BUSULFAN	1828			ANSM	349-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
1502	METRONIDAZOLE	6922			DISULFIRAM	3554			ANSM	349-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
1503	METRONIDAZOLE	6922					FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ANSM	349-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
1504	METRONIDAZOLE	6922			LITHIUM	6448			ANSM	349-METRONIDAZOLE.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
1505	METRONIDAZOLE	6922			RIFAMPICIN	9384			ANSM	349-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped.
1506	AMPHOTERICIN B	732					AMINOGLYCOSIDES	J01GB-001	ANSM	35-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously: increased risk of nephrotoxicity	Take into account	
1507	AMPHOTERICIN B	732			CICLOSPORIN	3008			ANSM	35-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
1508	AMPHOTERICIN B	732			TACROLIMUS	42316			ANSM	35-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
1509	AMPHOTERICIN B	732			ZIDOVUDINE	11413			ANSM	35-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously: increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
1510	METYRAPONE	6923					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	350-METYRAPONE.html	Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of the increase of its hepatic metabolism by the phenytoin.	Precaution for use	Double the dosage of the metyrapone.
1511	MEXILETINE	6926			CAFFEINE	1886			ANSM	351-MEXILETINE.html	Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine	Take into account	
1512	MEXILETINE	6926			FLUVOXAMINE	42355			ANSM	351-MEXILETINE.html	Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and EKG. Adjustment of the dosage of the mexiletine during the treatment with the fluvoxamine and after it is stopped.
1513	MEXILETINE	6926					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	351-MEXILETINE.html	Decrease of the antiarrhythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the mexiletine; if there is reason for it, adjustment of the dosage of the mexiletine during the treatment with the phenytoin and after it is stopped.
1514	MEXILETINE	6926					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	351-MEXILETINE.html	Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the mexiletine and after it is stopped.
1515	MIANSERIN	6929					ENZYMATIC INDUCERS	N03-J05-001	ANSM	352-MIANSERIN.html	Risk of ineffectiveness of the mianserin	Not recommended	
1516	MICONAZOLE	6932					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	353-MICONAZOLE.html	Unpredictable hemorrhages, possibly serious	CONTRAINDICATION	
1517	MICONAZOLE	6932			HALOFANTRINE	50749			ANSM	353-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
1518	MICONAZOLE	6932					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	353-MICONAZOLE.html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring.
1519	MICONAZOLE	6932			PIMOZIDE	8331			ANSM	353-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1520	MICONAZOLE	6932					BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	353-MICONAZOLE.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	CONTRAINDICATION	
1521	MIDAZOLAM	6960					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	354-MIDAZOLAM.html	Risk of decrease of the plasma concentrations of the midazolam by the anticonvulsant	Take into account	
1522	MIDAZOLAM	6960					AZOLE ANTIFUNGALS	J02AC-001	ANSM	354-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation.	Precaution for use	- with midazolam IV and sublingual
1523	MIDAZOLAM	6960			CLARITHROMYCIN	21212			ANSM	354-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism with increase of sedation.	Not recommended	--with the midazolam by mouth
1524	MIDAZOLAM	6960			DILTIAZEM	3443			ANSM	354-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the diltiazem
1525	MIDAZOLAM	6960			ERYTHROMYCIN	4053			ANSM	354-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Not recommended	--with the midazolam by mouth
1526	MIDAZOLAM	6960					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	354-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use	- with the midazolam via IV and sublingual
1527	MIDAZOLAM	6960			ST JOHNS WORT	258326			ANSM	354-MIDAZOLAM.html	Risk of decrease of the plasma concentrations of midazolam by the St Johns wort	Take into account	
1528	MIDAZOLAM	6960					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	354-MIDAZOLAM.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir	CONTRAINDICATION	
1529	MIDAZOLAM	6960			RIFAMPICIN	9384			ANSM	354-MIDAZOLAM.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
1530	MIDAZOLAM	6960			ROXITHROMYCIN	9478			ANSM	354-MIDAZOLAM.html	Slight increase of sedation	Take into account	
1531	MIDAZOLAM	6960			STIRIPENTOL	37119			ANSM	354-MIDAZOLAM.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the stiripentol.
1532	MIDAZOLAM	6960			TELAPREVIR	1102261			ANSM	354-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Contraindication	- with the midazolam by mouth
1533	MIDAZOLAM	6960			VERAPAMIL	11170			ANSM	354-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation)	Precaution for use	Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.
1534	MIDECAMYCIN	30005			CICLOSPORIN	3008			ANSM	355-MIDECAMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the macrolide is stopped.
1535	MIDODRINE	6963			DIGOXIN	3407			ANSM	356-MIDODRINE.html	Disorders of autoregulation (increase of the bradycardia inducing effect of the midodrine) and disorders of atrioventricular conduction	Not recommended	If administering these substances together cannot be avoided, strengthen clinical monitoring and EKG.
1536	MIDODRINE	6963					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	356-MIDODRINE.html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped.	CONTRAINDICATION	
1537	ST JOHNS WORT	258326					METABOLIZED ANTICONVULSANTS	N03A-002	ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant.	CONTRAINDICATION	
1538	ST JOHNS WORT	258326					PROTON PUMP INHIBITORS	A02BC-001	ANSM	357-ST-JOHNS-WORT.html	Risk of ineffectiveness of the treatment by the proton pump inhibitor due to increase of its metabolism by the St Johns wort	Take into account	
1539	ST JOHNS WORT	258326					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzymatic inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (thrombolitic event)	CONTRAINDICATION	In case of an accidental use of the two substances together, do not stop the St Johns Wort suddenly, but test the INR before and then after the St Johns Wort is stopped.
1540	ST JOHNS WORT	258326			BEDAQUILINE	1364504			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
1541	ST JOHNS WORT	258326			CARBAMAZEPINE	2002			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine	Not recommended	
1542	ST JOHNS WORT	258326			COBICISTAT	1306284			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	CONTRAINDICATION	
1543	ST JOHNS WORT	258326			CYPROTERONE	3014			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the effectiveness of the cyproterone, due to increase of its hepatic metabolism by the St Johns Wort	CONTRAINDICATION	
1544	ST JOHNS WORT	258326			DACLATASVIR	1606218			ANSM	357-ST-JOHNS-WORT.html	Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1545	ST JOHNS WORT	258326			DASABUVIR	1597381			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort	CONTRAINDICATION	
1546	ST JOHNS WORT	258326			DIGOXIN	3407			ANSM	357-ST-JOHNS-WORT.html	Decrease of the digoxinemia, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure).	CONTRAINDICATION	In the case of the two substances being taken by accident, do not stop the St Johns Wort abruptly but test the plasma concentrations (or the effectiveness) of the digoxin before and then after the St Johns Wort is stopped.
1547	ST JOHNS WORT	258326			DOLUTEGRAVIR	1433868			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort	Not recommended	
1548	ST JOHNS WORT	258326			DRONEDARONE	233698			ANSM	357-ST-JOHNS-WORT.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite	Not recommended	
1549	ST JOHNS WORT	258326			ERIBULINE	1045453			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of eribuline by the St Johns wort	Not recommended	
1550	ST JOHNS WORT	258326					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, of the contraceptive, which can have possibly serious consequences (pregnancy).	CONTRAINDICATION	
1551	ST JOHNS WORT	258326			IDELALISIB	1544460			ANSM	357-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
1552	ST JOHNS WORT	258326					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	357-ST-JOHNS-WORT.html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1553	ST JOHNS WORT	258326					REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	357-ST-JOHNS-WORT.html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1554	ST JOHNS WORT	258326					IMMUNOSUPPRESSANTS	L04A	ANSM	357-ST-JOHNS-WORT.html	Decrease of the blood concentrations of the immunosuppressant, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (rejection of a graft)	CONTRAINDICATION	
1555	ST JOHNS WORT	258326					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)	CONTRAINDICATION	In the case of the substances being taken together by accident, do not stop the St Johns Wort abruptly, but test the plasma concentrations (or the effectiveness) of the protease inhibitor before and then after the St Johns Wort is stopped.
1556	ST JOHNS WORT	258326					METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns Wort	CONTRAINDICATION	
1557	ST JOHNS WORT	258326					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	357-ST-JOHNS-WORT.html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1558	ST JOHNS WORT	258326			IRINOTECAN	51499			ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	CONTRAINDICATION	
1559	ST JOHNS WORT	258326			ISAVUCONAZOLE	1720882			ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1560	ST JOHNS WORT	258326			ITRACONAZOLE	28031			ANSM	357-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1561	ST JOHNS WORT	258326			IVABRADINE	77417			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the effectiveness of the ivabradine due to increase of its metabolism by the St Johns wort	Not recommended	
1562	ST JOHNS WORT	258326			LEDIPASVIR	1591922			ANSM	357-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolidm by the St Johns wort	CONTRAINDICATION	
1563	ST JOHNS WORT	258326			LOMITAPIDE	1364479			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of the lomitapide	Not recommended	
1564	ST JOHNS WORT	258326			LURASIDONE	1040028			ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1565	ST JOHNS WORT	258326			MACITENTAN	1442132			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort	Not recommended	
1566	ST JOHNS WORT	258326			MARAVIROC	620216			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of virological response	Not recommended	
1567	ST JOHNS WORT	258326			MIDAZOLAM	6960			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of midazolam by the St Johns wort	Take into account	
1568	ST JOHNS WORT	258326			NEVIRAPINE	53654			ANSM	357-ST-JOHNS-WORT.html	Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1569	ST JOHNS WORT	258326			NINTEDANIB	1592737			ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the millepertuis	Not recommended	
1570	ST JOHNS WORT	258326			OXYCODONE	7804			ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the St Johns wort	Not recommended	Possible adjustment of the dosage of the oxycodone.
1571	ST JOHNS WORT	258326					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy)	CONTRAINDICATION	
1572	ST JOHNS WORT	258326			PROPAFENONE	8754			ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the time the substances are administered together and after the St Johns wort is stopped.
1573	ST JOHNS WORT	258326			QUETIAPINE	51272			ANSM	357-ST-JOHNS-WORT.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
1574	ST JOHNS WORT	258326			REGORAFENIB	1312397			ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort	Not recommended	
1575	ST JOHNS WORT	258326			RILPIVIRINE	1102270			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1576	ST JOHNS WORT	258326			SIMEPREVIR	1482790			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
1577	ST JOHNS WORT	258326			SIMVASTATIN	36567			ANSM	357-ST-JOHNS-WORT.html	Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
1578	ST JOHNS WORT	258326			SOFOSBUVIR				ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of sofobusvir due to decrease of its intestinal absorption by the St Johns wort	CONTRAINDICATION	
1579	ST JOHNS WORT	258326			TELAPREVIR	1102261			ANSM	357-ST-JOHNS-WORT.html	Risk of very large decrease of the concentrations of telaprevir	CONTRAINDICATION	
1580	ST JOHNS WORT	258326			TELITHROMYCIN	274786			ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the anti-infective treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort	Not recommended	
1581	ST JOHNS WORT	258326					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	357-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the theophylline, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome)	CONTRAINDICATION	In case of accidental use of the substances together, do not stop the St Johns wort abruptly but test the plasma concentrations (or the effectiveness) of the medication taken with it before and then after stopping the St Johns wort.
1582	ST JOHNS WORT	258326			TICAGRELOR	1116632			ANSM	357-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect	CONTRAINDICATION	
1583	ST JOHNS WORT	258326			ULIPRISTAL	1005921			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Choose a therapeutic alternative that is little or not metabolized.
1584	ST JOHNS WORT	258326			VERAPAMIL	11170			ANSM	357-ST-JOHNS-WORT.html	Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect	CONTRAINDICATION	
1585	ST JOHNS WORT	258326			VISMODEGIB	1242987			ANSM	357-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of vismodegib	CONTRAINDICATION	
1586	ST JOHNS WORT	258326			VORICONAZOLE	121243			ANSM	357-ST-JOHNS-WORT.html	Large reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect	CONTRAINDICATION	
1587			MINERALOCORTICOIDS	H02AA0			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	358-MINERALOCORTICOIDS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great in patients with Addisons disease treated with the hydrocortisone and in the case of organ transplants.	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped.
1588			MINERALOCORTICOIDS	H02AA0	RIFAMPICIN	9384			ANSM	358-MINERALOCORTICOIDS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in the case of organ transplants	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped.
1589	MIRABEGRON	1300786			FLECAINIDE	4441			ANSM	359-MIRABEGRON.html	Increase of the plasma concentrations of the flecainide by decrease of its metabolism by the mirabegron	Precaution for use	Clinical monitoring and possible reduction of the dosage of the flecainide during the administration of these medications together.
1590	MIRABEGRON	1300786			METOPROLOL	6918			ANSM	359-MIRABEGRON.html	With the metoprolol used in heart failure, increase of the plasma concentrations of the metoprolol due to decrease of its metabolism by the mirabegron	Precaution for use	Clinical monitoring and possible reduction of the dosage of the metoprolol during the administration of these medications together.
1591	MIRABEGRON	1300786			PROPAFENONE	8754			ANSM	359-MIRABEGRON.html	Increase of the plasma concentrations of the propafenone by decrease of its metabolism by the mirabegron	Precaution for use	Clinical monitoring and possible reduction of the dosage of the propafenone during the administration with the mirabegron
1592	ANAGRELIDE	596724			ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events	Not recommended	
1593	ANAGRELIDE	596724					PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	36-ANAGRELIDE.html	Increase of hemorraghic events	Not recommended	
1594	ANAGRELIDE	596724					MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	36-ANAGRELIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together.
1595	MITOMYCIN C	632					VINCA ALKALOIDS	L01CA	ANSM	360-MITOMYCIN C.html	Risk of increase of the pulmonary toxicity of the mitomycin and of the vinca-alkaloids	Take into account	
1596	MITOTANE	7004			DASABUVIR	1597381			ANSM	361-MITOTANE.html	Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane	CONTRAINDICATION	
1597	MITOTANE	7004			SPIRONOLACTONE	9997			ANSM	361-MITOTANE.html	Risk of blockage of the action of the mitotane by the spironolactone	CONTRAINDICATION	
1598	MIZOLASTINE	61455			CLARITHROMYCIN	21212			ANSM	362-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1599	MIZOLASTINE	61455			ERYTHROMYCIN	4053			ANSM	362-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1600	MIZOLASTINE	61455					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	362-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1601	MIZOLASTINE	61455			ITRACONAZOLE	28031			ANSM	362-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1602	MIZOLASTINE	61455			KETOCONAZOLE	6135			ANSM	362-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1603	MIZOLASTINE	61455			TELITHROMYCIN	274786			ANSM	362-MIZOLASTINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1604	MOCLOBEMIDE	30121			CIMETIDINE	2541			ANSM	363-MOCLOBEMIDE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring with possible adjustment of the dosage of moclobemide
1605	MODAFINIL	30125			CICLOSPORIN	3008			ANSM	364-MODAFINIL.html	Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant	Not recommended	
1606	MODAFINIL	30125					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	364-MODAFINIL.html	Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential	Not recommended	Use oral contraceptives containing estrogens and progestins that have 50 micrograms of estrogen or another method of contraception.
1607	MODAFINIL	30125			SOFOSBUVIR				ANSM	364-MODAFINIL.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil	Not recommended	
1608	MONTELUKAST	88249					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	365-MONTELUKAST.html	Risk of lower effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the inducer and after it is stopped.
1609	MONTELUKAST	88249			RIFAMPICIN	9384			ANSM	365-MONTELUKAST.html	Risk of lower effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped.
1610	MORPHINE	7052			RIFAMPICIN	9384			ANSM	366-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped.
1611			OPIOIDS	N0-R0			BARBITURATES	N05CA-001	ANSM	367-OPIOIDS.html	Increased risk of respiratory depression, which could be fatal in case of overdose	Take into account	
1612			OPIOIDS	N0-R0			BENZODIAZEPINES AND RELATED	N05-001	ANSM	367-OPIOIDS.html	Increased risk of respiratory depression, which could be fatal in case of overdose	Take into account	
1613			AGONIST-ANTAGONIST OPIOIDS	NO2A-001			STEP II OPIOID ANALGESICS	N02A-003	ANSM	368-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome.	Not recommended	
1614			AGONIST-ANTAGONIST OPIOIDS	NO2A-001			STEP III OPIOID ANALGESICS	N02A-002	ANSM	368-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	CONTRAINDICATION	
1615			AGONIST-ANTAGONIST OPIOIDS	NO2A-001			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	ANSM	368-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Not recommended	
1616			AGONIST-ANTAGONIST OPIOIDS	NO2A-001	METHADONE	6813			ANSM	368-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the effect of the methadone due to competitive blocking of the receptors	CONTRAINDICATION	
1617			AGONIST-ANTAGONIST OPIOIDS	NO2A-001			PARTIAL AGONIST OPIOIDS	PARAG	ANSM	368-AGONIST-ANTAGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect and/or of appearance of a withdrawal syndrome	CONTRAINDICATION	
1618			PARTIAL AGONIST OPIOIDS	PARAG			STEP II OPIOID ANALGESICS	N02A-003	ANSM	369-PARTIAL-AGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect	Not Recommended	
1619			PARTIAL AGONIST OPIOIDS	PARAG			STEP III OPIOID ANALGESICS	N02A-002	ANSM	369-PARTIAL-AGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect	CONTRAINDICATION	
1620			PARTIAL AGONIST OPIOIDS	PARAG			AGONIST-ANTAGONIST OPIOIDS	NO2A-001	ANSM	369-PARTIAL-AGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect and/or appearance of a withdrawal syndrome	CONTRAINDICATION	
1621			PARTIAL AGONIST OPIOIDS	PARAG			OPIOIDS FOR REPLACEMENT THERAPY	N07BC	ANSM	369-PARTIAL-AGONIST-OPIOIDS.html	Risk of appearance of a withdrawal syndrome	CONTRAINDICATION	
1622	ANAKINRA	72435					ANTI-TNF ALPHA	4ABO	ANSM	37-ANAKINRA.html	Increased risk of serious infections and of neutropenia.	Not recommended	
1623	ANAKINRA	72435			ETANERCEPT	214555			ANSM	37-ANAKINRA.html	Increased risk of serious infections and of neutropenia	Not recommended	
1624			OPIOIDS FOR REPLACEMENT THERAPY	N07BC			PARTIAL AGONIST OPIOIDS	PARAG	ANSM	370-OPIOIDS-FOR-REPLACEMENT-THERAPY.html	Risk of appearance of a withdrawal syndrome	CONTRAINDICATION	
1625	MYCOPHENOLATE MOFETIL	7145					PROTON PUMP INHIBITORS	A02BC-001	ANSM	371-MYCOPHENOLATE-MOFETIL.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
1626	MYCOPHENOLATE MOFETIL	7145					FLUOROQUINOLONES	J01MA-001	ANSM	371-MYCOPHENOLATE-MOFETIL.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
1627	MYCOPHENOLATE MOFETIL	7145					AMINOPENICILLINS	J01CA	ANSM	371-MYCOPHENOLATE-MOFETIL.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
1628	MYCOPHENOLATE MOFETIL	7145					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	371-MYCOPHENOLATE-MOFETIL.html	Risk of general vaccine disease, possibly fatal.	CONTRAINDICATION	And during the 3 months following the end of the treatment
1629	MYCOPHENOLATE SODIUM	408142					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	372-MYCOPHENOLATE-SODIUM.html	Risk of general vaccine disease, possibly fatal	CONTRAINDICATION	And during the 3 months following the end of the treatment with these substances together.
1630	NEBIVOLOL	31555			FLUOXETINE	4493			ANSM	373-NEBIVOLOL.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
1631	NEBIVOLOL	31555			PAROXETINE	32937			ANSM	373-NEBIVOLOL.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
1632			NEUROLEPTICS	N05AA-003			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	374-NEUROLEPTICS.html	Vasidilator effect and risk of hypotension, especially orthostatic (additive effect)	Take into account	
1633			NEUROLEPTICS	N05AA-003	LITHIUM	6448			ANSM	374-NEUROLEPTICS.html	Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1634			NEUROLEPTICS	N05AA-003	ORLISTAT	37925			ANSM	374-NEUROLEPTICS.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1635			ANTIEMITIC NEUROLEPTICS	A03FA-001			DOPAMINERGICS	N04B-002	ANSM	375-ANTIEMETIC-NEUROLEPTICS.html	Reciprocal antagonism between the dopaminergic and the neuropleptic	CONTRAINDICATION	Use an antiemetic without extrapyramidal effects.
1636			ANTIEMITIC NEUROLEPTICS	A03FA-001	LEVODOPA	6375			ANSM	375-ANTIEMETIC-NEUROLEPTICS.html	Reciprocal antagonism between the levodopa and the neuroleptic	CONTRAINDICATION	Use an antiemitic without extrapyramidal effects.
1637			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001			ANTIPARKINSONIAN DOPAMINERGICS	N04B-001	ANSM	376-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or increase the psychotic disorders. When a treatment with neuroleptics is necessary for a Parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of "neuroleptic malignant syndrome" (NMS)).	Not recommended	
1638			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001			DOPAMINERGICS, EXCEPT PARKINSON	G02CB-002	ANSM	376-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the dopamine agonist and the neuroleptics	CONTRAINDICATION	
1639			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	LEVODOPA	6375			ANSM	376-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the levodopa and the neuroleptics	Not recommended	With a parkinsons patient, use the minimum effective doses of each of the two medications.
1640			NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES	N05A-002			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	377-NEUROLEPTICS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	-with citalopram, domperidone, escitalopram, hydroxyzine and piperaquine
1641	NEVIRAPINE	53654					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	378-NEVIRAPINE.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
1642	NEVIRAPINE	53654			ATAZANAVIR	343047			ANSM	378-NEVIRAPINE.html	Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism	Not recommended	If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together
1643	NEVIRAPINE	53654			FLUCONAZOLE	4450			ANSM	378-NEVIRAPINE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
1644	NEVIRAPINE	53654			FOSAMPRENAVIR	358262			ANSM	378-NEVIRAPINE.html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
1645	NEVIRAPINE	53654			INDINAVIR	114289			ANSM	378-NEVIRAPINE.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together.
1646	NEVIRAPINE	53654			KETOCONAZOLE	6135			ANSM	378-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing.	CONTRAINDICATION	
1647	NEVIRAPINE	53654			ST JOHNS WORT	258326			ANSM	378-NEVIRAPINE.html	Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1648	NEVIRAPINE	53654			RIFAMPICIN	9384			ANSM	378-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
1649	NEVIRAPINE	53654			VORICONAZOLE	121243			ANSM	378-NEVIRAPINE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine.	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together.
1650	NICARDIPINE	7396					IMMUNOSUPPRESSANTS	L04A	ANSM	379-NICARDIPINE.html	Increase of the blood concentrations of the immunosuppressant, due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the treatment with nicardipine and after it is stopped.
1651			AGONIST OPIOID ANALGESICS	N01A-N02A			OTHER AGONIST OPIOID ANALGESICS	N01A-N02A	ANSM	38-AGONIST-OPIOID-ANALGESICS.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
1652			AGONIST OPIOID ANALGESICS	N01A-N02A			MORPHINE LIKE ANTITUSSIVES	R05DA0-001	ANSM	38-AGONIST-OPIOID-ANALGESICS.html	Increased risk of respiratory depression, which can be fatal in cases of overdose	Take into account	
1653			AGONIST OPIOID ANALGESICS	N01A-N02A			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	ANSM	38-AGONIST-OPIOID-ANALGESICS.html	Increased risk of respiratory depression which can be fatal in cases of overdose	Take into account	
1654	NIFEDIPINE	7417			CICLOSPORIN	3008			ANSM	380-NIFEDIPINE.html	Risk of addition of undesirable effects of the gum disorders type	Not recommended	Use another dihydropyridine
1655	NIFEDIPINE	7417			CIMETIDINE	2541			ANSM	380-NIFEDIPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped.
1656	NIFEDIPINE	7417			DILTIAZEM	3443			ANSM	380-NIFEDIPINE.html	Large increase of the concentrations of nefedipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	CONTRAINDICATION	
1657	NIMODIPINE	7426					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	381-NIMODIPINE.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the inducer and after it is stopped
1658	NIMODIPINE	7426			RIFAMPICIN	9384			ANSM	381-NIMODIPINE.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.
1659	NIMODIPINE	7426					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	381-NIMODIPINE.html	With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid).	Take into account	
1660	NINTEDANIB	1592737			AMIODARONE	703			ANSM	382-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the amiodarone	Precaution for use	Clinical monitoring during the administration of these medications together.
1661	NINTEDANIB	1592737			CARBAMAZEPINE	2002			ANSM	382-NINTEDANIB.html	Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the carbamazepine	Precaution for use	Clinical monitoring during the administration of these medications together
1662	NINTEDANIB	1592737			CICLOSPORIN	3008			ANSM	382-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ciclosporin	Precaution for use	Clinical monitoring during the administration of these medications together.
1663	NINTEDANIB	1592737			ERYTHROMYCIN	4053			ANSM	382-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the erythromycin	Precaution for use	Clinical monitoring during the administration of these medications together.
1664	NINTEDANIB	1592737					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	382-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ritonavir boosted protease inhibitor	Precaution for use	Clinical monitoring during the administration of these medications together.
1665	NINTEDANIB	1592737			ITRACONAZOLE	28031			ANSM	382-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the itraconazole	Precaution for use	Clinical monitoring during the administration of these medications together.
1666	NINTEDANIB	1592737			KETOCONAZOLE	6135			ANSM	382-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ketoconazole	Precaution for use	Clinical monitoring during the administration of these medications together.
1667	NINTEDANIB	1592737			ST JOHN'S WORT	258326			ANSM	382-NINTEDANIB.html	Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the St Johns wort	Not recommended	
1668	NINTEDANIB	1592737					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	382-NINTEDANIB.html	Decrease if the plasma concentrations of the nintedanib by decrease of its absorption by the phenytoin or the fosphenytoin	Precaution for use	Clinical monitoring during the administration of these medications together.
1669	NINTEDANIB	1592737			RIFAMPICIN	9384			ANSM	382-NINTEDANIB.html	Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the rifampicin	Precaution for use	Clinical monitoring during the administration of these medications together.
1670	NINTEDANIB	1592737			VERAPAMIL	11170			ANSM	382-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the verapamil.	Precaution for use	Clinical monitoring during the administration of these medications together.
1671	NORFLOXACIN	7517			CAFFEINE	1886			ANSM	383-NORFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
1672	NORFLOXACIN	7517					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	383-NORFLOXACIN.html	Increased risk of ventricular arrhythmias, especially of torsades de points.	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
1673	NORFLOXACIN	7517					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	383-NORFLOXACIN.html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
1674	NORTRIPTYLINE	7531			BUPROPION	42347			ANSM	384-NORTRIPTYLINE.html	Risk of increase of the undesirable effects of the nortriptyline due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the nortriptyline during the treatment with the bupropion.
1675	NOSCAPINE	7533					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	385-NOSCAPINE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	
1676	OLANZAPINE	61381			CARBAMAZEPINE	2002			ANSM	386-OLANZAPINE.html	Risk of decrease of the plasma concentrations of the olanzapine and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and if needed, adjustment of the dosage of the olanzapine.
1677	OLANZAPINE	61381			FLUVOXAMINE	42355			ANSM	386-OLANZAPINE.html	Increase of the concentrations of the olanzapine, with risk of increase of its undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and possible reduction of the dosage of the olanzapine during the treatment with fluvoxamine.
1678	OLAPARIB				AMIODARONE	703			ANSM	387-OLAPARIB.html	Increase of the plasma concentrations of olaparib by the amiodarone	Not recommended	If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day with the amiodarone
1679	OLAPARIB				DILTIAZEM	3443			ANSM	387-OLAPARIB.html	Increase of the plasma concentrations of olaparib by the diltiazam	Not recommended	If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day.
1680	OLAPARIB				FLUCONAZOLE	4450			ANSM	387-OLAPARIB.html	Increase of the plasma concentrations of olaparib by the fluconazole	Not recommended	If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day.
1681	OLAPARIB						ENZYMATIC INDUCERS	N03-J05-001	ANSM	387-OLAPARIB.html	Decrease, possibly very large depending on the inducer, of the plasma concentrations of the olaparib due to increase of its hepatique metabolism by the inducer	Not recommended	
1682	OLAPARIB						STRONG INHIBITORS OF CYP3A4	InJ02-J05	ANSM	387-OLAPARIB.html	Increase of the plasma concentrations of olaparib by the inhibitor	Not recommended	If administering these medications together cannot be avoided, limit the dose of olaparib to 150mg twice a day.
1683	OLAPARIB				VERAPAMIL	11170			ANSM	387-OLAPARIB.html	Increase of the plasm concentrations of olaparib by the verapamil.	Not recommended	If administering these medications together cannot be avoided, limit the dose of olaparid to 200 mg twice a day.
1684			OMBITASVIR + PARITAPREVIR	OMPA	FUSIDIC ACID	4608			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1685			OMBITASVIR + PARITAPREVIR	OMPA			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1686			OMBITASVIR + PARITAPREVIR	OMPA	ALFUZOSIN	17300			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the alfuzosin due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1687			OMBITASVIR + PARITAPREVIR	OMPA	AMIODARONE	703			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the amiodarone due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1688			OMBITASVIR + PARITAPREVIR	OMPA	ATORVASTATIN	83367			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1689			OMBITASVIR + PARITAPREVIR	OMPA	COLCHICINE	2683			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	with patients having renal and/or hepatic insufficiency
1690			OMBITASVIR + PARITAPREVIR	OMPA	ETHINYLESTRADIOL	4124			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	CONTRAINDICATION	
1691			OMBITASVIR + PARITAPREVIR	OMPA			ENZYMATIC INDUCERS	N03-J05-001	ANSM	388-OMBITASVIR + PARITAPREVIR.html	Decrease of the plasma concentrations of the bitherapy due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
1692			OMBITASVIR + PARITAPREVIR	OMPA			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the bitherapy due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	-except with the ritonavir
1693			OMBITASVIR + PARITAPREVIR	OMPA	MIDAZOLAM	6960			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1694			OMBITASVIR + PARITAPREVIR	OMPA	PIMOZIDE	8331			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1695			OMBITASVIR + PARITAPREVIR	OMPA	QUETIAPINE	51272			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1696			OMBITASVIR + PARITAPREVIR	OMPA	QUINIDINE	9068			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the quinidine due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1697			OMBITASVIR + PARITAPREVIR	OMPA	SILDENAFIL	136411			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1698			OMBITASVIR + PARITAPREVIR	OMPA	SIMVASTATIN	36567			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1699			OMBITASVIR + PARITAPREVIR	OMPA	TICAGRELOR	1116632			ANSM	388-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1700	OMEPRAZOLE	7646			DIGOXIN	3407			ANSM	389-OMEPRAZOLE.html	Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole	Precaution for use	Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient.
1701	OMEPRAZOLE	7646			TACROLIMUS	42316			ANSM	389-OMEPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function and adjustment of the dosage during the administration of the substances together and after it is stopped.
1702			STEP II OPIOID ANALGESICS	N02A-003			AGONIST-ANTAGONIST OPIOIDS	NO2A-001	ANSM	39-STEP-II-OPIOID-ANALGESICS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Not recommended	
1703			STEP II OPIOID ANALGESICS	N02A-003			PARTIAL AGONIST OPIOIDS	PARAG	ANSM	39-STEP-II-OPIOID-ANALGESICS.html	Risk of decrease of the antalgic effect	Not recommended	
1704	ONDANSETRON	26225			APOMORPHINE	1043			ANSM	390-ONDANSETRON.html	Severe hypotension and loss of consciousness have been reported when ondansetron is administered with apomorphine	CONTRAINDICATION	
1705	ONDANSETRON	26225					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	390-ONDANSETRON.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together.
1706	ONDANSETRON	26225			TRAMADOL	10689			ANSM	390-ONDANSETRON.html	Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemetic effect of the ondansetron	Take into account	
1707	GOLD						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	391-GOLD.html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)	Take into account	
1708			PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS	L01XA			AMINOGLYCOSIDES	J01GB-001	ANSM	392-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html	Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency	Take into account	
1709			PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS	L01XA			LOOP DIURETICS	C03CA-001	ANSM	392-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html	Risk of addition of the ototoxic and/or nephrotoxic effects	Take into account	
1710	ORLISTAT	37925			AMIODARONE	703			ANSM	393-ORLISTAT.html	Risk of decrease of the plasma concentrations of the amiodarone and of its active metabolite	Precaution for use	Clinical monitoring and, if needed, EKG
1711	ORLISTAT	37925					TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	393-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1712	ORLISTAT	37925					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	393-ORLISTAT.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the orlistat and after it is stopped.
1713	ORLISTAT	37925			CICLOSPORIN	3008			ANSM	393-ORLISTAT.html	Decrease of the blood concentrations of ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity	Not recommended	Take the orlistat at a different time from the ciclosporin (at least three hours apart). Reinforce testing of the blood dosages of the ciclosporin, especially at the beginning of the administration of the two medications together, and at the time of a possible increase of the dosage of the orlistat.
1714	ORLISTAT	37925					THYROID HORMONES	H03AA	ANSM	393-ORLISTAT.html	Risk of disequilibrium of the thyroid replacement therapy in cases where there is treatment with orlistat	Take into account	
1715	ORLISTAT	37925					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	393-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1716	ORLISTAT	37925			LITHIUM	6448			ANSM	393-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1717	ORLISTAT	37925					MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	393-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1718	ORLISTAT	37925					NEUROLEPTICS	N05AA-003	ANSM	393-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1719	ORLISTAT	37925					VITAMIN D	A11CC	ANSM	393-ORLISTAT.html	Decrease of the absorption of the vitamin D	Take into account	
1720	ORNIDAZOLE	7701					FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ANSM	394-ORNIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
1721	OXCARBAZEPINE	32624					NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	395-OXCARBAZEPINE.html	Risk of decrease of the effectiveness of the hormonal treatment, due to increase of its hepatic metabolism by the oxcarbazepine.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the treatment with the oxcarbazepine and after it is stopped.
1722	OXCARBAZEPINE	32624			LAMOTRIGINE	28439			ANSM	395-OXCARBAZEPINE.html	Decrease of the concentrations of the lamotrigine with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	Clinical monitoring and testing of the plasma concentrations, with adjustment of the dosage of the lamotrigine if needed.
1723	OXCARBAZEPINE	32624			PERAMPANEL	1356552			ANSM	395-OXCARBAZEPINE.html	Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.	Take into account	
1724	OXCARBAZEPINE	32624			TOPIRAMATE	38404			ANSM	395-OXCARBAZEPINE.html	Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	Clinical monitoring and, if needed, adjustment of the dosage of the topiramate during the treatment with the oxcarbazepine and after it is stopped.
1725	OXPRENOLOL	7801			ERGOTAMINE	4025			ANSM	396-OXPRENOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these substances together.
1726	OXYCODONE	7804					ENZYMATIC INDUCERS	N03-J05-001	ANSM	397-OXYCODONE.html	Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the inducer	Not recommended	Possible adjustment of the dosage of oxycodone.
1727	OXYCODONE	7804					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	397-OXYCODONE.html	Increase of the plasma concentrations of the oxycodone	Not recommended	Clinical monitoring and possible adjustment of the dosage of oxycodone during the length of the treatment with the enzyme inhibitor.
1728	OXYCODONE	7804			ST JOHN'S WORT	258326			ANSM	397-OXYCODONE.html	Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the St Johns wort	Not recommended	Possible adjustment of the dosage of the oxycodone
1729	PACLITAXEL	56946			CLOPIDOGREL	32968			ANSM	398-PACLITAXEL.html	Increase of the concentrations of the paclitaxel by the clopidogrel, with risk of increase of undesirable effects.	Take into account	
1730	GRAPEFRUIT (JUICE AND FRUIT)				ALISKIREN	325646			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Risk of decrease of the effectiveness of the aliskiren when grapefruit is consumed	Not recommended	
1731	GRAPEFRUIT (JUICE AND FRUIT)				ATORVASTATIN	83367			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase of the plasma concentrations of the cholesterol lowering medication, with risk of appearance of undesirable effects, especially muscular ones.	Take into account	
1732	GRAPEFRUIT (JUICE AND FRUIT)				AVANAFIL	1291301			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase of the plasma concentrations of the avanafil, with risk of hypotension.	Not recommended	
1733	GRAPEFRUIT (JUICE AND FRUIT)				BUSPIRONE	1827			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Risk of increase of the undesirable effects of the buspirone by decrease of its metabolism by the grapefruit	Take into account	
1734	GRAPEFRUIT (JUICE AND FRUIT)				CARBAMAZEPINE	2002			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase of the plasma concentrations of carbamazepine, with risk of overdose, due to inhibition of its metabolism by the grapefruit	Not recommended	
1735	GRAPEFRUIT (JUICE AND FRUIT)				DRONEDARONE	233698			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase of the concentrations of dronedarone by inhibition of its metabolism by the grapefruit	Not recommended	
1736	GRAPEFRUIT (JUICE AND FRUIT)				HALOFANTRINE	50749			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1737	GRAPEFRUIT (JUICE AND FRUIT)						IMMUNOSUPPRESSANTS	L04A	ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase of the bioavailability of the immunosuppressant and as a result of its undesirable effects.	Not recommended	
1738	GRAPEFRUIT (JUICE AND FRUIT)				IVABRADINE	77417			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit	Not recommended	
1739	GRAPEFRUIT (JUICE AND FRUIT)				LERCANIDIPINE	135056			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increased risk of undesirable effects, especially edema, due to decrease of the intestinal metabolism of the dihydropyridine	Take into account	
1740	GRAPEFRUIT (JUICE AND FRUIT)				LURASIDONE	1040028			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase of the plasma concentrations of the lurasidone due to decrease of its metabolism by the grapefruit	Not recommended	
1741	GRAPEFRUIT (JUICE AND FRUIT)				REGORAFENIB	1312397			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase of the plasma concentrations of regorafenib by decrease of its hepatic metabolism by the grapefruit	Not recommended	
1742	GRAPEFRUIT (JUICE AND FRUIT)				SERTRALINE	36437			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase sometimes large of the concentrations of the antidepressant in certain patients due to decrease of its intestinal metabolism	Not recommended	
1743	GRAPEFRUIT (JUICE AND FRUIT)				SIMVASTATIN	36567			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Large increase of the plasma concentrations of the lipid lowering drug, with risk of appearance of undesirable effects, especially muscular ones	Not recommended	
1744	GRAPEFRUIT (JUICE AND FRUIT)				TICAGRELOR	1116632			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Doubling of the plasma concentrations of the antiagregant, with risk of increase of the undesirable effects, especially hemorrhagic	Not recommended	
1745	GRAPEFRUIT (JUICE AND FRUIT)				VARDENAFIL	306674			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase of the plasma concentrations of the vardenafil, with risk of hypotension	Not recommended	
1746	GRAPEFRUIT (JUICE AND FRUIT)				VERAPAMIL	11170			ANSM	399-GRAPEFRUIT-(JUICE-OR-FRUIT).html	Increase of the plasma concentrations of verapamil, with risk of undesirable effects	Take into account	
1747	ACETOHYDROXAMIC ACID	16728			IRON	1431589			ANSM	4-ACETOHYDROXAMIC-ACID.html	Decrease of the digestive absorption of these two medications due to chelation of the iron	Take into account	
1748			STEP III OPIOID ANALGESICS	N02A-002			AGONIST-ANTAGONIST OPIOIDS	NO2A-001	ANSM	40-STEP-III-OPIOID-ANALGESICS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	CONTRAINDICATION	
1749			STEP III OPIOID ANALGESICS	N02A-002			PARTIAL AGONIST OPIOIDS	PARAG	ANSM	40-STEP-III-OPIOID-ANALGESICS.html	Risk of decrease of the antalgic effect	CONTRAINDICATION	
1750	PANOBINOSTAT	1603350					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	400-PANOBINOSTAT.html	Risk of increase of the undesirable effects, especially cardiac ones, of the panobinostat due to decrease of its metabolism by the inhibitor	Precaution for use	Clinical monitoring and EKG. Possible adjustment of the dosage of the panobinostat
1751	PARACETAMOL	161					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	401-PARACETAMOL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the paracetamol and after it is stopped.
1752	PAROXETINE	32937			CARBAMAZEPINE	2002			ANSM	402-PAROXETINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.
1753	PAROXETINE	32937			MEQUITAZINE	29528			ANSM	402-PAROXETINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1754	PAROXETINE	32937			METOPROLOL	6918			ANSM	402-PAROXETINE.html	Risk of increase of the undesirable effects of the metoprolol, with especially excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the metoprolol during the length of the treatment with the paroxetine and after it is stopped
1755	PAROXETINE	32937			NEBIVOLOL	31555			ANSM	402-PAROXETINE.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
1756	PAROXETINE	32937			PIMOZIDE	8331			ANSM	402-PAROXETINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	C0NTRAINDICATION	
1757	PAROXETINE	32937			RISPERIDONE	35636			ANSM	402-PAROXETINE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects.	Precaution for use	Clinical monitoring and, if needed, adjustment of the dosage of the risperidone.
1758	PAROXETINE	32937			TAMOXIFEN	10324			ANSM	402-PAROXETINE.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine	Not recommended	
1759	PAROXETINE	32937			VORTIOXETINE	1455099			ANSM	402-PAROXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the paroxetine and after it is stopped.
1760	PEFLOXACIN	7960					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	403-PEFLOXACIN.html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
1761	PEG-INTERFERON ALFA-2A	120608			TELBIVUDINE	474128			ANSM	404-PEG-INTERFERON-ALFA-2A.html	Increased risk of peripheral neuropathy	CONTRAINDICATION	
1762	PEMETREXED	68446			ACETYLSALICYLIC ACID				ANSM	405-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-in case of weak to moderate renal function
1763	PEMETREXED	68446					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	405-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the NSAIs)	Not recommended	--in case of weak to moderate renal function
1764			PENEMS	J01DH			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	406-PENEMS.html	Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable.	Not recommended	
1765	PENICILLAMINE	7975			IRON	1431589			ANSM	407-PENICILLAMINE.html	Decrease of the digestive absorption of the penicillamine	Precaution for use	Take the iron salts at a different time from the penicillamine (more than 2 hours apart if possible).
1766			PENICILLINS	J01C	METHOTREXATE	6851			ANSM	408-PENICILLINS.html	Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins	Not recommended	
1767			AMINOPENICILLINS	J01CA	ALLOPURINOL	519			ANSM	409-AMINOPENICILLINS.html	Increased risk of cutaneous reactions	Take into account	
1768			AMINOPENICILLINS	J01CA	MYCOPHENOLATE MOFETIL	7145			ANSM	409-AMINOPENICILLINS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
1769			SOMATOSTATIN ANALOGS	H01CB0-001	CICLOSPORIN	3008			ANSM	41-SOMATOSTATIN-ANALOGS.html	With the ciclosporin administered orally:reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).	Precaution for use	Increase the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analogue is stopped.
1770			SOMATOSTATIN ANALOGS	H01CB0-001	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
1771			SOMATOSTATIN ANALOGS	H01CB0-001	PIOGLITAZONE	33738			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia: decrease of increase of the need for glitazone, due to decrease or increase of the secretion of endogenour glucogon	Precaution for use	Reinforce self-monitoring of blood glucose and adjust the dosage of glitazone if needed during the treatment with the somatastin analog.
1772			SOMATOSTATIN ANALOGS	H01CB0-001	REPAGLINIDE	73044			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for repaglinde due to decrease or increase of the secretion of endogenous glucagon .	Precaution for use	Strengthen self-monitoring of blood glucose, and adjust the dosage of the repaglinide if needed during the treatment with the somatostatin analog.
1773			SOMATOSTATIN ANALOGS	H01CB0-001			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Strengthen self-monitoring of blood glucose, and adjust the dosage of the sulfonamide if needed during the treatment with the somatostatin analog.
1774	PENTAMIDINE	7994			DIDANOSINE	3364			ANSM	410-PENTAMIDINE.html	Increased risk of onset of pancreatitis due to addition of undesirable effects	Precaution for use	Monitoring of the blood amylase level. Do not use these two medications together if the blood amylase level is at the high range of normal.
1775	PENTAMIDINE	7994			FOSCARNET	33562			ANSM	410-PENTAMIDINE.html	Risk of severe hypocalcemia	Precaution for use	Monitoring of the calcemia and supplementation if necessary.
1776	PENTAMIDINE	7994			STAVUDINE	59763			ANSM	410-PENTAMIDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together
1777	PENTAMIDINE	7994			ZALCITABINE	3363			ANSM	410-PENTAMIDINE.html	Increased risk of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together
1778	PENTOSTATIN	8011			CYCLOPHOSPHAMIDE	3002			ANSM	411-PENTOSTATIN.html	Increase of the risk of pulmonary toxicity which could be fatal	Not recommended	
1779	PENTOSTATIN	8011			FLUDARABINE	24698			ANSM	411-PENTOSTATIN.html	Increase of the risk of pulmonary toxicity which could be fatal	Not recommended	
1780	PENTOXIFYLLINE	8013					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	412-PENTOXIFYLLINE.html	Increase of the risk of hemorrhage	Take into account	
1781	PENTOXIFYLLINE	8013					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	412-PENTOXIFYLLINE.html	Increase of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped.
1782	PENTOXIFYLLINE	8013					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	412-PENTOXIFYLLINE.html	Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the pentoxifylline and after it is stopped.
1783	PERAMPANEL	1356552					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	413-PERAMPANEL.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
1784	PERAMPANEL	1356552			CYPROTERONE	3014			ANSM	413-PERAMPANEL.html	Fore doses of perampanel > or = to 12 mg/day, risk of decrease of the effectiveness of the cyproterone	Not recommended	When used as a hormonal contraceptive: the use of another method of contraception in particular a barrier type is preferred for the length of time these substances are taken together and a cycle following
1785	PERAMPANEL	1356552			OXCARBAZEPINE	32624			ANSM	413-PERAMPANEL.html	Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.	Take into account	
1786	PERAMPANEL	1356552					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	413-PERAMPANEL.html	For doses of perampanel >=12 mg/day: Risk of decrease of the contraceptive effectiveness	Not recommended	Another method of contraception, in particular a barrier type, should be used.
1787	PERAMPANEL	1356552			RIFAMPICIN	9384			ANSM	413-PERAMPANEL.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
1788	PETHIDINE	6754					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	414-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
1789	PETHIDINE	6754					REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	414-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	CONTRAINDICATION	
1790	PETHIDINE	6754					MAOI-B	N04BD0-001	ANSM	414-PETHIDINE.html	Symptoms of central nervous system excitability evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
1791			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	CHOLIC ACID	1440856			ANSM	415-PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE.html	Antagonist effect of the phenobarbital	CONTRAINDICATION	
1792			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	CARBAMAZEPINE	2002			ANSM	415-PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE.html	Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness	Take into account	Use prudence with respect to the interpretation of the plasma concentrations.
1793			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	FELBAMATE	24812			ANSM	415-PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE.html	Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenobarbital with adjustment of the dosage if needed.
1794			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001			FOLATES	V03-	ANSM	415-PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE.html	Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	Clinical monitoring, testing of the plasma concentrations, and adjustment, if there is reason for it, of the dosage of the phenobarbital during the folic supplementation and after it is stopped.
1795			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	IFOSFAMIDE	5657			ANSM	415-PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE.html	Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital	Not recommended	
1796			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	METOPROLOL	6918			ANSM	415-PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE.html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
1797			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	415-PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE.html	In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)In cases of previous treatment with the pheyntoin and the addition of phenobarbital or of primidone, unpredictable changes:--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)	Take into account	
1798			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	PROPRANOLOL	8787			ANSM	415-PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE.html	Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
1799			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	415-PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE.html	Increase of the hyperammonemia with increased risk of encephalopathy	Precaution for use	Regular clinical and biological monitoring.
1800			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	AMIODARONE	703			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)	Precaution for use	Clinical monitoring, testing of the plasma concentrations of phenytoin, and possible adjustment of its dosage
1801			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	CARBAMAZEPINE	2002			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)	Take into account	Use prudence in the interpretation of the plasma concentrations.
1802			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	CIMETIDINE	2541			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with the possibility of appearance of the usual signs of overdose	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring, plasma concentration dosages of phenytoin, and possible adjustment of its dosage during the treatment with the cimetidine and after it is stopped.
1803			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	CIPROFLOXACIN	2551			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with the ciprofloxacin	Precaution for use	Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.
1804			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	CLOPIDOGREL	32968			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin.
1805			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	CLOZAPINE	2626			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the phenytoin.
1806			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB			CYTOTOXICS	L01	ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only [not the fosphenytoin] by the cytotoxic, or risk of increase of the toxicity or loss of the effectiveness of the cytotoxic due to the increase of its hepatic metabolism by the phenytoin or the fosphenytoin	Not recommended	
1807			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	DIAZEPAM	3322			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin.
1808			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	DISULFIRAM	3554			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)	Not recommended	If the administration of these substances together cannot be avoided, clinical monitoring and monitoring of the plasma concentrations of phenytoin during the treatment with the disulfiram and after it is stopped.
1809			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	FELBAMATE	24812			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate	Precaution for use	Clinical monitoring, testing of the plasma concentrations of phenytoin, and if needed, adjustment of its dosage during the treatment with the felbamate.
1810			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	FLUCONAZOLE	4450			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin	Precaution for use	Strict clinical and biological monitoring.
1811			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	FLUOXETINE	4493			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin	Precaution for use	Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with the fluoxetine and after it is stopped.
1812			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	FLUVOXAMINE	42355			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage of the phenytoin during the treatment with the fluvoxamine and after it is stopped.
1813			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB			FOLATES	V03-	ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin. Possible adjustment of the dosage of the phenytoin during the folic supplementation and after it is stopped.
1814			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	FUROSEMIDE	460			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the diuretic effect which can reach 50%	Precaution for use	Possibly use higher doses of furosemide.
1815			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ISONIAZID	6038			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped.
1816			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	METYRAPONE	6923			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of the increase of its hepatic metabolism by the phenytoin.	Precaution for use	Double the dosage of the metyrapone.
1817			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	MEXILETINE	6926			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the antiarrythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)	Precaution for use	Clinical monitoring, EKG, and, possibly monitoring of the plasma concentrations of the mexiletine; if there is reason for it, adjustment of the dosage of the mexiletine during the treatment with the phenytoin and after it is stopped.
1818			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	MICONAZOLE	6932			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring.
1819			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	NINTEDANIB	1592737			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the phenytoin or the fosphenytoin.	Precaution for use	Clinical monitoring during the administration of these substances together
1820			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)In cases of previous treatment with the phenytoin and the addition of phenobarbital or of primidone, unpredictable changes:--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)	Take into account	
1821			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	SUCRALFATE	10156			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the digestive absorption of the phenytoin.	Precaution for use	Take the sucralfate at a different time from the phenytoin (more than 2 hours apart if possible).
1822			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	SULFAFURAZOLE	10207			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of anti-infective should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped.
1823			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	SULFAMETHIZOLE	10179			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped.
1824			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	SULFAMETHOXAZOLE	10180			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism).	Not recommended	Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped.
1825			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	TICLOPIDINE	10594			ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin).	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin.
1826			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	416-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the hyperammoniemia, with increased risk of encephalopathy	Precaution for use	Regular clinical and biological monitoring
1827	PILOCARPINE	8328					ACETYLCHOLINESTERASE INHIBITORS	NO6DA-001	ANSM	417-PILOCARPINE.html	Risk of addition of the undesirable cholinergic effects, especially digestive	Take into account	
1828	PIMOZIDE	8331			APREPITANT	358255			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1829	PIMOZIDE	8331			DALFOPRISTIN	229369			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1830	PIMOZIDE	8331			DILTIAZEM	3443			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1831	PIMOZIDE	8331			EFAVIRENZ	195085			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1832	PIMOZIDE	8331			FLUCONAZOLE	4450			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1833	PIMOZIDE	8331					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1834	PIMOZIDE	8331			JOSAMYCIN	6084			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1835	PIMOZIDE	8331			MICONAZOLE	6932			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1836	PIMOZIDE	8331					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	418-PIMOZIDE.html	Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the combination ombitasvir + paritaprevir	CONTRAINDICATION	
1837	PIMOZIDE	8331			PAROXETINE	32937			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1838	PIMOZIDE	8331			QUINUPRISTINE	135098			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1839	PIMOZIDE	8331			SERTRALINE	36437			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1840	PIMOZIDE	8331			STIRIPENTOL	37119			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1841	PIMOZIDE	8331			TRICLABENDAZOLE	38608			ANSM	418-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the medication that tends to produce torsades de pointes).	CONTRAINDICATION	Wait 24 hours between stopping the triclabendazole and the dose of the medication that tends to produce torsades de pointes and vice versa.
1842	PIOGLITAZONE	33738					SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	419-PIOGLITAZONE.html	Risk of hyypoglycemia or hyperglycemia: decrease or increase of the need for glitazone, due to decrease of increase of the secretion of endogenous glucagon	Precaution for use	Increase self monitoring of blood glucose and adjust if needed the dosage of the glitazone during the treatment with the somatostatin analog
1843	PIOGLITAZONE	33738			GEMFIBROZIL	4719			ANSM	419-PIOGLITAZONE.html	Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring.
1844	PIOGLITAZONE	33738			RIFAMPICIN	9384			ANSM	419-PIOGLITAZONE.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampcin	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped.
1845			ANDROGENS	A14AA0			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	42-ANDROGENS.html	Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the Vitamin K antagonist during the treatment with the androgen and after it is stopped.
1846			ANDROGENS	A14AA0			ENZYMATIC INDUCERS	N03-J05-001	ANSM	42-ANDROGENS.html	Risk of decrease of the plasma concentrations of the androgen and consequently of its effectiveness, due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical and biological monitoring during the administration of these substances together and 1 to 2 weeks after the inducer is stopped.
1847	PIRFENIDONE	88221			FLUVOXAMINE	42355			ANSM	420-PIRFENIDONE.html	Increase of the plasma concentrations of pirfenidone with signs of overdose	CONTRAINDICATION	
1848	PITAVASTATIN	861634			CICLOSPORIN	3008			ANSM	421-PITAVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin	CONTRAINDICATION	
1849	POLYMYXIN B	8536					AMINOGLYCOSIDES	J01GB-001	ANSM	422-POLYMYXIN-B.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
1850	POLYMYXIN B	8536					CURARES	M03A-001	ANSM	422-POLYMYXIN-B.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	Monitor the degree of curarization at the end of anesthesia
1851	POSACONAZOLE	282446					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	423-POSACONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the posaconazole	Precaution for use	Clinical monitoring. If possible, plasma dosages of the posaconazole and possible adjustment of its dosage.
1852	POSACONAZOLE	282446					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	423-POSACONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the H2 receptor antagonist	Not recommended	--only with the oral suspension form of posaconazole
1853	POSACONAZOLE	282446					PROTON PUMP INHIBITORS	A02BC-001	ANSM	423-POSACONAZOLE.html	Decrease of the absorption of the azole antifungal, due to increase of the gastric pH by the inhibitor	Not recommended	--only for the oral suspension form of posaconazole
1854	POSACONAZOLE	282446			ATORVASTATIN	83367			ANSM	423-POSACONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)	CONTRAINDICATION	
1855	POSACONAZOLE	282446			DEXAMETHASONE	3264			ANSM	423-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
1856	POSACONAZOLE	282446			DIGOXIN	3407			ANSM	423-POSACONAZOLE.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias.	Precaution for use	Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia, with adjustment of the dosage of the digoxin during the treatment with the posaconazole and after it is stopped.
1857	POSACONAZOLE	282446					IMMUNOSUPPRESSANTS	L04A	ANSM	423-POSACONAZOLE.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these medications are administered together, strict testing of renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.
1858	POSACONAZOLE	282446			RIFABUTIN	55672			ANSM	423-POSACONAZOLE.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Not recommended	Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.
1859	POSACONAZOLE	282446			RIFAMPICIN	9384			ANSM	423-POSACONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
1860	POSACONAZOLE	282446			SIMVASTATIN	36567			ANSM	423-POSACONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)	CONTRAINDICATION	
1861	POSACONAZOLE	282446					VINCA ALKALOIDS	L01CA	ANSM	423-POSACONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole	Not recommended	
1862	POTASSIUM	8588					ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	424-POTASSIUM.html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).	Not recommended	Avoid administering these substances together unless there is pre-existing hypokalemia.
1863	POTASSIUM	8588			CICLOSPORIN	3008			ANSM	424-POTASSIUM.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Avoid the administration of these two substances together unless there is pre-existing hypokalemia.
1864	POTASSIUM	8588					POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	424-POTASSIUM.html	Potentially lethal hyperkalemia, especially with patients having renal insufficiency (addition of the hyperkaliemia producing effects)	Contraindication:	-aside from hypokalemia or in case of parenteral use of the potassium salts
1865	POTASSIUM	8588					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	424-POTASSIUM.html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Unless there is hypokalemia.
1866	POTASSIUM	8588			TACROLIMUS	42316			ANSM	424-POTASSIUM.html	Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia producing effects)	Not recommended	Avoid administering these substances together unless there is a preexisting hypokalemia.
1867	POVIDONE-IODINE	8611					MERCURIAL ANTISEPTICS	D08AK0	ANSM	425-POVIDONE-IODINE.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
1868	PRAVASTATIN	42463			CLARITHROMYCIN	21212			ANSM	426-PRAVASTATIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical and biological monitoring during the treatment with the antibiotic
1869	PRAVASTATIN	42463			ERYTHROMYCIN	4053			ANSM	426-PRAVASTATIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	Clinical and biological monitoring during the treatment with the antibiotic.
1870	PRAZIQUANTEL	8628					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	427-PRAZIQUANTEL.html	Very large decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment due to increase of its hepatic metabolism by the inducer	Not recommended	
1871	PRAZIQUANTEL	8628			DEXAMETHASONE	3264			ANSM	427-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
1872	PRAZIQUANTEL	8628			RIFAMPICIN	9384			ANSM	427-PRAZIQUANTEL.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	CONTRAINDICATION	
1873	PREDNISOLONE	8638			CICLOSPORIN	3008			ANSM	428-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
1874	LATEX CONDOMS						MINERAL OILS	A06AA-	ANSM	429-LATEX-CONDOMS.html	Risk of rupture of the condom when used with lubricants containing mineral oils (paraffin oil, silicone oil, etc...)	CONTRAINDICATION	Use a hydrosoluble lubricant (glycerin, polyacrylamide...).
1875			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001			ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	A01AD	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less then 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult
1876			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Reduction of the compensatory cardiovascular reactions by the beta blocking agents. The beta-andrenergic inhibition can be elevated by the beta-mimetics during surgery.	Precaution for use	As a general rule, do not stop the treatment with the beta-blocking agent and, in any event, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.
1877			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Reduction of the compensatory cardiovascular reactions by the beta blocking agents. The beta-adrenergic inhibition can be elevated during the surgery by the beta-stimulants.	Precaution for use	As a general rule, do not stop the treatment with the beta blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.
1878			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ISONIAZID	6038			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after.
1879			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ISOPRENALINE	6054			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
1880			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
1881			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Perioperative hypertension	Precaution for use	In the case of scheduled surgery, it is preferable to stop the treatment several days before surgery.
1882	PRIMIDONE	8691			AFATINIB	1430438			ANSM	430-PRIMIDONE.html	Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the primidone	Precaution for use	Clinical monitoring during the administration of these together and 1 to 2 weeks after they are stopped.
1883	PRISTINAMYCIN	66958					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	431-PRISTINAMYCIN.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pristinamycin and after it is stopped
1884	PRISTINAMYCIN	66958			COLCHICINE	2683			ANSM	431-PRISTINAMYCIN.html	Increase of the undesirable effects of the colchicine with potentially fatal consequences	CONTRAINDICATION	
1885	PRISTINAMYCIN	66958					IMMUNOSUPPRESSANTS	L04A	ANSM	431-PRISTINAMYCIN.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the medications together and after it is stopped.
1886	PROBENECID	8698			DIPROPHYLLINE	3714			ANSM	432-PROBENECID.html	Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)	Precaution for use	Reduce the dosage of diprophylline during the treatment with the probenicid
1887	PROBENECID	8698			METHOTREXATE	6851			ANSM	432-PROBENECID.html	Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid	CONTRAINDICATION	
1888	PROCARBAZINE	8702					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	433-PROCARBAZINE.html	Increase of the hypersensitivity reactions (hypereosinophilia, rash), due to increase of the metabolism of the procarbazine by the inducer	Take into account	
1889			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ALDESLEUKIN	70223			ANSM	434-IODINATED-X-RAY-CONTRAST-MEDIA.html	Increase of the risk of reaction to the contrast media in cases of previous treatment with interleukin2: skin rash or more rarely low blood pressure, oliguria or even renal failure	Take into account	
1890			IODINATED X-RAY CONTRAST MEDIA	VO8A-001			DIURETICS	C0E-001	ANSM	434-IODINATED-X-RAY-CONTRAST-MEDIA.html	In case of dehydration caused by the diuretics, increased risk of acute functional renal insufficiency, in particular when large doses of the contrast media are used	Precaution for use	Rehydrate before administration of the iodinated product
1891			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	METFORMIN	6809			ANSM	434-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam.	CONTRAINDICATION	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later.
1892			PROGESTIN CONTRACEPTIVES	G03-001	APREPITANT	358255			ANSM	435-PROGESTIN-CONTRACEPTIVES.html	(Except IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness	Precaution for use	Use another method of contraception, in particular a barrier type, during the length of time that these are administered together and one cycle after.
1893			PROGESTIN CONTRACEPTIVES	G03-001	BOCEPREVIR	1102129			ANSM	435-PROGESTIN-CONTRACEPTIVES.html	Aside from the combination ethinylestradiol (0.035mg)/norethisterone (1 mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir	Precaution for use	Use an additional or alternative, reliable contraceptive method during the administration of these medications together.
1894			PROGESTIN CONTRACEPTIVES	G03-001	BOSENTAN	75207			ANSM	435-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after.
1895			PROGESTIN CONTRACEPTIVES	G03-001	GRISEOFULVIN	5021			ANSM	435-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after.
1896			PROGESTIN CONTRACEPTIVES	G03-001			ENZYMATIC INDUCERS	N03-J05-001	ANSM	435-PROGESTIN-CONTRACEPTIVES.html	Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer	Not recommended	Another reliable contraceptive method, in particular a barrier type, should be used during the administration of these medications together and a cycle after.
1897			PROGESTIN CONTRACEPTIVES	G03-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	435-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir	Not recommended	Another method of contraception, in particular a barrier type (condom or IUD), should be used during the time the substances are administered together and one cycle following.
1898			PROGESTIN CONTRACEPTIVES	G03-001	ST JOHNS WORT	258326			ANSM	435-PROGESTIN-CONTRACEPTIVES.html	Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy)	CONTRAINDICATION	
1899			PROGESTIN CONTRACEPTIVES	G03-001	PERAMPANEL	1356552			ANSM	435-PROGESTIN-CONTRACEPTIVES.html	For doses of perampanel >=12 mg/day: Risk of decrease of the contraceptive effectiveness	Not recommended	Another method of contraception, in particular a barrier type, should be used.
1900			PROGESTIN CONTRACEPTIVES	G03-001	ULIPRISTAL	1005921			ANSM	435-PROGESTIN-CONTRACEPTIVES.html	Risk of antagonism of the effects of the progestin contraceptive	Not recommended	Do not restart the progestin contraceptive treatment fewer than 12 days after stopping the ulipristal.
1901			NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	BOSENTAN	75207			ANSM	436-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html	Risk of decrease of the effectiveness of the progestogen	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the bosentan and after it is stopped
1902			NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003			ENZYMATIC INDUCERS	N03-J05-001	ANSM	436-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html	Decrease of the effectiveness of the progestogen	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the inducer and after it is stopped.
1903			NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	ULIPRISTAL	1005921			ANSM	436-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html	Risk of antagonism of the effects of the progestogen	Not recommended	In a uterine fibroid indication, do no restart a progestogen treatment fewer than 12 days after the ulipristal is ended.
1904	PROGUANIL	2382					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	437-PROGUANIL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped.
1905	PROGUANIL	2382					THYROID HORMONES	H03AA	ANSM	437-PROGUANIL.html	Risk of clinically low thyroid with patients having thyroid replacement therapy	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped.
1906	PROPAFENONE	8754			ABIRATERONE	1100072			ANSM	438-PROPAFENONE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the abiraterone
1907	PROPAFENONE	8754					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	438-PROPAFENONE.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the inducer	Precaution of use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of it and the inducer together and after the inducer is stopped.
1908	PROPAFENONE	8754					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	438-PROPAFENONE.html	Increase of the anticoagulant effect and of the risk of hemorrhage. Mechanism proposed: inhibition of the metabolism of the vitamin K antagonist	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the propafenone and after it is stopped.
1909	PROPAFENONE	8754					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	438-PROPAFENONE.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG.
1910	PROPAFENONE	8754			BUPROPION	42347			ANSM	438-PROPAFENONE.html	Risk of increase of the undesirable effects of the propafenone due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the bupropion.
1911	PROPAFENONE	8754			CINACALCET	407990			ANSM	438-PROPAFENONE.html	Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with cinacalcet.
1912	PROPAFENONE	8754			DARIFENACIN	136198			ANSM	438-PROPAFENONE.html	Increase of the plasma concentrations of propafenone, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use.	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with darifenacin.
1913	PROPAFENONE	8754			DIGOXIN	3407			ANSM	438-PROPAFENONE.html	Risk of increase of the digoxinemia, especially with older patients	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with propafenone and after it is stopped.
1914	PROPAFENONE	8754			DULOXETINE	72625			ANSM	438-PROPAFENONE.html	Increase of the plasma concentrations of propafenone with risk of overdosage due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with the duloxetine and after it is stopped.
1915	PROPAFENONE	8754			ESMOLOL	49737			ANSM	438-PROPAFENONE.html	Disorders of contractility, autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG.
1916	PROPAFENONE	8754			ST JOHNS WORT	258326			ANSM	438-PROPAFENONE.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the time the substances are administered together and after the St Johns wort is stopped.
1917	PROPAFENONE	8754			MIRABEGRON	1300786			ANSM	438-PROPAFENONE.html	Increase of the plasma concentrations of the propafenone by decrease of its metabolism by the mirabegron	Precaution for use	Clinical monitoring and possible reduction of the dosage of the propafenone during the administration of these substances together.
1918	PROPAFENONE	8754			RIFAMPICIN	9384			ANSM	438-PROPAFENONE.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the substances together and after the rifampicin is stopped.
1919	PROPAFENONE	8754			TERBINAFINE	37801			ANSM	438-PROPAFENONE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the terbinafine.
1920	PROPAFENONE	8754			THEOPHYLLINE	10438			ANSM	438-PROPAFENONE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone.	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
1921	PROPRANOLOL	8787			ERGOTAMINE	4025			ANSM	439-PROPRANOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together.
1922	PROPRANOLOL	8787			FLUVOXAMINE	42355			ANSM	439-PROPRANOLOL.html	Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia	Precaution for use	Increased clinical monitoring, and, if needed, adjustment of the dosage of the propranolol during the treatment with the fluvoxamine and after it is stopped.
1923	PROPRANOLOL	8787					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	439-PROPRANOLOL.html	Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
1924	PROPRANOLOL	8787			RIFAMPICIN	9384			ANSM	439-PROPRANOLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
1925			ANTABUSE (REACTION)	123-ANT	ALCOHOL				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of the medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol.
1926	PYRAZINAMIDE	8987			ISONIAZID	6038			ANSM	440-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical and biological monitoring.
1927	PYRIMETHAMINE	9010			TRIMETHOPRIM	10829			ANSM	441-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections).
1928	QUETIAPINE	51272					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	442-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
1929	QUETIAPINE	51272					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	442-QUETIAPINE.html	Large increase of the concentrations of quetiapine, with risk of overdose	CONTRAINDICATION	
1930	QUETIAPINE	51272			ST JOHNS WORT	258326			ANSM	442-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
1931	QUETIAPINE	51272					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	442-QUETIAPINE.html	Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination	CONTRAINDICATION	
1932	QUETIAPINE	51272			RIFAMPICIN	9384			ANSM	442-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
1933	QUINIDINE	9068					URINARY ALKALIZERS	B05-001	ANSM	443-QUINIDINE.html	Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).	Precaution for use	Clinical monitoring, EKG, and possibly testing of the quinidinemia; if there is reason for it, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
1934	QUINIDINE	9068			ALISKIREN	325646			ANSM	443-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	CONTRAINDICATION	
1935	QUINIDINE	9068			COBICISTAT	1306284			ANSM	443-QUINIDINE.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	CONTRAINDICATION	
1936	QUINIDINE	9068			DABIGATRAN				ANSM	443-QUINIDINE.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.
1937	QUINIDINE	9068			DIGOXIN	3407			ANSM	443-QUINIDINE.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)	Precaution for use	Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage.
1938	QUINIDINE	9068			DRONEDARONE	233698			ANSM	443-QUINIDINE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine	Precaution for use	Start the treatment with quinidine at minimum recommended dosages, and adjust the doses according to the EKG.
1939	QUINIDINE	9068					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	443-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1940	QUINIDINE	9068			ITRACONAZOLE	28031			ANSM	443-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine	CONTRAINDICATION	
1941	QUINIDINE	9068					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	443-QUINIDINE.html	Increase of the plasma concentrations of the quidinine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination	CONTRAINDICATION	
1942	QUINIDINE	9068			STIRIPENTOL	37119			ANSM	443-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1943	QUINIDINE	9068			TAMOXIFEN	10324			ANSM	443-QUINIDINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine	Not recommended	
1944	QUINIDINE	9068			TRICLABENDAZOLE	38608			ANSM	443-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	CONTRAINDICATION	Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse.
1945	QUINIDINE	9068			VERAPAMIL	11170			ANSM	443-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
1946	QUINIDINE	9068			VORICONAZOLE	121243			ANSM	443-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1947	QUINIDINE	9068			VORTIOXETINE	1455099			ANSM	443-QUINIDINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the quinidine and after it is stopped.
1948	QUININE	9071					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	444-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer.	Precaution for use	Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped.
1949	QUININE	9071			DIGOXIN	3407			ANSM	444-QUININE.html	Moderate increase of the digoxinemia	Precaution for use	Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.
1950	QUININE	9071					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	444-QUININE.html	Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory difficulties (cinchonism)	Not recommended	-with the protease inhibitors
1951	QUININE	9071			MEFLOQUINE	6694			ANSM	444-QUININE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine.
1952	QUININE	9071			RIFAMPICIN	9384			ANSM	444-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
1953	QUINUPRISTINE	135098			DIHYDROERGOTAMINE	3418			ANSM	445-QUINUPRISTINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
1954	QUINUPRISTINE	135098			ERGOTAMINE	4025			ANSM	445-QUINUPRISTINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
1955	QUINUPRISTINE	135098					IMMUNOSUPPRESSANTS	L04A	ANSM	445-QUINUPRISTINE.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
1956	QUINUPRISTINE	135098			PIMOZIDE	8331			ANSM	445-QUINUPRISTINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1957	RACECADOTRIL	16738					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	446-RACECADOTRIL.html	Risk of increase of the undesirable effects of the angioedema type.	Contraindication	-in case of previous angioedema while taking ACE inhibitors
1958	RALTEGRAVIR	719872			RIFAMPICIN	9384			ANSM	447-RALTEGRAVIR.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	If administering these medications together cannot be avoided, doubling the dose of raltegravir can be considered
1959	RANOLAZINE	35829					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	448-RANOLAZINE.html	Risk of large decrease of the concentrations of ranolazine	Not recommended	
1960	RANOLAZINE	35829			ATORVASTATIN	83367			ANSM	448-RANOLAZINE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine	Precaution for use	Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction.
1961	RANOLAZINE	35829			DIGOXIN	3407			ANSM	448-RANOLAZINE.html	Increase of the digoxinemia	Precaution for use	Clinical and biological monitoring, and possibly EKG. Adjustment of the dosage of the digoxin if needed.
1962	RANOLAZINE	35829					IMMUNOSUPPRESSANTS	L04A	ANSM	448-RANOLAZINE.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine	Precaution for use	Clinical and biological monitoring, and possible adjustment of the dosage of the immunosuppressant.
1963	RANOLAZINE	35829					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	448-RANOLAZINE.html	Increase of the concentrations of ranolazine due to decrease of its metabolism by the inhibitor	CONTRAINDICATION	
1964	RANOLAZINE	35829			RIFAMPICIN	9384			ANSM	448-RANOLAZINE.html	Very large decrease of the concentrations of ranolazine.	Not recommended	
1965	RANOLAZINE	35829			SIMVASTATIN	36567			ANSM	448-RANOLAZINE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine	Precaution for use	Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction.
1966	REGORAFENIB	1312397					ENZYMATIC INDUCERS	N03-J05-001	ANSM	449-REGORAFENIB.html	Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the inducer	Not recommended	
1967	REGORAFENIB	1312397					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	449-REGORAFENIB.html	Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
1968	REGORAFENIB	1312397			ST JOHNS WORT	258326			ANSM	449-REGORAFENIB.html	Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort	Not recommended	
1969	REGORAFENIB	1312397			GRAPEFRUIT JUICE				ANSM	449-REGORAFENIB.html	Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the grapefruit	Not recommended	
1970			CALCIUM CHANNEL BLOCKERS	CO8CA-001			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended:	with the nimodipine
1971			CALCIUM CHANNEL BLOCKERS	CO8CA-001	IDELALISIB	1544460			ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Increase of the undesirable effects of the calcium channel blockers, of the orthostatic hypotension sort, especially with older patients	Precaution for use	Clinical monitoring and adjustment of the dosage of the calcium channel blocker during the treatment with idelalisib and after it is stopped.
1972			CALCIUM CHANNEL BLOCKERS	CO8CA-001			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.	Precaution for use	Clinical monitoring and dosage adjustment during the treatment with the enzymatic inhibitor and after it is stopped.
1973			CALCIUM CHANNEL BLOCKERS	CO8CA-001	RIFAMPICIN				ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	with the nimodipine
1974	REPAGLINIDE	73044					SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	450-REPAGLINIDE.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the need for repaglinde due to decrease or increase of the secretion of endogenous glucagon .	Precaution for use	Strengthen self-monitoring of blood glucose, and adjust the dosage of the repaglinide if needed during the treatment with the somatostatin analog
1975	REPAGLINIDE	73044			CICLOSPORIN	3008			ANSM	450-REPAGLINIDE.html	The concentrations of repaglinide more than doubled due to increase of its absorption	Not recommended	
1976	REPAGLINIDE	73044			CLARITHROMYCIN	21212			ANSM	450-REPAGLINIDE.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering agent during the treatment with the clarithromycin.
1977	REPAGLINIDE	73044			CLOPIDOGREL	32968			ANSM	450-REPAGLINIDE.html	Increase of the concentrations of repaglinide by the clopidogrel, with risk of increase of undesirable effects	Take into account	
1978	REPAGLINIDE	73044			DEFERASIROX	614373			ANSM	450-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide, due to inhibition of its hepatic metabolism by the deferasirox	Not recommended	If administering these medications together cannot be avoided, strict clinical and biological monitoring.
1979	REPAGLINIDE	73044			GEMFIBROZIL	4719			ANSM	450-REPAGLINIDE.html	Risk of severe hypoglycemia, even coma, due to substantial increase of the plasma concentrations of repaglinide by the gemfibrozil	CONTRAINDICATION	
1980	REPAGLINIDE	73044			TRIMETHOPRIM	10829			ANSM	450-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these medications together cannot be avoided, strict clinical and biological monitoring.
1981	RESERPINE	9260					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	451-RESERPINE.html	Psychomotor agitation, convulsions, hypertension	CONTRAINDICATION	
1982	RESERPINE	9260			LEVODOPA	6375			ANSM	451-RESERPINE.html	Inhibition of the effects of the levodopa	CONTRAINDICATION	
1983			CHELATING RESINS	C10-V0	MEDICATIONS ADMINISTERED BY ORAL ROUTE				ANSM	452-CHELATING RESINS.html	Taking chelating resins can decrease the intestinal absorption and, potentially, the effectiveness of other medications taken simultaneously	Precaution for use	As a general rule, the doses of the resin should be taken at a different time from that of other medications, at an interval of more than 2 hours apart, if possible
1984			CHELATING RESINS	C10-V0			THYROID HORMONES	H03AA	ANSM	452-CHELATING RESINS.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	Take the thyroid hormones at a different time from the resin (more than 2 hours apart, if possible).
1985			RETINOIDS	D05-D10			OTHER RETINOIDS	D05-D10	ANSM	453-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	CONTRAINDICATION	
1986			RETINOIDS	D05-D10			TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	453-RETINOIDS.html	Risk of intracranial hypertension	CONTRAINDICATION	
1987			RETINOIDS	D05-D10	VITAMIN A	11246			ANSM	453-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	CONTRAINDICATION	
1988	RIBAVIRIN	9344					ANTIPURINES	ANTIPUR	ANSM	454-RIBAVIRIN.html	Increased risk of serious undesirable effects, due to inhibition of the metabolism of the immunomodulator by the ribavirin	Not recommended	
1989	RIBAVIRIN	9344			DIDANOSINE	3364			ANSM	454-RIBAVIRIN.html	Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite	Not recommended	
1990	RIBAVIRIN	9344			STAVUDINE	59763			ANSM	454-RIBAVIRIN.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1991	RIBAVIRIN	9344			ZIDOVUDINE	11413			ANSM	454-RIBAVIRIN.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
1992	RIFABUTIN	55672			ATOVAQUONE	60212			ANSM	455-RIFABUTIN.html	Moderate decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Take into account	
1993	RIFABUTIN	55672			CLARITHROMYCIN	21212			ANSM	455-RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and of those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together.
1994	RIFABUTIN	55672			COBICISTAT	1306284			ANSM	455-RIFABUTIN.html	Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat	Precaution for use	Adjustment of the dosage of the rifabutin (in principle, reduction of the doses by half).
1995	RIFABUTIN	55672			EFAVIRENZ	195085			ANSM	455-RIFABUTIN.html	Decrease by about half of the concentrations of rifabutin, due to increase of its hepatic metabolism by the efavirenz	Precaution for use	Adjustment of the dosage of the rifabutin during the treatment with efavirenz.
1996	RIFABUTIN	55672			ELVITEGRAVIR	1306286			ANSM	455-RIFABUTIN.html	Decrease of the minimal concentrations of elvitegravir	Take into account	
1997	RIFABUTIN	55672			FLUCONAZOLE	4450			ANSM	455-RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the treatment with the two medications together.
1998	RIFABUTIN	55672					THYROID HORMONES	H03AA	ANSM	455-RIFABUTIN.html	Described for phenytoin, rifampicin, and carbamazepine. Risk of clinical hypothyroidism in patients with low thyroid, due to increase of the metabolism of the T3 and T4	Precaution for use	Monitoring of serum concentrations of T3 and of T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with rifabutin and after it is stopped.
1999	RIFABUTIN	55672					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	455-RIFABUTIN.html	Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin for another.	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
2000	RIFABUTIN	55672			POSACONAZOLE	282446			ANSM	455-RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Not recommended	Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.
2001	RIFABUTIN	55672			VORICONAZOLE	121243			ANSM	455-RIFABUTIN.html	Decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifabutin for one thing; and risk of increase of the undesirable effects (uveitis) of the rifabutin for another	Not recommended	If the administration of these substances together is judged necessary, clinical monitoring and adjustment of the dosage of the voriconazole (generally doubled) during the treatment with the rifabutin.
2002	RIFAMPICIN	9384			ABIRATERONE	1100072			ANSM	456-RIFAMPICIN.html	Large decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
2003	RIFAMPICIN	9384			AFATINIB	1430438			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring during the administration of these medications together and 1 to 2 weeks after they are stopped.
2004	RIFAMPICIN	9384			ALBENDAZOLE	430			ANSM	456-RIFAMPICIN.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.
2005	RIFAMPICIN	9384					CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	--with nimodipine
2006	RIFAMPICIN	9384					CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrythmic (increase of its hepatic metabolism).	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentration of the antiarrythmic. If needed, adjustment of the dosage of the antiarrythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrythmic)
2007	RIFAMPICIN	9384					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	456-RIFAMPICIN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped.
2008	RIFAMPICIN	9384			APIXABAN	1364430			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
2009	RIFAMPICIN	9384			APREPITANT	358255			ANSM	456-RIFAMPICIN.html	Very large decrease of the concentrations of aprepitant	Not recommended	
2010	RIFAMPICIN	9384			ATORVASTATIN	83367			ANSM	456-RIFAMPICIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
2011	RIFAMPICIN	9384			ATOVAQUONE	60212			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of atorvaquone by the enzymatic inducer	Not recommended	
2012	RIFAMPICIN	9384			BOCEPREVIR	1102129			ANSM	456-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of treatment with the two medications together.
2013	RIFAMPICIN	9384			BOSENTAN	75207			ANSM	456-RIFAMPICIN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
2014	RIFAMPICIN	9384			BUSPIRONE	1827			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.
2015	RIFAMPICIN	9384			CARBAMAZEPINE	2002			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, testing of the plasma concentrations and adjustment of the dosage of the carbamazepine during the treatment with the rifampicin and after it is stopped.
2016	RIFAMPICIN	9384			CARVEDILOL				ANSM	456-RIFAMPICIN.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
2017	RIFAMPICIN	9384			CLARITHROMYCIN	21212			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and risk of lower effectiveness of the clarithromycin, especially with HIV patients, due to increase of its metabolism by the rifampicin	Precaution for use	Regular clinical and biological monitoring.
2018	RIFAMPICIN	9384			CLOZAPINE	2626			ANSM	456-RIFAMPICIN.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
2019	RIFAMPICIN	9384			COBICISTAT	1306284			ANSM	456-RIFAMPICIN.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	CONTRAINDICATION	
2020	RIFAMPICIN	9384			DABIGATRAN				ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
2021	RIFAMPICIN	9384			DEFERASIROX	614373			ANSM	456-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.
2022	RIFAMPICIN	9384			DELAMANID	1344662			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
2023	RIFAMPICIN	9384			DRONEDARONE	233698			ANSM	456-RIFAMPICIN.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
2024	RIFAMPICIN	9384			EFAVIRENZ	195085			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
2025	RIFAMPICIN	9384			EXEMESTANE	258494			ANSM	456-RIFAMPICIN.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
2026	RIFAMPICIN	9384			FENTANYL	4337			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
2027	RIFAMPICIN	9384			FLUCONAZOLE	4450			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the fluconazole due to increase of its metabolism by the rifampicin	Not recommended	
2028	RIFAMPICIN	9384					GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped.
2029	RIFAMPICIN	9384			HALOPERIDOL	5093			ANSM	456-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped.
2030	RIFAMPICIN	9384					THYROID HORMONES	H03AA	ANSM	456-RIFAMPICIN.html	Risk of clinically low thyroid in patients with already low thyroid, due to increase of the metabolism of the T3 and of the T4.	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the rifampicin and after it is stopped.
2031	RIFAMPICIN	9384			HYDROXYCHLOROQUINE	5521			ANSM	456-RIFAMPICIN.html	Risk of lower therapeutic effect of the hydroxychloroquine, due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoringand possible adjustment of the dosage of the hydroxychloroquine during the treatment with rifampicin and after it is stopped.
2032	RIFAMPICIN	9384			IDELALISIB	1544460			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer	Not recommended	
2033	RIFAMPICIN	9384					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	456-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	CONTRAINDICATION	Until additional data with the ritonavir boosted inhibitors is available.
2034	RIFAMPICIN	9384					METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
2035	RIFAMPICIN	9384			ISONIAZID	6038			ANSM	456-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical and biological monitoring of this classic combination. In case of hepatitis, stop the isoniazid.
2036	RIFAMPICIN	9384			IVABRADINE	77417			ANSM	456-RIFAMPICIN.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.
2037	RIFAMPICIN	9384			KETOCONAZOLE	6135			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
2038	RIFAMPICIN	9384			LEDIPASVIR	1591922			ANSM	456-RIFAMPICIN.html	Large decrease of the plasma concentrations of ledipasvir due to increase of its hepatic metabolism by the rifampicin	CONTRAINDICATION	
2039	RIFAMPICIN	9384			LINEZOLIDE	190376			ANSM	456-RIFAMPICIN.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
2040	RIFAMPICIN	9384			METOPROLOL	6918			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
2041	RIFAMPICIN	9384			METRONIDAZOLE	6922			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped.
2042	RIFAMPICIN	9384			MIDAZOLAM	6960			ANSM	456-RIFAMPICIN.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
2043	RIFAMPICIN	9384					MINERALOCORTICOIDS	H02AA0	ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in cases of organ transplants	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped.
2044	RIFAMPICIN	9384			MONTELUKAST	88249			ANSM	456-RIFAMPICIN.html	Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped.
2045	RIFAMPICIN	9384			MORPHINE	7052			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped.
2046	RIFAMPICIN	9384			NEVIRAPINE	53654			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
2047	RIFAMPICIN	9384			NIMODIPINE	7426			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.
2048	RIFAMPICIN	9384			NINTEDANIB	1592737			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the rifampicin	Precaution for use	Clinical monitoring during the administration of these medications together.
2049	RIFAMPICIN	9384			PERAMPANEL	1356552			ANSM	456-RIFAMPICIN.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
2050	RIFAMPICIN	9384			PIOGLITAZONE	33738			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped.
2051	RIFAMPICIN	9384			POSACONAZOLE	282446			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
2052	RIFAMPICIN	9384			PRAZIQUANTEL	8628			ANSM	456-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	CONTRAINDICATION	
2053	RIFAMPICIN	9384			PROPAFENONE	8754			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precautions for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the two substances together and after the rifampicin is stopped.
2054	RIFAMPICIN	9384			PROPRANOLOL	8787			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
2055	RIFAMPICIN	9384			QUETIAPINE	51272			ANSM	456-RIFAMPICIN.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
2056	RIFAMPICIN	9384			QUININE	9071			ANSM	456-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
2057	RIFAMPICIN	9384			RALTEGRAVIR	719872			ANSM	456-RIFAMPICIN.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	If administering these together cannot be avoided, doubling the dose of raltegravir can be considered
2058	RIFAMPICIN	9384			RANOLAZINE	35829			ANSM	456-RIFAMPICIN.html	Very large decrease of the concentrations of ranolazine.	Not recommended	
2059	RIFAMPICIN	9384			RIVAROXABAN	1114195			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
2060	RIFAMPICIN	9384			SIMVASTATIN	36567			ANSM	456-RIFAMPICIN.html	Very large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
2061	RIFAMPICIN	9384			TELAPREVIR	1102261			ANSM	456-RIFAMPICIN.html	Very large decrease of the concentrations of telaprevir	CONTRAINDICATION	
2062	RIFAMPICIN	9384			TELITHROMYCIN	274786			ANSM	456-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the anti-infective treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin.	Not recommended	
2063	RIFAMPICIN	9384			TENOFOVIR ALAFENAMIDE	1721603			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the rifampicin	Not recommended	Clinical monitoring during the administration of these medications together and 1 to 2 weeks after the rifampicin is stopped.
2064	RIFAMPICIN	9384			TERBINAFINE	37801			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
2065	RIFAMPICIN	9384					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction)	Precaution for use	Clinical monitoring and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped.
2066	RIFAMPICIN	9384			TIAGABINE	31914			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases where it is administered with the rifampicin.
2067	RIFAMPICIN	9384			TICAGRELOR	1116632			ANSM	456-RIFAMPICIN.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
2068	RIFAMPICIN	9384			ULIPRISTAL	1005921			ANSM	456-RIFAMPICIN.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer.	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
2069	RIFAMPICIN	9384					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	456-RIFAMPICIN.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	Clinical and biological monitoring, and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped.
2070	RIFAMPICIN	9384					VITAMIN D	A11CC	ANSM	456-RIFAMPICIN.html	Decrease of the concentrations of vitamin D more marked than in the absence of the treatment with the rifampicin	Precaution for use	Concentration dosage of vitamin D and supplementation if necessary.
2071	RIFAMPICIN	9384			VORICONAZOLE	121243			ANSM	456-RIFAMPICIN.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	CONTRAINDICATION	
2072	RIFAMPICIN	9384			ZOLPIDEM	39993			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
2073	RIFAMPICIN	9384			ZOPICLONE	40001			ANSM	456-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
2074	RILPIVIRINE	1102270					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	457-RILPIVIRINE.html	Risk of decrease of the plasma concentrations of the rilpivirine	Take into account	If necessary, use an active H2 antagonist in one dose per day, to be taken at least 12 hours before or at least 4 hours after.
2075	RILPIVIRINE	1102270					PROTON PUMP INHIBITORS	A02BC-001	ANSM	457-RILPIVIRINE.html	Decrease of the plasma concentrations of rilpivirine by the proton pump inhibitor (decreased absorption because of increase of the gastric pH)	CONTRAINDICATION	
2076	RILPIVIRINE	1102270			DEXAMETHASONE	3264			ANSM	457-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	CONTRAINDICATION	With the exception of dexamethasone administered in a single dose
2077	RILPIVIRINE	1102270					ENZYMATIC INDUCERS	N03-J05-001	ANSM	457-RILPIVIRINE.html	Large decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
2078	RILPIVIRINE	1102270			ST JOHNS WORT	258326			ANSM	457-RILPIVIRINE.html	Risk of decrease of the plasma concentratons of rilpivirine due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
2079	RIOCIGUAT	1439816					NITRATE DERIVATIVES AND RELATED	C01D-001	ANSM	458-RIOCIGUAT.html	Risk of serious hypotension (synergic effect)	CONTRAINDICATION	
2080	RIOCIGUAT	1439816					TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	458-RIOCIGUAT.html	Risk of serious hypotension (synergic effect)	CONTRAINDICATION	
2081	RIOCIGUAT	1439816					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	458-RIOCIGUAT.html	Increase of the plasma concentrations of riociguat due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
2082	RISPERIDONE	35636			CARBAMAZEPINE	2002			ANSM	459-RISPERIDONE.html	Risk of decrease of the active fraction of the risperidone and of its therapeutic effectiveness due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone.
2083	RISPERIDONE	35636			FLUOXETINE	4493			ANSM	459-RISPERIDONE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of the undesirable effects	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone.
2084	RISPERIDONE	35636			PAROXETINE	32937			ANSM	459-RISPERIDONE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects.	Precaution for use	Clinical monitoring and, if needed, adjustment of the dosage of the risperidone.
2085			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
2086			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ALISKIREN	325646			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease	Contraindication	- for patients with diabetes or renal insufficiency
2087			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Acute renal insufficiency with patients at risk (older patient, dehydration, treatment with diuretics, changes in renal function), due to decrease of the glomerular filtration (inhibition of the vasodilater prostaglandins due to the non steroidal anti-inflammatories.) These effects are generally reversible. In addition, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment and regularly while these substances are administered together.
2088			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Risk of hyperkalemia (potentially lethal) especially in case of renal insufficiancy (addition of the hyperkaliemia inducing effects)/	Not recommended	--if the combination of these durgs in justified, strict testing of the kaliemia and of renal function
2089			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001			POTASSIUM LOWERING DIURETICS	C03	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Risk of abrupt arterial hypotension and/or acute renal insufficiency at the beginning of or at an increase of the dosage of a treatment with an angiotensin II antagonist in cases where there is pre-existing fluid depletion.	Precaution for use	With arterial hypertension, where there has been pre-existing diuretic treatment that has caused fluid depletion, it is necessary:
2090			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	EPLERENONE	298869			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Increase of the risk of hyperkalemia, especially with older patients	Precaution for use	Strict testing of the kalemia and of the renal function during the administration of these substances together.
2091			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	In indications where the administration of these substances together is possible, increased risk of degradation of renal function, even acute renal insufficiency, and increase of the hyperkalemia as well as hypotension and fainting or loss of consciousness.	Take into account	
2092			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	LITHIUM	6448			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Increase of the lithemia that can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	If the use of an angiotensin II antagonist is indispensable, strict monitoring of the lithemia and adjustment of the dosage
2093			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	POTASSIUM	8588			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).	Not recommended	Avoid administering these substances together unless there is pre-existing hypokelimia.
2094	RIVAROXABAN	1114195					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	460-RIVAROXABAN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect.	Not recommended	
2095	RIVAROXABAN	1114195			FLUCONAZOLE	4450			ANSM	460-RIVAROXABAN.html	Increase of the plasma concentrations of the rivaroxaban by the fluconazole, with increase of the risk of bleeding	Not recommended	
2096	RIVAROXABAN	1114195					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	460-RIVAROXABAN.html	Increase of the plasma concentrations of rivaroxaban, with increase of the risk of bleeding	Not recommended	
2097	RIVAROXABAN	1114195			RIFAMPICIN	9384			ANSM	460-RIVAROXABAN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
2098	ROPINIROLE	72302					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	461-ROPINIROLE.html	Increase of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with ropinirole and after it is stopped.
2099	ROPINIROLE	72302			CIPROFLOXACIN	2551			ANSM	461-ROPINIROLE.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped.
2100	ROPINIROLE	72302			ENOXACIN				ANSM	461-ROPINIROLE.html	Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with the enoxacin and after it is stopped.
2101	ROPINIROLE	72302			FLUVOXAMINE	42355			ANSM	461-ROPINIROLE.html	Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with fluvoxamine and after it is stopped.
2102	ROSUVASTATIN	301542			CICLOSPORIN	3008			ANSM	462-ROSUVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin	CONTRAINDICATION	
2103	ROSUVASTATIN	301542					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	462-ROSUVASTATIN.html	Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption	Precaution for use	Clinical and biological monitoring.
2104	ROXITHROMYCIN	9478			ATORVASTATIN	83367			ANSM	463-ROXITHROMYCIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type	Precaution for use	Use weaker doses of the cholesterol lowering medication
2105	ROXITHROMYCIN	9478			CICLOSPORIN	3008			ANSM	463-ROXITHROMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped.
2106	ROXITHROMYCIN	9478			MIDAZOLAM	6960			ANSM	463-ROXITHROMYCIN.html	Slight increase of sedation	Take into account	
2107	ROXITHROMYCIN	9478			SIMVASTATIN	36567			ANSM	463-ROXITHROMYCIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type	Precaution for use	Use weaker doses of the cholesterol lowering medication
2108	ROXITHROMYCIN	9478					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	463-ROXITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
2109	ROXITHROMYCIN	9478					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	463-ROXITHROMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
2110	RUFINAMIDE	69036					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	464-RUFINAMIDE.html	Moderate decrease of the concentrations of ethinylestradiol	Precaution for use	Another contraceptive method, in particular a barrier type, should be used.
2111	RUFINAMIDE	69036					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	464-RUFINAMIDE.html	Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg.	Precaution for use	With children who weigh less than 30 kg: do not exceed the total dose of 600mg/day after the period of titration.
2112	SACUBITRIL	1656328			ALISKIREN	325646			ANSM	465-SACUBITRIL.html	With diabetic patients or those with renal insufficiency, increase of the undesirable effects such as hypotension, hyperkaliemia	CONTRAINDICATION	
2113	SACUBITRIL	1656328					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	465-SACUBITRIL.html	Increase of the risk of angioedema	CONTRAINDICATION	
2114	SALMETEROL	36117			ITRACONAZOLE	28031			ANSM	466-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole	Take into account	
2115	SALMETEROL	36117			KETOCONAZOLE	6135			ANSM	466-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
2116	SERTRALINE	36437					ENZYMATIC INDUCERS	N03-J05-001	ANSM	467-SERTRALINE.html	Risk of ineffectiveness of the antidepressant treatment	Not recommended	
2117	SERTRALINE	36437			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	467-SERTRALINE.html	Increase, sometimes large, of the concentrations of the antidepressant with some patients due to decrease of its intestinal metabolism	Not recommended	
2118	SERTRALINE	36437			PIMOZIDE	8331			ANSM	467-SERTRALINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
2119	SILDENAFIL	136411			JOSAMYCIN	6084			ANSM	468-SILDENAFIL.html	Increase of the plasma concentrations of sildenafil, with risk of hypotension	Precaution for use	Start the treatment with sildenafil at the minimum dose when it is administered with the josamycin
2120	SILDENAFIL	136411					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	468-SILDENAFIL.html	Increase of he plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the therapy with the ombitasvir+paritaprevir	CONTRAINDICATION	
2121	SIMEPREVIR	1482790			DEXAMETHASONE	3264			ANSM	469-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
2122	SIMEPREVIR	1482790					ENZYMATIC INDUCERS	N03-J05-001	ANSM	469-SIMEPREVIR.html	Decrease of he plasma concentrations of simeprevir due to increase of its hepatic metabolism by the inducer	Not recommended	
2123	SIMEPREVIR	1482790					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	469-SIMEPREVIR.html	Risk of increase of the plasma concentrations of simeprevir due to decrease of its heptatic metabolism by the inhibitor	Not recommended	
2124	SIMEPREVIR	1482790			ST JOHNS WORT	258326			ANSM	469-SIMEPREVIR.html	Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
2125			PLATELET AGGREGATION INHIBITORS	B01AC-001	ANAGRELIDE	596724			ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of hemorrhagic events	Not recommended	
2126			PLATELET AGGREGATION INHIBITORS	B01AC-001			ORAL ANTICOAGULANTS	B01A-001	ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of the risk of hemorrhage	Take into account	
2127			PLATELET AGGREGATION INHIBITORS	B01AC-001	DEFIBROTIDE	1311089			ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increased risk of hemorrhage	Not recommended	
2128			PLATELET AGGREGATION INHIBITORS	B01AC-001			HEPARINS	B01AB	ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of the risk of hemorrhage	Take into account	
2129			PLATELET AGGREGATION INHIBITORS	B01AC-001			THROMBOLYTICS	B01AD	ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of the risk of hemorrhage	Take into account	
2130	SIMVASTATIN	36567			AMIODARONE	703			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction
2131	SIMVASTATIN	36567			AMLODIPINE	17767			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
2132	SIMVASTATIN	36567			AZITHROMYCIN	18631			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent.	Precaution for use	Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction
2133	SIMVASTATIN	36567			CARBAMAZEPINE	2002			ANSM	470-SIMVASTATIN.html	Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism	Not recommended	
2134	SIMVASTATIN	36567			CICLOSPORIN	3008			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin	Precaution for use	Do not exceed the dosage of 10 mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction.
2135	SIMVASTATIN	36567			CLARITHROMYCIN	21212			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent.	CONTRAINDICATION	
2136	SIMVASTATIN	36567			DANAZOL	3102			ANSM	470-SIMVASTATIN.html	Increased risk of onset of rhabdomyolysis	Not recommended	If administering these medications together is deemed necessary, do not exceed the dose of 10 mg of simvastatin.
2137	SIMVASTATIN	36567			DILTIAZEM	3443			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent.	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction.
2138	SIMVASTATIN	36567			DRONEDARONE	233698			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Not recommended	
2139	SIMVASTATIN	36567			ERYTHROMYCIN	4053			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	CONTRAINDICATION	
2140	SIMVASTATIN	36567					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	CONTRAINDICATION	
2141	SIMVASTATIN	36567			ITRACONAZOLE	28031			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	CONTRAINDICATION	
2142	SIMVASTATIN	36567			KETOCONAZOLE	6135			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	CONTRAINDICATION	Use a statin not affected by this type of interaction
2143	SIMVASTATIN	36567			ST JOHNS WORT	258326			ANSM	470-SIMVASTATIN.html	Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
2144	SIMVASTATIN	36567					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	470-SIMVASTATIN.html	Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the therapy with ombitavir+paritaprevir	CONTRAINDICATION	
2145	SIMVASTATIN	36567			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	470-SIMVASTATIN.html	Significant increase of the plasma concentrations of the cholesterol lowering agent, with risk of onset of undesirable effects, especially muscular	Not recommended	
2146	SIMVASTATIN	36567			POSACONAZOLE	282446			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor).	CONTRAINDICATION	
2147	SIMVASTATIN	36567			RANOLAZINE	35829			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine	Precaution for use	Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction
2148	SIMVASTATIN	36567			RIFAMPICIN	9384			ANSM	470-SIMVASTATIN.html	Very large decrease of the plasma concentrations of simvastatin due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
2149	SIMVASTATIN	36567			ROXITHROMYCIN	9478			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type	Precaution for use	Use weaker doses of cholesterol lowering agent.
2150	SIMVASTATIN	36567			STIRIPENTOL	37119			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	CONTRAINDICATION	
2151	SIMVASTATIN	36567			TELAPREVIR	1102261			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	CONTRAINDICATION	
2152	SIMVASTATIN	36567			TELITHROMYCIN	274786			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication)	CONTRAINDICATION	
2153	SIMVASTATIN	36567			VERAPAMIL	11170			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction
2154	SIMVASTATIN	36567			VORICONAZOLE	121243			ANSM	470-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin	CONTRAINDICATION	
2155	SIROLIMUS	35302			CICLOSPORIN	3008			ANSM	471-SIROLIMUS.html	Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together	Precaution for use	It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped
2156	SIROLIMUS	35302			VERAPAMIL	11170			ANSM	471-SIROLIMUS.html	Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
2157	SODIUM BICARBONATE				LITHIUM	6448			ANSM	472-SODIUM-BICARBONATE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts.	Precaution for use	Avoid excess amounts of sodium and take into account the presence of sodium in certain medications such as antacids.
2158	SODIUM CHLORIDE	9863			LITHIUM	6448			ANSM	473-SODIUM CHLORIDE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	Avoid excessive sodium and take into account the presence of sodium in some medications such as antacids.
2159	SODIUM OXYBATE	9899			ALCOHOL (DRINK OF INGREDIENT)				ANSM	474-SODIUM-OXYBATE.html	Increase by the alcohol of the sedative effect of these substances. The alteration of vigilence can make driving vehicles or operating machinery dangerous	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol
2160	SOFOSBUVIR				AMIODARONE	703			ANSM	475-SOFOSBUVIR.html	Only for interactions with the combinatons daclatasvir/sofosbuvir or ledispavir/sofosbuvir:Possibly abrupt onset of bradycardia, that can have fatal consequences	Not recommended	If administering these together cannot be avoided, clinical monitoring and strict EKG, in particular during the first weeks of treatment with the bitherapy.
2161	SOFOSBUVIR						ENZYMATIC INDUCERS	N03-J05-001	ANSM	475-SOFOSBUVIR.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the enzymatic inducer	Contraindication	--with the rifampicin
2162	SOFOSBUVIR				ST JOHNS WORT	258326			ANSM	475-SOFOSBUVIR.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the St Johns wort	CONTRAINDICATION	
2163	SOFOSBUVIR				MODAFINIL	30125			ANSM	475-SOFOSBUVIR.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil	Not recommended	
2164	SORBITOL	9945			THE FRENCH DOCUMENT LISTS 'CATIORESINE SULFO CALCIQUE'				ANSM	476-SORBITOL.html	With the resin administered by oral and rectal route: risk of colonic necrosis, possibly fatal	CONTRAINDICATION	
2165	SORBITOL	9945			THE FRENCH DOCUMENT LISTS 'CATIORESINE SULFO SODIQUE'				ANSM	476-SORBITOL.html	With the resin administered by oral and rectal route: risk of colonic necrosis, possibly fatal.	Not recommended	
2166			SPERMICIDES	R02AA	MEDICATIONS USED BY VAGINAL ROUTE				ANSM	477-SPERMICIDES.html	All topical vaginal treatment is susceptible to disrupting the action of a topical spermicidal contraceptive	Not recommended	
2167	SPIRAMYCIN	9991			LEVODOPA	6375			ANSM	478-SPIRAMYCIN.html	In case of administration with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa.
2168	SPIRONOLACTONE	9997					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	479-SPIRONOLACTONE.html	With the spironolactone in dosages from 12.5 to 50 mg per day, and with weak doses of the ACE inhibitor.In the treatment of class III or IV heart failure (NYHA) with an ejection fraction <35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescription conditions for this combination of medications.	Precaution for use	Verify the absence of pre-existing hyperkalemia and renal insufficiency. Strict biological monitoring of the kalemia and of the creatinemia (1 time per week during the first month, then one time per month thereafter).
2169	SPIRONOLACTONE	9997			MITOTANE	7004			ANSM	479-SPIRONOLACTONE.html	Risk of blocking of the action of the mitotane by the spironolactone	CONTRAINDICATION	
2170			ANTIARRHYTHMIC AGENTS	C01B-001			OTHER ANTIARRHYTHMIC AGENTS	C01B-001	ANSM	48-ANTIARRHYTHMIC-AGENTS.html	The combination of two antiarrhythmic agents is very delicate. In the majority of cases, it is contraindicated or not recommended.	Contraindication	Not recommended
2171	STAVUDINE	59763			ISONIAZID	6038			ANSM	480-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
2172	STAVUDINE	59763			PENTAMIDINE	7994			ANSM	480-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
2173	STAVUDINE	59763			RIBAVIRIN	9344			ANSM	480-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
2174	STAVUDINE	59763			THALIDOMIDE	10432			ANSM	480-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
2175	STAVUDINE	59763			ZALCITABINE	3363			ANSM	480-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites.	Not recommended	
2176	STAVUDINE	59763			ZIDOVUDINE	11413			ANSM	480-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites.	Not recommended	
2177	STIRIPENTOL	37119					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	481-STIRIPENTOL.html	Increase of the plasma concentrations of the anticonvulsant, with risk of overdose, due to inhibition of its hepatic metabolism by the stiripentol	Precaution for use	Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of its dosage.
2178	STIRIPENTOL	37119			ATORVASTATIN	83367			ANSM	481-STIRIPENTOL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the chlosterol lowering medication)	CONTRAINDICATION	
2179	STIRIPENTOL	37119			CAFFEINE	1886			ANSM	481-STIRIPENTOL.html	Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of caffeine.
2180	STIRIPENTOL	37119			CLOBAZAM	21241			ANSM	481-STIRIPENTOL.html	Increase of the plasma concentrations of these anticonvulsants, with risk of overdose, due to inhibition of their hepatic metabolism	Precaution for use	Clinical monitoring, plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of the dosage of that anticonvulsant as well.
2181	STIRIPENTOL	37119			DIAZEPAM	3322			ANSM	481-STIRIPENTOL.html	Increase of the plasma concentrations of the diazepam, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of the dosage of the anticonvulsant as well.
2182	STIRIPENTOL	37119			DIHYDROERGOTAMINE	3418			ANSM	481-STIRIPENTOL.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)	CONTRAINDICATION	
2183	STIRIPENTOL	37119			ERGOTAMINE	4025			ANSM	481-STIRIPENTOL.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)	CONTRAINDICATION	
2184	STIRIPENTOL	37119			HALOFANTRINE	50749			ANSM	481-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes.	Not recommended	
2185	STIRIPENTOL	37119					IMMUNOSUPPRESSANTS	L04A	ANSM	481-STIRIPENTOL.html	Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)	CONTRAINDICATION	
2186	STIRIPENTOL	37119			MIDAZOLAM	6960			ANSM	481-STIRIPENTOL.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the stiripentol.
2187	STIRIPENTOL	37119			PIMOZIDE	8331			ANSM	481-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
2188	STIRIPENTOL	37119			QUINIDINE	9068			ANSM	481-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
2189	STIRIPENTOL	37119			SIMVASTATIN	36567			ANSM	481-STIRIPENTOL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	CONTRAINDICATION	
2190	STIRIPENTOL	37119					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	481-STIRIPENTOL.html	Possible increase of the theophyllinemia, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring, plasma dosage, and possible adjustment of the dosage of theophylline.
2191	STRONTIUM	81638			CALCIUM	1428011			ANSM	482-STRONTIUM.html	With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the calcium salts (more than two hours apart, if possible).
2192	STRONTIUM	81638					TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	482-STRONTIUM.html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the tetracycline antibiotic (more than two hours apart, if possible).
2193	STRONTIUM	81638			IRON	1431589			ANSM	482-STRONTIUM.html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the iron salts (more than two hours apart, if possible).
2194	STRONTIUM	81638					FLUOROQUINOLONES	J01MA-001	ANSM	482-STRONTIUM.html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the fluoroquinolones (more than two hours apart, if possible).
2195	STRONTIUM	81638			ZINC	1431163			ANSM	482-STRONTIUM.html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible).
2196			SUBSTANCES WITH ABSORPTION REDUCED BY GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	RBGI			GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	A07BC-A02AD	ANSM	483-SUBSTANCES-WITH-ABSORPTION-REDUCED-BY-GASTRO-INTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html	Decrease of the absorption of these substances	Precaution for use	Take the gastro-intestinal targeted medications, antacids, and absorbants at a different time from these substances (more than 2 hours apart, if possible).
2197			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANAGRELIDE	596724			ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these together.
2198			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES	P01B-001	ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially torsades de pointes	Contraindication	--with citalopram, domperidone, escitalopram, hydroxyzine, and piperaquin
2199			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	AZITHROMYCIN	18631			ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
2200			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG
2201			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			BRADYCARDIA INDUCING DRUGS	C0N0S0	ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these together
2202			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	CIPROFLOXACIN	2551			ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together
2203			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	CLARITHROMYCIN	21212			ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
2204			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	HYDROXYCHLOROQUINE	5521			ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	--with citalopram, domperidone, escitalopram, hydroxyzine and piperaquine
2205			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			POTASSIUM LOWERING AGENTS	C03-001	ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Correct all hypokaliemia before administering the product and do clinical and electrolyte monitoring and EKG.
2206			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	LEVOFLOXACIN	82122			ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together.
2207			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	METHADONE	6813			ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	--with citalopram, dromperidone, escitalopram, hydroxyzine, piperaquine
2208			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES	N05A-002	ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	--with citalopram, dromperidone, escitalopram, hydroxyzine, piperaquine
2209			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	NORFLOXACIN	7517			ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together
2210			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ONDANSETRON	26225			ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together
2211			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ROXITHROMYCIN	9478			ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together
2212			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)	C01B	ANSM	484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	--For dolasetron, erythromycin, spiramycin and vicamine, only the forms administerd by IV route are concerned by this interaction
2213			SUBSTRATES AT RISK OF CYP3A4	L01N01	CRIZOTINIB	1148495			ANSM	485-SUBSTRATES-AT-RISK-OF-CYP3A4.html	Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib	Not recommended	
2214			SUBSTRATES AT RISK OF CYP3A4	L01N01	IDELALISIB	1544460			ANSM	485-SUBSTRATES-AT-RISK-OF-CYP3A4.html	Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idealisib	Not recommended	
2215			SUBSTRATES AT RISK OF CYP3A4	L01N01			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	485-SUBSTRATES-AT-RISK-OF-CYP3A4.html	Increase of the undesirable effects particular to each substrate, with frequently severe consequences	Take into account	
2216	SUCRALFATE	10156					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	486-SUCRALFATE.html	Decrease of the digestive absorption of the vitamin K antagonist	Precaution for use	Take the sucralfate at a different time from the vitamin K antagonist (more than 2 hours apart, if possible).
2217	SUCRALFATE	10156			DIGOXIN	3407			ANSM	486-SUCRALFATE.html	Decrease of the digestive absorption of the digoxin	Precaution for use	Take the sucralfate at a different time from the digoxin (more that 2 hours apart, if possible).
2218	SUCRALFATE	10156					FLUOROQUINOLONES	J01MA-001	ANSM	486-SUCRALFATE.html	Decrease of the digestive absorption of the fluorquinolones	Precaution for use	Take the sucralfate at a different time from the fluoroquinolones (more than 2 hours apart, if possible).
2219	SUCRALFATE	10156					THYROID HORMONES	H03AA	ANSM	486-SUCRALFATE.html	Decrease of the digestive absorption of the thyroid hormones.	Precaution for use	Take the thyroid hormones at a different time from the sucralfate (more than 2 hours apart, if possible).
2220	SUCRALFATE	10156					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	486-SUCRALFATE.html	Decrease of the digestive absorption of the phenytoin	Precaution for use	Take the sucalfate at a different time from the phenytoin (more than 2 hours apart, if possible).
2221	SUCRALFATE	10156			SULPIRIDE	10239			ANSM	486-SUCRALFATE.html	Decrease of the digestive absorption of the sulpiride	Precaution for use	Take the sucralfate at a different time from the sulpiride (more than 2 hours apart, if possible).
2222	SUFENTANIL	56795					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	487-SUFENTANIL.html	Increase of the opioid analgesics effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.
2223	SULFAFURAZOLE	10207					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	488-SULFAFURAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution of use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.
2224	SULFAFURAZOLE	10207					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	488-SULFAFURAZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	The use of another class of antibiotic is preferred; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped.
2225	SULFAMETHIZOLE	10179					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	489-SULFAMETHIZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped.
2226	SULFAMETHIZOLE	10179			METHENAMINE	6832			ANSM	489-SULFAMETHIZOLE.html	Precipitation of crystals in the urinary tract (due to the acidification of the urine)	Not recommended	
2227	SULFAMETHIZOLE	10179					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	489-SULFAMETHIZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the antibacterial sulfonamide and after it is stopped.
2228			CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003			BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001	ANSM	49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html	Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
2229			CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html	Negative inotropic effect with risk of acute decompensated heart failure	CONTRAINDICATION	
2230	SULFAMETHOXAZOLE	10180					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	490-SULFAMETHOXAZOLE.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	If the administration of the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole and after it is stopped.
2231	SULFAMETHOXAZOLE						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	490-SULFAMETHOXAZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the antibacterial sulfonamide and after it is stopped.
2232			ANTIBACTERIAL SULFONAMIDES	JO1E	METHOTREXATE	6851			ANSM	491-ANTIBACTERIAL-SULFONAMIDES.html	Increase of the hematological toxicity of the methotrexate	Precaution for use	Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the administration of the substances together and after it is stopped.
2233			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ALCOHOL (DRINK OF INGREDIENT)				ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Antabuse effect, especially for glibenclamide, glipizide, tolbutamide. Increase of the hypoglycemic reaction (inhibition of the compensation reactions) that can make possible the onset of hypoglycemic coma	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
2234			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB			SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the need for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Reinforce self-monitoring of blood glucose and adjust the dosage of the blood glucose lowering sulfonamide if needed during the treatment with the somatostatin analog.
2235			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB			BETA-2 MIMETICS or BETA 2 ADRENERGIC AGONISTS	R03C-001	ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring. Possibly change to insulin if the situation requires.
2236			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	All the beta blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment.
2237			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	All the beta blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of the treatment.
2238			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	CHLORPROMAZINE				ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With large doses (100mg per day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the neuroleptic during the treatment and after it is stopped.
2239			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	CLARITHROMYCIN	21212			ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetique	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
2240			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	DANAZOL	3102			ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Diabetes inducing effect of the danazol	Not recommended	If the administration of the substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic during the treatment with the danazol and after it is stopped.
2241			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	FLUCONAZOLE	4450			ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Increase of the half life of the sulfonamide with possible onset of manifestations of hypoglymemia	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the sulfonamide during the treatment with the fluconazole.
2242			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in diabetic patients treated with glucose lowering sulfonamides. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for the glucose lowering sulfonamides)	Precaution for use	Reinforce self -monitoring of blood glucose.
2243			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	MICONAZOLE	6932			ANSM	492-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	CONTRAINDICATION	
2244	SULFASALAZINE	9524			DIGOXIN	3407			ANSM	493-SULFASALAZINE.html	Decrease of the digoxinemia that can reach 50%	Precaution for use	Clinical monitoring, EKG, and, possibly, monitoring of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the sulfasalazine and after it is stopped.
2245	SULFINPYRAZONE	10205			CICLOSPORIN	3008			ANSM	494-SULFINPYRAZONE.html	Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with sulfinpyrazone and after it is stopped.
2246	SULPIRIDE	10239			SUCRALFATE	10156			ANSM	495-SULPIRIDE.html	Decrease of the digestive absorption of the sulpiride	Precaution for use	Take the sucralfate at a different time from the sulpiride (more than 2 hours apart, if possible).
2247	SUNITINIB	357977					THYROID HORMONES	H03AA	ANSM	496-SUNITINIB.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
2248	SUXAMETHONIUM	10154					ACETYLCHOLINESTERASE INHIBITORS	ACETCHO	ANSM	497-SUXAMETHONIUM.html	Risk of lengthening of the motor block, increased in the case of partial deficit of pseudo-cholinesterase	Take into account	
2249			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	498-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
2250			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	498-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
2251			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	498-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped	Not recommended	
2252			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	498-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	CONTRAINDICATION	
2253			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	499-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
2254			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	499-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html	Paroxysmal hypertension with the possibility of arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
2255			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	499-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html	Increase of the pressor action of the sympathomimetic, most often moderate.	Precaution for use	Only use under strict medical monitoring.
2256			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	499-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html	By extrapolation from the non selective MAOIs: risk of increase of the pressor action	Precaution for use	To be used only under strict medical monitoring.
2257			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	499-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html	Paroxysmal hypertension with possibility of arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
2258	ACETYLSALICYLIC ACID	1191			ACETAZOLAMIDE	167			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the undesirable effects, and especially of metabolic acidosis, of the acetylsalicylic acid in large doses and of the acetazolamide, due to decrease of the elimination of the acetylsalicylic acid by the acetazolamide	Not recommended	
2259	ACETYLSALICYLIC ACID	1191			ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events	Not recommended	
2260	ACETYLSALICYLIC ACID	1191					ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3g per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
2261	ACETYLSALICYLIC ACID	1191					ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, especially in cases with a previous gastro duodenal ulcer.	Contraindication	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3g per day)
2262	ACETYLSALICYLIC ACID	1191					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
2263	ACETYLSALICYLIC ACID	1191			CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities.	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes.
2264	ACETYLSALICYLIC ACID	1191			DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 g per day):increase of the risk of digestive ulceration and hemorrhage	Take into account	
2265	ACETYLSALICYLIC ACID	1191					DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 g per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
2266	ACETYLSALICYLIC ACID	1191					GLUCOCORTICOIDS (EXCEPT FOR HYDROCORTISONE IN REPLACEMENT THERAPY)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
2267	ACETYLSALICYLIC ACID	1191					LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastro duodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3 g per day)
2268	ACETYLSALICYLIC ACID	1191					LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
2269	ACETYLSALICYLIC ACID	1191			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)				ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastro duodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3 g per day)
2270	ACETYLSALICYLIC ACID	1191			UNFRACTIONATED HEPARIN (PREVENTIVE DOSES)				ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring	Take into account	
2271	ACETYLSALICYLIC ACID	1191					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 g per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
2272	ACETYLSALICYLIC ACID	1191					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
2273	ACETYLSALICYLIC ACID	1191			METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, especially hematological, of the methotrexate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication
2274	ACETYLSALICYLIC ACID	1191			PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-in case of weak to moderate renal function
2275	ACETYLSALICYLIC ACID	1191					THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
2276	ACETYLSALICYLIC ACID	1191			TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation actions	Not recommended	--except for validated indications for this combination in acute coronary syndromes
2277	ACETYLSALICYLIC ACID	1191			TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation actions	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
2278	ACETYLSALICYLIC ACID	1191					URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
2279			CLASS IA ANTIARRHYTHMICS	C01B-002			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic, due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring, EKG, and testing of the plasma concentrations; if needed, adjustment of the dosage of the antiarrhythmic during the treatment with the inducer and after it is stopped.
2280			CLASS IA ANTIARRHYTHMICS	C01B-002	ESMOLOL	49737			ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Disorders of contractility, auto- regulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
2281			CLASS IA ANTIARRHYTHMICS	C01B-002	RIFAMPICIN	9384			ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic (increase of its hepatic metabolism).	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the antiarrhythmic. If needed, adjustment of the dosage of the antiarrhythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrhythmic)
2282			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			OTHER INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	500-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or of hypertensive crises.	CONTRAINDICATION	
2283			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	500-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
2284			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	500-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
2285			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	500-INDIRECT-SYMPATHOMIMETICS.html	Perioperative hypertension	Precaution for use	In the case of scheduled surgery, it is preferable to stop the treatment several days before surgery.
2286			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	500-INDIRECT-SYMPATHOMIMETICS.html	Paroxystic hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped	CONTRAINDICATION	
2287			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	500-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
2288			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			ALPHA-SYMPATHOMIMETICS (ORAL AND/OR NASAL)	R01AA	ANSM	500-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	CONTRAINDICATION	
2289	TACROLIMUS	42316					AMINOGLYCOSIDES	J01GB-001	ANSM	501-TACROLIMUS.html	Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
2290	TACROLIMUS	42316			AMIODARONE	703			ANSM	501-TACROLIMUS.html	Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone	Precaution for use	Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during its administration with the amiodarone and when the amiodarone is stopped.
2291	TACROLIMUS	42316			AMPHOTERICIN B	732			ANSM	501-TACROLIMUS.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
2292	TACROLIMUS	42316					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	501-TACROLIMUS.html	Risk of addition of the nephrotoxic effects, especially with older patients	Precaution for use	Monitor renal function at the beginning of treatment with the NSAI.
2293	TACROLIMUS	42316			CLINDAMYCIN	2582			ANSM	501-TACROLIMUS.html	Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity.	Precaution for use	Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage.
2294	TACROLIMUS	42316			DABIGATRAN				ANSM	501-TACROLIMUS.html	Risk of increase of the plasma concentrations of dabigatran	Not recommended	
2295	TACROLIMUS	42316			DANAZOL	3102			ANSM	501-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration with the danazol and after it is stopped, with testing of the renal function.
2296	TACROLIMUS	42316					POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	501-TACROLIMUS.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
2297	TACROLIMUS	42316			JOSAMYCIN	6084			ANSM	501-TACROLIMUS.html	Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin	Not recommended	
2298	TACROLIMUS	42316			LANSOPRAZOLE	17128			ANSM	501-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped.
2299	TACROLIMUS	42316			OMEPRAZOLE	7646			ANSM	501-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
2300	TACROLIMUS	42316			POTASSIUM	8588			ANSM	501-TACROLIMUS.html	Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Avoid administering these substances together unless there is preexisting hypokalemia.
2301	TACROLIMUS	42316			VERAPAMIL	11170			ANSM	501-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
2302	TAMOXIFEN	10324					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	502-TAMOXIFEN.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist.
2303	TAMOXIFEN	10324			BUPROPION	42347			ANSM	502-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine [sic]	Not recommended	
2304	TAMOXIFEN	10324			DULOXETINE	72625			ANSM	502-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine	Not recommended	
2305	TAMOXIFEN	10324			FLUOXETINE	4493			ANSM	502-TAMOXIFEN.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine	Not recommended	
2306	TAMOXIFEN	10324			PAROXETINE	32937			ANSM	502-TAMOXIFEN.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine	Not recommended	
2307	TAMOXIFEN	10324			QUINIDINE	9068			ANSM	502-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine	Not recommended	
2308	TAMOXIFEN	10324			TERBINAFINE	37801			ANSM	502-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine	Not recommended	
2309	TAMSULOSINE	77492			AMIODARONE	703			ANSM	503-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires.
2310	TAMSULOSINE	77492			DILTIAZEM	3443			ANSM	503-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires.
2311	TAMSULOSINE	77492					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	503-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Not recommended	
2312	TAMSULOSINE	77492			VERAPAMIL	11170			ANSM	503-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires.
2313	TELAPREVIR	1102261			AMIODARONE	703			ANSM	504-TELAPREVIR.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia	CONTRAINDICATION	
2314	TELAPREVIR	1102261					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	504-TELAPREVIR.html	Risk of very large decrease of the concentrations of telaprevir.	CONTRAINDICATION	
2315	TELAPREVIR	1102261			ATORVASTATIN	83367			ANSM	504-TELAPREVIR.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
2316	TELAPREVIR	1102261			COLCHICINE	2683			ANSM	504-TELAPREVIR.html	Risk of increase of the undesirable effects of the colchicine, due to decrease of its metabolism	Not recommended	In particular with patients having renal and hepatic insufficiency.
2317	TELAPREVIR	1102261			DIGOXIN	3407			ANSM	504-TELAPREVIR.html	Increase of the digoxinemia	Precaution for use	Clinical and biological monitoring, and adjustment, if needed, of the dosage of the digoxin during the treatment with the telaprevir and after it is stopped.
2318	TELAPREVIR	1102261					NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	504-TELAPREVIR.html	Decrease of the effectiveness of the estrogen	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the telaprevir and after it is stopped.
2319	TELAPREVIR	1102261					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	504-TELAPREVIR.html	Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the telaprevir	Precaution for use	Use an additional or alternative, reliable contraceptive method during the administration of the substances together and two cycles after.
2320	TELAPREVIR	1102261					IMMUNOSUPPRESSANTS	L04A	ANSM	504-TELAPREVIR.html	Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the substances together and after it is stopped.
2321	TELAPREVIR	1102261					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	504-TELAPREVIR.html	Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure	Not recommended	
2322	TELAPREVIR	1102261			ITRACONAZOLE	28031			ANSM	504-TELAPREVIR.html	Risk of increase of the plasma concentrations of telaprevir and of the itraconazole	Precaution for use	Clinical monitoring. Avoid large doses of itraconaole (>200 mg per day).
2323	TELAPREVIR	1102261			MIDAZOLAM	6960			ANSM	504-TELAPREVIR.html	Increase of the plasma concentrations of medazolam due to decrease of its hepatic metabolism, with increase of sedation	Contraindication	-with the midazolam by mouth
2324	TELAPREVIR	1102261			ST JOHNS WORT	258326			ANSM	504-TELAPREVIR.html	Risk of very large decrease of the concentrations of telaprevir	CONTRAINDICATION	
2325	TELAPREVIR	1102261			RIFAMPICIN	9384			ANSM	504-TELAPREVIR.html	Very large decrease of the concentrations of telaprevir	CONTRAINDICATION	
2326	TELAPREVIR	1102261			SIMVASTATIN	36567			ANSM	504-TELAPREVIR.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	CONTRAINDICATION	
2327	TELAPREVIR	1102261			TENOFOVIR ALAFENAMIDE	1721603			ANSM	504-TELAPREVIR.html	Risk of decrease of the effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the telaprevir	Not recommended	
2328	TELBIVUDINE	474128			PEG-INTERFERON ALFA-2A	120608			ANSM	505-TELBIVUDINE.html	Increased risk of peripheral neuropathy	CONTRAINDICATION	
2329	TELITHROMYCIN	274786					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	506-TELITHROMYCIN.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of its hepatic metabolism by the inducerr	Not recommended	
2330	TELITHROMYCIN	274786			ATORVASTATIN	83367			ANSM	506-TELITHROMYCIN.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication	CONTRAINDICATION	
2331	TELITHROMYCIN	274786			DEXAMETHASONE	3264			ANSM	506-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
2332	TELITHROMYCIN	274786			DIGOXIN	3407			ANSM	506-TELITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the dogoxinemia during the treatment with the telithromycin and after it is stopped.
2333	TELITHROMYCIN	274786					IMMUNOSUPPRESSANTS	L04A	ANSM	506-TELITHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	When these are taken together, strict testing of the renal function, blood concentration dosage of the immunosuppressant and possible adjustment of the dosage.
2334	TELITHROMYCIN	274786					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	506-TELITHROMYCIN.html	Risk of increase of the undesirable effects, especially of cardiac arrhythmia type	CONTRAINDICATION	with the patient with severe renal or hepatic insufficiency
2335	TELITHROMYCIN	274786			ST JOHNS WORT	258326			ANSM	506-TELITHROMYCIN.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort	Not recommended	
2336	TELITHROMYCIN	274786			MIZOLASTINE	61455			ANSM	506-TELITHROMYCIN.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	CONTRAINDICATION	
2337	TELITHROMYCIN	274786			RIFAMPICIN	9384			ANSM	506-TELITHROMYCIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin	Not recommended	
2338	TELITHROMYCIN	274786			SIMVASTATIN	36567			ANSM	506-TELITHROMYCIN.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering drug).	CONTRAINDICATION	
2339	TELITHROMYCIN	274786			VENLAFAXINE	39786			ANSM	506-TELITHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2340	TELITHROMYCIN	274786					VINCA ALKALOIDS	L01CA	ANSM	506-TELITHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the telithromycin	Precaution for use	Strict clinical and biological monitoring. Possibly, use another antibiotic.
2341	TENOFOVIR ALAFENAMIDE	1721603			BOCEPREVIR	1102129			ANSM	507-TENOFOVIR-ALAFENAMIDE.html	Risk of lower effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the boceprevir	Not recommended	
2342	TENOFOVIR ALAFENAMIDE	1721603			CICLOSPORIN	3008			ANSM	507-TENOFOVIR-ALAFENAMIDE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	In case of co-administration with the ciclosporine, the dose of tenofovir alafenamide must be limited to 10 mg per day.
2343	TENOFOVIR ALAFENAMIDE	1721603			COBICISTAT	1306284			ANSM	507-TENOFOVIR-ALAFENAMIDE.html	With the atazanavir, the darunavir or the lopinavir boosted with cobicistat, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	In case of co-administration, the dose of tenofovir alafenamide must be limited to 10 mg per day. The administration with the other protease inhibitors of HIV has not been studied.
2344	TENOFOVIR ALAFENAMIDE	1721603					ENZYMATIC INDUCERS	N03-J05-001	ANSM	507-TENOFOVIR-ALAFENAMIDE.html	Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the inducer	Not recommended	If the administration of these medications together cannot be avoided, clinical monitoring during the administration and 1 to2 weeks after the inducer is stopped.
2345	TENOFOVIR ALAFENAMIDE	1721603					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	507-TENOFOVIR-ALAFENAMIDE.html	With the atazanavir, the darunavir or the lopinavir, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	If these are administered together, the dose of tenofovir alafenamide must be limited to 10 mg per day. Administration with the other protease inhibitors of HIV has not been studied.
2346	TENOFOVIR ALAFENAMIDE	1721603			ITRACONAZOLE	28031			ANSM	507-TENOFOVIR-ALAFENAMIDE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	In case of co-administration with the itraconazole, the dose of tenofovir alafenamide must be limited to 10 mg per day.
2347	TENOFOVIR ALAFENAMIDE	1721603			KETOCONAZOLE	6135			ANSM	507-TENOFOVIR-ALAFENAMIDE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	In case of co-administration with the ketoconazole, the dose of tenofovir alafenamide must be limited to 10 mg per day.
2348	TENOFOVIR ALAFENAMIDE	1721603			RIFAMPICIN	9384			ANSM	507-TENOFOVIR-ALAFENAMIDE.html	Decrease of the plasma concentrations of tenofovir alafenamide due to decrease of its absorption by the rifampicin	Not recommended	Clinical monitoring during the administration of these medications together and 1 to 2 weeks after the rifampicin is stopped.
2349	TENOFOVIR ALAFENAMIDE	1721603			TELAPREVIR	1102261			ANSM	507-TENOFOVIR-ALAFENAMIDE.html	Risk of reduction of the effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the telaprevir	Not recommended	
2350	TENOFOVIR ALAFENAMIDE	1721603			VERAPAMIL	11170			ANSM	507-TENOFOVIR-ALAFENAMIDE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorptioin	Precaution for use	In case of co-administration with the verapamil, the dose of tenofovir alafenamide must be limited to 10 mg per day
2351	TENOFOVIR DISOPROXIL	300195					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	508-TENOFOVIR-DISOPROXIL.html	Risk of increase of the nephrotoxicity of the tenofovir, especially with large doses of the anti-inflammatory or in the presence of factors of risk of renal insufficiency.	Precaution for use	When these are administered together, monitor renal function.
2352	TENOFOVIR DISOPROXIL	300195			ATAZANAVIR	343047			ANSM	508-TENOFOVIR-DISOPROXIL.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same substances together	Take into account	Do not administer the atazanavir with the tenofovir without ritonavir.
2353	TENOFOVIR DISOPROXIL	300195			DIDANOSINE	3364			ANSM	508-TENOFOVIR-DISOPROXIL.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitochondrial toxicity of the didanosine	Not recommended	
2354	TENOFOVIR DISOPROXIL	300195			LEDIPASVIR	1591922			ANSM	508-TENOFOVIR-DISOPROXIL.html	When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir	Precaution for use	Clinical and biological monitoring, especially of the renal function.
2355	TERBINAFINE	37801			CICLOSPORIN	3008			ANSM	509-TERBINAFINE.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Testing of the blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped.
2356	TERBINAFINE	37801			FLECAINIDE	4441			ANSM	509-TERBINAFINE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecaidine during the treatment with the terbinafine.
2357	TERBINAFINE	37801			MEQUITAZINE	29528			ANSM	509-TERBINAFINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
2358	TERBINAFINE	37801			METOPROLOL	6918			ANSM	509-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine.
2359	TERBINAFINE	37801			PROPAFENONE	8754			ANSM	509-TERBINAFINE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the terbinafine.
2360	TERBINAFINE	37801			RIFAMPICIN	9384			ANSM	509-TERBINAFINE.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
2361	TERBINAFINE	37801			TAMOXIFEN	10324			ANSM	509-TERBINAFINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine.	Nor recommended	
2362	TERBINAFINE	37801			VORTIOXETINE	1455099			ANSM	509-TERBINAFINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the terbinafine and after it is stopped.
2363			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of excessive bradycardia (addition of the bradycardia inducing effects)	Precaution for use	Regular clinical monitoring, especially at the beginning of the administration of the substances together
2364			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	PILOCARPINE	8328			ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of addition of the undesirable cholinergic effects, especially digestive ones	Take into account	
2365			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	SUXAMETHONIUM	10154			ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of lengthening of the motor block, increased in the case of partial deficit of pseudocholinesterase	Take into account	
2366	TERIFLUNOMIDE	1310520					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	510-TERIFLUNOMIDE.html	Risk of general vaccine disease, possibly fatal	Not recommended	
2367	TETRABENAZINE	10390					DOPAMINERGICS	N04B-002	ANSM	511-TETRABENAZINE.html	Reciprocal antagonism between the dopaminergic and the tetrabenazine	Not recommended	
2368	TETRABENAZINE	10390					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	511-TETRABENAZINE.html	Risk of hypertensive crises. Because of the duration of the action of the MAOI, this interaction is still theoretically possible two weeks after the MAOI is stopped	CONTRAINDICATION	
2369	TETRABENAZINE	10390			LEVODOPA	6375			ANSM	511-TETRABENAZINE.html	Reciprocal antagonism between the levodopa and the tetrabenazine	Not recommended	
2370	THALIDOMIDE	10432			DIDANOSINE	3364			ANSM	512-THALIDOMIDE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
2371	THALIDOMIDE	10432			STAVUDINE	59763			ANSM	512-THALIDOMIDE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
2372	THALIDOMIDE	10432			ZALCITABINE	3363			ANSM	512-THALIDOMIDE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
2373	THEOPHYLLINE	10438			LITHIUM	6448			ANSM	513-THEOPHYLLINE.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
2374	THEOPHYLLINE	10438			PROPAFENONE	8754			ANSM	513-THEOPHYLLINE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
2375	THEOPHYLLINE	10438			VEMURAFENIB	1147220			ANSM	513-THEOPHYLLINE.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects.	Precaution for use	Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped.
2376			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations and of the effectiveness of the theophylline due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and, if needed, monitoring of the theophyllinemia. Possible adjustment of the dosage of the theophylline during the treatment with the inducer and after it is stopped.
2377			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	CIMETIDINE	2541			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia. If there is reason for it, adjustment of the theophylline during the treatment with the cimetidine and after it is stopped.
2378			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	CIPROFLOXACIN	2551			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin.	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
2379			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	CLARITHROMYCIN	21212			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
2380			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	DIPYRIDAMOLE	3521			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theophylline	Precaution for use	Interrupt a treatment with theophylline at least 5 days before myocardial perfusion imaging with the dipyridamole.
2381			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ENOXACIN	3925			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Overdose of theophylline due to substantial decrease of its metabolism	CONTRAINDICATION	
2382			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ERYTHROMYCIN	4053			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous with children	Not recommended	
2383			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	FLUCONAZOLE	4450			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)	Precaution for use	Clinical monitoring and, possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the fluconazole and after it is stopped.
2384			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	FLUVOXAMINE	42355			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if needed, adjustment of the dosage of the theophylline during the treatment with the fluvoxamine and after it is stopped.
2385			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	HALOTHANE	5095			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
2386			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA			XANTHINE OXYDASE INHIBITORS	M04AA0	ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	In case of large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism	Precaution for use	Clinical monitoring and testing of the theophyllinemia up to two or three weeks after the beginning of the treatment with the inhibitor; if there is reason for it, adjustment of the dosage during the treatment with these substances together.
2387			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the protease inhibitor and after it is stopped.
2388			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	JOSAMYCIN	6084			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
2389			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	MEXILETINE	6926			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the mexiletine and after it is stopped.
2390			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ST JOHNS WORT	258326			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations of the theophylline, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome)	CONTRAINDICATION	In case of accidental use of the substances together, do not stop the St Johns wort abruptly but test the plasma concentrations (or the effectiveness) of the substance taken with it before and then after stopping the St Johns wort.
2391			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	NORFLOXACIN	7517			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring, and possibly monitoring of the theophyllinemia.
2392			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	PEFLOXACIN	7960			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and, possibly monitoring of the theophyllinemia.
2393			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	PENTOXIFYLLINE	8013			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the pentoxifylline and after it is stopped.
2394			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	RIFAMPICIN	9384			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction)	Precaution for use	Clinical monitoring, and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped.
2395			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ROXITHROMYCIN	9478			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children.	Take into account	
2396			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	STIRIPENTOL	37119			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Possible increase of the theophyllinemia, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring, plasma dosage, and possible adjustment of the dosage of theophylline.
2397			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	TIABENDAZOLE	10450			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment (and after it is stopped, in the case where the anthelmintic is prescribed for a period exceeding 48 hours).
2398			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	TICLOPIDINE	10594			ANSM	514-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the ticlopidine and after it is stopped.
2399			THROMBOLYTICS	B01AD	ACETYLSALICYLIC ACID	1191			ANSM	515-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
2400			THROMBOLYTICS	B01AD			PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	515-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
2401			THROMBOLYTICS	B01AD			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	515-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
2402			THROMBOLYTICS	B01AD	DEFIBROTIDE	1311089			ANSM	515-THROMBOLYTICS.html	Accrued risk of hemorrhage	CONTRAINDICATION	
2403			THROMBOLYTICS	B01AD			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	515-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
2404			THROMBOLYTICS	B01AD			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	515-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
2405	TIABENDAZOLE	10450					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	516-TIABENDAZOLE .html	Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment (and after it is stopped, in the case where the anthelmintic is prescribed for a period exceeding 48 hours).
2406	TIAGABINE	31914					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	517-TIAGABINE.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism by the inducer	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with an anticonvulsant enzymatic inducer.
2407	TIAGABINE	31914			RIFAMPICIN	9384			ANSM	517-TIAGABINE.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with the rifampicin.
2408	TIANEPTINE	38252					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	518-TIANEPTINE.html	Risk of drop in blood pressure, paroxystic hypertension, hyperthermia, convulsions, death	Not recommended	
2409	TIBOLONE	38260					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	519-TIBOLONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tibolone and after it is stopped.
2410			ORAL ANTICOAGULANTS	B01A-001			OTHER ORAL ANTICOAGULANTS	B01A-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Risk of increase of hemorrhagic events when one oral anticoagulant is replaced with another.	Take into account	Take into account the half-life of the oral anticoagulant and observe, if the situation requires, a delay for clearance before the start of treatment with another. Be sure to inform the patient.
2411			ORAL ANTICOAGULANTS	B01A-001	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication with:	- anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
2412			ORAL ANTICOAGULANTS	B01A-001			PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage	Take into account	
2413			ORAL ANTICOAGULANTS	B01A-001			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the oral anticoagulant's risk of hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories)	Contraindication	- with: Phenylbutazone
2414			ORAL ANTICOAGULANTS	B01A-001	DEFIBROTIDE	1311089			ANSM	52-ORAL-ANTICOAGULANTS.html	Increased risk of hemorrhage	Not recommended	
2415			ORAL ANTICOAGULANTS	B01A-001			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) with large doses or in treatment prolonged beyond 10 days.	Precaution for use	When administering substances from these groups together is justified, strengthen monitoring: if the situation requires, with the vitamin K atagonists, biological monitoring on the 8th day, then every two weeks after that during the corticotherapy and after it is stopped.
2416			ORAL ANTICOAGULANTS	B01A-001			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage	Precaution for use	If administering these together cannot be avoided, reinforce clinical monitoring and, if the situation requires, biological monitoring.
2417			ORAL ANTICOAGULANTS	B01A-001			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage	Precaution for use	Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration with the SSRI and after it is stopped.
2418			ORAL ANTICOAGULANTS	B01A-001	IPILIMUMAB	1094833			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of digestive system hemorrhages	Precaution for use	Strict clinical monitoring.
2419			ORAL ANTICOAGULANTS	B01A-001			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hermorrhage.	Precaution for use	Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration of these medications together and after they are stopped.
2420	TICAGRELOR	1116632			ACETYLSALICYLIC ACID				ANSM	520-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
2421	TICAGRELOR	1116632					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	520-TICAGRELOR.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect	Not recommended	
2422	TICAGRELOR	1116632			DABIGATRAN				ANSM	520-TICAGRELOR.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Take into account	
2423	TICAGRELOR	1116632			DILTIAZEM	3443			ANSM	520-TICAGRELOR.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
2424	TICAGRELOR	1116632					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	520-TICAGRELOR.html	Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
2425	TICAGRELOR	1116632			ST JOHNS WORT	258326			ANSM	520-TICAGRELOR.html	Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect.	CONTRAINDICATION	
2426	TICAGRELOR	1116632					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	520-TICAGRELOR.html	Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir	CONTRAINDICATION	
2427	TICAGRELOR	1116632			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	520-TICAGRELOR.html	Doubling of the plasma concentrations of the antiagregant, with risk of increase of its undesirable effects, especially hemorrhagic ones	Not recommended	
2428	TICAGRELOR	1116632			RIFAMPICIN	9384			ANSM	520-TICAGRELOR.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
2429	TICAGRELOR	1116632			VERAPAMIL	11170			ANSM	520-TICAGRELOR.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
2430	TICLOPIDINE	10594			ACETYLSALICYLIC ACID	1191			ANSM	521-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
2431	TICLOPIDINE	10594			CICLOSPORIN	3008			ANSM	521-TICLOPIDINE.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage if the ticlopidine is stopped.
2432	TICLOPIDINE	10594					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	521-TICLOPIDINE.html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin.
2433	TICLOPIDINE	10594					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	521-TICLOPIDINE.html	Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline).	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the ticlopidine and after it is stopped.
2434			GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	A07BC-A02AD	MEDICATIONS ADMINISTERED BY ORAL ROUTE				ANSM	522-GASTROINTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html	Decrease of the absorption of certain other medications ingested simultaneously	Precaution for use	As a precaution, it is preferable to take these gastrointestinal targeted medications, antacids, and absorbent medications at a different time from any other medication (more than 2 hours apart, if possible).
2435			GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	A07BC-A02AD			SUBSTANCES WITH ABSORPTION REDUCED BY GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	RBGI	ANSM	522-GASTROINTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html	Decrease of the absorption of these substances	Precaution for use	Take the medications, antacids, or absorbants at a different time from these substances (more than 2 hours apart, if possible).
2436	TOPIRAMATE	38404			CARBAMAZEPINE	2002			ANSM	523-TOPIRAMATE.html	Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and if needed, adjustment of the dosage of the toprimate during the treatment with the carbamazepine and after it is stopped.
2437	TOPIRAMATE	38404					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	523-TOPIRAMATE.html	For doses of topiramate >= 200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concontrations of estrogen	Not recommended	Another method of contraception, in particular a barrier type, should be used.
2438	TOPIRAMATE	38404			LITHIUM	6448			ANSM	523-TOPIRAMATE.html	For doses of topiramate >=200mg/day: increase of the lithemia that can reach toxic levels, with signs of overdose of lithium	Precaution for use	Clinical and biological monitoring. Adjustment of the dosage of lithium.
2439	TOPIRAMATE	38404			OXCARBAZEPINE	32624			ANSM	523-TOPIRAMATE.html	Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	Clinical monitoring, and if needed, adjustment of the dosage of the topiramate during the treatment with the oxcarbazepine and after it is stopped.
2440	TOPIRAMATE	38404					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	523-TOPIRAMATE.html	Increase of the hyperammoniemia, with increased risk of encephalopathy	Precaution for use	Regular clinical and biological monitoring.
2441			TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)	C01B			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	524-TORSADES-DE-POINTES-INDUCING-MEDICATIONS-(EXCEPT-ANTIPARASITICS,-NEUROLEPTICS,-METHADONE).html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	--for dolasetron, erythromycin, spiramycin, and vincamine, only the forms administered by IV route are affected by this interaction.
2442	TRABECTEDINE	397736			ITRACONAZOLE	28031			ANSM	525-TRABECTEDINE.html	Risk of increase of the plasma concentrations of the trabectedine by the itraconazole	Not recommended	If administering these medications together is necessary, clinical monitoring and possible adjustment of the dosage of the trabectedine during the length of the treatment with the itraconazole
2443			NICOTINE SUBSTITUION TREATMENT	N07BA			MEDICATIONS AT RISK WHEN WITHDRAWING FROM TOBACCO	N0-R0-002	ANSM	526-NICOTINE-SUBSTITUTION-TREATMENT.html	Risk of overdose when replacing tobacco by the substitution treatment	Take into account	
2444	TRAMADOL	10689					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	527-TRAMADOL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped.
2445	TRAMADOL	10689			BUPROPION	42347			ANSM	527-TRAMADOL.html	Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications	Take into account	
2446	TRAMADOL	10689					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	527-TRAMADOL.html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	CONTRAINDICATION	
2447	TRAMADOL	10689					REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	527-TRAMADOL.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not recommended	
2448	TRAMADOL	10689					MAOI-B	N04BD0-001	ANSM	527-TRAMADOL.html	Risk of appearance of a serotonin syndrome	Take into account	
2449	TRAMADOL	10689					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	527-TRAMADOL.html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
2450	TRAMADOL	10689			ONDANSETRON	26225			ANSM	527-TRAMADOL.html	Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemitic effect of the ondansetron	Take into account	
2451	TRAMADOL	10689			VENLAFAXINE	39786			ANSM	527-TRAMADOL.html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
2452	TRASTUZUMAB EMTANSINE						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	528-TRASTUZUMAB-EMTANSINE.html	Increase of the plasma concentrations of the DM1, a component of the trastuzumab emtansine, due to inhibition of its metabolism by the inhibitor	Not recommended	
2453	TRICLABENDAZOLE	38608			DIHYDROERGOTAMINE	3418			ANSM	529-TRICLABENDAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	CONTRAINDICATION	Wait 24 hours between stopping the triclabendazole and the dose of the medication derived from ergot of rye, and the reverse.
2454	TRICLABENDAZOLE	38608			ERGOTAMINE	4025			ANSM	529-TRICLABENDAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	CONTRAINDICATION	Wait 24 hours between stopping the thiclabendazole and the ergotamine, and the reverse.
2455	TRICLABENDAZOLE	38608			PIMOZIDE	8331			ANSM	529-TRICLABENDAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	CONTRAINDICATION	Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse.
2456	TRICLABENDAZOLE	38608			QUINIDINE	9068			ANSM	529-TRICLABENDAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	CONTRAINDICATION	Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse.
2457			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ABIRATERONE	1100072			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Significant decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
2458			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	AFATINIB	1430438			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of afatinib due to increase of its metabolism by these substances	Precaution for use	Clinical monitoring during the administration of these substances together and 1 to 2 weeks after they are stopped.
2459			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ALBENDAZOLE	430			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness. .	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and it is stopped.
2460			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	with the nimodipine
2461			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrythmic, due to increase of its hepatic metabolism by the inducer.	Precaution for use	Clinical monitoring, EKG, and testing of the plasma concentrations; if needed, adjustment of the dosage of the antiarrythmic during the treatment with the inducer and after it is stopped.
2462			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer.	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the anticonvulsant inducer and a week after it is stopped.
2463			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	APIXABAN	1364430			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decreased of the plasma concentrations of the apixaban by the anticonvulsant enzymatic inducer, with risk of lower therapeutic effect.	Not recommended	
2464			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	APREPITANT	358255			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of very large decrease of the concentrations of aprepitant	Not recommended	
2465			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	BOCEPREVIR	1102129			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these substances together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of the administration of the substances together
2466			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	BOSENTAN	75207			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of bosentan	Not recommended	
2467			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	COBICISTAT	1306284			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	CONTRAINDICATION	
2468			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	DABIGATRAN				ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
2469			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	DEFERASIROX	614373			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.
2470			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	DELAMANID				ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentratioins of delamanid due to increase of its hepatic metabolism by the inducer.	CONTRAINDICATION	
2471			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	DOXYCYCLINE	3640			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the doxycycline due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the doxycycline
2472			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	DRONEDARONE	233698			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without notable modification of the active metabolite	Not recommended	
2473			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the effectiveness of the estrogen .	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped.
2474			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	FENTANYL	4337			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant	Not recommended	Choose another opioid.
2475			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have Addisons disease treated with hydrocortisone and in cases of organ transplants	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped.
2476			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	HALOPERIDOL	5093			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Clinical monitoring and, if needed, dosage adjustment during the treatment with carbamazepine and after it is stopped.	Precaution for use	Clinical monitoring and, if needed, dosage adjustment during the treatment with the carbazabine and after it is stopped.
2477			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			THYROID HORMONES	H03AA	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of clinically low thyroid in patients with hypothyroidism, due to increase of the metabolism of the T3 and of the T4	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the inducer and after it is stopped.
2478			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	IDELALISIB	1544460			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer	Not Recommended	
2479			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together
2480			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
2481			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	IVABRADINE	77417			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of these substances together and after the inducer is stopped.
2482			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	LEDIPASVIR	1591922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer.	CONTRAINDICATION	
2483			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	METRONIDAZOLE				ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the enzymatic inducer and after it is stopped.
2484			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	MIDAZOLAM	6960			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentration of the midazolam by the anticonvulsant	Take into account	
2485			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			MINERALOCORTICOIDS	H02AA0	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great in patients with Addisons disease treated with the hydrocortisone and in the case of transplants.	Precaution for use	Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped.
2486			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	MONTELUKAST	88249			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the inducer and after it is stopped.
2487			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	NIMODIPINE	7426			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the inducer and after it is stopped.
2488			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	PERAMPANEL	1356552			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
2489			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	POSACONAZOLE	282446			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the posaconazole	Precaution for use	Clinical monitoring. If possible, plasma dosages of the posaconazole and possible adjustment of its dosage.
2490			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	PRAZIQUANTEL	8628			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Very large decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment due to increase of its hepatic metabolism by the inducer	Not recommended	
2491			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	PROCARBAZINE	8702			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Increase of the hypersensitivity reactions (hypereosinophilia, rash), due to increase of the metabolism of the procarbazine by the inducer	Take into account	
2492			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	PROPAFENONE	8754			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the inducer	Precaution of use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during theadministration of it and the inducer together and after the inducer is stopped.
2493			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	QUETIAPINE	51272			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
2494			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	QUININE				ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer.	Precaution for use	Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped
2495			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	RANOLAZINE	35829			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of large decrease of the concentrations of ranolazine	Not recommended	
2496			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	RIVAROXABAN	1114195			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect.	Not recommended	
2497			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	STIRIPENTOL	37119			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Increase of the plasma concentrations of the anticonvulsant, with risk of overdose, due to inhibition of its hepatic metabolism by the stiripentol.	Precaution for use	Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of its dosage.
2498			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	TELAPREVIR	1102261			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of very large decrease of the concentrations of telaprevir	CONTRAINDICATION	
2499			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	TELITHROMYCIN	274786			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment due to increase of its hepatic metabolism by the inducer	Not recommended	
2500			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the theophylline due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and, if needed, monitoring of the theophyllinemia. Possible adjustment of the dosage of the theophylline during the treatment with the inducer and after it is stopped
2501			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	TIAGABINE	31914			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism by the inducer	Precaution for use	An increase of the dosage of tiagabine can prove necessary when it is administered with an anticonvulsant enzymatic inducer
2502			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	TICAGRELOR	1116632			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolsim by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect.	Not recommended	
2503			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ULIPRISTAL	1005921			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
2504			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001			VITAMIN D	A11CC	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the concentrations of Vitamin D greater than in the absence of the inducer	Precaution for use	Concentration dosage of vitamin D and supplementation if necessary.
2505			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	VORICONAZOLE	121243			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	-for carbamazipine, phenobarbital, primidone: Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the inducerFor phenytoin, fosphenytoin: Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the phenytoin, for one thing; and increase of the plasma concentrations of the phenytoin due to decrease of its hepatic metabolism by the voriconazole for another thing	Contraindication	-for carbamazepine, phenobarbital, primidone
2506	TRIMETHOPRIM	10829			CICLOSPORIN	3008			ANSM	530-TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
2507	TRIMETHOPRIM	10829			METHOTREXATE	6851			ANSM	530-TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	CONTRAINDICATION	
2508	TRIMETHOPRIM	10829			PYRIMETHAMINE	9010			ANSM	530-TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with strong doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections).
2509	TRIMETHOPRIM	10829			REPAGLINIDE	73044			ANSM	530-TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical and biological monitoring.
2510			TRIPTANS	N02CC-001			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	531-TRIPTANS.html	Risk of arterial hypertension, of constriction of coronary arteries	CONTRAINDICATION	Wait 6 to 24 hours, depending on the triptan, between taking it and the ergot alkaloid.
2511			TRIPTANS	N02CC-001			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	531-TRIPTANS.html	Risk of appearance of a serotonin syndrome	Take into account	
2512			TRIPTANS METABOLIZED BY THE MAO	N02CC-002			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	532-TRIPTANS-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	CONTRAINDICATION	
2513			TRIPTANS METABOLIZED BY THE MAO	N02CC-002			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	532-TRIPTANS-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	CONTRAINDICATION	
2514			TRIPTANS METABOLIZED BY THE MAO	N02CC-002			MAOI-B	N04BD0-001	ANSM	532-TRIPTANS-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	CONTRAINDICATION	
2515			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	533-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
2516			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	533-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
2517			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003			MAOI-B	N04BD0-001	ANSM	533-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
2518	ULIPRISTAL	1005921					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	534-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
2519	ULIPRISTAL	1005921					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	534-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to decrease of its absorption	Take into account	
2520	ULIPRISTAL	1005921					PROTON PUMP INHIBITORS	A02BC-001	ANSM	534-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to decrease of its absorption	Take into account	
2521	ULIPRISTAL	1005921			CYPROTERONE	3014			ANSM	534-ULIPRISTAL.html	Risk of antagonism of the progestative effects	Not recommended	Do not take a progestative treatment fewer than 12 hours after stopping the ulipristal.
2522	ULIPRISTAL	1005921					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	534-ULIPRISTAL.html	Risk of antagonism of the effects of the estrogen-progestin contraceptive	Not recommended	Do not restart the combined estrogen-progestin treatment fewer than 12 days after stopping the ulipristal.
2523	ULIPRISTAL	1005921					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	534-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir	Not recommended	Choose a therapeutic alternative that is little or not at all metabolised.
2524	ULIPRISTAL	1005921			ST JOHNS WORT	258326			ANSM	534-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
2525	ULIPRISTAL	1005921					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	534-ULIPRISTAL.html	Risk of antagonism of the effects of the progestin contraceptive	Not recommended	Do not restart a progestin treatment fewer than 12 days after stopping the ulipristal.
2526	ULIPRISTAL	1005921					NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	ANSM	534-ULIPRISTAL.html	Risk of antagonism of the effects of the progestin contraceptive	Not recommended	In an indication for uterine fibroids, do not restart a progestin treatment fewer than 12 days after the ulipristal is stopped.
2527	ULIPRISTAL	1005921			RIFAMPICIN	9384			ANSM	534-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Chose a therapeutic alternative that is little or not at all metabolized.
2528			URICOSURICS	M04AB0	ACETYLSALICYLIC ACID	1191			ANSM	535-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
2529			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ABATACEPT	614391			ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of general vaccine disease, possibly fatal	Not recommended	as well as during the 3 months following the end of the treatment
2530			ATTENUATED LIVE VIRUS VACCINES	J07B-001			MONOCLONAL ANTIBODIES (EXCEPT ANTI-TNF ALPHA)	MONANT	ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of general vaccine disease, possibly fatal.	Not recommended with	-- belimumab, blinatumomab, canakinumab, obinutuzumab, ofatumumab, rituximab, tocilizumab, ustekinumab
2531			ATTENUATED LIVE VIRUS VACCINES	J07B-001			ANTI-TNF ALPHA	LO4AB	ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease	CONTRAINDICATION	And during the 3 months following the end of the treatment
2532			ATTENUATED LIVE VIRUS VACCINES	J07B-001	BELATACEPT	1112973			ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of general vaccine disease, possibly fatal	Not recommended	
2533			ATTENUATED LIVE VIRUS VACCINES	J07B-001			CYTOTOXICS	L01	ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease	CONTRAINDICATION	--And during the 6 months following the end of the chemotherapy
2534			ATTENUATED LIVE VIRUS VACCINES	J07B-001	DIMETHYL (FUMERATE OF)	1373478			ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Possible increase of the risk of infection	Take into account	
2535			ATTENUATED LIVE VIRUS VACCINES	J07B-001			ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001	ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease. This risk is increased in older patients already immunodepressed by the underlying disease.	Take into account	In particular, use an inactive vaccine when one exists (poliomyelitis).
2536			ATTENUATED LIVE VIRUS VACCINES	J07B-001			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	With the exception of inhaled and local routes and for dosages greater than 10mg/day of prednisone equivalent (or >2mg/kg/day with children or >20 mg/day for children weighing more than 10 kg) for more than two weeks and for administration in "bolus" of the corticoids:risk of possibly fatal general vaccine disease.	CONTRAINDICATION	And during the 3 months following the end of the corticotherapy
2537			ATTENUATED LIVE VIRUS VACCINES	J07B-001	HYDROXYCARBAMIDE	5552			ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	In its indication for the patient with drepanocytosis, theoretic risk of general fatal vaccine disease.	Not recommended	Administering these medications together should only be considered if the benefits are estimated to be superior to this risk.
2538			ATTENUATED LIVE VIRUS VACCINES	J07B-001			IMMUNOSUPPRESSANTS	L04A	ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease.	CONTRAINDICATION	And during the 3 months following the treatment
2539			ATTENUATED LIVE VIRUS VACCINES	J07B-001	MYCOPHENOLATE MOFETIL				ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease.	CONTRAINDICATION	And during the 3 months following the end of the treatment.
2540			ATTENUATED LIVE VIRUS VACCINES	J07B-001	MYCOPHENOLATE SODIUM	408142			ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease	CONTRAINDICATION	And during the 3 months after the end of the treatment.
2541			ATTENUATED LIVE VIRUS VACCINES	J07B-001	TERIFLUNOMIDE	1310520			ANSM	536-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of general vaccine disease, possibly fatal	Not recommended	
2542			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ACETAZOLAMIDE	167			ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the hyperammonemia, with accrued risk of encephalopathy	Precaution for use	Regular clinical and biological monitoring.
2543			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	AZTREONAM	1272			ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosage of the anticonvulsant during the treatment with the antibiotic and after it is stopped.
2544			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	CARBAMAZEPINE	2002			ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, plasma dosages and adjustment of the dosage of the two anticonvulsants.
2545			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	FELBAMATE	24812			ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the plasma concentrations of the valproic acid, with risk of overdose.	Precaution for use	Clinical and biological monitoring, and possible adjustment of the dosage of the valproic acid or of the valpromide during the treatment with the felbamate and after it is stopped.
2546			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	LAMOTRIGINE	28439			ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increased risk of serious cutaneous reactions (Lyell's syndorme). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)	Not recommended	If this combination of medications is judged necessary, strict clinical monitoring.
2547			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	NIMODIPINE	7426			ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid)	Take into account	
2548			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0			PENEMS	J01DH	ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable	Not recommended	
2549			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the hyperammonemia, with accrued risk of encephalopathy	Precaution for use	Regular clinical and biological monitoring
2550			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the hyperammonemia, with accrued risk of encephalopathy	Precaution for use	Regular clinical and biological monitoring
2551			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	RIFAMPICIN	9384			ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	Clinical and biological monitoring and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped.
2552			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	RUFINAMIDE	69036			ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg	Precaution for use	With children weighing less than 30kg: do not exceed the total dose of 600 mg/day after the period of titration.
2553			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	TOPIRAMATE	38404			ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the hyperammonemia with accrued risk of encephalopathy	Precaution for use	Regular clinical and biological monitoring.
2554			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ZIDOVUDINE (AZT)	11413			ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid.	Precaution for use	Regular clinical and biological monitoring. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together.
2555			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ZONISAMIDE				ANSM	537-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the hyperammonemia, with accued risk of encephalopathy	Precaution for use	Regular clinical and biological monitoring
2556	VARDENAFIL	306674			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	538-VARDENAFIL.html	Increase of the plasma concentrations of the vardenafil, with risk of hypotension.	Not recommended	
2557	VEMURAFENIB	1147220			BUPROPION	42347			ANSM	539-VEMURAFENIB.html	Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity	Take into account	
2558	VEMURAFENIB	1147220					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	539-VEMURAFENIB.html	Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness	Not recommended	
2559	VEMURAFENIB	1147220			IFOSFAMIDE	5657			ANSM	539-VEMURAFENIB.html	Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity	Take into account	
2560	VEMURAFENIB	1147220					IMMUNOSUPPRESSANTS	L04A	ANSM	539-VEMURAFENIB.html	Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness	Not recommended	
2561	VEMURAFENIB	1147220					ENZYMATIC INDUCERS	N03-J05-001	ANSM	539-VEMURAFENIB.html	Risk of decrease of the concentrations of the vemurafenib, with lower effectiveness	Not recommended	
2562	VEMURAFENIB	1147220			THEOPHYLLINE	10438			ANSM	539-VEMURAFENIB.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped.
2563			METABOLIZED ANTICONVULSANTS	N03A-002	ST JOHNS WORT				ANSM	54-METABOLIZED-ANTICONVULSANTS.html	Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant.	CONTRAINDICATION	
2564	VENLAFAXINE	39786			CLARITHROMYCIN	21212			ANSM	540-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2565	VENLAFAXINE	39786			ERYTHROMYCIN	4053			ANSM	540-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2566	VENLAFAXINE	39786					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	540-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose.	Take into account	
2567	VENLAFAXINE	39786			ITRACONAZOLE	28031			ANSM	540-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2568	VENLAFAXINE	39786			KETOCONAZOLE	6135			ANSM	540-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2569	VENLAFAXINE	39786			TELITHROMYCIN	274786			ANSM	540-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2570	VENLAFAXINE	39786			TRAMADOL	10689			ANSM	540-VENLAFAXINE.html	Risk of appearance of convulsions and/or of a serotonin syndrome	Take into account	
2571	VENLAFAXINE	39786			VORICONAZOLE	121243			ANSM	540-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2572	VERAPAMIL	11170			AFATINIB	1430438			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the verapamil	Precaution for use	It is recommended that the verapamil be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours distant from the dose of afatinib.
2573	VERAPAMIL	11170			ALISKIREN	325646			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	Clinical monitoring.
2574	VERAPAMIL	11170			AMIODARONE	703			ANSM	541-VERAPAMIL.html	For verapamil by injection:--risk of bradycardia or of atrioventricular blockFor verapamil by mouth:--risk of bradycardia or of atrioventricular block, especially with older persons	Not recommended with	--the verapamil via IV
2575	VERAPAMIL	11170			ATORVASTATIN	83367			ANSM	541-VERAPAMIL.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication	Precaution for use	Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
2576	VERAPAMIL	11170					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	541-VERAPAMIL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	The administration of these medications together should only be undertaken under strict clinical monitoring and EKG, in particular with older patients or at the beginning of treatment.
2577	VERAPAMIL	11170					BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	541-VERAPAMIL.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction	CONTRAINDICATION	
2578	VERAPAMIL	11170			BUSPIRONE	1827			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
2579	VERAPAMIL	11170			CICLOSPORIN	3008			ANSM	541-VERAPAMIL.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders.	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
2580	VERAPAMIL	11170			CLONIDINE	2599			ANSM	541-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
2581	VERAPAMIL	11170			COLCHICINE	2683			ANSM	541-VERAPAMIL.html	Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil	Not recommended	
2582	VERAPAMIL	11170			DABIGATRAN				ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose, or even 75 mg/day in case of moderate renal insufficiency
2583	VERAPAMIL	11170			DANTROLENE	3105			ANSM	541-VERAPAMIL.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.	CONTRAINDICATION	
2584	VERAPAMIL	11170			DIGOXIN	3407			ANSM	541-VERAPAMIL.html	Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extrarenal elimination of the digoxin	Precaution for use	Clinical monitoring, EKG and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped.
2585	VERAPAMIL	11170			DOXORUBICIN	3639			ANSM	541-VERAPAMIL.html	Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations	Take into account	
2586	VERAPAMIL	11170			DRONEDARONE	233698			ANSM	541-VERAPAMIL.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG.
2587	VERAPAMIL	11170			ERIBULINE	1045453			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of eribuline by the verapamil.	Not recommended	
2588	VERAPAMIL	11170			ERYTHROMYCIN	4053			ANSM	541-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
2589	VERAPAMIL	11170			ESMOLOL	49737			ANSM	541-VERAPAMIL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	-in case of alteration of the left ventricular function.
2590	VERAPAMIL	11170			EVEROLIMUS	141704			ANSM	541-VERAPAMIL.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of the dosage during the administration of the two medications together and after it is stopped.
2591	VERAPAMIL	11170			FIDAXOMICIN	1111103			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
2592	VERAPAMIL	11170			IBRUTINIB	1442981			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of the administration of the two medications together.
2593	VERAPAMIL	11170					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	541-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, as the situation requires.
2594	VERAPAMIL	11170			IVABRADINE	77417			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules.	CONTRAINDICATION	
2595	VERAPAMIL	11170			MIDAZOLAM	6960			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation).	Precaution for use	Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.
2596	VERAPAMIL	11170			ST JOHNS WORT	258326			ANSM	541-VERAPAMIL.html	Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect.	CONTRAINDICATION	
2597	VERAPAMIL	11170			NINTEDANIB	1592737			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of the nintedanib due to increase of it absorption by the verapamil	Precaution for use	Clinical monitoring during the administration of these substances together
2598	VERAPAMIL	11170			OLAPARIB	1597582			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of olaparib by the verapamil	Not recommended	If administering these together cannot be avoided, limit the dose of olaparib to 200 mg twice a day.
2599	VERAPAMIL	11170			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of verapamil, with risk of the appearance of undesirable effects	Take into account	
2600	VERAPAMIL	11170			QUINIDINE	9068			ANSM	541-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
2601	VERAPAMIL	11170			SIMVASTATIN	36567			ANSM	541-VERAPAMIL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction.
2602	VERAPAMIL	11170			SIROLIMUS	35302			ANSM	541-VERAPAMIL.html	Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil).	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
2603	VERAPAMIL	11170			TACROLIMUS	42316			ANSM	541-VERAPAMIL.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
2604	VERAPAMIL	11170			TAMSULOSINE	77492			ANSM	541-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires.
2605	VERAPAMIL	11170			TENOFOVIR ALAFENAMIDE	1721603			ANSM	541-VERAPAMIL.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	In case of co-administration with the verapamil, the dose of tenofovir alafenamide must be limited to 10mg per day.
2606	VERAPAMIL	11170			TICAGRELOR	1116632			ANSM	541-VERAPAMIL.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
2607	VIDARABINE	11194			ALLOPURINOL	519			ANSM	542-VIDARABINE.html	Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral	Not recommended	
2608			VINCA ALKALOIDS	L01CA	CLARITHROMYCIN	21212			ANSM	543-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin	Precaution for use	Strict clinical and biological monitoring. Possibly, use another antibiotic.
2609			VINCA ALKALOIDS	L01CA	COBICISTAT	1306284			ANSM	543-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat	Precaution for use	Strict clinical monitoring and possible adjustment of the dosage of the antimitotic.
2610			VINCA ALKALOIDS	L01CA	ERYTHROMYCIN	4053			ANSM	543-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin	Precaution for use	Strict clinical and biological monitoring. Possibly, use another antibiotic.
2611			VINCA ALKALOIDS	L01CA			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	543-VINCA-ALKALOIDS.html	Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor.	Precaution for use	Strict clinical monitoring and possible adjustment of the dosage of the antimitotic.
2612			VINCA ALKALOIDS	L01CA	ITRACONAZOLE	28031			ANSM	543-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the itraconazole	Not recommended	
2613			VINCA ALKALOIDS	L01CA	KETOCONAZOLE	6135			ANSM	543-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole	Not recommended	
2614			VINCA ALKALOIDS	L01CA	MITOMYCIN C	632			ANSM	543-VINCA-ALKALOIDS.html	Risk of increase of the pulmonary toxicity of the mitomycin and of the vinca alkaloids	Take into account	
2615			VINCA ALKALOIDS	L01CA	POSACONAZOLE	282446			ANSM	543-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole	Not recommended	
2616			VINCA ALKALOIDS	L01CA	TELITHROMYCIN	274786			ANSM	543-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism of the telithromycin	Precaution for use	Strict clinical and biological monitoring. Possibly, use another antibiotic.
2617	VISMODEGIB	1242987					ENZYMATIC INDUCERS	N03-J05-001	ANSM	544-VISMODEGIB.html	Risk of decrease of the plasma concentrations of vismodegib due to increase of its hepatic metabolism by the inducer	Not recommended	
2618	VISMODEGIB	1242987			ST JOHNS WORT	258326			ANSM	544-VISMODEGIB.html	Risk of decrease of the plasma concentrations of vismodegib	CONTRAINDICATION	
2619	VITAMIN A	11246					TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	545-VITAMIN-A.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension	CONTRAINDICATION	
2620	VITAMIN A	11246					RETINOIDS	D05-D10	ANSM	545-VITAMIN-A.html	Risk of symptoms evocative of hypervitaminosis A	CONTRAINDICATION	
2621			VITAMIN D	A11CC			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	546-VITAMIN-D.html	Decrease of the concentrations of vitamin D more noticeable than in the absence of the inducer	Precaution for use	Concentration dosage of vitamin D and supplementation if necessary.
2622			VITAMIN D	A11CC	ORLISTAT	37925			ANSM	546-VITAMIN-D.html	Decrease of the absorption of the vitamin D	Take into account	
2623			VITAMIN D	A11CC	RIFAMPICIN				ANSM	546-VITAMIN-D.html	Decrease of the concentrations of vitamin D more noticeable than in the absence of treatment with the rifampacin	Precaution for use	Concentration dosage of vitamin D and supplementation if necessary.
2624	VORICONAZOLE	121243			AMIODARONE	703			ANSM	547-VORICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, due to possible decrease of the metabolism of the amiodarone.	Precaution for use	Clinical monitoring and EKG, and possible adjustment of the dosage of the amiodarone.
2625	VORICONAZOLE	121243					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	547-VORICONAZOLE.html	--for carbamazepine, phenobarbital, primidone: Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the inducer--for phenytoin, fosphenytoin: Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the phenytoin, for one thing; and increase of the plasma concentrations of the phenytoin due to decrease of its hepatic metabolism by the voriconazole, for another.	Contraindication	--for carbamazepine, phenobarbital, primidone
2626	VORICONAZOLE	121243					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	547-VORICONAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with voriconazole and a week after it is stopped.
2627	VORICONAZOLE	121243					OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ANSM	547-VORICONAZOLE.html	In case of prolonged use by oral or inhaled route:increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the voriconazole, with risk of appearance of Cushings syndrome even of adrenal insufficiency	Take into account	
2628	VORICONAZOLE	121243			DEXAMETHASONE	3264			ANSM	547-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
2629	VORICONAZOLE	121243			DIHYDROERGOTAMINE	3418			ANSM	547-VORICONAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	CONTRAINDICATION	
2630	VORICONAZOLE	121243			EFAVIRENZ	195085			ANSM	547-VORICONAZOLE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz	Not recommended	If administering these substances together cannot be avoided, strict clinical monitoring and adjustment of the dosage of the voriconazole and of the efavirenz during the administration of the two together.
2631	VORICONAZOLE	121243			GLIPIZIDE	4821			ANSM	547-VORICONAZOLE.html	Risk of increase of the plasma concentrations of the glipizide at the origin of potentially severe hypoglycemia	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during and after the treatment with voriconazole.
2632	VORICONAZOLE	121243					IMMUNOSUPPRESSANTS	L04A	ANSM	547-VORICONAZOLE.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole.	Not recommended	--with the everolimus, the sirolimus, and the temsirolimus
2633	VORICONAZOLE	121243					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	547-VORICONAZOLE.html	Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment	Not recommended	
2634	VORICONAZOLE	121243			ST JOHNS WORT	258326			ANSM	547-VORICONAZOLE.html	Significant reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect	CONTRAINDICATION	
2635	VORICONAZOLE	121243			NEVIRAPINE	53654			ANSM	547-VORICONAZOLE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together.
2636	VORICONAZOLE	121243			QUINIDINE	9068			ANSM	547-VORICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
2637	VORICONAZOLE	121243			RIFABUTIN	55672			ANSM	547-VORICONAZOLE.html	Decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifabutin for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin for another.	Not recommended	If the administration of the substances together is judged necessary, clinical monitoring and adjustment of the dosage of the voriconazole (generally doubled) during the treatment with the rifabutin.
2638	VORICONAZOLE	121243			RIFAMPICIN	9384			ANSM	547-VORICONAZOLE.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	CONTRAINDICATION	
2639	VORICONAZOLE	121243			SIMVASTATIN	36567			ANSM	547-VORICONAZOLE.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin	CONTRAINDICATION	
2640	VORICONAZOLE	121243			VENLAFAXINE	39786			ANSM	547-VORICONAZOLE.html	Increase of the concentrations of venlafaxine with risk of overdose.	Take into account	
2641	VORTIOXETINE	1455099			CINACALCET	407990			ANSM	548-VORTIOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with cinacalcet and after it is stopped.
2642	VORTIOXETINE	1455099			FLUOXETINE	4493			ANSM	548-VORTIOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine by decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the fluoxetine and after it is stopped.
2643	VORTIOXETINE	1455099					ENZYMATIC INDUCERS	N03-J05-001	ANSM	548-VORTIOXETINE.html	Reduction of the plasma concentrations of the vortioxetine	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the administration with the inducer and 1 to 2 weeks after it is stopped.
2644	VORTIOXETINE	1455099			PAROXETINE	32937			ANSM	548-VORTIOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the viortioxetine during the treatment with the paroxetine and after it is stopped.
2645	VORTIOXETINE	1455099			QUINIDINE	9068			ANSM	548-VORTIOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	Clinical monitoring andpossible adjustment of the dosage of the vortioxetine during the treatment with the quinidine and after it is stopped.
2646	VORTIOXETINE	1455099			TERBINAFINE	37801			ANSM	548-VORTIOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the terbinafine and after it is stopped
2647	YOHIMBINE	220982			CLONIDINE	2599			ANSM	549-YOHIMBINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
2648			MONOCLONAL ANTIBODIES (EXCEPT ANTI-TNF ALPHA)	MONANT			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	55-MONOCLONAL-ANTIBODIES-(EXCEPT-ANTI-TNF-ALPHA).html	Risk of general vaccine disease, possibly fatal.	Not recommended with:	--belimumab, blinatumomab, canakinumab, obinutuzumab, ofatumumab, rituximab, tocilizumab, ustekinumab
2649	ZALCITABINE	3363			DIDANOSINE	3364			ANSM	550-ZALCITABINE.html	Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and monitoring of the amylasemia. Do not administer these substances together if the amylasemia is at the high range of normal.
2650	ZALCITABINE	3363			GANCICLOVIR	4678			ANSM	550-ZALCITABINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together.
2651	ZALCITABINE	3363			LAMIVUDINE	68244			ANSM	550-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
2652	ZALCITABINE	3363			PENTAMIDINE	7994			ANSM	550-ZALCITABINE.html	Increased risk of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
2653	ZALCITABINE	3363			STAVUDINE	59763			ANSM	550-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral, due to inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
2654	ZALCITABINE	3363			THALIDOMIDE	10432			ANSM	550-ZALCITABINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
2655	ZIDOVUDINE	11413			AMPHOTERICIN B	732			ANSM	551-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
2656	ZIDOVUDINE	11413			DAPSONE	3108			ANSM	551-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
2657	ZIDOVUDINE	11413			FLUCYTOSINE	4451			ANSM	551-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
2658	ZIDOVUDINE	11413			GANCICLOVIR	4678			ANSM	551-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in weak doses.
2659	ZIDOVUDINE	11413			RIBAVIRIN	9344			ANSM	551-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.
2660	ZIDOVUDINE	11413			STAVUDINE	59763			ANSM	551-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
2661	ZIDOVUDINE	11413					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	551-ZIDOVUDINE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid	Precaution for use	Regular clinical and biological monitoring. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together.
2662	ZINC	1431163			CALCIUM	1428011			ANSM	552-ZINC.html	Decrease of the digestive absorption of the zinc by the calcium	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart if possible).
2663	ZINC	1431163					TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	552-ZINC.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
2664	ZINC	1431163			IRON	1431589			ANSM	552-ZINC.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
2665	ZINC	1431163					FLUOROQUINOLONES	J01MA-001	ANSM	552-ZINC.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
2666	ZINC	1431163			STRONTIUM	81638			ANSM	552-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
2667	ZOLPIDEM	39993					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	553-ZOLPIDEM.html	Slight increase of the sedative effect of the zolpidem	Take into account	
2668	ZOLPIDEM	39993			RIFAMPICIN	9384			ANSM	553-ZOLPIDEM.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
2669	ZONISAMIDE						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	554-ZONISAMIDE.html	Increase of the hyperammonemia, with increased risk of encephalopathy	Precaution for use	Regular clinical and biological monitoring.
2670	ZOPICLONE	40001					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	555-ZOPICLONE.html	Slight increase of the sedative effect of the zopiclone	Take into account	
2671	ZOPICLONE	40001			RIFAMPICIN	9384			ANSM	555-ZOPICLONE.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring.Possibly use another hypnotic.
2672			TRICYCLIC ANTIDEPRESSANTS	N06AA-001			ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	A01AD	ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenalin in 10 minutes or 0.3 mg in an hour for an adult
2673			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	BACLOFEN	1292			ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Risk of increase of the muscular hypotonia.	Take into account	
2674			TRICYCLIC ANTIDEPRESSANTS	N06AA-001			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)	Take into account	
2675			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	CLONIDINE	2599			ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Described for desipramine, imipramine: inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
2676			TRICYCLIC ANTIDEPRESSANTS	N06AA-001			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects	Precaution for use	Increased clinical monitoring and, if necessary, adjustment of the dosage
2677			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ORLISTAT	37925			ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Risk of therapeutic failure in cases of concomitant treatment with orlistat	Take into account	
2678			TRICYCLIC ANTIDEPRESSANTS	N06AA-001			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Paroxysmal hypertension with the possibility of arrhythmia (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
2679			AZOLE ANTIFUNGALS	J02AC-001	COLCHICINE	2683			ANSM	57-AZOLE-ANTIFUNGALS.html	Increase of the undesirable effects of the colchicine with potentially fatal consequences	Not recommended	
2680			AZOLE ANTIFUNGALS	J02AC-001	HALOFANTRINE	50749			ANSM	57-AZOLE-ANTIFUNGALS.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	Not recommended	If it is possible, interrupt the azole antifungal. If administering the substances together cannot be avoided, testing of the QT before the beginning of the treatment and EKG monitoring
2681			AZOLE ANTIFUNGALS	J02AC-001	MIDAZOLAM	6960			ANSM	57-AZOLE-ANTIFUNGALS.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation.	Precaution for use with:	-midazolam IV route
2682			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001	ANSM	58-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Risk of severe orthostatic hypotension	Not recommended	
2683			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001			ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001	ANSM	58-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Greater risk of orthostatic hypotension. .	Take into account	
2684			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	58-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html	Risk of orthostatic hypotension, especially with older patients	Not recommended	-with the doxazosine
2685			CENTRAL ANTIHYPERTENSIVES	C02AC-001			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	59-CENTRAL-ANTIHYPERTENSIVES.html	Large increase of blood pressure in cases of sudden termination of the treatment with the central antihypertensive	Precaution for use	Avoid ending treatment with the central antihypertensive abruptly. Clinical monitoring.
2686			CENTRAL ANTIHYPERTENSIVES	C02AC-001			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	59-CENTRAL-ANTIHYPERTENSIVES.html	Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in case of heart failure treated with a beta-blocking agent and vasodilator	Not recommended	
2687	ASCORBIC ACID	1151			DEFEROXAMINE	3131			ANSM	6-ASCORBIC-ACID.html	With large doses of ascorbic acid and by intravenous route: cardiac function anomalies, even acute heart failure (generally reversible by ending the administration of the Vitamin C).	Precaution for use	In the case of hemochromatosis, only give Vitamin C after having started the treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
2688			ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001	ANSM	60-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Risk of greater orthostatic hypotension	Take into account	
2689			ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001	ANSM	60-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Greater risk of orthostatic hypotension	Take into account	
2690			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			OTHER NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	With the other non steroidal anti-inflammatory drugs: increase of the risk of causing ulcers and digestive hemorrhage	Not recommended	
2691			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
2692			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Acute renal insufficiency with patients at risk (older patient, dehydration, treatment with diuretics, changes in renal function), due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the non-steroidal anti-inflammatories). These effects are generally reversible. In addition, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment and regularly while these substances are administered together.
2693			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			ORAL ANTICOAGULANTS	B01A-001	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the oral anticoagulants risk of hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories)	Contraindication	-with phenylbutazone
2694			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Reduction of the antihypertensive effect (inhibition of the vasodilating prostaglandins by the non steroidal anti-inflammatories and fluid retention with the phenylbutazone	Take into account	
2695			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	CICLOSPORIN	3008			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of addition of the nephrotoxic effects, especially with older patients.	Precaution for use	Monitor renal function at the beginning of the treatment with the NSAI
2696			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	DEFERASIROX	614373			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
2697			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			DIURETICS	C0E-001	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Acute renal insufficiency with the patient at risk (older patient and/or dehydrated one) due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the NSAIs). Furthermore, reduction of the antihypertensive effect	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment
2698			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of ulceration and of gastrointestinal hemorrhage	Take into account	
2699			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring
2700			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage	Take into account	
2701			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring
2702			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage	Take into account	
2703			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Acute renal insufficiency with patients at risk (older patients, dehydrated ones, those taking diuretics, those with altered renal function) due to decrease of the glomerular filtration (inhibition of the vasodilating prostaglandins due to the NSAIs). These effects are generally reversible. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment and regularly during the administration of the substances together.
2704			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSR1s)	NO6AB	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage	Take into account	
2705			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	LITHIUM	6448			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the lithemia that can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	If administering the substances together cannot be avoided, monitor the lithemia strictly and adjust the dosage of the lithium during the treatment with the substances together and after the NSAI is stopped
2706			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	METHOTREXATE	6851			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).	Contraindication	-with the phenylbutazone, regardless of the dose of methotrexate and for all the forms of phenylbutazone, including topical.
2707			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	PEMETREXED	68446			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the NSAIs)	Not recommended	-in case of weak to moderate renal function
2708			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	PENTOXIFYLLINE	8013			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrage	Take into account	
2709			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	TACROLIMUS	42316			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of addition of the nephrotoxic effects, especially with older patients	Precaution for use	Monitor the renal function at the beginning of treatment with the NSAI
2710			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	TENOFOVIR DISOPROXIL	300195			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of increase of the nephrotoxicity of the tenofovir, especially with large doses of the anti-inflammatory or in the presence of factors of risk of renal insufficiency	Precaution for use	When these are administered together, monitor renal function.
2711			ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES	P01B-001			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	62-ANTIPARASITICS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	with citalopram, domperidone, escitalopram, hydroxyzine and piperaquine
2712			ANTIPARKINSONIAN ANTICHOLINERGICS	N04AA-001			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	63-ANTIPARKINSONIAN-ANTICHOLINERGICS.html	Risk of increase of neuropsychological disorders.	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
2713			ANTIPARKINSONIAN DOPAMINERGICS	N04B-001			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	64-ANTIPARKINSONIAN-DOPAMINERGICS.html	Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or aggravate the psychotic disorders. When a treatment with neuroleptics is necessary for a Parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of "neuroleptic malignant syndrome" (NMS)).	Not recommended	
2714			ANTIPURINES	ANTIPUR			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	65-ANTIPURINES.html	Decrease of the effect of the Vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist at the beginning of the treatment with the immuno-inhibitor and after it is stopped
2715			ANTIPURINES	ANTIPUR			DERIVATIVES OF AMINOSALICYLIC ACID (ASA)	A07EC-001	ANSM	65-ANTIPURINES.html	Risk of increase of the myelotoxicity of the immunoinhibitor, by inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TPMT)	Take into account	
2716			ANTIPURINES	ANTIPUR			XANTHINE OXYDASE INHIBITORS	M04AA0	ANSM	65-ANTIPURINES.html	Possibly serious medullary insufficiency	CONTRAINDICATION	
2717			ANTIPURINES	ANTIPUR	RIBAVIRIN	9344			ANSM	65-ANTIPURINES.html	Increased risks of serious undesirable effects, due to inhibition of the metabolism of the immunoinhibitor by the ribavirin	Not recommended	
2718			H2 RECEPTOR ANTAGONISTS	A02BA-001	ATAZANAVIR	343047			ANSM	66-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the plasma concentrations of the atazanavir	Take into account	
2719			H2 RECEPTOR ANTAGONISTS	A02BA-001	CYANOCOBALAMIN	11248			ANSM	66-H2-RECEPTOR-ANTAGONISTS.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of vitamin B12	Take into account	
2720			H2 RECEPTOR ANTAGONISTS	A02BA-001			TYROSINE-KINASE INHIBITORS	L01XE	ANSM	66-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the bioavailabilty of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption	Take into account	-except with the vandetanib
2721			H2 RECEPTOR ANTAGONISTS	A02BA-001	ITRACONAZOLE	28031			ANSM	66-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
2722			H2 RECEPTOR ANTAGONISTS	A02BA-001	KETOCONAZOLE	6135			ANSM	66-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
2723			H2 RECEPTOR ANTAGONISTS	A02BA-001	POSACONAZOLE	282446			ANSM	66-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Not recommended	-only with the oral suspension form of posaconazole
2724			H2 RECEPTOR ANTAGONISTS	A02BA-001	RILPIVIRINE	1102270			ANSM	66-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the plasma concentrations of the rilpivirine	Take into account	If necessary, use an active H2 antihistmine in one dose per day, to be taken at least 12 hours before, or at least 4 hours after.
2725			H2 RECEPTOR ANTAGONISTS	A02BA-001	ULIPRISTAL	1005921			ANSM	66-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the effect of the ulipristal due to decrease of its absorption	Take into account	
2726			PROTON PUMP INHIBITORS	A02BC-001	ATAZANAVIR	343047			ANSM	67-PROTON-PUMP-INHIBITORS.html	Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure	Not recommended	
2727			PROTON PUMP INHIBITORS	A02BC-001	CYANOCOBALAMIN	11248			ANSM	67-PROTON-PUMP-INHIBITORS.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.	Take into account	
2728			PROTON PUMP INHIBITORS	A02BC-001			METABLOIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	67-PROTON-PUMP-INHIBITORS.html	Risk of decrease of the bioavailability of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption	Take into account	-except with the imatinib and the vandetanib
2729			PROTON PUMP INHIBITORS	A02BC-001	ITRACONAZOLE	28031			ANSM	67-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the antisecretory	Take into account	
2730			PROTON PUMP INHIBITORS	A02BC-001	KETOCONAZOLE	6135			ANSM	67-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the antisecretory	Take into account	
2731			PROTON PUMP INHIBITORS	A02BC-001	LEDIPASVIR	1591922			ANSM	67-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of ledipasvir when the proton pump inhibitor is administered before the ledipasvir	Precaution for use	It is recommended that the proton pump inhibitor and the ledipasvir be taken simultaneously.
2732			PROTON PUMP INHIBITORS	A02BC-001	METHOTREXATE	6851			ANSM	67-PROTON-PUMP-INHIBITORS.html	Risk of increase of the toxicity of the methotrexate due to decrease of its elimination	Not recommended	-with the methotrexate in doses > 20mg /week
2733			PROTON PUMP INHIBITORS	A02BC-001	ST JOHN'S WORT	258326			ANSM	67-PROTON-PUMP-INHIBITORS.html	Risk of ineffectiveness of the treatment by the antisecretory due to increase of its metabolism by the St Johns wort	Take into account	
2734			PROTON PUMP INHIBITORS	A02BC-001	MYCOPHENOLATE MOFETIL				ANSM	67-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
2735			PROTON PUMP INHIBITORS	A02BC-001	POSACONAZOLE	282446			ANSM	67-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal, due to increase of the intragastric pH by the antisecretory	Not recommended	Not recommended
2736			PROTON PUMP INHIBITORS	A02BC-001	RILPIVIRINE	1102270			ANSM	67-PROTON-PUMP-INHIBITORS.html	Decrease of the plasma concentrations of the rilpivirine by the proton pump inhibitor (decreased absorption due to the increase of the gastric pH).	CONTRAINDICATION	
2737			PROTON PUMP INHIBITORS	A02BC-001	ULIPRISTAL	1005921			ANSM	67-PROTON-PUMP-INHIBITORS.html	Risk of decrease of the effect of the ulipristal, due to decrease of its absorption	Take into account	
2738			MERCURIAL ANTISEPTICS	D08AK0	POVIDONE-IODINE	8611			ANSM	68-MERCURIAL-ANTISEPTICS.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
2739			URINARY ANTISPASMODICS	DFST			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	69-URINARY-ANTISPASMODICS.html	Risk of increase of undesirable effects	Contraindication	-with the darifenacin
2740	CHOLIC ACID	1440856					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	7-CHOLIC-ACID.html	Antagonist effect of the phenobarbital	CONTRAINDICATION	
2741			ANTI-TNF ALPHA	LO4AB	ABATACEPT	614391			ANSM	70-ANTI-TNF-ALPHA.html	Increase of the immunodepression	Not recommended	
2742			ANTI-TNF ALPHA	LO4AB	ANAKINRA	72435			ANSM	70-ANTI-TNF-ALPHA.html	Increased risk of serious infections and neutropenia	Not recommended	
2743			ANTI-TNF ALPHA	LO4AB	CANAKINUMAB	853491			ANSM	70-ANTI-TNF-ALPHA.html	Risk of increase of serious infections	Not recommended	
2744			ANTI-TNF ALPHA	LO4AB			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	70-ANTI-TNF-ALPHA.html	Risk of general vaccine disease possibly fatal	CONTRAINDICATION	And during the 3 months following the end of the treatment.
2745			MORPHINE LIKE ANTITUSSIVES	R05DA0-001			AGONIST OPIOID ANALGESICS	N01A-N02A	ANSM	71-MORPHINE-LIKE-ANTITUSSIVES.html	Increased risk of respiratory depression, which can be fatal in cases of overdose	Take into account	
2746			MORPHINE LIKE ANTITUSSIVES	R05DA0-001	METHADONE	6813			ANSM	71-MORPHINE-LIKE-ANTITUSSIVES.html	Increased risk of respiratory depression, which can be fatal in cases of overdose	Take into account	
2747			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002			AGONIST OPIOID ANALGESICS	N01A-N02A	ANSM	72-TRUE-MORPHINE-ANTITUSSIVES.html	Increased risk of respiratory depression which can be fatal in cases of overdose	Take into account	
2748			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	METHADONE				ANSM	72-TRUE-MORPHINE-ANTITUSSIVES.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
2749			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002			AGONIST-ANTAGONIST OPIOIDS	NO2A-001	ANSM	72-TRUE-MORPHINE-ANTITUSSIVES.html	Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Not recommended	
2750			VITAMIN K ANTAGONISTS	B01AA-001	ALCOHOL (DRINK OR INGREDIENT)				ANSM	73-VITAMIN-K-ANTAGONISTS.html	Possible variations of the anticoagulating effect, with increase in case of acute intoxication or decrease in case of chronic alcoholism (increased metabolism)	Take into account	
2751			VITAMIN K ANTAGONISTS	B01AA-001	ALLOPURINOL	519			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the allopurinol and a week after it is stopped.
2752			VITAMIN K ANTAGONISTS	B01AA-001	ALPHA-TOCOPHEROL	11256			ANSM	73-VITAMIN-K-ANTAGONISTS.html	With the vitamin E used in doses greater than or equal to 500 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with vitamin E and after it is stopped.
2753			VITAMIN K ANTAGONISTS	B01AA-001	AMINOGLUTETHIMIDE	677			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Described for warfarin and acenocoumarol.Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with aminoglutethimide and two weeks after it is stopped
2754			VITAMIN K ANTAGONISTS	B01AA-001	AMIODARONE	703			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the amiodorone and a week after it is stopped
2755			VITAMIN K ANTAGONISTS	B01AA-001			ANDROGENS	A14AA0	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage due to direct effect on the coagulation and/or the fibrinolytic systems	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the androgen and after it is stopped
2756			VITAMIN K ANTAGONISTS	B01AA-001			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the anticonvulsant inducer and a week after it is stopped
2757			VITAMIN K ANTAGONISTS	B01AA-001			ANTIPURINES	ANTIPUR	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the Vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequesnt testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antipurine and a week after it is stopped
2758			VITAMIN K ANTAGONISTS	B01AA-001	APREPITANT	358255			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during and after the administration of the medications together.
2759			VITAMIN K ANTAGONISTS	B01AA-001	BOSENTAN	75207			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist
2760			VITAMIN K ANTAGONISTS	B01AA-001	CEFAMANDOLE	2178			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped
2761			VITAMIN K ANTAGONISTS	B01AA-001	CEFOPERAZONE	2184			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the cephalosporine and after it is stopped
2762			VITAMIN K ANTAGONISTS	B01AA-001	CEFOTETAN	2184			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution of use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it stopped.
2763			VITAMIN K ANTAGONISTS	B01AA-001	CEFTRIAXONE	2193			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped
2764			VITAMIN K ANTAGONISTS	B01AA-001	CIMETIDINE	2541			ANSM	73-VITAMIN-K-ANTAGONISTS.html	With the cimetidine used in doses greater than or equal to 800mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped.
2765			VITAMIN K ANTAGONISTS	B01AA-001	CLINDAMYCIN	2582			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin Kantagonist during the treatment with clindamycin and after it is stopped.
2766			VITAMIN K ANTAGONISTS	B01AA-001	COLCHICINE	2683			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the colchicine and a week after it is stopped
2767			VITAMIN K ANTAGONISTS	B01AA-001			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tetracycline antibiotic and after it is stopped
2768			VITAMIN K ANTAGONISTS	B01AA-001			CYTOTOXICS	L01	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy	Precaution for use	More frequent testing of the INR
2769			VITAMIN K ANTAGONISTS	B01AA-001	DANAZOL	3102			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage due to direct effect on coagulation and/or the fibrinolytic systems.	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with danazol and after it is stopped
2770			VITAMIN K ANTAGONISTS	B01AA-001	DEFERASIROX	614373			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
2771			VITAMIN K ANTAGONISTS	B01AA-001	DISULFIRAM	3554			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the disulfiram and a week after it is stopped
2772			VITAMIN K ANTAGONISTS	B01AA-001	DRONEDARONE	233698			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the dronedarone and a week after it is stopped.
2773			VITAMIN K ANTAGONISTS	B01AA-001	ECONAZOLE	3743			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Regardless of the route of administration of the econazole:increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped
2774			VITAMIN K ANTAGONISTS	B01AA-001	EFAVIRENZ	195085			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist
2775			VITAMIN K ANTAGONISTS	B01AA-001			FIBRATES	C01AB-001	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fibrate and a week after it is stopped.
2776			VITAMIN K ANTAGONISTS	B01AA-001	FLUCONAZOLE	4450			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped
2777			VITAMIN K ANTAGONISTS	B01AA-001			FLUOROQUINOLONES	J01MA-001	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
2778			VITAMIN K ANTAGONISTS	B01AA-001			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	If it is not possible to avoid administering these together, more frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the cytotoxic and a week after it is stopped.
2779			VITAMIN K ANTAGONISTS	B01AA-001	GLUCOSAMINE	4845			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist
2780			VITAMIN K ANTAGONISTS	B01AA-001	GRISEOFULVINE	5021			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvine	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the griseofulvine and a week after it is stopped
2781			VITAMIN K ANTAGONISTS	B01AA-001			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage	Precaution for use	When the heparin alternates with the vitamin K antagonist, strenghten clinical monitoring.
2782			VITAMIN K ANTAGONISTS	B01AA-001	IMATINIB	282388			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage	Not recommended	If administering these together cannot be avoided, strict clinical monitoring and more frequent testing of the INR
2783			VITAMIN K ANTAGONISTS	B01AA-001			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist.
2784			VITAMIN K ANTAGONISTS	B01AA-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Variation of the effect of the vitamin K antagonist, most often by decreasing it	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the length of the treatment
2785			VITAMIN K ANTAGONISTS	B01AA-001	ITRACONAZOLE	28031			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the itraconazole and a week after it is stopped.
2786			VITAMIN K ANTAGONISTS	B01AA-001	LEVOCARNITINE	42955			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequenttesting of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with levocarnitine and a week after it is stopped.
2787			VITAMIN K ANTAGONISTS	B01AA-001			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage the vitamin K antagonist during the treatment with the macrolide and after it is stopped
2788			VITAMIN K ANTAGONISTS	B01AA-001	METHYLPREDNISOLONE				ANSM	73-VITAMIN-K-ANTAGONISTS.html	For doses of 0.5g to 1g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythylprednisolone or in the presence of any signs of hemorrhage
2789			VITAMIN K ANTAGONISTS	B01AA-001	MICONAZOLE	6932			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Unpredictable hemorrhage, possibly serious	CONTRAINDICATION	
2790			VITAMIN K ANTAGONISTS	B01AA-001	ST JOHN'S WORT	258326			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzymatic inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have serious consequences (thrombolitic event)	CONTRAINDICATION	In case of an accidental use of the two substances together, do not stop the St Johns Wort suddenly, but test the INR before and then after the St Johns Wort is stopped.
2791			VITAMIN K ANTAGONISTS	B01AA-001	NEVIRAPINE	53654			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
2792			VITAMIN K ANTAGONISTS	B01AA-001	NOSCAPINE	7533			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	
2793			VITAMIN K ANTAGONISTS	B01AA-001	ORLISTAT	37925			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the orlistat and after it is stopped
2794			VITAMIN K ANTAGONISTS	B01AA-001	PARACETAMOL	161			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the paracetamol and after it is stopped
2795			VITAMIN K ANTAGONISTS	B01AA-001	PENTOXIFYLLINE	8013			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped
2796			VITAMIN K ANTAGONISTS	B01AA-001	PRISTINAMYCIN	66958			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pristinamycin and after it is stopped.
2797			VITAMIN K ANTAGONISTS	B01AA-001	PROGUANIL	2382			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped.
2798			VITAMIN K ANTAGONISTS	B01AA-001	PROPAFENONE	8754			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the anticoagulant effect and of the risk of hemorrhage. Mecanism proposed: inhibition of the metabolism of the vitamin K antagonist	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the propafenone and after it is stopped.
2799			VITAMIN K ANTAGONISTS	B01AA-001	RIFAMPICIN	9384			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped.
2800			VITAMIN K ANTAGONISTS	B01AA-001	ROPINIROLE	72302			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with ropinirole and after it is stopped
2801			VITAMIN K ANTAGONISTS	B01AA-001	SUCRALFATE	10156			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Decrease of the digestive absorption of the vitamin K antagonist	Precaution for use	Take the sucralfate at a different time from the vitamin K antagonist (more than 2 hours apart, if possible)
2802			VITAMIN K ANTAGONISTS	B01AA-001	SULFAFURAZOLE	10207			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.
2803			VITAMIN K ANTAGONISTS	B01AA-001	SULFAMETHIZOLE	10179			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped.
2804			VITAMIN K ANTAGONISTS	B01AA-001	SULFAMETHOXAZOLE	10180			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	If administering the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole and after it is stopped.
2805			VITAMIN K ANTAGONISTS	B01AA-001	TAMOXIFEN	10324			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist
2806			VITAMIN K ANTAGONISTS	B01AA-001			THROMBOLYTICS	B01AD	ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage	Take into account	
2807			VITAMIN K ANTAGONISTS	B01AA-001	TIBOLONE	38260			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tibolone and after it is stopped
2808			VITAMIN K ANTAGONISTS	B01AA-001	TRAMADOL	10689			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped.
2809			VITAMIN K ANTAGONISTS	B01AA-001	VORICONAZOLE	121243			ANSM	73-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with voriconazole and a week after it is stopped.
2810	APIXABAN	1364430					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	74-APIXABAN.html	Decrease of the plasma concentrations of the apixaban by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect.	Not recommended	
2811	APIXABAN	1364430			FLUCONAZOLE	4450			ANSM	74-APIXABAN.html	Increase of the plasma concentrations of the apixiban by the fluconazole, with increase of the risk of bleeding	Not recommended	
2812	APIXABAN	1364430					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	74-APIXABAN.html	Increase of the plasma concentrations of the apixaban by the inhibitor, with increase of the risk of bleeding.	Not recommended	
2813	APIXABAN	1364430			RIFAMPICIN	9384			ANSM	74-APIXABAN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
2814	APOMORPHINE	1043			ONDANSETRON	26225			ANSM	75-APOMORPHINE.html	Severe hypotension and loss of consciousness have been reported when ondansetron and apomorphine were taken together.	CONTRAINDICATION	
2815	APREPITANT	358255					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	76-APREPITANT.html	Risk of very large decrease of the concentrations of aprepitant	Not recommended	
2816	APREPITANT	358255					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	76-APREPITANT.html	Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during and after the administration of the medications together.
2817	APREPITANT	358255			CYPROTERONE	3014			ANSM	76-APREPITANT.html	Risk of decrease of the concentrations of the cyproterone with risk of lower contraceptive effectiveness	Precaution for use	--In its use as a homonal contraceptive. Use a reliable contraceptive method, additional or alternative during the time these medications are taken together.
2818	APREPITANT	358255					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	76-APREPITANT.html	Decrease of the concentrations of the estrogen-progestin or of the progestin, with risk of lower contraceptive effectiveness.	Precaution for use	Chose another contraceptive method, in particular a barrier type, during the time these medications are taken together and a cycle following.
2819	APREPITANT	358255			IFOSFAMIDE	5657			ANSM	76-APREPITANT.html	Risk of increase of the neurotoxicity of the ifosfamide	Take into account	
2820	APREPITANT	358255			ITRACONAZOLE	28031			ANSM	76-APREPITANT.html	Increase of the concentrations of aprepitant due to decrease of its hepatic metabolism by the itraconazole.	Take into account	
2821	APREPITANT	358255			PIMOZIDE	8331			ANSM	76-APREPITANT.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
2822	APREPITANT	358255					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	76-APREPITANT.html	(Except for IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness.	Precaution for use	Choose another method of contraception, in particular a barrier type, during the administration of these medications together and a cycle after.
2823	APREPITANT	358255			RIFAMPICIN				ANSM	76-APREPITANT.html	Very large decrease of the concentrations of aprepitant	Not recommended	
2824	ARIPIPRAZOLE	89013					ENZYMATIC INDUCERS	N03-J05-001	ANSM	77-ARIPIPRAZOLE.html	Decrease of the plasma concentrations of the aripiprazole	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the aripiprazole during the administration of these medications together and 1 to 2 weeks after the inducer is stopped.
2825	ATALUREN						AMINOGLYCOSIDES	J01GB-001	ANSM	78-ATALUREN.html	Risk of increase of the renal toxicity of the aminoglycoside	CONTRAINDICATIOIN	
2826	ATAZANAVIR	343047					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	79-ATAZANAVIR.html	Risk of decrease of the plasma concentrations of the atazanavir	Take into account	
2827	ATAZANAVIR	343047					PROTON PUMP INHIBITORS	A02BC-001	ANSM	79-ATAZANAVIR.html	Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure	Not recommended	
2828	ATAZANAVIR	343047			BUPRENORPHINE	1819			ANSM	79-ATAZANAVIR.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
2829	ATAZANAVIR	343047			CLARITHROMYCIN	21212			ANSM	79-ATAZANAVIR.html	Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these drugs together
2830	ATAZANAVIR	343047			EFAVIRENZ	195085			ANSM	79-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism	Not recommended	If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together
2831	ATAZANAVIR	343047			NEVIRAPINE	53654			ANSM	79-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism	Not recommended	If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together
2832	ATAZANAVIR	343047			TENOFOVIR DISOPROXIL	300195			ANSM	79-ATAZANAVIR.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together [sic]	Take into account	Do not administer atazanavir with the tenofovir without ritonavir
2833	ATAZANAVIR	343047					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	79-ATAZANAVIR.html	Risk of decrease of the plasma concentrations of the atazanavir	Take into account	
2834	ATAZANAVIR	343047					PROTON PUMP INHIBITORS	A02BC-001	ANSM	79-ATAZANAVIR.html	Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure	Not recommended	
2835	ATAZANAVIR	343047			BUPRENORPHINE	1819			ANSM	79-ATAZANAVIR.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
2836	ATAZANAVIR	343047			CLARITHROMYCIN	21212			ANSM	79-ATAZANAVIR.html	Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical and biological monitoring, especially at the beginning of the administration of these drugs together
2837	ATAZANAVIR	343047			EFAVIRENZ	195085			ANSM	79-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism	Not recommended	If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together
2838	ATAZANAVIR	343047			NEVIRAPINE	53654			ANSM	79-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism	Not recommended	If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together
2839	ATAZANAVIR	343047			TENOFOVIR DISOPROXIL	300195			ANSM	79-ATAZANAVIR.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together [sic]	Take into account	Do not administer atazanavir with the tenofovir without ritonavir
2840	CLODRONIC ACID	3350			ESTRAMUSTINE	4089			ANSM	8-CLODRONIC-ACID.html	Risk of increase of the plasma concentrations of estrasmustine by the clodronate	Precaution for use	Clinical monitoring during the administration of these substances together.
2841	ATORVASTATIN	83367			AZITHROMYCIN	18631			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication	Precaution for use	Use weaker doses of the cholesterol-lowering medication or another statin not affected by this type of interaction
2842	ATORVASTATIN	83367			BOCEPREVIR	1102129			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the atorvastatin	Precaution for use	Do not exceed the dosage of 20 mg/day of atorvastatin. If the therapeutic objective is not attained with this dosage, use another statin not affected by this type of interaction.
2843	ATORVASTATIN	83367			CICLOSPORIN	3008			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the intestinal absorption of the cholesterol-lowering medication)	Precaution for use	Do not exceed the dosage of 10mg/day of atorvastatin. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.
2844	ATORVASTATIN	83367			CLARITHROMYCIN	21212			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering drug	Precaution for use	Administer weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
2845	ATORVASTATIN	83367			DILTIAZEM	3443			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent	Precaution for use	Use weaker doses of cholesterol-lowering agent or another statin not affected by this type of interaction
2846	ATORVASTATIN	83367			ERYTHROMYCIN	4053			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent	Precaution for use	Use weaker doses of cholesterol-lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
2847	ATORVASTATIN	83367					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Not recommended	Use weaker doses of atorvastatin. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
2848	ATORVASTATIN	83367			ITRACONAZOLE	28031			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
2849	ATORVASTATIN	83367			KETOCONAZOLE				ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
2850	ATORVASTATIN	83367					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	80-ATORVASTATIN.html	Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the therapy with the two drug combination	CONTRAINDICATION	
2851	ATORVASTATIN	83367			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	80-ATORVASTATIN.html	Increase of the plasma concentrations of the hypokaliemiant, with risk of undesirable effects, especially muscular ones	Take into account	
2852	ATORVASTATIN	83367			POSACONAZOLE	282446			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)	CONTRAINDICATION	
2853	ATORVASTATIN	83367			RANOLAZINE	35829			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine	Precaution for use	Use weaker doses of cholesterol-lowering agent or another statin not affected by this type of interaction
2854	ATORVASTATIN	83367			RIFAMPICIN	9384			ANSM	80-ATORVASTATIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
2855	ATORVASTATIN	83367			ROXITHROMYCIN	9478			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type	Precaution for use	Use weaker doses of cholesterol lowering agent
2856	ATORVASTATIN	83367			STIRIPENTOL	37119			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)	CONTRAINDICATION	
2857	ATORVASTATIN	83367			TELAPREVIR	1102261			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
2858	ATORVASTATIN	83367			TELITHROMYCIN	274786			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (dose-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)	CONTRAINDICATION	
2859	ATORVASTATIN	83367			VERAPAMIL	11170			ANSM	80-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication	Precaution for use	Use weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
2860	ATOVAQUONE	60212			EFAVIRENZ	195085			ANSM	81-ATOVAQUONE.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
2861	ATOVAQUONE	60212					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	81-ATOVAQUONE.html	Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism	Not recommended	
2862	ATOVAQUONE	60212			RIFABUTIN	55672			ANSM	81-ATOVAQUONE.html	Moderate decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Take into account	
2863	ATOVAQUONE	60212			RIFAMPICIN	9384			ANSM	81-ATOVAQUONE.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
2864			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	82-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency	Take into account	
2865			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ITRACONAZOLE	28031			ANSM	82-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the itraconazole, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency	Take into account	
2866			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	KETOCONAZOLE	6135			ANSM	82-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency	Take into account	
2867			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	VORICONAZOLE	121243			ANSM	82-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the voriconazole, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency	Take into account	
2868	AVANAFIL	1291301			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	83-AVANAFIL.html	Increase of the plasma concentrations of the avanafil, with risk of hypotension	Not recommended	
2869	AZITHROMYCIN	18631			ATORVASTATIN	83367			ANSM	84-AZITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication	Precaution for use	Use weaker doses of the cholesterol lowering medication or another statin not affected by this type of interaction.
2870	AZITHROMYCIN	18631			CICLOSPORIN	3008			ANSM	84-AZITHROMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the two substances together and after the macrolide is stopped.
2871	AZITHROMYCIN	18631			DIGOXIN	3407			ANSM	84-AZITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the azithromycin and after it is stopped.
2872	AZITHROMYCIN	18631			IVABRADINE	77417			ANSM	84-AZITHROMYCIN.html	Increased risk of problems with ventricular rhythm, especially of torsades de pointes. In addition, increase of the plasm concentrations of the ivabradine due to decrease of its metabolism by the azithromycin.	Precaution for use	Clinical monitoring and EKG during the administration of these together.
2873	AZITHROMYCIN	18631			SIMVASTATIN	36567			ANSM	84-AZITHROMYCIN.html	Increased risk of the undesirable effects (concentration-dependent) of the rhabdomyolosis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Use weaker doses of the cholesterol lowering agent or chose another statin not affected by this type of interaction.
2874	AZITHROMYCIN	18631					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	84-AZITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
2875	AZTREONAM	1272					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	85-AZTREONAM.html	Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosage of the anticonvulsant during the treatment with the antibiotic and after it is stopped.
2876	BACLOFEN	1292					TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	86-BACLOFEN.html	Risk of increase of hypotonia	Take into account	
2877	BACLOFEN	1292			LEVODOPA	6375			ANSM	86-BACLOFEN.html	Risk of aggravation of the Parkinsons syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)	Take into account	
2878			BARBITURATES	N05CA-001			BENZODIAZEPINES AND RELATED	N05-001	ANSM	87-BARBITURATES.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
2879			BARBITURATES	N05CA-001			OPIOIDS	N0-R0	ANSM	87-BARBITURATES.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
2880	BEDAQUILINE	1364504					ENZYMATIC INDUCERS	N03-J05-001	ANSM	88-BEDAQUILINE.html	Decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
2881	BEDAQUILINE	1364504					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	88-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
2882	BEDAQUILINE	1364504			ST JOHNS WORT				ANSM	88-BEDAQUILINE.html	Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
2883	BELATACEPT	1112973					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	89-BELATACEPT.html	Risk of general vaccine disease, possibly fatal.	Not recommended	
2884	FOLINIC ACID	6313					FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ANSM	9-FOLINIC-ACID.html	Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil.	Take into account	
2885			BENZODIAZEPINES AND RELATED	N05-001			BARBITURATES	N05CA-001	ANSM	90-BENZODIAZEPINES-RELATED.html	Increased risk of respiratory depression, which can be fatal in the case of overdose	Take into account	
2886			BENZODIAZEPINES AND RELATED	N05-001	BUPRENORPHINE	1819			ANSM	90-BENZODIAZEPINES-RELATED.html	With the buprenorphine used in replacement therapy: increased risk of respiratory depression, which can be fatal.	Take into account	Evaluate carefully the risk /benefit relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed doses.
2887			BENZODIAZEPINES AND RELATED	N05-001	CLOZAPINE	2626			ANSM	90-BENZODIAZEPINES-RELATED.html	Accrued risk of drop in blood pressure with respiratory and/or cardiac arrest.	Take into account	
2888			BENZODIAZEPINES AND RELATED	N05-001			OPIOIDS	N0-R0	ANSM	90-BENZODIAZEPINES-RELATED.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
2889			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	HALOTHANE	5095			ANSM	91-BETA-2-MIMETICS.html	In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity	Not recommended	Interrupt treatment with the beta-2 agonist if the anesthesia must be done with halothane
2890			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	INSULIN	5856			ANSM	91-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
2891			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	91-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring. Possibly change to insulin, if the situation requires.
2892			BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001	AMIODARONE	703			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL-AND-SOTALOL).html	Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
2893			BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001			CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL-AND-SOTALOL).html	Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
2894			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated during the surgical procedure by the beta-mimetics	Precaution for use	As a general rule, do not stop the treatment with the beta-blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.
2895			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			CENTRAL ANTIHYPERTENSIVES	C02AC-001	ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	Large increase of blood pressure in cases of sudden discontinuation of the treatment with the central hypertensive	Precaution for use	Avoid stopping the treatment with the central antihypertensive abruptly. Clinical monitoring
2896			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	Reduction of the antihypertensive effect (inhibition of the vasodilator prostaglandins by the non steroidal anti-inflammatories and fluid retention with the phenylbutazone)	Take into account	
2897			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			DIHYDROPYRIDINES	C08CA-002	ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (addition of the negative inotropic effects). The beta-blocking agent can furthermore minimize the sympathetic reflex reaction brought into play in the case of excessive hemodynamic repercussion	Take into account	
2898			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	DILTIAZEM	3443			ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure	Not recommended	The administration of these medications together should only be done under clinical monitoring and strict EKG, in particular with older patients or at the beginning of treatment.
2899			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	DIPYRIDAMOLE	3521			ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	With the dipyridamole by injection: increase of the antihypertensive effect	Take into account	
2900			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			GLINIDES	A10BX-001	ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient, and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose
2901			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			GLIPTINS	A10B-001	ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose
2902			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	INSULIN	5856			ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
2903			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	LIDOCAINE	6387			ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	With lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
2904			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	PROPAFENONE	8754			ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG.
2905			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment.
2906			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	VERAPAMIL	11170			ANSM	93-BETA-BLOCKING -AGENTS-(EXCEPT-ESMOLOL).html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure	Not recommended	The administration of these medications together should only be undertaken under strict clinical monitoring and EKG, in particular with older patients or at the beginning of treatment.
2907			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	AMIODARONE	703			ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia.	Precaution for use	Regular clinical monitoring and EKG
2908			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated by the beta-stimulants during the surgery	Precaution for use	As a general rule, do not stop the treatment with the beta blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.
2909			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003	ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	CONTRAINDICATION	
2910			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			ACETYLCHOLINESTERASE INHIBITORS	ACETCHO	ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Risk of excessive bradycardia (addition of the bradycardia inducing effects)	Precaution for use	Regular clinical monitoring, especially at the beginning of the administration of the substances together
2911			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)	Take into account	
2912			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			CENTRAL ANTIHYPERTENSIVES	C02AC-001	ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in cases of heart failure treated with a beta-blocking agent and vasodilator	Not recommended	
2913			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	DIGOXIN	3407			ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Difficulties of autoregulation (bradycardia, sinus arrest) and of sinoatrial and atrioventricular conduction	Take into account	
2914			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			DIHYDROPYRIDINES	C08CA-002	ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative iotropic effect of the dihydropyridines in vitro more or less marked and susceptible of adding to the negative inotropic effects of the beta-blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion	Take into account	
2915			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	DILTIAZEM	3443			ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction	CONTRAINDICATION	
2916			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			GLINIDES	A10BX-001	ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, strengthen self-monitoring of blood glucose.
2917			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	INSULIN	5856			ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
2918			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	LIDOCAINE	6387			ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
2919			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			NEUROLEPTICS	N05AA-003	ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)	Take into account	
2920			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Increased risk of ventricular arrythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG.
2921			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment.
2922			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	VERAPAMIL	11170			ANSM	94-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction	CONTRAINDICATION	
2923			BISPHOSPHONATES	M05B-001	CALCIUM	1428011			ANSM	95-BISPHOSPHONATES.html	For calcium salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	Take the calcium salts and antacids at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).
2924			BISPHOSPHONATES	M05B-001	IRON	1431589			ANSM	95-BISPHOSPHONATES.html	For the iron salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	Take the iron salts at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).
2925	BLEOMYCIN	1622			BRENTUXIMAB				ANSM	96-BLEOMYCIN.html	Risk of increase of pulmonary toxicity	CONTRAINDICATION	
2926	BOCEPREVIR	1102129					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	97-BOCEPREVIR.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these substances together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of the administration of them together.
2927	BOCEPREVIR	1102129			ATORVASTATIN	83367			ANSM	97-BOCEPREVIR.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the atorvastatin	Precaution for use	Do not exceed the dosage of 20mg/day of atorvastatin. If the therapeutic objective is not reached with this dosage, use another statin not affected by this type of interaction.
2928	BOCEPREVIR	1102129			DROSPIRENONE	840781			ANSM	97-BOCEPREVIR.html	Increase by more than double of the concentrations of drosperinone when taken with the boceprevir	Nor recommended	Choose a contraceptive with another progestin, especially in cases of hyperkalemia
2929	BOCEPREVIR	1102129					NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	97-BOCEPREVIR.html	Decrease of the effectiveness of the estrogen.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration with the boceprevir.
2930	BOCEPREVIR	1102129					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	97-BOCEPREVIR.html	Aside from the combination with ethinylestradiol (0.035mg)/noresthisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism by the hormonal contraceptive by the boceprevir	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the time these medications are taken together.
2931	BOCEPREVIR	1102129					IMMUNOSUPPRESSANTS	L04A	ANSM	97-BOCEPREVIR.html	Increase of the blood concentrations of the immunosuppressant (substantial for the ciclosporin, extremely large for the tacrolimus)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
2932	BOCEPREVIR	1102129					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	97-BOCEPREVIR.html	Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure	Not recommended	
2933	BOCEPREVIR	1102129			METHADONE	6813			ANSM	97-BOCEPREVIR.html	Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
2934	BOCEPREVIR	1102129					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	97-BOCEPREVIR.html	Aside from the combination with ethinylestradiol (0.035mg)/noresthisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the time these medications are taken together.
2935	BOCEPREVIR	1102129			RIFAMPICIN	9384			ANSM	97-BOCEPREVIR.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of treatment with the two medications together.
2936	BOCEPREVIR	1102129			TENEFOVIR ALAFENAMIDE	1721603			ANSM	97-BOCEPREVIR.html	Risk of decrease of the effectiveness of the tenefovir alafenamide by decrease of its intracellular activity by the boceprevir	Not recommended	
2937	BORTEZOMIB	358258					ENZYMATIC INDUCERS	N03-J05-001	ANSM	98-BORTEZOMIB.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
2938	BORTEZOMIB	358258					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	98-BORTEZOMIB.html	Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the bortezomib during the length of the treatment with the enzymatic inhibitor.
2939	BOSENTAN	75207					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	99-BOSENTAN.html	Risk of decrease of the plasma concentrations of bosentan	Not recommended	
2940	BOSENTAN	75207					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	99-BOSENTAN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of INR. Possible adjustment of the dosage of the vitamin K antagonist.
2941	BOSENTAN	75207			CICLOSPORIN	3008			ANSM	99-BOSENTAN.html	Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan	CONTRAINDICATION	
2942	BOSENTAN	75207			CYPROTERONE	3014			ANSM	99-BOSENTAN.html	Risk of decrease of the effectiveness of the cyproterone	Precaution for use	In its indications such as anti-androgen, clinical monitoring and if possible adjustment of the dosage of the cyproterone during the administratin with the bosentan and after it is stopped.
2943	BOSENTAN	75207					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	99-BOSENTAN.html	Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the length of time the two substances are administered together and for a cycle after.
2944	BOSENTAN	75207			GLIBENCLAMIDE	4815			ANSM	99-BOSENTAN.html	Risk of reduced effectiveness of the glibenclamide due to decrease of its plasma concentrations, because of the inducer effect of the bosentan. Furthermore, cases of hepotoxicity have been reported with these two substances administered together.	Precaution for use	Monitoring of the glycemia, adjustment of the treatment if needed, and monitoring of the hepatic biological constants.
2945	BOSENTAN	75207					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	99-BOSENTAN.html	Increased risk of the undesirable effects of the bosantan, especially hepatic attacks, due to decrease of its metabolism by the inhibitor	Precaution for use	Clinical and biological monitoring during the administration of these together.
2946	BOSENTAN	75207					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	99-BOSENTAN.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism.	Precaution for use	Use an additional or alternative reliable method of contraception during the time these substances are administered together and one cycle following
2947	BOSENTAN	75207					NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	ANSM	99-BOSENTAN.html	Risk of decrease of the effectiveness of the progestogen	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the bosentan and after it is stopped.
2948	BOSENTAN	75207			RIFAMPICIN	9384			ANSM	99-BOSENTAN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
